NOVEL CARBOXYLESTERASE NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF

Abstract: The present invention relates to arthropod esterase proteins; to arthropod esterase nucleic acid molecules, including those that encode such esterase proteins; to antibodies raised against such esterase proteins; and to other compounds that inhibit arthropod esterase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from hematophagous arthropod infestation.

Description: NOVEL CARBOXYLESTERASE NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF FIELD OF THE INVENTION The present invention relates to arthropod esterase nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies, and/or other inhibitors, as well as their use to protect an animal from hematophagous arthropod infestation. BACKGROUND OF THE INVENTION Hematophagous arthropod infestation of animaft is a health and economic concern because hematophagous arthropods are known to cause and/or transmit a variety of diseases. Hematophagous arthropods directly cause a variety of diseases, including allergies, and also carry a variety of infectious agents including, but not limited to, endoparasites (e.g., nematodes, cestodes, trematodes and protozoa), bacteria and viruses. In particular, the bites of hematophagous arthropods are a problem for animals maintained as pets because the infestation becomes a source of annoyance not only for the pet but also for the pet owner who may find his or her home generally contaminated with insects. As such, hematophagous arthropods are a problem not only when they are on an animal but also when they are in the general environment of the animal. Bites from hematophagous arthropods are a particular problem because they not only can lead to disease transmission but also can cause a hypersensitive response in animals which is manifested as disease. For example, bites from fleas can cause an allergic disease called flea allergic (or allergy) dermatitis (FAD). A hypersensitive response in animals typically results in localired tissue inflammation and damage, causing substantial discomfort to the animal. The medical importance of arthropod infestation has prompted the development of reagents capable of controlling arthropod infestation. Commonly encountered methods to control arthropod infestation are generally focused on use of insecticides. While some of these products are efficacious, most, at best, offer protection of a very limited duration. Furthermore, many of the methods are often not successful in reducing arthropod populations. In particular, insecticides have been used to prevent hematophagous arthropod infestation of animals by adding such insecticides to shampoos, powders, collars, sprays, foggers and liquid bath treatments (i.e., dips). Reduction of hematophagous arthropod infestation on the pet has been unsuccessful for one or more of the following reasons: (1) failure of owner compliance (frequent administration is required); (2) behavioral or physiological intolerance of the pet to the pesticide product or means of administration; and (3) the emergence of hematophagous arthropod populations resistant to the prescribed dose of pesticide. However, hematophagous arthropod populations have been found to become resistant to insecticides. Prior investigators have described insect carboxylesterase (CE) protein biochemistry, for example, Chen et al., Insect Biochem. Molec. Biol, 24:347-355, 1994; Whyard et al., Biochemical Genetics, 32:924, 1994 and Argentine et al., Insect Biochem. Molec Biol, 25:621-630, 1995. Other investigators have disclosed certain insect CE amino acid sequences, for example, Mouches et al., Proc Natl Acad Sci USA, 87:2574- 2578, 1990 and Cooke et al, Proc Natl Acad Sci USA, 86:1426-1430, 1989, and nucleic acid sequence (Vaughn et al., J. Biol. Chem., 270:17044-17049, 1995). Prior investigators have described certain insect juvenile hormone esterase (JHE) nucleic acid and amino acid sequences: for example, sequence ϊox Heliothis virescens is disclosed by Hanzlik et al, J. Biol. Chem., 264:12419-12425, 1989; Eldridge et al., App Environ Microbiol, 58:1583-1591, 1992; Bonning et al., Insect Biochem. Molec. Biol, 22:453-458, 1992; Bonning et al., Natural and Engineered Pest Management Agents, pp. 368-383, 1994 andUarshman et al., Insect Biochem. Molec. Biol, 24:671-676, 1994 ; sequence fo™ anduca sexta ; s disclosed by Vankatesh et al., J Biol Chem, 265:21727- 21732, 1990; sequence for Trichoplusia ni is disclosed by Venkataraman et al., Dev. Genet., 15:391-400, 1994 and Jones et al., Biochem. J., 302:827-835, 1994; and sequence for Lymantria dispar is disclosed by Valaitis, Insect Biochem. Molec. Biol, 22:639-648, 1992. Identification of an esterase of the present invention is unexpected, however, because even the most similar nucleic acid sequence identified by previous investigators could not be used to identify an esterase of the present invention. In addition, identification of an esterase protein of the present invention is unexpected because a protein fraction from flea prepupal larvae that was obtained by monitoring for serine protease activity surprisingly also contained esterase proteins of the present invention. In summary, there remains a need to develop a reagent and a method to protect animals or plants from hematophagous arthropod infestation. SUMMARY OF THE INVENTION The present invention relates to a novel product and process for protection of animals or plants from arthropod infestation. According to the present invention there are provided arthropod esterase proteins and mimetopes thereof; arthropod nucleic acid molecules, including those that encode such proteins; antibodies raised against such esterase proteins (i.e., anti-arthropod esterase antibodies); and compounds that inhibit arthropod esterase activity (i.e, inhibitory compounds or inhibitors). The present invention also includes methods to obtain such proteins, mimetopes, nucleic acid molecules, antibodies and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, mimetopes, nucleic acid molecules, antibodies, and/or inhibitory compounds, as well as use of such therapeutic compositions to protect animals from arthropod infestation. Identification of an esterase of the present invention is unexpected, however, because the most similar nucleic acid sequence identified by previous investigators could not be used to identify an esterase of the present invention. In addition, identification of an esterase protein of the present invention is unexpected because a protein fraction from flea prepupal larvae that was obtained by monitoring for serine protease activity surprisingly also contained esterase proteins of the present invention. One embodiment of the present invention is an isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene comprising a nucleic acid sequence including SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51 , SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74. The present invention also includes a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule encoding a protein comprising at least one of the following amino acid sequences:SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:l 1, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and/or SEQ ID NO:74; and particularly a nucleic acid molecule that hybridizes with a nucleic acid sequence that is a complement of a nucleic acid sequence encoding any of the amino acid sequences. A preferred nucleic acid molecule of the present invention includes a nucleic acid molecule comprising a nucleic acid sequence including SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ JD O:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74, and allelic variants thereof. The present invention also includes an isolated carboxylesterase nucleic acid molecule comprising a nucleic acid sequence encoding a protein comprising an amino acid sequence including SEQ ID NO:5, SEQ ID NO: 19, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44 and/or SEQ ID NO:53. SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43 and SEQ ID NO:44 represent N-terminal amino acid sequences of carboxylesterases isolated from prepupal flea larvae, the production of which are described in the Examples of the present application. The present invention also relates to recombinant molecules, recombinant viruses and recombinant cells that include a nucleic acid molecule of the present invention. Also included are methods to produce such nucleic acid molecules, recombinant molecules, recombinant viruses and recombinant cells. Another embodiment of the present invention includes an isolated esterase protein that is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to (a) a nucleic acid molecule that includes at least one of the following nucleic acid sequences:SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO: 35, SEQ ID NO:38, SEQ ID NO:52, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO: 69, and SEQ ID NO:71; and/or (b) a nucleic acid molecule encoding a protein including at least one of the following amino acid sequences: SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55 and SEQ ID NO:74. One embodiment is a carboxylesterase protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to a nucleic acid molecule that encodes a protein comprising at least one of the following amino acid sequences: SEQ ID NO:5, SEQ ID NO: 19, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO 43, SEQ ID NO:44 and/or SEQ ID NO:53. Preferred proteins of the present invention are isolated flea proteins including at least one of the following amino acid sequences:SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:l l, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; also included are proteins encoded by allelic variants of nucleic acid molecules encoding proteins comprising any of the above-listed amino acid sequences. The present invention also relates to mimetopes of arthropod esterase proteins as well as to isolated antibodies that selectively bind to arthropod esterase proteins or mimetopes thereof. Also included are methods, including recombinant methods, to produce proteins, mimetopes and antibodies of the present invention. The present invention also includes a formulation of flea carboxylesterase proteins, in which the proteins, when submitted to 14% Tris-glycine SDS-PAGE, comprise a fractionation profile as depicted in Fig. 3, in which the proteins have carboxylesterase activity. Also included in the present invention is a formulation of flea carboxylesterase proteins, in which the proteins, when submitted to IEF-PAGE, comprise a fractionation profile as depicted in Fig. 4, lane 3, lane 4, lane 5, lane 6 and/or lane 7, wherein the proteins have carboxylesterase activity. Another embodiment of the present invention is an isolated flea protein or a formulation of flea proteins that hydrolyzes -napthyl acetate to produce α-napthol, when the protein is incubated in the presence of α-napthyl acetate contained in 20 mM Tris at pH 8.0 for about 15 minutes at about 37°C. Yet another embodiment of the present invention is an isolated flea protein or a formulation of flea proteins that hydrolyzes the methyl ester group of juvenile hormone to produce a juvenile hormone acid. Another embodiment of the present invention is a method to identify a compound capable of inhibiting flea carboxylesterase activity, the method comprising: (a) con^ac' ing an isolated flea carboxylesterase with a putative inhibitory compound under conditions in which, in the absence of the compound, the protein has carboxylesterase activity; and (b) determining if the putative inhibitory compound inhibits the activity. Also included in the present invention is a test kit to identify a compound capable of inhibiting flea carboxylesterase activity, the test kit comprising an isolated flea carboxylesterase protein having esterase activity and a means for determining the extent of inhibition of the activity in the presence of a putative inhibitory compound. Yet another embodiment of the present invention is a therapeutic composition that is capable of reducing hematophagous ectoparasite infestation. Such a therapeutic composition includes at least one of the following protective compounds: an isolated hematophagous ectoparasite carboxylesterase protein or a mimetope thereof, an isolated carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene, an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein, and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase. A therapeutic composition of the present invention can also include an excipient, an adjuvant and/or a carrier. Preferred esterase nucleic acid molecule compounds of the present invention include naked nucleic acid vaccines, recombinant virus vaccines and recombinant cell vaccines. Also included in the present invention is a method to protect an animal from hematophagous ectoparasite infestation, comprising the step of administering to the animal a therapeutic composition of the present invention. BRIEF DESCRIPTION OF THE FIGURES Fig. 1 depicts SDS-PAGE analysis of DFP-labeled esterase proteins. Fig. 2 depicts carboxylesterase activity of certain esterase proteins of the present invention. Fig. 3 depicts SDS-PAGE analysis of carboxylesterase activity of certain esterase proteins of the present invention. Fig. 4 depicts IEF analysis of certain esterase proteins of the present invention. Fig. 5 depicts juvenile hormone esterase activity of certain esterase proteins of the present invention. DETAILED DESCRIPTION OF THE INVENTION The present invention provides for isolated arthropod esterase proteins, isolated arthropod esterase nucleic acid molecules, antibodies directed against arthropod esterase proteins and other inhibitors of arthropod esterase activity. As used herein, the terms isolated arthropod esterase proteins and isolated arthropod esterase nucleic acid molecules refers to esterase proteins and esterase nucleic acid molecules derived from arthropods and, as such, can be obtained from their natural source or can be produced using, for example, recombinant nucleic acid technology or chemical synthesis. Also included in the present invention is the use of these proteins, nucleic acid molecules, antibodies and inhibitors as therapeutic compositions to protect animals from hematophagous ectoparasite infestation as well as in other applications, such as those disclosed below. Arthropod esterase proteins and nucleic acid molecules of the present invention have utility because they represent novel targets for anti-arthropod vaccines and drugs. The products and processes of the present invention are advantageous because they enable the inhibition of arthropod development, metamorphosis, feeding, digestion and reproduction processes that involve esterases. While not being bound by theory, it is believed that expression of arthropod esterase proteins are developmentally regulated, thereby suggesting that esterase proteins are involved in arthropod development and/or reproduction. The present invention is particularly advantageous because the proteins of the present invention were identified in larval fleas, thereby suggesting the importance of the proteins as developmental proteins. One embodiment of the present invention is an esterase formulation that includes one or more esterase proteins capable of binding to diisopropylfluorophosphate (DFP). A preferred embodiment of an esterase formulation of the present invention comprises one or more arthropod esterase proteins that range in molecular weight from about 20 kilodaltons (kD) to about 200 kD, more preferably from about 40 kD to about 100 kD, and even more preferably from about 60 kD to about 75 kD, as determined by SDS- PAGE (sodium dodecyl sulfate polyacrylamide gel elec t ro' ihoresis). An even more preferred formulation includes one or more flea esterase proteins having elution (or migration) patterns as shown in Fig. 1. Another embodiment of the present invention is a formulation comprising one or more hematophagous ectoparasite carboxylesterase (CE) proteins. The present invention includes the discovery that such a formulation has general CE activity. General CE activity can be identified using methods known to those of skill in the art and described in the Examples section herein. A suitable formulation of the present invention comprises one or more flea proteins capable of hydrolyzing α-napthyl acetate to produce α-napthol when the proteins are incubated in the presence of α-napthyl acetate contained in 20 mm Tris at pH 8.0 for about 15 minutes at about 37 °C. General CE activity can be identified following such incubation by detecting the production of from about 0.3 to about 2.5 absorbance units in the presence of Fast Blue when measured at 590 nm. A preferred CE formulation of the present invention includes one or more flea CE proteins having acidic to neutral isoelectric points, or pi values. An isoelectric pH, or pi, value refers to the pH value at which a molecule has no net electric charge and fails to move in an electric field. A preferred formulation of the present invention includes one or more proteins having a pi value ranging from about pi 2 to about 10, more preferably from about pi 3 to about 8, and even more preferably from about pi 4.7 to about 5.2, as determined by IEF-PAGE. An esterase formulation, including a CE formulation, of the present invention can be prepared by a method that includes the steps of: (a) preparing an extract by isolating flea tissue, homogenizing the tissue by sonication and clarifying the extract by centrifugation at a low speed spin, e.g., about 18,000 rpm for about 30 minutes; (b) recovering soluble proteins from said centrifuged extract and applying the proteins to a p-aminobenzamidine agarose bead column; (c) recovering unbound protein from the column and clarifying by filtration; (d) applying the clarified protein to a gel filtration column and eluting and collecting fractions with esterase activity; (e) dilayzing the eluate against 20 mM MES buffer, pH 6.0, containing 10 mM NaCl; (f) applying the dialysate to a cation exchange chromatography column, eluting protein bound to the column with a linear gradier i of from about 10 mM NaCl to about 1 M NaCl in 20 mM MES buffer, pH 6, and collecting fractions having esterase activity; (g) adjusting the pH of the resulting fractions to pH 7 and applying the fractions to an anion exchange chromatography column; (h) eluting protein bound to the column with a linear gradient of from about 0 to about 1 M NaCl in 25 mM Tris buffer, pH 6.8 and collecting fractions having esterase activity, such activity elutes from the column at about 170 mM NaCl. Tissue can be obtained from unfed fleas or from fleas that recently consumed a blood meal (i.e., blood-fed fleas). Such flea tissues are referred to herein as, respectively, unfed flea and fed flea tissue. Preferred flea tissue from which to obtain an esterase formulation of the present invention includes pre-pupal larval tissue, wandering flea larvae, 3rd instar tissue, fed adult tissue and unfed adult tissue. In a preferred embodiment, a CE formulation of the present invention comprises a flea protein comprising amino acid sequence SEQ ID NO:5, SEQ ID NO: 19, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44 and/or SEQ ID NO:53. Another embodiment of the present invention is a juvenile hormone esterase (JHE) formulation comprising one or more arthropod JHE proteins, the arthropod being of the order Hemiptera, Anoplura, Mallophaga, Diptera, Siphonaptera, Parasitiformes, Acariformes and Acarina. The present invention includes the discovery that such a formulation has JHE activity. JHE activity can be identified using methods known to those of skill in the art and described in the Examples section herein. A suitable formulation of the present invention comprises one or more arthropod proteins capable of hydrolyzing a methyl ester group of juvenile hormone to produce a juvenile hormone acid. Preferably, such a protein is capable of releasing of at least about 120 counts per minute when such a protein is incubated in the presence of 3 H-juvenile hormone to create a reaction mixture, the reaction mixture is combined with isooctane, the aqueous phase is recovered and the amount of 3 H-juvenile hormone present in that phase is determined. Such a protein is also preferably capable of causing release of methane thiol when such protein is incubated in the presence of methyl 1-heptylthioacetothioate (HEPTAT) using the method generally disclosed in McCutchen et al., Insect Biochem. Molec. Bio 1 .., Vol. 25, No. 1, pg 119-126, 1995, which is incorporated in its entirety by this reference. In one embodiment, a juvenile hormone esterase formulation of the present invention comprises a protein comprising amino acid sequence SEQ ID NO:74. According to the present invention, an arthropod that is not of the order lepidoptera includes an arthropod of the order Hemiptera, Anoplura, Mallophaga, Diptera, Siphonaptera, Parasitiformes, Acariformes and Acarina. Preferred arthropods include Hemiptera cimicidae, Hemiptera reduviidae, Anoplura pediculidae, Anoplura pthiridae, Diptera culicidae, Diptera simuliidae, Diptera psychodidae, Diptera ceratopogonidae, Diptera chaoboridae, Diptera tabanidae, Diptera rhagionidae, athericidae, Diptera chloropidae, Diptera muscidae, Diptera hippoboscidae, Diptera calliphoridae, Diptera sarcophagidae, Diptera oestridae, Diptera gastrophilidae, Diptera cuterebridae, Siphonaptera ceratophyllidae, Siphonaptera leptopsyllidae, Siphonaptera pulicidae, Siphonaptera tungidae, Parasitiformes dermanyssidae, Acariformes tetranychidae, Acariformes cheyletide, Acariformes demodicidae, Acariformes erythraeidae, Acariformes trombiculidae, Acariformes psoroptidae, Acariformes sarcoptidae, Acarina argasidae and Acarina ixodidae. Preferred Diptera muscidae include Musca, Hydrotaea, Stomoxys Haematobia. Preferred Siphonaptera include Ceratophyllidae nosopsyllus, Ceratophyllidae diamanus, Ceratophyllidae ceratophyllus, Leptopsyllidae leptopsylla, Pulicidae pulex, Pulicidae ctenocephalides, Pulicidae xenopsylla, Pulicidae echidnophaga and Tungidae tunga. Preferred Parasitiformes dermanyssidae include Ornithonyssus and Liponyssoides. Preferred Acarina include Argasidae argas, Argasidae ornithodoros, Argasidae otobius, Ixodidae ixodes, Ixodidae hyalomma, Ixodidae nosomma, Ixodidae rhipicephalus, Ixodidae boophilus, Ixodidae dermacentor, Ixodidae haemaphysalus, Ixodidae amblyomma and Ixodidae anocentor. One embodiment of a JHE formulation of the present invention is one or more arthropod JHE proteins that range in molecular weight from about 20 kD to about 200 kD, more preferably from about 40 kD to about 100 kD, and even more preferably from about 60 kD to about 75 kD, as determined by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). A JHE formulation of the present invention can be prepared by a method that includes the steps of: (a) preparing soluble proteins from arthropod extracts as described above for CE purification and purifying such soluble proteins by gel filtration; (b) collecting fractions having JHE activity from the gel filtration step, loading the fractions onto a cation exchange column, eluting the cation exchange column with a linear gradient of from about 10 mM NaCl to about 1 M NaCl in 20 mM MES buffer, pH 6 and collecting fractions having JHE activity; (c) adjusting the pH of the collected fractions to about pH 7 are dialyzed against about 10 mM phosphate buffer (pH 7.2) containing about 10 mM NaCl; (d) applying the dialysate to a hydroxyapatite column, eluting protein bound to the column with a linear gradient of from about 10 mM phosphate buffer (pH 7.2) containing 10 mM NaCl to about 0.5 M phosphate buffer (pH 6.5) containing 10 mM NaCl and collecting fractions having JHE activity; (e) dialyzing the fractions against 20 mM Tris buffer (pH 8.0) containing 10 mM NaCl; (f) applying the dialysate an anion exchange chromatography column and eluting protein bound to the column with a linear gradient of from about 10 mM to about 1 M NaCl in 20 mM Tris buffer, pH 8 and collecting fractions containing JHE activity. A JHE formulation of the present invention can be prepared by a method that includes the steps of: (a) preparing flea extracts as described herein in the Examples section and applying the extract to p-aminobenzamidine linked agarose beads and collecting protein not bound to the beads; (b) applying the unbound protein to a Superdex 200 HR gel filtration column and collecting fractions having JHE activity; (c) applying the fractions to an anion exchange chromatography column, eluting the anion exchange column with a linear gradient of 0 to 1 M NaCl in 25 mM Tris buffer, pH 6.8 and collecting fractions having JHE activity; (d) dialyzing the fractions overnight against about 1 L of 20 mM Tris buffer, pH 8.0, containing 10 mM NaCl; (e) applying the dialysate to a Poros 10 HQ anion exchange column, eluting the column with buffer containing about 120 mM NaCl and collecting fractions having JHE activity. Suitable arthropods from which to isolate a JHE formulation of the present invention include, but are not limited to agricultural pests, stored product pests, forest pests, structural pests or animal health pests. Suitable agricultural pests of the present invention include , but are not limited to Colorπdr potato beetles, corn earworms, fleahoppers, weevils, pink boll worms, cotton aphids, beet armyworms, lygus bugs, hessian flies, sod webworms, whites grubs, diamond back moths, white flies, planthoppers, leafhoppers, mealy bugs, mormon crickets and mole crickets. Suitable stored product pests of the present invention include, but are not limited to dermestids, anobeids, saw toothed grain beetles, indian mealmoths, flour beetles, long-hom wood boring beetles and metallic wood boring beetles. Suitable forest pests of the present invention include , but are not limited to southern pine bark bettles, gypsy moths, elm beetles, ambrosia bettles, bag worms, tent worms and tussock moths. Suitable structural pests of the present invention include, but are not limited to, bess beetles, termites, fire ants, carpenter ants, wasps, hornets, cockroaches, silverfish, Musca domestica and Musca autumnalis. Suitable animal health pests of the present invention include, but are not limited to fleas, ticks, mosquitoes, black flies, lice, true bugs, sand flies, Psychodidae, tsetse flies, sheep blow flies, cattle grub, mites, horn flies, heel flies, deer flies, Culicoides and warble flies. Preferred arthropods from which to isolate a JHE formulation of the present invention include fleas, midges, mosquitos, sand flies, black flies, horse flies, snipe flies, louse flies, horn flies, deer flies, tsetse flies, buffalo flies, blow flies, stable flies, myiasis-causing flies, biting gnats, lice, mites, bee, wasps, ants, true bugs and ticks, preferably fleas, ticks and blow flies, and more preferably fleas. Preferred fleas from which to isolate JHE proteins include Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla. More preferred fleas include Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla (Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans, with C. felis being even more preferred. Suitable tissue from which to isolate a JHE formulation of the present invention includes unfed fleas or fleas that recently consumed a blood meal (i.e., blood-fed fleas). Such flea tissues are referred to herein as, respectively, unfed flea and fed flea tissue. Preferred flea tissue from which to obtain a JHE formulation of the present invention includes pre-pupal larval tissue, 3rd instar tissue, fed or unfed adult tissue, with unfed adult gut tissue bei.ig more prefeTed than fed or unfed whole adult tissue. It is of note that a JHE formulation of the present invention obtained from pre-pupal larval tissue does not hydrolyze α-napthyl acetate. Another embodiment of the present invention is an esterase formulation comprising a combination of one or more arthropod CE and JHE proteins of the present invention. Suitable arthropods from which to isolate a combined CE and JHE formulation include those arthropods described herein for the isolation of a JHE formulation of the present invention. Preferred arthropods from which to isolate a combined CE and JHE formulation include fleas, midges, mosquitos, sand flies, black flies, horse flies, horn flies, deer flies, tsetse flies, buffalo flies, blow flies, stable flies, myiasis-causing flies, biting gnats, lice, bee, wasps, ants, true bugs and ticks, preferably fleas, ticks and blow flies, and more preferably fleas. Suitable flea tissue from which to isolate a combined CE and JHE formulation of the present invention includes 3rd instar tissue, fed or unfed adult tissue and unfed adult tissue, with unfed adult gut tissue being more preferred than fed or unfed whole adult tissue. In one embodiment, a formulation of the present invention comprises an esterase having both CE and JHE activity. Preferably, a formulation of the present invention that comprises an esterase having both CE and JHE activity comprises a flea protein comprising amino acid sequence SEQ ID NO:8 and/or SEQ ID NO:37. Another embodiment of the present invention is an isolated protein comprising an artliropod esterase protein. It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, a protein refers to one or more proteins or at least one protein. As such, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" can be used interchangeably. Furthermore, a compound "selected from the group consisting of refers to one or more of the compounds in the list that follows, including mixtures (i.e., combinations) of two or more of the compounds. According to the present invention, an isolated, or biologically pure, protein, is a protein that has been removed from its natural milieu. As such, "isolated" and "biologically pure" do not necessarily reflect the extent to which the protein has been purified. An isolated protein of the present invention can be obtained from its natural source, can be produced using recombinant DNA technology or can be produced by chemical synthesis. As used herein, an isolated arthropod esterase protein can be a full-length protein or any homolog of such a protein. An isolated protein of the present invention, including a homolog, can be identified in a straight- forward manner by the protein's ability to elicit an immune response against arthropod esterase proteins, to hydrolyze α- napthyl acetate, to hydrolyze the methyl ester group of juvenile hormone or bind to DFP. Esterase proteins of the present invention include CE and JHE proteins. As such, an esterase protein of the present invention can comprise a protein capable of hydrolyzing α-napthyl acetate, hydrolyzing the methyl ester group of juvenile hormone and/or binding to DFP. Examples of esterase homologs include esterase proteins in which amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitoylation, amidation and/or addition of glycerophosphatidyl inositol) such that the homolog includes at least one epitope capable of eliciting an immune response against an arthropod esterase protein. That is, when the homolog is administered to an animal as an immunogen, using techniques known to those skilled in the art, the animal will produce an immune response against at least one epitope of a natural arthropod esterase protein. The ability of a protein to effect an immune response, can be measured using techniques known to those skilled in the art. Esterase protein homologs of the present invention also include esterase proteins that hydrolyze α-napthyl acetate and/or that hydrolyze the methyl ester group of juvenile hormone. Artliropod esterase protein homologs can be the result of natural allelic variation or natural mutation. Esterase protein homologs of the present invention can also be produced using techniques known in the art including, but not limited to, direct modifications to the protein or modifications to the gene encoding the protein using, for example, classic or recombinant nucleic acid techniques to effect random or targeted mutagenesis. Isolated esterase proteins of the present invention have the fυrtb sr characteristic of being encoded by nucleic acid molecules that hybridize under stringent hybridization conditions to a gene encoding a Ctenocephalides felis protein (i.e., a C. felis esterase gene). As used herein, stringent hybridization conditions refer to standard hybridization conditions under which nucleic acid molecules, including oligonucleotides, are used to identify similar nucleic acid molecules. Such standard conditions are disclosed, for example, in Sambrook et al., Molecular Cloning: A Laboratoiγ Manual, Cold Spring Harbor Labs Press, 1989; Sambrook et al., ibid., is incorporated by reference herein in its entirety. Stringent hybridization conditions typically permit isolation of nucleic acid molecules having at least about 70% nucleic acid sequence identity with the nucleic acid molecule being used to probe in the hybridization reaction. Formulae to calculate the appropriate hybridization and wash conditions to achieve hybridization permitting 30% or less mismatch of nucleotides are disclosed, for example, in Meinkoth et al., 1984, Anal. Biochem. 138, 267-284; Meinkoth et al., ibid., is incoφorated by reference herein in its entirety. As used herein, a C. felis esterase gene includes all nucleic acid sequences related to a natural C. felis esterase gene such as regulatory regions that control production of the C. felis esterase protein encoded by that gene (such as, but not limited to, transcription, translation or post-translation control regions) as well as the coding region itself. In one embodiment, a C. felis esterase gene of the present invention includes the nucleic acid sequence SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74. Nucleic acid sequence SEQ ID NO:l represents the deduced sequence of the coding s'ra'.d of a PCR amplified nucleic acid molecule denoted herein as nfEl 401 , the production of which is disclosed in the Examples. The complement of SEQ ID NO:l (represented herein by SEQ ID NO:3) refers to the nucleic acid sequence of the strand complementary to the strand having SEQ ID NO:l, which can easily be determined by those skilled in the art. Likewise, a nucleic acid sequence complement of any nucleic acid sequence of the present invention refers to the nucleic acid sequence of the nucleic acid strand that is complementary to (i.e., can form a complete double helix with) the strand for which the sequence is cited. Nucleic acid sequence SEQ ID NO:4 represents the deduced sequence of the coding strand of a PCR amplified nucleic acid molecule denoted herein as nfE2 364 , the production of which is disclosed in the Examples. The complement of SEQ ID NO:4 is represented herein by SEQ ID NO:6. Nucleic acid sequence SEQ ID NO:7 represents the deduced sequence of the coding strand of a PCR amplified nucleic acid molecule denoted herein as nfE3 42I , the production of which is disclosed in the Examples. The complement of SEQ ID NO:7 is represented herein by SEQ ID NO:9. Nucleic acid sequence SEQ ID NO: 10 represents the deduced sequence of the coding strand of a PCR amplified nucleic acid molecule denoted herein as nfE4 524 , the production of which is disclosed in the Examples. The complement of SEQ ID NO: 10 is represented herein by SEQ ID NO: 12. Nucleic acid sequence SEQ ID NO: 13 represents the deduced sequence of the coding strand of an apparent coding region of a complementary DNA (cDNA) nucleic acid molecule denoted herein as ιιfE5 1982 , the production of which is disclosed in the Examples. The complement of SEQ ID NO: 13 is represented herein by SEQ ID NO: 15. Nucleic acid sequence SEQ ID NO: 18 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE6 1792 , the production of which is disclosed in the Examples. The complement of SEQ ID NO: 18 is represented herein by SEQ ID NO:20. Nucleic acid sequence SEQ ID NO:24 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as • ιf£7 2836 , the production of which is disclosed in the Examples. The complement of SEQ ID NO:24 is represented herein by SEQ ID NO:26. Nucleic acid sequence SEQ ID NO:30 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE8 2801 , the production of which is disclosed in the Examples. The complement of SEQ ID NO:30 is represented herein by SEQ ID NO:32. Nucleic acid sequence SEQ ID NO:36 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE9 2007 , the production of which is disclosed in the Examples. The complement of SEQ ID NO:36 is represented herein by SEQ ID NO:38. Nucleic acid sequence SEQ ID NO:57 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE5 2144 , the production of which is disclosed in the Examples. The complement of SEQ ID NO:57 is represented herein by SEQ ID NO:59. Nucleic acid sequence SEQ ID NO:67 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE10ι 987 , the production of which is disclosed in the Examples. The complement of SEQ ID NO:67 is represented herein by SEQ ID NO:69. It should be noted that since nucleic acid sequencing technology is not entirely error-free, the nucleic acid sequences and amino acid sequences presented herein represent, respectively, apparent nucleic acid sequences of nucleic acid molecules of the present invention and apparent amino acid sequences of esterase proteins of the present invention. In another embodiment, a C. felis esterase gene can be an allelic variant that includes a similar but not identical sequence to SEQ ID NO: l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74. An allelic variant of a C. felis esterase gene is a gene that occurs at essentially the same locus (or loci) in the genome as the gene including SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO: 74, but which, due to natural variations caused by, for example, mutation or recombination, has a similar but not identical sequence. Allelic variants typically encode proteins having similar activity to that of the protein encoded by the gene to which they are being compared. Allelic variants can also comprise alterations in the 5' or 3' untranslated regions of the gene (e.g., in regulatory control regions). Allelic variants are well known to those skilled in the art and would be expected to be found within a given artliropod since the genome is diploid and/or among a group of two or more arthropods. The minimal size of an esterase protein homolog of the present invention is a size sufficient to be encoded by a nucleic acid molecule capable of forming a stable hybrid (i.e., hybridize under stringent hybridization conditions) with the complementary sequence of a nucleic acid molecule encoding the corresponding natural protein. As such, the size of the nucleic acid molecule encoding such a protein homolog is dependent on nucleic acid composition and percent homology between the nucleic acid molecule and complementary sequence. It should also be noted that the extent of homology required to form a stable hybrid can vary depending on whether the homologous sequences are interspersed throughout the nucleic acid molecules or are clustered (i.e., localized) in distinct regions on the nucleic acid molecules. The minimal size of such nucleic acid molecules is typically at least about 12 to about 15 nucleotides in length if the nucleic acid molecules are GC-rich and at least about 15 to about 17 bases in length if they are AT-rich. As such, the minimal size of a nucleic acid molecule used to encode an esterase protein homolog of the present invention is from about 12 to about 18 nucleotides in length. Thus, the minimal size of an esterase protein homolog of the present invention is from about 4 to about 6 amino acids in length. There is no limit, other than a practical limit, on the maximal size of such a nucleic acid molecule in that the nucleic acid molecule can include a portion of a gene, an entire gene, multiple genes, or portions thereof. The preferred size of a protein encoded by a nucleic acid molecule of the present invention depends on whether a full-length, fusion, multivalent, or functional portion of such a protein is desired. One embodiment of the present invention includes an arthropod esterase protein having CE enzyme activity. Such a CE protein preferably includes: a catalytic triad of serine — histidine — glutamic acid as well as the essential amino acids arginine and aspartic acid at positions similar to those described for juvenile hormone esterase, for example by Ward et al., 1992, Int J Biochem 24: 1933-1941 ; this reference is incorporated by reference herein in its entirety. Analysis of the apparent full-length protein sequences disclosed herein indicates that each of these amino acid sequences includes these amino acid motifs, as well as surrounding consensus sequences. Suitable arthropods from which to isolate esterase proteins having general CE activity of the present invention (including isolation of the natural protein or production of the protein by recombinant or synthetic techniques) preferably include insects and acarines but not Culicidae, Drosophilidae, Calliphoridae, Sphingidae, Lymantriidae, Noctuidae, Fulgoroidae andAphididae. Preferred artliropods from which to isolate CE proteins having general CE activity include fleas, ticks, black flies, lice, true bugs, sand flies, Psychodidae, tsetse flies, cattle grub, mites, horn flies, heel flies, deer flies, Culicoides and warble flies. Preferred arthropods from which to isolate an esterase proteins having general CE activity include fleas, midges,, sand flies, black flies, horse flies, snipe flies, louse flies, hen flies, deer flies, tsetse flies, buffalo flies, blow flies, stable flies, myiasis-causing flies, biting gnats, lice, mites, bee, wasps, ants, true bugs and ticks, preferably fleas, ticks and blow flies, and more preferably fleas. Preferred fleas from which to isolate esterase proteins having general CE activity include Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla. More preferred fleas include Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla (Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans, with C. felis being even more preferred. A preferred arthropod esterase protein of the present invention is a compound that when administered to an animal in an effective manner, is capable of protecting that animal from hematophagous ectoparasite infestation. In accordance with the present invention, the ability of an esterase protein of the present invention to protect an animal from hematophagous ectoparasite infestation refers to the ability of that protein to, for example, treat, ameliorate and/or prevent infestation caused by hematophagous arthropods. In particular, the phrase "to protect an animal from hematophagous ectoparasite infestation" refers to reducing the potential for hematophagous ectoparasite population expansion on and around the animal (i.e., reducing the hematophagous ectoparasite burden). Preferably, the hematophagous ectoparasite population size is decreased, optimally to an extent that the animal is no longer bothered by hematophagous ectoparasites. A host animal, as used herein, is an animal from which hematophagous ectoparasites can feed by attaching to and feeding through the skin of the animal. Hematophagous ectoparasites, and other ectoparasites, can live on a host animal for an extended period of time or can attach temporarily to an animal in order to feed. At any given time, a certain percentage of a hematophagous ectoparasite population can be on a host animal whereas the remainder can be in the environment of the animal. Such an environment can include not only adult hematophagous ectoparasites, but also hematophagous ectoparasite eggs and/or hematophagous ectoparasite larvae. The environment can be of any size such that hematophagous ectoparasites in the environment are able to jump onto and off of a host animal. For example, the environment of an animal can include plants, such as crops, from which hematophagous ectoparasites infest an animal. As such, it is desirable not only to reduce the hematophagous ectoparasite burden on an animal per se, but also to reduce the hematophagous ectoparasite burden in the environment of the animal. In one embodiment, an esterase protein of the present invention can elicit an immune response (including a humoral and/or cellular immune response) against a hematophagous ectoparasite. Suitable hematophagous ectoparasites to target include any hematophagous ectoparasite that is essentially incapable of infesting an animal administered an esterase protein of the present invention. As such, a hematophagous ectoparasite to target includes any hematophagous ectoparasite that produces a protein having one or more epitopes that can be targeted by a humoral and/or cellular immune response against an esterase protein of the present invention and/or that can be targeted by a compound that otherwise inhibits esterase activity (e.g., a compound that inhibits hydrolysis of α- napthyl acetate, hydrolysis of the methyl ester group of juvenile hormone, and/or binds to DFP), thereby resulting in the decreased ability of the hematophagous ectoparasite to infest an animal. Preferred hematophagous ectoparasite to target include ectoparasites disclosed herein as being useful in the production of esterase proteins of the present invention. The present invention also includes mimetopes of esterase proteins of the present invention. As used herein, a mimetope of an esterase protein of the present invention refers to any compound that is able to mimic the activity of such a protein (e.g., ability to elicit an immune response against an artliropod esterase protein of the present invention and/or ability to inhibit esterase activity), often because the mimetope has a structure that mimics the esterase protein. It is to be noted, however, that the mimetope need not have a structure similar to an esterase protein as long as the mimetope functionally mimics the protein. Mimetopes can be, but are not limited to: peptides that have been modified to decrease their susceptibility to degradation; anti-idiotypic and/or catalytic antibodies, or fragments thereof; non-proteinaceous immunogenic portions of an isolated protein (e.g., carbohydrate structures); synthetic or natural organic or inorganic molecules, including nucleic acids; and/or any other peptidomimetic compounds. Mimetopes of the present invention can be designed using computer-generated structures of esterase proteins of the present invention. Mimetopes can also be obtained by generating random samples of molecules, such as oligonucleotides, peptides or other organic molecules, and screening such samples by affinity chromatography teclmiques using the corresponding binding partner, (e.g., an esterase substrate, an esterase substrate analog, or an anti-esterase antibody). A preferred mimetope is a peptidomimetic compound that is structurally and/or functionally similar to an esterase protein of the present invention, particularly to the active site of the esterase protein. The present invention also includes mimetopes of esterase proteins of the present invention. As used herein, a mimetope of an esterase protein of the present invention refers to any compound that is able to mimic the activity of such an esterase protein, often because the mimetope has a structure that mimics the esterase protein. Mimetopes can be, but are not limited to: peptides that have been modified to decrease their susceptibility to degradation; anti-idiotypic and/or catalytic antibodies, or fragments thereof; non-proteinaceous immunogenic portions of an isolated protein (e.g., carbohydrate structures); and synthetic or natural organic molecules, including nucleic acids. Such mimetopes can be designed using computer-generated structures of proteins of the present invention. Mimetopes can also be obtained by generating random samples of molecules, such as oligonucleotides, peptides or other organic molecules, and screening such samples by affinity chromatography techniques using the corresponding binding partner. One embodiment of an artliropod esterase protein of the present invention is a fusion protein that includes an arthropod esterase protein-containing domain attached to one or more fusion segments. Suitable fusion segments for use with the present invention include, but are not limited to, segments that can: enhance a protein's stability; act as an immunopotentiator to enhance an immune response against an esterase protein; and/or assist purification of an esterase protein (e.g., by affinity chromatography). A suitable fusion segment can be a domain of any size that has the desired function (e.g., imparts increased stability, imparts increased immunr genicity to a protein, and/or simplifies purification of a protein). Fusion segments can be joined to amino and/or carboxyl termini of the esterase-containing domain of the protein and can be susceptible to cleavage in order to enable straight- forward recovery of an esterase protein. Fusion proteins are preferably produced by culturing a recombinant cell transformed with a fusion nucleic acid molecule that encodes a protein including the fusion segment attached to either the carboxyl and/or amino terminal end of an esterase-containing domain. Preferred fusion segments include a metal binding domain (e.g., a poly- histidine segment); an immunoglobulin binding domain (e.g., Protein A; Protein G; T cell; B cell; Fc receptor or complement protein antibody-binding domains); a sugar binding domain (e.g., a maltose binding domain); and/or a "tag" domain (e.g., at least a portion of β-galactosidase, a strep tag peptide, other domains that can be purified using compounds that bind to the domain, such as monoclonal antibodies). More preferred fusion segments include metal binding domains, such as a poly-histidine segment; a maltose binding domain; a strep tag peptide, such as that available from Biometra in Tampa, FL; and an S10 peptide. Examples of particularly preferred fusion proteins of the present invention include PHIS-PfE6 540 , PHIS-PfE7 275 , PHIS-PfE7 570 , PHIS-PfE8 570 and PHIS-PfE9 528 , production of which are disclosed herein. In another embodiment, an artliropod esterase protein of the present invention also includes at least one additional protein segment that is capable of protecting an animal from hematophagous ectoparasite infestations. Such a multivalent protective protein can be produced by culturing a cell transformed with a nucleic acid molecule comprising two or more nucleic acid domains joined together in such a manner that the resulting nucleic acid molecule is expressed as a multivalent protective compound containing at least two protective compounds, or portions thereof, capable of protecting an animal from hematophagous ectoparasite infestation by, for example, targeting two different artliropod proteins. Examples of multivalent protective compounds include, but are not limited to, an esterase protein of the present invention attached to one or more compounds protective against one or more arthropod compounds. Preferred second compounds are proteinaceous compounds that effect active immunization (e.g., antigen vaccines), passive immunization (e.g., antibodies), or that otherwise inhibit a artliropod activity that when inhibited can reduce hematophagous ectoparasite burden on and around an animal. Examples of second compounds include a compound that inhibits binding between an artliropod protein and its ligand (e.g., a compound that inhibits flea ATPase activity or a compound that inhibits binding of a peptide or steroid hormone to its receptor), a compound that inhibits hormone (including peptide or steroid hormone) synthesis, a compound that inhibits vitellogenesis (including production of vitellin and/or transport and maturation thereof into a major egg yolk protein), a compound that inhibits fat body function, a compound that inhibits muscle action, a compound that inhibits the nervous system, a compound that inhibits the immune system and/or a compound that inhibits hematophagous ectoparasite feeding. Examples of second compounds also include proteins obtained from different stages of hematophagous ectoparasite development. Particular examples of second compounds include, but are not limited to, serine proteases, cysteine proteases, aminopeptidases, serine protease inhibitor proteins, calreticulins, larval serum proteins and echdysone receptors, as well as antibodies to and inhibitors of such proteins. In one embodiment, an artliropod esterase protein of the present invention is attached to one or more additional compounds protective against hematophagous ectoparasite infestation. In another embodiment, one or more protective compounds, such as those listed above, can be included in a multivalent vaccine comprising an artliropod esterase protein of the present invention and one or more other protective molecules as separate compounds. A preferred isolated protein of the present invention is a protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecules nfEl 401 , nfE2 364 , nfE3 42l , nfE4 524 , nfE5ι 982 , nfE5 1515 , nfE5 2144 , nfE5 1650 , nfE6 1488 , nfE6 1792 , nfE6 1650 , nfE7 2836 , nfE7 1788 , nfE7 1710 , nfE7 650 , nfE8 2801 , nfE8ι 785 , nfE8 1710 , nfE9 2007 , nfE9 1584 , nfE9 1540 , nfE10 1987 and/or nfE10 1590 . A further preferred isolated protein is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ TD NO: 17, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:38, SEQ ID NO:52, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:69 and/or SEQ ID NO:71. Translation of SEQ ID NO:l suggests that nucleic acid molecule nfEl 401 encodes a non-full-length arthropod esterase protein of about 103 amino acids, referred to herein as PfEl 103 , represented by SEQ ID NO:2, assuming the first codon spans from nucleotide 92 through nucleotide 94 of SEQ ID NO:l. Comparison of amino acid sequence SEQ ID NO:2 (i.e., the amino acid sequence of PfEl , 03 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:2, showed the most homology, i.e., about 33% identity, between SEQ ID NO:2 and alpha esterase protein from Drosophila melanogaster. Translation of SEQ ID NO:4 suggests that nucleic acid molecule nfE2 364 encodes a non-full-length arthropod esterase protein of about 121 amino acids, referred to herein as Pf£2, 2 ,, represented by SEQ ID NO:5, assuming the first codon spans from nucleotide 2 through nucleotide 4 of SEQ ID NO:4. Comparison of amino acid sequence SEQ ID NO:5 (i.e., the amino acid sequence of PfE2, 21 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:5, showed the most homology, i.e., about 38% identity, between SEQ ID NO:5 and alpha esterase protein from Drosophila melanogaster. Translation of SEQ ID NO:7 suggests that nucleic acid molecule nfE3 421 encodes a non-full-length arthropod esterase protein of about 103 amino acids, referred to herein as Pf£3, 03 , represented by SEQ ID NO:8, assuming the first codon spans from nucleotide 113 through nucleotide 115 of SEQ ID NO:7. Comparison of amino acid sequence SEQ ID NO:8 (i.e., the amino acid sequence of PfE3, 03 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO: 8, showed the most homology, i.e., about 39% identity, between SEQ ID NO:8 and alpha esterase protein from Drosophila melanogaster. Translation of SEQ ID NO: 10 suggests that nucleic acid molecule nfE4 524 encodes a non- full-length arthropod esterase protein of about 137 amino acids, referred to herein as PfE4, 37 , represented by SEQ ID NO: 11 , assuming the first d m spans from nucleotide 113 through nucleotide 115 of SEQ ID NO: 10. Comparison of amino acid sequence SEQ ID NO:l 1 (i.e., the amino acid sequence of PfE4, 37 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:l 1, showed the most homology, i.e., about 30% identity, between SEQ ID NO:l 1 and Leptinotarsa decemlineata acetylcholinesterase. Translation of SEQ ID NO:57 suggests that nucleic acid molecule nfE5 2144 encodes a full-length arthropod esterase protein of about 550 amino acids, referred to herein as PfE5 550 , represented by SEQ ID NO:58, assuming an open reading frame in which the initiation codon spans from nucleotide 30 through nucleotide 32 of SEQ ID NO:57 and the termination (stop) codon spans from nucleotide 1680 through nucleotide 1682 of SEQ ID NO:57. The complement of SEQ ID NO:57 is represented herein by SEQ ID NO:59. The coding region encoding PfE5 550 is represented by the nucleic acid molecule nfE5, 650 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:60 and a complementary strand with nucleic acid sequence SEQ ID NO:61. The deduced amino acid sequence of PfE5 550 (i.e., SEQ ID NO:58) predicts that PfE5 550 has an estimated molecular weight of about 61.8 kD and an estimated pi of about 5.5. Comparison of amino acid sequence SEQ ID NO:58 (i.e., the amino acid sequence of PfE5 550 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:58 showed the most homology, i.e., about 36% identity between SEQ ID NO:58 and Drosophila melanogaster alpha esterase protein. Translation of SEQ ID NO: 18 suggests that nucleic acid molecule nfE6 I792 encodes a full-length artliropod esterase protein of about 550 amino acids, referred to herein as PfE6 550 , represented by SEQ ID NO: 19, assuming an open reading frame having an initiation codon spanning from nucleotide 49 through nucleotide 51 of SEQ ID NO: 18 and a stop codon spanning from nucleotide 1699 through nucleotide 1701 of SEQ ID NO: 18. The coding region encoding PfE6 550 , is represented by nucleic acid molecule nfE6, 650 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:21 and a complementary strand with nucleic acid sequence SEQ ID NO:22. The proposed mature protein, denoted herein as PfE6 530 , contains about 530 amino acids which is represented herein as SEQ ID NO:5 J. The nucleic acid molecule encoding PfE6 530 is denoted herein as nfE6, 590 and has a coding strand having the nucleic acid sequence SEQ ID NO:23. The deduced amino acid sequence SEQ ID NO: 19 suggests a protein having a molecular weight of about 61.8 kD and an estimated pi of about 5.5. Comparison of amino acid sequence SEQ ID NO: 19 (i.e., the amino acid sequence of PfE6 550 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO: 19 showed the most homology, i.e., about 28% identity between SEQ ID NO: 19 and Drosophila melanogaster alpha esterase protein. Translation of SEQ ID NO:24 suggests that nucleic acid molecule nfE7 2836 encodes a full-length arthropod esterase protein of about 596 amino acids, referred to herein as PfE7 596 , represented by SEQ ID NO:25, assuming an open reading frame having an initiation codon spanning from nucleotide 99 through nucleotide 101 of SEQ ID NO:24 and a stop codon spanning from nucleotide 1887 through nucleotide 1889 of SEQ ID NO:24. The coding region encoding PfE7 596 , is represented by nucleic acid molecule nfE7, 788 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:28 and a complementary strand with nucleic acid sequence SEQ ID NO:29. The proposed mature protein, denoted herein as PfE7 570 , contains about 570 amino acids which is represented herein as SEQ ID NO:54. The nucleic acid molecule encoding PfE7 570 is denoted herein as nfE7, 710 and has a coding strand having the nucleic acid sequence SEQ ID NO:27. The deduced amino acid sequence SEQ ID NO:25 suggests a protein having a molecular weight of about 68.7 kD and an estimated pi of about 6.1. Comparison of amino acid sequence SEQ ID NO:25 (i.e., the amino acid sequence of PfE7 596 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:25 showed the most homology, i.e., about 27% identity between SEQ ID NO:25 and Drosophila melanogaster alpha esterase protein. Translation of SEQ ID NO:30 suggests that nucleic acid molecule nfE8 2801 encodes a full-length arthropod esterase protein of about 595 amino acids, referred to herein as PfE8 595 , represented by SEQ ID NO:31, assuming an open reading frame having an initiation codon spanning from nucleotide 99 through nucleotide 101 of SEQ ID NO:30 and a stop codon spanning from nucleotide 1884 through nucleotide 1886 of SEQ ID NO- 30. The coding region encoding PfE8 595 , is represented by nucleic acid molecule nfE8, 785 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:34 and a complementary strand with nucleic acid sequence SEQ ID NO:35. The proposed mature protein, denoted herein as PfE8 570 , contains about 570 amino acids which is represented herein as SEQ ID NO:55. The nucleic acid molecule encoding PfE8 570 is denoted herein as nfE8, 710 and has a coding strand having the nucleic acid sequence SEQ ID NO:33. The deduced amino acid sequence SEQ ID NO:31 suggests a protein having a molecular weight of about 68.6 kD and an estimated pi of about 6.1. Comparison of amino acid sequence SEQ ID NO:31 (i.e., the amino acid sequence of PfE8 595 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:31 showed the most homology, i.e., about 28% identity between SEQ ID NO:31 and estalpha-2 esterase of Culex pipiens quinquefasciatus. Translation of SEQ ID NO:36 suggests that nucleic acid molecule ιιfE9 2007 encodes a full-length arthropod esterase protein of about 528 amino acids, referred to herein as PfE9 528 , represented by SEQ ID NO:37, assuming an open reading frame having an initiation codon spanning from nucleotide 11 through nucleotide 13 of SEQ ID NO:36 and a stop codon spanning from nucleotide 1595 through nucleotide 1597 of SEQ ID NO:36. The coding region encoding PfE9 528 , is represented by nucleic acid molecule nfE9 1584 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:51 and a complementary strand with nucleic acid sequence SEQ ID NO:52. The deduced amino acid sequence SEQ ID NO:37 suggests a protein having a molecular weight of about 60 kD and an estimated pi of about 5.43. Comparison of amino acid sequence SEQ ID NO:37 (i.e., the amino acid sequence of PfE9 528 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:37 showed the most homology, i.e., about 37% identity between SEQ ID NO:37 and alpha esterase protein from Drosophila melanogaster. Translation of SEQ ID NO:67 suggests that nucleic acid molecule nfE10, 987 encodes a full-length flea esterase protein of about 530 amino acids, referred to herein as PfE10 530 , having amino acid sequence SEQ ID NO:68, assuming an open reading frame in which the initiation codon spans from nucleotide 231 through nucleotide 233 of SEQ ID NO:67 and a stop codon spanning from nucleotide 1821 through nucleotide 1823 of SEQ ID NO:67. The complement of SEQ ID NO:67 is represented herein by SEQ ID NO:69. The coding region encoding PfE10 530 , is represented by nucleic acid molecule nfE10, 590 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:70 and a complementary strand with nucleic acid sequence SEQ ID NO:71. The amino acid sequence of PfE10 530 (i.e., SEQ ID NO:68) predicts that PfE10 530 has an estimated molecular weight of about 59.5 kD and an estimated pi of about 5.5. Comparison of amino acid sequence SEQ ID NO:68 (i.e., the amino acid sequence of PfE10 530 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:68 showed the most homology, i.e., about 30% identity between SEQ ID NO:68 and Culexpipens esterase bl precurser protein (swissprot # P16854). More preferred arthropod esterase proteins of the present invention include proteins comprising amino acid sequences that are at least about 40%, preferably at least about 45%o, more preferably at least about 50%, even more preferably at least about 55%), even more preferably at least about 60%, even more preferably at least about 70%), even more preferably at least about 80%, even more preferably at least about 90%>, and even more preferably at least about 95%, identical to amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:l 1, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and/or SEQ ID NO:74. More preferred artliropod esterase proteins of the present invention include proteins encoded by a nucleic acid molecule comprising at least a portion of nfEl 401 , nfE2 364 , nfE3 42 „ nf£4 524 , nfE5, 982 , nfE5, 515 , nfE5 2144 , nfE5 1650 , nfE6, 488 , nfE6 1792 , nfE6 1650 , nfE7 2836 , nfE7, 788 , nfE7, 710 , nfE7 650 , nfE8 280 „ nfE8 1785 , nfE8, 710 , nfE9 2007 , nfE9, 584 , nfE9, 540 , nfE10, 987 and/or nfE10, 590 , or of allelic variants of such nucleic acid molecules. More preferred is an esterase protein encoded by nfEl 401 , nfE2 364 , nfE3 421 , nfE4 524 , nfE5, 9g2 , nfE5, 5 , 5 , nfE5 2 , 44 , nfE5, 650 , nfE6 1488 , nfE6, 792 , nfE6, 650 , nfE7 2836 , nfE7 1788 , nfE7, 7 , 0 , nfE7 650 , nfE8 280 „ nf£8, 785 , nfE8 17I0 , nfE9 2007 , nfE9, 584 , ufF.9 1540 , nfE10 I9 7 and/or nfEl 0, 590 , or by an allelic variant of such nucleic acid molecules. Particularly preferred arthropod esterase proteins are PfEl , 03 , PfE2, 21 , PfE3, 03 , PfE4, 37 , PfE5 5 o 5 , PfE5 550 , PfE6 550 , PfE6 530 , PfE7 596 , PfE7 570 , PfE8 595 , PfE8 570 , PfE9 528 and PfE10 530 . In one embodiment, a preferred esterase protein of the present invention is encoded by at least a portion of SEQ ID NO: 1 , SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:60 and/or SEQ ID NO:67, and, as such, has an amino acid sequence that includes at least a portion of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:l 1, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58 and/or SEQ ID NO:68. Also preferred is a protein encoded by an allelic variant of a nucleic acid molecule comprising at least a portion of the above-listed nucleic acid sequences. Particularly preferred esterase proteins of the present invention include SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:l 1, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and/or SEQ ID NO:74. (including, but not limited to, the proteins consisting of such sequences, fusion proteins and multivalent proteins) and proteins encoded by allelic variants of SEQ ID NO:l, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:60 and/or SEQ ID NO:67. Another embodiment of the present invention is an isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a C felis esterase gene. The identifying characteristics of such a gene are heretofore described. A nucleic acid molecule of the present invention can include an isolated natural arthropod esterase gene or a homolog thereof, the latter cf v hich is described in more detail below. A nucleic acid molecule of the present invention can include one or more regulatory regions, full- length or partial coding regions, or combinations thereof. The minimal size of a nucleic acid molecule of the present invention is the minimal size that can form a stable hybrid with a C. felis esterase gene under stringent hybridization conditions. In accordance with the present invention, an isolated nucleic acid molecule is a nucleic acid molecule that has been removed from its natural milieu (i.e., that has been subject to human manipulation) and can include DNA, RNA, or derivatives of either DNA or RNA. As such, "isolated" does not reflect the extent to which the nucleic acid molecule has been purified. An isolated arthropod esterase nucleic acid molecule of the present invention can be isolated from its natural source or can be produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification, cloning) or chemical synthesis. Isolated esterase nucleic acid molecules can include, for example, natural allelic variants and nucleic acid molecules modified by nucleotide insertions, deletions, substitutions, and/or inversions in a manner such that the modifications do not substantially interfere with the nucleic acid molecule's ability to encode an esterase protein of the present invention or to form stable hybrids under stringent conditions with natural gene isolates. An arthropod esterase nucleic acid molecule homolog can be produced using a number of methods known to those skilled in the art (see, for example, Sambrook et al., ibid.). For example, nucleic acid molecules can be modified using a variety of techniques including, but not limited to, classic mutagenesis and recombinant DNA techniques (e.g., site-directed mutagenesis, chemical treatment, restriction enzyme cleavage, ligation of nucleic acid fragments and/or PCR amplification), synthesis of oligonucleotide mixtures and ligation of mixture groups to "build" a mixture of nucleic acid molecules and combinations thereof. Nucleic acid molecule homologs can be selected by hybridization with a C. felis esterase gene or by screening for the function of a protein encoded by the nucleic acid molecule (e.g., ability to elicit an immune response against at least one epitope of an arthropod esterase protein, hydrolyze α-napthyl acetate, hvdr jlyze the methyl ester group of juvenile hormone and/or bind to DFP). An isolated nucleic acid molecule of the present invention can include a nucleic acid sequence that encodes at least one arthropod esterase protein of the present invention, examples of such proteins being disclosed herein. Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding an arthropod esterase protein. A preferred nucleic acid molecule of the present invention, when administered to an animal, is capable of protecting that animal from infestation by a hematophagous ectoparasite. As will be disclosed in more detail below, such a nucleic acid molecule can be, or can encode, an antisense RNA, a molecule capable of triple helix formation, a ribozyme, or other nucleic acid-based drug compound. In additional embodiments, a nucleic acid molecule of the present invention can encode a protective esterase protein (e.g., an esterase protein of the present invention), the nucleic acid molecule being delivered to the animal, for example, by direct injection (i.e, as a naked nucleic acid) or in a vehicle such as a recombinant virus vaccine or a recombinant cell vaccine. One embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfEl 40 , and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:l and/or SEQ ID NO:3. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE2 364 and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:4 and/or SEQ ID NO:6. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE3 2 , and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:7 and/or SEQ ID NO:9. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE4 524 and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO: 10 and/or SEQ ID NO: 12. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE5 2144 and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:57 and/or SEQ ID NO:59. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE6, 792 and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO: 18 and/or SEQ ID NO:20. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE7 2836 and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:24 and/or SEQ ID NO:26. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE8 280 , and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:30 and/or SEQ ID NO:32. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE9 2007 and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:36 and/or SEQ ID NO:38. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE10, 987 and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:67 and/or SEQ ID NO:69. Comparison of nucleic acid sequence SEQ ID NO:l (i.e., the nucleic acid sequence of nfEl 401 ) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:l showed no identifiable identity with anv sequence reported in GenBank. Comparison of nucleic acid sequence SEQ ID NO:4 (i.e., the coding strand of nucleic acid sequence of nfE2 364 ) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:4 showed the most homolog, i.e., about 43% identity, between SEQ ID NO:4 and a H. virescens juvenile hormone esterase gene. Comparison of nucleic acid sequence SEQ ID NO:7 (i.e., the coding strand of nucleic acid sequence of nfE3 421 ) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:7 showed the most homolog, i.e., about 53% identity, between SEQ ID NO:7 and a Torpedo marmorata acetylcholinesterase gene. Comparison of nucleic acid sequence SEQ ID NO: 10 (i.e., the coding strand of nucleic acid sequence of nf£4 524 ) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO: 10 showed the most homolog, i.e., about 47% identity, between SEQ ID NO: 10 and an Anas platyrhyncos thioesterase B gene. Comparison of nucleic acid sequence SEQ ID NO:57 (i.e., the coding strand of nucleic acid sequence of nfE5 2144 ) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:57 showed the most homolog, i.e., about 41% identity, between SEQ ID NO:57 and a esterase mRNA from Myzus persicae. Comparison of nucleic acid sequence SEQ ID NO: 18 (i.e., the coding strand of nucleic acid sequence of nfE6, 792 ) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO: 18 showed the most homolog, i.e., about 41% identity, between SEQ ID NO: 18 and a esterase gene from Myzus persicae. Comparison of nucleic acid sequence SEQ ID NO:24 (i.e., the coding strand of nucleic acid sequence of nfE7 2836 ) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:24 showed the most homolog, i.e., about 48% identity, between SEQ ID NO:24 and an Anas platychyncos thioesterase B gene. Comparison of nucleic acid sequence SEQ ID NO:30 (i.e., the coding strand of nucleic acid sequence of nfE8 2g01 ) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:30 showed the most homolog, i.e., about 46% identity, between SEQ ID NO:30 and a Mus musculus carboxyl ester lipase gene. Comparison of nuc:eic acid sequence SEQ ID NO:36 (i.e., the coding strand of nucleic acid sequence of nfE9 2007 ) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:36 showed the most homolog, i.e., about 47% identity, between SEQ ID NO:36 and a hamster mRNA for CE precursor gene. Comparison of nucleic acid sequence SEQ ID NO:67 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:67 showed the most homology, i.e., about 48%> identity, between SEQ ID NO:67 and a Lucilia cuprina alpha esterase gene (genembl # U56636) gene. Preferred arthropod esterase nucleic acid molecules include nucleic acid molecules having a nucleic acid sequence that is at least about 55%, preferably at least about 60%, more preferably at least about 65%, more preferably at least about 70%, more preferably at least about 75%, more preferably at least about 80%, more preferably at least about 90%>, and even more preferably at least about 95% identical to nucleic acid sequence SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO: 76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74. Another preferred nucleic acid molecule of the present invention includes at least a portion of nucleic acid sequence SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID > NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74, that is capable of hybridizing to a C. felis esterase gene of the present invention, as well as allelic variants thereof. A more preferred nucleic acid molecule includes the nucleic acid sequence SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO: 16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO: 74, as well as allelic variants thereof. Such nucleic acid molecules can include nucleotides in addition to those included in the SEQ ID NOs, such as, but not limited to, a full-length gene, a full- length coding region, a nucleic acid molecule encoding a fusion protein, or a nucleic acid molecule encoding a multivalent protective compound. Particularly preferred nucleic acid molecules include nfEl 401 , nfE2 364 , nfE3 421 , nfE4 524 , nfE5, 982 , nfE5 1515 , nfE5 2144 , nfE5, 650 , nfE6, 488 , nfE6 1792 , nfE6, 65 o, nfE7 2836 , nfE7 1788 , nfE7, 710 , nfE7 650 , nfE8 2g0 ,, nfE8, 785 , nfE8 I7 , 0 , nfE9 2007 , nfE9 1584 , nfE9 1540 , nfE10 1987 and nfE10, 590 . The present invention also includes a nucleic acid molecule encoding a protein having at least a portion of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 , SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and/or SEQ ID NO:74, including nucleic acid molecules that have been modified to accommodate codon usage properties of the cells in which such nucleic acid molecules are to be expressed. Knowing the nucleic acid sequences of certain arthropod esterase nur e' acid molecules of the present invention allows one skilled in the art to, for example, (a) make copies of those nucleic acid molecules, (b) obtain nucleic acid molecules including at least a portion of such nucleic acid molecules (e.g., nucleic acid molecules including full-length genes, full-length coding regions, regulatory control sequences, truncated coding regions), and (c) obtain esterase nucleic acid molecules from other artliropods. Such nucleic acid molecules can be obtained in a variety of ways including screening appropriate expression libraries with antibodies of the present invention; traditional cloning techniques using oligonucleotide probes of the present invention to screen appropriate libraries or DNA; and PCR amplification of appropriate libraries or DNA using oligonucleotide primers of the present invention. Preferred libraries to screen or from which to amplify nucleic acid molecule include flea pre-pupal, 3rd instar or adult cDNA libraries as well as genomic DNA libraries. Similarly, preferred DNA sources to screen or from which to amplify nucleic acid molecules include flea pre-pupal, 3rd instar or adult cDNA and genomic DNA. Techniques to clone and amplify genes are disclosed, for example, in Sambrook et al, ibid. The present invention also includes nucleic acid molecules that are oligonucleotides capable of hybridizing, under stringent hybridization conditions, with complementary regions of other, preferably longer, nucleic acid molecules of the present invention such as those comprising arthropod esterase genes or other arthropod esterase nucleic acid molecules. Oligonucleotides of the present invention can be RNA, DNA, or derivatives of either. The minimum size of such oligonucleotides is the size required for formation of a stable hybrid between an oligonucleotide and a complementary sequence on a nucleic acid molecule of the present invention. Minimal size characteristics are disclosed herein. The present invention includes oligonucleotides that can be used as, for example, probes to identify nucleic acid molecules, primers to produce nucleic acid molecules or therapeutic reagents to inhibit esterase protein production or activity (e.g., as antisense-, triplex formation-, ribozyme- and/or RNA drug-based reagents). The present invention also includes the use of such oligonucleotides to protect animals from disease using one or more of such technologies. Appropriate oligonucleotide-containing therapeutic compositions can be administered to an animal using techniques known to those skilled in the art. One embodiment of the present invention includes a recombinant vector, which includes at least one isolated nucleic acid molecule of the present invention, inserted into any vector capable of delivering the nucleic acid molecule into a host cell. Such a vector contains heterologous nucleic acid sequences, that is nucleic acid sequences that are not naturally found adjacent to nucleic acid molecules of the present invention and that preferably are derived from a species other than the species from which the nucleic acid molecule(s) are derived. The vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a virus or a plasmid. Recombinant vectors can be used in the cloning, sequencing, and/or otherwise manipulation of artliropod esterase nucleic acid molecules of the present invention. One type of recombinant vector, referred to herein as a recombinant molecule, comprises a nucleic acid molecule of the present invention operatively linked to an expression vector. The phrase operatively linked refers to insertion of a nucleic acid molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell. As used herein, an expression vector is a DNA or RNA vector that is capable of transforming a host cell and of effecting expression of a specified nucleic acid molecule. Preferably, the expression vector is also capable of replicating within the host cell. Expression vectors can be either prokaryotic or eukaryotic, and are typically viruses or plasmids. Expression vectors of the present invention include any vectors that function (i.e., direct gene expression) in recombinant cells of the present invention, including in bacterial, fungal, endoparasite, insect, other animal, and plant cells. Preferred expression vectors of the present invention can direct gene expression in bacterial, yeast, insect and mammalian cells and more preferably in the cell types disclosed herein. In particular, expression vectors of the present invention contain regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell and that control the expression of nucleic acid molecules of the present invention. In particular, recombinant molecules of the present invention include transcription control sequences. Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences. Suitable transcription control sequences include any transcription control sequence that can function in at least one of the recombinant cells of the present invention. A variety of such transcription control sequences are known to those skilled in the art. Preferred transcription control sequences include those which function in bacterial, yeast, insect and mammalian cells, such as, but not limited to, tac, lac, trp, trc, oxy-pro, omp/lpp, rrnB, bacteriophage lambda(such as lambda p L and lambda p R and fusions that include such promoters), bacteriophage T7, lilac, bacteriophage T3, bacteriophage SP6, bacteriophage SP01, metallothionein, alpha-mating factor, Pichia alcohol oxidase, alphavirus subgenomic promoters (such as Sindbis virus subgenomic promoters), antibiotic resistance gene, baculovirus, Heliothis zea insect virus, vaccinia virus, herpesvirus, raccoon poxvirus, other poxvirus, adenovirus, cytomegalovirus (such as intermediate early promoters), simian virus 40, retrovirus, actin, retroviral long terminal repeat, Rous sarcoma virus, heat shock, phosphate and nitrate transcription control sequences as well as other sequences capable of controlling gene expression in prokaryotic or eukaryotic cells. Additional suitable transcription control sequences include tissue-specific promoters and enhancers as well as lymphokine-inducible promoters (e.g., promoters inducible by interferons or interleukins). Transcription control sequences of the present invention can also include naturally occurring transcription control sequences naturally associated with arthropods, such as, C. felis. Suitable and preferred nucleic acid molecules to include in recombinant vectors of the present invention are as disclosed herein. Preferred nucleic acid molecules to include in recombinant vectors, and particularly in recombinant molecules, include nfEl 40 „ nfE2 364 , nfE3 42 „ nfE4 524 , nfE5 1982 , nfE5 1515 , nf£5 2144 , nfE5 !650 , nfE6, 488 , nfE6, 792 , nfE6, 650 , nfE7 2836 , nfE7 1788 , nfE7 I710 , nfE7 650 , nfE8 280 „ nfE8, 785 , nfE8 1710 , nfE9 2007 , nfE9 1584 , nfE9, 54 o, nfE10, 987 and/or nfE10, 590 . Particularly preferred recombinant molecules of the present invention include pCro-nfE6, 488 , pTrc-nfE7 650 , pTrc-nfE7, 710 , pTrc-nfE8, 710ι pTrc-nfE5, 65 o, pTrc-nfE9, 540 , pFB-nfE6, 679 , pVL-nfE7, 80 , pVL-fE8 1792 and pVL-nfE9, 60 o, the production of which are described in the Examples section. Recombinant molecules of the present invention may also (a) contain secretory signals (i.e., signal segment nucleic acid sequences) to enable an expressed artliropod protein of the present invention to be secreted from the cell that produces the protein and/or (b) contain fusion sequences which lead to the expression of nucleic acid molecules of the present invention as fusion proteins. Examples of suitable signal segments include any signal segment capable of directing the secretion of a protein of the present invention. Preferred signal segments include, but are not limited to, tissue plasminogen activator (t-PA), interferon, interleukin, growth hormone, histocompatibility and viral envelope glycoprotein signal segments, as well as natural signal sequences. Suitable fusion segments encoded by fusion segment nucleic acids are disclosed herein. In addition, a nucleic acid molecule of the present invention can be joined to a fusion segment that directs the encoded protein to the proteosome, such as a ubiquitin fusion segment. Recombinant molecules may also include intervening and/or untranslated sequences surrounding and/or within the nucleic acid sequences of nucleic acid molecules of the present invention. Another embodiment of the present invention includes a recombinant cell comprising a host cell transformed with one or more recombinant molecules of the present invention. Transformation of a nucleic acid molecule into a cell can be accomplished by any method by which a nucleic acid molecule can be inserted into the cell. Transformation techniques include, but are not limited to, transfection, electroporation, microinjection, lipofection, adsoφtion, and protoplast fusion. A recombinant cell may remain unicellular or may grow into a tissue, organ or a multicellular organism. Transformed nucleic acid molecules of the present invention can remain extrachromosomal or can integrate into one or more sites within a chromosome of the transformed (i.e., recombinant) cell in such a manner that their ability to be expressed is retained. Preferred nucleic acid molecules with which to transform a cell include arthropod esterase nucleic acid molecules disclosed herein. Particularly preferred nucleic acid molecules with which to transfo -m a cell include nfEl 40 „ nfE2 364 , nfE3 42 „ nfE4 524 , nfE5, 982 , nfE5 1515 , nfE5 2144 , nfE5, 650 , nfE6, 488 , nfE6 !792 , nfE6 1650 , nfE7 2g36 , nfE7 I788 , nfE7 I710 , nfE7 650 , nfE8 280 „ nfE8, 785 , nfE8, 710 , nfE9 2007 , nfE9 1584 , nfE9, 54 o, nfE10, 987 and/or nfE10, 59 o. Suitable host cells to transform include any cell that can be transformed with a nucleic acid molecule of the present invention. Host cells can be either untransfomied cells or cells that are already transformed with at least one nucleic acid molecule (e.g., nucleic acid molecules encoding one or more proteins of the present invention and/or other proteins useful in the production of multivalent vaccines). Host cells of the present invention either can be endogenously (i.e., naturally) capable of producing arthropod esterase proteins of the present invention or can be capable of producing such proteins after being transformed with at least one nucleic acid molecule of the present invention. Host cells of the present invention can be any cell capable of producing at least one protein of the present invention, and include bacterial, fungal (including yeast), parasite, other insect, other animal and plant cells. Preferred host cells include bacterial, mycobacterial, yeast, insect and mammalian cells. More preferred host cells include Salmonella, Escherichia, Bacillus, Listeria, Saccharomyces, Spodoptera, Mycobacteria, Trichoplusia, BHK (baby hamster kidney) cells, MDCK cells (normal dog kidney cell line for canine herpesvirus cultivation), CRFK cells (normal cat kidney cell line for feline herpesvirus cultivation), CV-1 cells (African monkey kidney cell line used, for example, to culture raccoon poxvirus), COS (e.g., COS-7) cells, and Vero cells. Particularly preferred host cells are Escherichia coli, including E. coli K-12 derivatives; Salmonella typhi; Salmonella typhimurium, including attenuated strains such as UK-1 x 3987 and SR-11 x 4072; Spodoptera frugiperda; Trichoplusia ni; BHK cells; MDCK cells; CRFK cells; CV-1 cells; COS cells; Vero cells; and non-tumorigenic mouse myoblast G8 cells (e.g., ATCC CRL 1246). Additional appropriate mammalian cell hosts include other kidney cell lines, other fibroblast cell lines (e.g., human, murine or chicken embryo fibroblast cell lines), myeloma cell lines, Chinese hamster ovary cells, mouse NIH/3T3 cells, LMTK 31 cells and/or HeLa cells. In one embodiment, the proteins may be expressed as heterologous proteins in myeloma cell lines employing immunoglobulin promoters. A recombinant cell is preferably produced by transforming a host cell with one or more recombinant molecules, each comprising one or more nucleic acid molecules of the present invention operatively linked to an expression vector containing one or more transcription control sequences. The phrase operatively linked refers to insertion of a nucleic acid molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell. A recombinant molecule of the present invention is a molecule that can include at least one of any nucleic acid molecule heretofore described operatively linked to at least one of any transcription control sequence capable of effectively regulating expression of the nucleic acid molecule(s) in the cell to be transformed, examples of which are disclosed herein. Particularly preferred recombinant molecules include pCro-nfE6, 88 , pTrc-nfE7 650 , pTrc-nfE7 1710 , pTrc-nfE8, 7I0 , pTrc-nfE5 1650 , pTrc-nfE9 1540 , pFB-nfE6 1679 , pVL-nfE7, 802 , pVL-fE8 1792 and pVL-nfE9, 600 . A recombinant cell of the present invention includes any cell transformed with at least one of any nucleic acid molecule of the present invention. Suitable and preferred nucleic acid molecules as well as suitable and preferred recombinant molecules with which to transform cells are disclosed herein. Particularly preferred recombinant cells include E. co//:pCro-nfE6, 488 , E. co//:pTrc-nfE7, 7 , 0 , E co// ' :pTrc-nfE7 650 , E. col .pTrc- nfE8 1710 , E. co/ :pTrc-nfE5 1650 , E. co//:pTrc-nfE9, 540 , S. frugiperda:pYL-nϊE7 m2 , S. frugipei"da:pV -nfE8 J92 , S. frugiperda:pVL-nfE9 ιm and S. frugiperda:pFB-nfE6 ](ll ,. Details regarding the production of these recombinant cells are disclosed herein. Recombinant cells of the present invention can also be co-transformed with one or more recombinant molecules including arthropod esterase nucleic acid molecules encoding one or more proteins of the present invention and one or more other nucleic acid molecules encoding other protective compounds, as disclosed herein (e.g., to produce multivalent vaccines). Recombinant DNA technologies can be used to improve expression of transformed nucleic acid molecules by manipulating, for example, the number of copies of the ni cleic acid m ecules within a host cell, the efficiency with which those nucleic acid molecules are transcribed, the efficiency with which the resultant transcripts are translated, and the efficiency of post-translational modifications. Recombinant techniques useful for increasing the expression of nucleic acid molecules of the present invention include, but are not limited to, operatively linking nucleic acid molecules to high-copy number plasmids, integration of the nucleic acid molecules into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals (e.g., ribosome binding sites, Shine-Dalgarno sequences), modification of nucleic acid molecules of the present invention to correspond to the codon usage of the host cell, deletion of sequences that destabilize transcripts, and use of control signals that temporally separate recombinant cell growth from recombinant enzyme production during fermentation. The activity of an expressed recombinant protein of the present invention may be improved by fragmenting, modifying, or derivatizing nucleic acid molecules encoding such a protein. Isolated esterase proteins of the present invention can be produced in a variety of ways, including production and recovery of natural proteins, production and recovery of recombinant proteins, and chemical synthesis of the proteins. In one embodiment, an isolated protein of the present invention is produced by culturing a cell capable of expressing the protein under conditions effective to produce the protein, and recovering the protein. A preferred cell to culture is a recombinant cell of the present invention. Effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production. An effective medium refers to any medium in which a cell is cultured to produce an arthropod esterase protein of the present invention. Such medium typically comprises an aqueous medium having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. Cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are within the expertise of one of ordinary skill in the art. Examples of suitable conditions are included in the Examples section. Depending on the vector and host system used for production, resultant proteins of the present invention may either remain within the recombinant cell; be secreted into the fermentation medium; be secreted into a space between two cellular membranes, such as the periplasmic space in E. coli; or be retained on the outer surface of a cell or viral membrane. The phrase "recovering the protein", as well as similar phrases, refers to collecting the whole fermentation medium containing the protein and need not imply additional steps of separation or purification. Proteins of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization. Proteins of the present invention are preferably retrieved in "substantially pure" form. As used herein, "substantially pure" refers to a purity that allows for the effective use of the protein as a therapeutic composition or diagnostic. A therapeutic composition for animals, for example, should exhibit no substantial toxicity and preferably should be capable of stimulating the production of antibodies in a treated animal. The present invention also includes isolated (i.e., removed from their natural milieu) antibodies that selectively bind to an arthropod esterase protein of the present invention or a mimetope thereof (i.e., anti-arthropod esterase antibodies). As used herein, the term "selectively binds to" an esterase protein refers to the ability of antibodies of the present invention to preferentially bind to specified proteins and mimetopes thereof of the present invention. Binding can be measured using a variety of methods standard in the art including enzyme immunoassays (e.g., ELISA), immunoblot assays, etc.; see, for example, Sambrook et al., ibid. An anti-arthropod esterase antibody preferably selectively binds to an arthropod esterase protein in such a way as to reduce the activity of that protein. Isolated antibodies of the present invention can include antibodies in a bodily fluid (such as, but not limited to, serum), or antibodies tha f hr ve been purified to varying degrees. Antibodies of the present invention can be polyclonal or monoclonal, functional equivalents such as antibody fragments and genetically-engineered antibodies, including single chain antibodies or chimeric antibodies that can bind to more than one epitope. A preferred method to produce antibodies of the present invention includes (a) administering to an animal an effective amount of a protein, peptide or mimetope thereof of the present invention to produce the antibodies and (b) recovering the antibodies. In another method, antibodies of the present invention are produced recombinantly using techniques as heretofore disclosed to produce arthropod esterase proteins of the present invention. Antibodies raised against defined proteins or mimetopes can be advantageous because such antibodies are not substantially contaminated with antibodies against other substances that might otherwise cause interference in a diagnostic assay or side effects if used in a therapeutic composition. Antibodies of the present invention have a variety of potential uses that are within the scope of the present invention. For example, such antibodies can be used (a) as therapeutic compounds to passively immunize an animal in order to protect the animal from artliropods susceptible to treatment by such antibodies and/or (b) as tools to screen expression libraries and/or to recover desired proteins of the present invention from a mixture of proteins and other contaminants. Furthermore, antibodies of the present invention can be used to target cytotoxic agents to hematophagous ectoparasites such as those discloses herein, in order to directly kill such hematophagous ectoparasites. Targeting can be accomplished by conjugating (i.e., stably joining) such antibodies to the cytotoxic agents using techniques known to those skilled in the art. Suitable cytotoxic agents are known to those skilled in the art. One embodiment of the present invention is a therapeutic composition that, when administered to an animal in an effective manner, is capable of protecting that animal from infestation by hematophagous ectoparasite. Therapeutic compositions of the present invention include at least one of the following protective compounds: an isolated hematophagous artliropod esterase protein (including a peptide); a mimetope of such a protein; an isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis esterase gene; an isolated antibody that selectively binds to an hematophagous arthropod esterase protein; and inhibitors of hematophagous arthropod esterase activity (including esterase substrate analogs). As used herein, a protective compound refers to a compound that, when administered to an animal in an effective manner, is able to treat, ameliorate, and/or prevent disease caused by an arthropod of the present invention. Preferred arthropods to target are heretofore disclosed. Examples of proteins, nucleic acid molecules, antibodies and inhibitors of the present invention are disclosed herein. A preferred therapeutic composition of the present invention includes at least one of the following protective compounds: an isolated hematophagous ectoparasite carboxylesterase protein (including a peptide); a mimetope of such a protein; an isolated hematophagous ectoparasite carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene; an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein; and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase (including a substrate analog). Suitable inhibitors of esterase activity are compounds that interact directly with an esterase protein's active site, thereby inhibiting that esterase's activity, usually by binding to or otherwise interacting with or otherwise modifying the esterase's active site. Esterase inhibitors can also interact with other regions of the esterase protein to inhibit esterase activity, for example, by allosteric interaction. Inhibitors of esterases are usually relatively small compounds and as such differ from anti-esterase antibodies. Preferably, an esterase inhibitor of the present invention is identified by its ability to bind to, or otherwise interact with, a flea esterase protein, thereby inhibiting the activity of the flea esterase. Esterase inhibitors can be used directly as compounds in compositions of the present invention to treat animals as long as such compounds are not harmful to host animals being treated. Esterase inhibitors can also be used to identify preferred types of arthropod esterases to target using compositions of the present invention, for example by affinity chromatography. Preferred esterase inhibitors of the present invention include, but are not limited to, flea esterase substrate analogs, and other molecules that bind to a flea esterase (e.g., to an allosteric site) in such a manner that esterase activity of the flea esterase is inhibited; examples include, but are not limited to, juvenile hormone analogs and cholinesterase inhibitors as well as other neural transmission inhibitors. An esterase substrate analog refers to a compound that interacts with (e.g., binds to, associates with, modifies) the active site of an esterase protein. A preferred esterase substrate analog inhibits esterase activity. Esterase substrate analogs can be of any inorganic or organic composition, and, as such, can be, but are not limited to, peptides, nucleic acids, and peptidomimetic compounds. Esterase substrate analogs can be, but need not be, structurally similar to an esterase's natural substrate as long as they can interact with the active site of that esterase protein. Esterase substrate analogs can be designed using computer-generated structures of esterase proteins of the present invention or computer structures of esterases' natural substrates. Substrate analogs can also be obtained by generating random samples of molecules, such as oligonucleotides, peptides, peptidomimetic compounds, or other inorganic or organic molecules, and screening such samples by affinity chromatography teclmiques using the corresponding binding partner, (e.g., a flea esterase). A preferred esterase substrate analog is a peptidomimetic compound (i.e., a compound that is structurally and/or functionally similar to a natural substrate of an esterase of the present invention, particularly to the region of the substrate that interacts with the esterase active site, but that inhibits esterase activity upon interacting with the esterase active site). Esterase peptides, mimetopes and substrate analogs, as well as other protective compounds, can be used directly as compounds in compositions of the present invention to treat animals as long as such compounds are not harmful to the animals being treated. The present invention also includes a therapeutic composition comprising at least one arthropod esterase-based compound of the present invention in combination with at least one additional compound protective against hematophagous ectoparasite infestation. Examples of such compounds are disclosed herein. In one embodiment, a therapeutic composition of the present invention c n '.e used to protect an animal from hematophagous ectoparasite infestation by administering such composition to a hematophagous ectoparasite, such as to a flea, in order to prevent infestation. Such administration could be oral, or by application to the environment (e.g., spraying). Examples of such compositions include, but are not limited to, transgenic vectors capable of producing at least one therapeutic composition of the present invention. In another embodiment, a hematophagous ectoparasite, such as a flea, can ingest therapeutic compositions, or products thereof, present in the blood of a host animal that has been administered a therapeutic composition of the present invention. Compositions of the present invention can be administered to any animal susceptible to hematophagous ectoparasite infestation (i.e., a host animal), including warm-blooded animals. Preferred animals to treat include mammals and birds, with cats, dogs, humans, cattle, chinchillas, ferrets, goats, mice, minks, rabbits, raccoons, rats, sheep, squirrels, swine, chickens, ostriches, quail and turkeys as well as other furry animals, pets, zoo animals, work animals and/or food animals, being more preferred. Particularly preferred animals to protect are cats and dogs. In accordance with the present invention, a host animal (i.e., an animal that is or is capable of being infested with a hematophagous ectoparasite) is treated by administering to the animal a therapeutic composition of the present invention in such a manner that the composition itself (e.g., an esterase inhibitor, an esterase synthesis suppressor (i.e., a compound that decreases the production of esterase in the hematophagous ectoparasite), an esterase mimetope, or an anti-esterase antibody) or a product generated by the animal in response to administration of the composition (e.g., antibodies produced in response to administration of an arthropod esterase protein or nucleic acid molecule, or conversion of an inactive inhibitor "prodrug" to an active esterase inhibitor) ultimately enters the hematophagous ectoparasite. A host animal is preferably treated in such a way that the compound or product thereof enters the blood stream of the animal. Hematophagous ectoparasites are then exposed to the composition or product when they feed from the animal. For example, flea esterase inhibitors administered to an animal are administered in such a way that the inhibitors enter the blood stream of the animal, where they can be taken αp by feeding fleas. In another embodiment, when a host animal is administered an arthropod esterase protein or nucleic acid molecule, the treated animal mounts an immune response resulting in the production of antibodies against the esterase (i.e., anti-esterase antibodies) which circulate in the animal's blood stream and are taken up by hematophagous ectoparasites upon feeding. Blood taken up by hematophagous ectoparasites enters the hematophagous ectoparasites where compounds of the present invention, or products thereof, such as anti-esterase antibodies, esterase inhibitors, esterase mimetopes and/or esterase synthesis suppressors, interact with, and reduce esterase activity in the hematophagous ectoparasite. The present invention also includes the ability to reduce larval hematophagous ectoparasite infestation in that when hematophagous ectoparasites feed from a host animal that has been administered a therapeutic composition of the present invention, at least a portion of compounds of the present invention, or products thereof, in the blood taken up by the hematophagous ectoparasite are excreted by the hematophagous ectoparasite in feces, which is subsequently ingested by hematophagous ectoparasite larvae. In particular, it is of note that flea larvae obtain most, if not all, of their nutrition from flea feces. In accordance with the present invention, reducing esterase activity in a hematophagous ectoparasite can lead to a number of outcomes that reduce hematophagous ectoparasite burden on treated animals and their surrounding environments. Such outcomes include, but are not limited to, (a) reducing the viability of hematophagous ectoparasites that feed from the treated animal, (b) reducing the fecundity of female hematophagous ectoparasites that feed from the treated animal, (c) reducing the reproductive capacity of male hematophagous ectoparasites that feed from the treated animal, (d) reducing the viability of eggs laid by female hematophagous ectoparasites that feed from the treated animal, (e) altering the blood feeding behavior of hematophagous ectoparasites that feed from the treated animal (e.g., hematophagous ectoparasites take up less volume per feeding or feed less frequently), (f) reducing the viability of hematophagous ectoparasite larvae, for example due to the feeding of larvae from feces of hemator hagous ectoparasites that feed from the treated animal and/or (g) altering the development of hematophagous ectoparasite larvae (e.g., by decreasing feeding behavior, inhibiting growth, inhibiting (e.g., slowing or blocking) molting, and/or otherwise inhibiting maturation to adults). Therapeutic compositions of the present invention also include excipients in which protective compounds are formulated. An excipient can be any material that the animal to be treated can tolerate. Examples of such excipients include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Nonaqueous vehicles, such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used. Other useful formulations include suspensions containing viscosity enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservatives include thimerosal or o-cresol, formalin and benzyl alcohol. Standard formulations can either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection. Thus, in a non-liquid formulation, the excipient can comprise dextrose, human serum albumin, dog serum albumin, cat serum albumin, preservatives, etc., to which sterile water or saline can be added prior to administration. In one embodiment of the present invention, a therapeutic composition can include an adjuvant. Adjuvants are agents that are capable of enhancing the immune response of an animal to a specific antigen. Suitable adjuvants include, but are not limited to, cytokines, chemokines, and compounds that induce the production of cytokines and chemokines (e.g., granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), colony stimulating factor (CSF), erythropoietin (EPO), interleukin 2 (IL-2), interleukin-3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12), interferon gamma, interferon gamma inducing factor I (IGIF), transforming growth factor beta, RANTES (regulated upon activation, normal T cell expressed and presumably secreted), macrophage inflammatory proteins (e.g., MIP-1 alpha and MIP-1 beta), and Leishmania elongation initiating factor (LEIF); bacterial components (e.g., endotoxins, in particular superantigens, exotoxins and cell wall components); aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins, viral coat proteins; block copolymer adjuvants (e.g., Hunter's Titermax™ adjuvant (Vaxcel™, Inc. Norcross, GA), Ribi adjuvants (Ribi ImmunoChem Research, Inc., Hamilton, MT); and saponins and their derivatives (e.g., Quil A (Superfos Biosector A/S, Denmark). Protein adjuvants of the present invention can be delivered in the form of the protein themselves or of nucleic acid molecules encoding such proteins using the methods described herein. In one embodiment of the present invention, a therapeutic composition can include a carrier. Carriers include compounds that increase the half-life of a therapeutic composition in the treated animal. Suitable carriers include, but are not limited to, polymeric controlled release vehicles, biodegradable implants, liposomes, bacteria, viruses, other cells, oils, esters, and glycols. One embodiment of the present invention is a controlled release formulation that is capable of slowly releasing a composition of the present invention into an animal. As used herein, a controlled release formulation comprises a composition of the present invention in a controlled release vehicle. Suitable controlled release vehicles include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, and transdermal delivery systems. Other controlled release formulations of the present invention include liquids that, upon administration to an animal, form a solid or a gel in situ. Preferred controlled release formulations are biodegradable (i.e., bioerodible). A preferred controlled release formulation of the present invention is capable of releasing a composition of the present invention into the blood of an animal at a constant rate sufficient to attain therapeutic dose levels of the composition to protect an animal from hematophagous ectoparasite infestation. The therapeutic composition is preferably released over a period of time ranging from about 1 to about 12 months. A preferred controlled release formulation of the present invention is capable of effr ~t' ig a treatment preferably for at least about 1 month, more preferably for at least about 3 months, even more preferably for at least about 6 months, even more preferably for at least about 9 months, and even more preferably for at least about 12 months. Acceptable protocols to administer therapeutic compositions of the present invention in an effective manner include individual dose size, number of doses, frequency of dose administration, and mode of administration. Determination of such protocols can be accomplished by those skilled in the art. A suitable single dose is a dose that is capable of protecting an animal from disease when administered one or more times over a suitable time period. For example, a preferred single dose of a protein, mimetope or antibody therapeutic composition is from about 1 microgram (μg) to about 10 milligrams (mg) of the therapeutic composition per kilogram body weight of the animal. Booster vaccinations can be administered from about 2 weeks to several years after the original administration. Booster administrations preferably are administered when the immune response of the animal becomes insufficient to protect the animal from disease. A preferred administration schedule is one in which from about 10 μg to about 1 mg of the therapeutic composition per kg body weight of the animal is administered from about one to about two times over a time period of from about 2 weeks to about 12 months. Modes of administration can include, but are not limited to, subcutaneous, intradermal, intravenous, intranasal, oral, transdermal, intraocular and intramuscular routes. According to one embodiment, a nucleic acid molecule of the present invention can be administered to an animal in a fashion to enable expression of that nucleic acid molecule into a protective protein or protective RNA (e.g., antisense RNA, ribozyme, triple helix forms or RNA drug) in the animal. Nucleic acid molecules can be delivered to an animal in a variety of methods including, but not limited to, (a) administering a naked (i.e., not packaged in a viral coat or cellular membrane) nucleic acid vaccine (e.g., as naked DNA or RNA molecules, such as is taught, for example in Wolff et al, 1990, Science 247, 1465-1468) or (b) administering a nucleic acid molecule packaged as a recombinant virus vaccine or as a recombinant cell vaccine (i.e., the nucleic acid molecule is delivered by a viral or cellular \ ehicle). A naked nucleic acid vaccine of the present invention includes a nucleic acid molecule of the present invention and preferably includes a recombinant molecule of the present invention that preferably is replication, or otherwise amplification, competent. A naked nucleic acid vaccine of the present invention can comprise one or more nucleic acid molecules of the present invention in the form of, for example, a bicistronic recombinant molecule having, for example one or more internal ribosome entry sites. Preferred naked nucleic acid vaccines include at least a portion of a viral genome (i.e., a viral vector). Preferred viral vectors include those based on alphaviruses, poxviruses, adenoviruses, heφesviruses, and retroviruses, with those based on alphaviruses (such as Sindbis or Semliki virus), species-specific heφesviruses and species-specific poxviruses being particularly preferred. Any suitable transcription control sequence can be used, including those disclosed as suitable for protein production. Particularly preferred transcription control sequence include cytomegalovirus intermediate early (preferably in conjunction with Intron-A), Rous Sarcoma Virus long terminal repeat, and tissue- specific transcription control sequences, as well as transcription control sequences endogenous to viral vectors if viral vectors are used. The incoφoration of "strong" poly(A) sequences are also preferred. Naked nucleic acid vaccines of the present invention can be administered in a variety of ways, with intramuscular, subcutaneous, intradermal, transdermal, intranasal and oral routes of administration being preferred. A preferred single dose of a naked nucleic acid vaccines ranges from about 1 nanogram (ng) to about 100 μg, depending on the route of administration and/or method of delivery, as can be determined by those skilled in the art. Suitable delivery methods include, for example, by injection, as drops, aerosolized and/or topically. Naked DNA of the present invention can be contained in an aqueous excipient (e.g., phosphate buffered saline) alone or a carrier (e.g., lipid-based vehicles). A recombinant virus vaccine of the present invention includes a recombinant molecule of the present invention that is packaged in a viral coat and that can be expressed in an animal after administration. Preferably, the recombinant molecule is packagin f --d ;ficient and/or encodes an attenuated virus. A number of recombinant viruses can be used, including, but not limited to, those based on alphaviruses, poxviruses, adenoviruses, heφesviruses, and retroviruses. Preferred recombinant virus vaccines are those based on alphaviruses (such as Sindbis virus), raccoon poxviruses, species-specific heφesviruses and species-specific poxviruses. An example of methods to produce and use alphavirus recombinant virus vaccines is disclosed in PCT Publication No. WO 94/17813, by Xiong et al., published August 18, 1994, which is incoφorated by reference herein in its entirety. When administered to an animal, a recombinant virus vaccine of the present invention infects cells within the immunized animal and directs the production of a protective protein or RNA nucleic acid molecule that is capable of protecting the animal from hematophagous ectoparasite infestation. For example, a recombinant virus vaccine comprising an arthropod CE nucleic acid molecule of the present invention is administered according to a protocol that results in the animal producing a sufficient immune response to protect itself from hematophagous ectoparasite infestation. A preferred single dose of a recombinant virus vaccine of the present invention is from about 1 x 10 4 to about 1 x 10 7 virus plaque forming units (pfu) per kilogram body weight of the animal. Administration protocols are similar to those described herein for protein- based vaccines, with subcutaneous, intramuscular, intranasal and oral administration routes being preferred. A recombinant cell vaccine of the present invention includes recombinant cells of the present invention that express at least one protein of the present invention. Preferred recombinant cells for this embodiment include Salmonella, E. coli, Listeria, Mycobacterium, S. frugiperda, yeast, (including Saccharomyces cerevisiae), BHK, CV- 1, myoblast G8, COS (e.g., COS-7), Vero, MDCK and CRFK recombinant cells. Recombinant cell vaccines of the present invention can be administered in a variety of ways but have the advantage that they can be administered orally, preferably at doses ranging from about 10 8 to about 10 12 cells per kilogram body weight. Administration protocols are similar to those described herein for protein-based vaccines. Recombinant cell vaccines can comprise whole cells, cells stripped of cell walls or cell lysates. The efficacy of a therapeutic composition of the present invention to protect an animal from hematophagous ectoparasite infestation can be tested in a variety of ways including, but not limited to, detection of anti-arthropod esterase antibodies (using, for example, proteins or mimetopes of the present invention), detection of cellular immunity within the treated animal, or challenge of the treated animal with hematophagous ectoparasites to determine whether, for example, the feeding, fecundity or viability of hematophagous ectoparasites feeding from the treated animal is disrupted. Challenge studies can include attachment of chambers containing hematophagous ectoparasites onto the skin of the treated animal. In one embodiment, therapeutic compositions can be tested in animal models such as mice. Such techniques are known to those skilled in the art. One preferred embodiment of the present invention is the use of artliropod protective compounds, such as proteins, mimetopes, nucleic acid molecules, antibodies and inhibitory compounds of the present invention, to protect an animal from hematophagous ectoparasite, and particularly flea, infestation. Preferred protective compounds of the present invention include, but are not limited to, C. felis esterase nucleic acid molecules, C. felis esterase proteins and mimetopes thereof, anti-C. felis esterase antibodies, and inhibitors of C. felis esterase activity. More preferred protective compounds of the present invention include, but are not limited to, CE or JHE formulations of the present invention, C. felis CE nucleic acid molecules, C. felis CE proteins and mimetopes thereof, anti-flea CE antibodies, anti-flea JHE antibodies, inhibitors of C. felis CE activity and inhibitors of flea JHE activity. Additional protection may be obtained by administering additional protective compounds, including other proteins, mimetopes, nucleic acid molecules, antibodies and inhibitory compounds, as disclosed herein. One therapeutic composition of the present invention includes an inhibitor of arthropod esterase activity, i.e., a compound capable of substantially interfering with the function of an arthropod esterase susceptible to inhibition by an inhibitor of arthropod esterase activity. An inhibitor of esterase activity can be identified using artliropod esterase proteins of the present invention. One embodiment of the present invention is a method to identify a compound capable of inhibiting esterase r tf ^ity of an rrthropod. Such a method includes the steps of (a) contacting (e.g., combining, mixing) an isolated flea esterase protein, preferably a C. felis esterase protein of the present invention, with a putative inhibitory compound under conditions in which, in the absence of the compound, the protein has esterase activity, and (b) determining if the putative inhibitory compound inhibits the esterase activity. Putative inhibitory compounds to screen include small organic molecules, antibodies (including mimetopes thereof) and substrate analogs. Methods to determine esterase activity are known to those skilled in the art; see, for example, the Examples section of the present application. The present invention also includes a test kit to identify a compound capable of inhibiting esterase activity of an arthropod. Such a test kit includes an isolated flea esterase protein, preferably a C. felis esterase protein, having esterase activity and a means for determining the extent of inhibition of esterase activity in the presence of (i.e., effected by) a putative inhibitory compound. Such compounds are also screened to identify those that are substantially not toxic in host animals. Esterase inhibitors isolated by such a method, and/or test kit, can be used to inhibit any esterase that is susceptible to such an inhibitor. Preferred esterase proteins to inhibit are those produced by arthropods. A particularly preferred esterase inhibitor of the present invention is capable of protecting an animal from hematophagous ectoparasite infestation. Effective amounts and dosing regimens can be determined using teclmiques known to those skilled in the art. The following examples are provided for the puφoses of illustration and are not intended to limit the scope of the present invention. EXAMPLES It is to be noted that the Examples include a number of molecular biology, microbiology, immunology and biochemistry teclmiques considered to be known to those skilled in the art. Disclosure of such teclmiques can be found, for example, in Sambrook et al., ibid., Borovsky, Arch Insect Biochem. and Phys., 7:187-210, 1988, and related references. Example 1 This example describes b iling of proteases and esterases with radiolabeled diisopropylfluorophosphate. Tissue samples were isolated from unfed or bovine blood-fed 1st instar Ctenocephalides felis flea larvae; bovine blood-fed or cat blood-fed 3rd instar Ctenocephalides felis flea larvae; bovine blood- fed or cat blood-fed Ctenocephalides felis prepupal flea larvae; bovine blood-fed or cat blood-fed adult Ctenocephalides felis flea midgut tissue, and whole unfed, bovine blood-fed or cat blood-fed adult Ctenocephalides felis fleas. The 1st instar, 3rd instar, prepupal and adult midgut tissues were then homogenized by freeze-fracture and sonicated in a Tris buffer comprising 50 mM Tris, pH 8.0 and 100 mM CaCl 2 . The whole adult flea sample was then homogenized by freeze-fracture and ground with a microtube mortar and pestle. The extracts were centrifuged at about 14,000 x g for 20 minutes (min.) and the soluble material recovered. The soluble material was then diluted to a final concentration of about 1 to about 1.2 tissue equivalents per microliter (μl) of Tris buffer. Each sample was labeled with [l,3- 3 H]-diisopropylfluorophosphate ( 3 H-DFP) (available from DuPont-NEN, Wilmington, DE) using the method generally described in Borovsky, ibid. About 20 tissue equivalents of each tissue sample were mixed with about 1 μCi of 3 H- DFP and incubated for about 18 hours at 4°C. Proteins contained in each sample were then resolved using a 14% Tris-glycine sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (available from Novex, San Diego, CA) under reducing conditions. The gel was soaked in Entensify (available from DuPont-NEN) according to manufacturers instructions, and exposed to X-ray film (available from Kodak X-Omat AR, Rochester, NY) for about 3 days at -70 °C. Analysis of the resulting autoradiogram (shown in Fig. 1) indicated that tissue samples from 3rd instar, prepupal larvae and whole adult flea contained proteins that labeled with DFP, having a molecular weight (MW) of about 60 kilodalton (kD). No proteins of this MW were labeled in tissue samples from unfed or fed 1st instar larvae and adult midgut. The results indicated preferred tissue distribution and stage-specific expression of DFP-labeled serine esterases in fleas. Example 2 This example describes the identification of general CE activity in flea tissue extracts. Tissue samples and soluble extracts were prepared as described above in Example 1, except not labelled, from unfed (UF) and bovine blood-fed 1st instar flea larvae, bovine blood-fed 3rd instar flea larvae, bovine blood-fed prepupal flea larvae, unfed whole adult fleas, cat blood-fed adult (ACF) whole fleas, cat blood-fed adult fleas that have had their heads and midguts removed (referred to herein as fed adult partial fleas), unfed adult flea midguts and cat blood-fed adult flea midguts. About 5 tissue equivalents of each tissue were assayed for general CE activity using the following method. Tissue samples of about 5 μl were added to separate wells of flat-bottomed microtiter plate (available from Becton Dickinson, Lincoln Park, NJ). A control well was prepared by adding about 5 μl of Tris buffer to an empty well of the plate. About 95 μl of 25 mM Tris-HCl (pH 8.0) was then added to each sample to increase the volume in each well to about 100 μl. About 100 μl of 0.25 mM α-napthyl acetate (available from Sigma, St. Louis, MO) dissolved in 25 mM Tris-HCl (pH 8.0) was then added to each well. The plate was then incubated for about 15 min. at 37°C. Following the incubation, about 40 μl of 0.3% Fast Blue salt BN (tetrazotized o-dianisidine; available from Sigma) dissolved in 3.3% SDS in water was added to each well. The microtiter plate was then analyzed using a Cambridge Technology, Inc. (Watertown, PA) model 7500 Microplate Reader set to 590 nm. The absorbance value for the control sample was subtracted from absorbance values of experimental samples, such that the background value was zero. The results shown in Fig. 2 indicated that general CE activity was detected in all tissue samples. The level of activity varied, with unfed and fed 1 st instar larvae, unfed adult flea midguts, and fed adult flea midguts having relatively lower activity than in the other tissues. Thus, the results indicated preferred tissue distribution and stage-specific expression of general CE activity in fleas. Example 3 This example describes the determination of general CE activity using isoelectric focusing (IEF)-PAGE and non-reducing SDS-PAGE. A. Non-reducing SDS-PAGE. Soluble extracts from unfed and bovine blood-fed 1st instar flea larvae, bovine blood-fed 3rd instar flea larvae, bovine blood-fed prepupal flea larvae, bovine blood-fed adult (ABF) whole fleas and cat blood-fed adult whole fleas were prepared using the method described in Example 1. Each soluble extract sample was combined with SDS sample buffer (available from Novex) and proteins in the samples were resolved by gel electrophoresis using 14%> Tris-glycine SDS electrophoresis gels (available from Novex). The gels were run at room temperature for about 1 hour at 200 volts. After electrophoresis, the gels were soaked for about for 30 minutes in 50 mM Tris, pH 8.0, containing 2.5%> Triton X-100 to renature the proteins. The gels were then soaked in 50 mM Tris, pH 8.0, for about 5 minutes and then stained for about 5 min. in 50 milliliters (ml) of 25 mM Tris, pH 8.0, containing 50 mg Fast blue salt BN and 10 mg α-napthyl acetate (dissolved in 1 ml acetone). Once protein was detected on the stained gels, the gels were rinsed with water and photographed. B. IEF-PAGE. Soluble extracts from unfed and bovine blood-fed 1st instar flea larvae, bovine blood-fed 3rd instar flea larvae, bovine blood-fed prepupal flea larvae, unfed and cat blood-fed whole fleas, cat blood-fed adult partial fleas and cat blood-fed adult midguts were prepared as described above in Section A. The extracts were each combined with IEF sample buffer pH 3-7 (available from Novex) and loaded onto pH 3-7 IEF electrophoresis gels (available from Novex). The gels were electrophoresed at room temperature first for about 1 hour at about 100 volts, then for about 1 hour at about 200 volts, and then for about 30 min. at about 500 volts. Following electrophoresis, the gels were soaked in 25 mM Tris buffer, pH 8.0, for about 5 min. and then stained for about 1- 5 min. in 50 ml of 25 mM Tris buffer, pH 8.0, containing 50 mg Fast blue salt BN and 10 mg α-napthyl acetate (dissolved in 1 ml acetone). Once protein was detected on the stained gels, the gels were rinsed with water and photographed. C. Results. The results from gel electrophoresis experiments described above in Sections A and B are shown in Figs. 3 and 4. The results indicated that certain flea tissues contain proteins having MW's of from about 60 to about 70 k ' ' nd native pi values of from about 4.7 to about 5.2 that have CE activity. In particular, CE activity was identified in prepupal larvae and fed adult flea extracts resolved by non-reduced SDS-PAGE. No CE activity was identified in unfed and fed 1st instar larvae or fed 3rd instar larvae extracts (see Fig. 3). When extracts were resolved by native IEF-PAGE, CE activity was identified in fed 3rd instar larvae, prepupal larvae, unfed and fed whole adult flea, and fed adult partial flea extracts (see Fig. 4, lanes 3-7)). No CE activity was identified in unfed or fed 1st instar larvae, or in fed adult flea midgut extracts (see Fig. 4, lanes 1, 2, and 8). Example 4 This example describes the purification of CE protein from prepupal flea larvae. About 15,000 bovine blood-fed prepupal flea larvae were collected and the larvae were homogenized in TBS by sonication in 50 ml Oak Ridge centrifuge tubes (available from Nalgene Co., Rochester, NY) by sonicating 4 times 20 seconds each at a setting of 5 of a model W-380 Sonicator (available from Heat Systems-Ultrasonics, Inc.). The sonicates were clarified by centrifugation at 18,000 RPM for 30 minutes to produce an extract. Soluble protein in the extract was removed by aspiration and diluted to a volume of about 20 ml in TBS (equivalent to about 1 larva per μl TBS). The extract was then added to a column containing about 5 ml of p-aminobenzamidine linked to agarose beads (available from Sigma, St. Louis, MO) and incubated overnight at 4°C. The column was then washed with about 30 ml TBS to remove unbound protein. The collected unbound protein was then concentrated to a volume of about 20 ml using a Macrosep 10 centrifugal protein concentrator (Filtron Technology Coφ., Northborough, MA) and filtered sequentially through a 1 μm syringe filter and then through a 0.2 μm syringe filter to clarify the sample for chromatography. Aliquots of about 0.5 ml were loaded onto a 20 ml Superdex 200 HR gel filtration column (available from Pharmacia, Piscataway, NJ) equilibrated in TBS, operated on a BioLogic liquid chromatography system (available from BioRad, Burlingame, CA). About 1 ml fractions were then collected. Repetitive runs were performed until about 30 ml of each fraction was collected. The fractions were analyzed for CE activity using th~ a'.say described above in Example 2. In preparation for cation exchange chromatography, fractions having CE activity (V e =16-18 ml) were combined and dialyzed against about 2 liters of 20 mM MES buffer (2-(N- moφholino)ethanesulfonic acid), pH 6.0, containing 10 mM NaCl, for about 1.5 hours, and then against about 1 liter of the same buffer overnight at 4°C. Prior to loading onto the cation exchange chromatography column, the sample was again filtered through a 0.2 μm syringe filter to remove precipitated proteins. The sample was then applied to a Bio-Scale S2 cation exchange column (available from BioRad) at a rate of about 0.5 ml/min. The column was washed with MES buffer until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 20 mM MES buffer, pH 6. Fractions were assayed for CE activity using the assay described above in Example 2. The results indicated that CE activity was not retained on the cation exchange column using the above conditions, and all of the activity was found in the flow- through fractions. Fractions containing CE activity were pooled and adjusted to pH 7 using 0.5 M Tris, pH 8.0, in preparation for anion exchange chromatography. The pooled fractions were then loaded onto a 4.5 mm x 50 mm Poros 10 HQ anion exchange chromatography column (available from PerSeptive Biosystems, Cambridge, MA) equilibrated in 25 mM Tris buffer, pH 6.8. The column was washed with the loading buffer, and bound proteins were eluted with a linear gradient of 0 to 1 M NaCl in 25 mM Tris buffer, pH 6.8. Fractions were tested for CE activity using the assay described above in Example 2. The results indicated that CE activity was eluted at about 170 mM NaCl. Fractions containing CE activity were pooled and diafiltered into TBS. Example 5 This example describes the determination of N-terminal amino acid sequences of 0 carboxylesterases isolated from prepupal flea larvae. A. Anion exchange chromatography fractions. Anion exchange chromatography fractions described above in Example 4 that contained proteins having CE activity were pooled, diafiltered into TBS buffer and concentrated 3-fold in a Speed- Vac Concentrator (available from Savant Instruments, '. Holbrook, NY). Proteins in the concentrated samples were then resolved on a reducing, 10% SDS-PAGE Tris-glycine gel (available from Novex) for 1 hour at about 200 V. The proteins on the gel were then blotted onto a polyvinylidene difluoride (PVDF) membrane (available from Novex) for about 70 min in 10 mM CAPS buffer (3- [cyclohexylamino]-l-propanesulfonic acid; available from Sigma), pH 11, with 0.5 mM 0 dithiothreitol (DTT). The membrane was then stained for 1 minute in 0.1 %> Coomassie Blue R-250 dissolved in 40%> methanol and 1% acetic acid. The membrane was destained in 50% methanol for about 10 minutes, rinsed with MilliQ water and air dried. Three stained protein bands were identified having apparent molecular weights of about 64 kD, 65 kD, and 66 kD, respectively. The portion of the membrane containing each band was excised separately. Protein contained in each membrane segment was subjected to N-terminal amino acid sequencing using a 473 A Protein Sequencer (available from Applied Biosystems, Foster City, CA) and using standard techniques. The results indicated that the N-terminal amino acid sequence of the putative 64 kD protein was DPPTVTLPQGEL (denoted SEQ ID NO:39); the N-terminal amino acid sequence of the putative 65 kD protein was DPPTVTLPQGELVGKATNEnxk (denoted SEQ ID NO:40); and the N-terminal amino acid sequence of the putative 66 kD protein was DppTVTLPQGEL (denoted SEQ ID NO:41), in which the lower case letters designate uncertainties and "x" designates an undetermined residue. B. Proteins Resolved by Native IEF-PAGE. Proteins isolated by anion exchange chromatography as described above in Section A were further resolved by native IEF-PAGE. Proteins were loaded onto a pH 3-10 IEF gel (available from Novex) and separated in Novex's IEF buffers according to Novex's standard procedure (60 min at 100 V; then 60 min at 200 V; and then 30 min at 500 V). Following electrophoresis, part of the gel was stained for CE activity using the method described above in Example 2. The remaining portion of the gel was blotted onto PVDF membrane by reversing the orientation of the gel and membrane so that positively charged proteins migrated to the membrane, electrophoresing the protein for 60 min at 10 V, using 0.7% acetic acid as the transfer buffer. The membrane was stained as described above in Section A. After the membrane was dried, stained protein bands on the membrane were compared to bands on the gel tested for CE ac' cy to identify corresponding bands. Protein bands on the membrane corresponding to proteins having CE activity were excised and submitted to N-terminal sequencing as described in Section A. N-terminal amino acid sequence was obtained for protein contained in two bands having pi values of about pi 4.8 and about pi 4.9. N-terminal amino acid sequence of the pi 4.8 band was DPPTVTLPQGELVGKALSNen (denoted SEQ ID NO:42) and N- terminal amino acid sequence of the pi 4.9 band was DPPTVTLP (denoted SEQ ID NO:43). A comparison of the N-terminal amino acid sequences identified here and described in Section A indicates closely related proteins having a consensus sequence of DPPTVTLPQGELVGKALTNEnGk (denoted SEQ ID NO:44). The amino acid sequences of SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43 and SEQ ID NO:44 are substantially contained within SEQ ID NO:5, SEQ ID NO: 19 and SEQ ID NO:53, which are described below in Example 11. Example 6 This example describes partial purification of CE from 3rd instar flea larvae. Using the extract preparation methods described in Example 1 without labelling, extracts were prepared from about 50,000 bovine blood-fed 3rd instar flea larvae. The extract was then further purified over a p-aminobenzamidine linked agarose bead column using the method also described in Example 1. Collected unbound protein was concentrated to about 70 ml using a 200 ml stirred cell fitted with a YM-10 membrane (available from Amicon, Beverly, MA). Seven ml (about 5,000 3rd instar flea larval equivalents) of the concentrated extract was used for the remainder of the purification scheme described in Example 4. Resulting fractions from the anion exchange cliromatography column were tested for CE activity using the assay described above in Example 2. The results indicated that CE activity was eluted in two overlapping peaks at about 120 mM and about 210 mM NaCl. Example 7 This example describes the identifica''o of JHE activity in different flea tissues. Tissue samples were prepared as described above in Example 1 from unfed and bovine blood- fed 1st instar flea larvae, bovine blood-fed 3rd instar flea larvae, bovine blood-fed prepupal flea larvae, unfed and cat blood- fed whole adult fleas, cat blood-fed adult partial fleas and cat blood-fed adult flea midguts. About 5 tissue equivalents of each tissue was assayed for JHE activity as follows. Unlabeled juvenile hormone (JH; available from ICN Biomedicals, Inc., Aurora, OH) was diluted in hexane to concentration of about 0.025 M. Labeled 10- 3 H-juvenile hormone ( 3 H-JH; available from Dupont-NEN) was diluted in hexane to concentration of about 80,000 cpm/μl. A JH substrate mixture was prepared by mixing about 20 μl of unlabeled JH with about 80 μl of 3 H-JH (about 5 μCi) in a 4 ml screw cap vial. The substrate mixture was then covered with nitrogen (i.e., "blanketed") and the solvent contained in the mixture was evaporated by heating the mixture at 35°C. When just dry, about 1 ml of absolute anhydrous ethanol (final concentration 5 x 10 "4 M, or 6400 cpm/μl) was added to the vial. The substrate mixture was then stored at -20°C. About 5 equivalents of each tissue (about 5 μl of protein) was added into the bottom of a small glass autosampler vial. About 95 μl of Tris-buffered saline (TBS) was added to each vial to bring the final volume in each vial to about 100 μl. Two control samples were also prepared by adding 100 μl TBS to two separate vials. About 1 μl of the substrate mixture described above was added to all of the vials including the control samples. The final JH concentration in each vial was about 5 x 10 "6 M. The vials were then capped and spun in a microfuge to bring all of the liquid to the bottom of each vial. The vials were then transferred to a heat block and incubated at 35°C for about 30 minutes. Following the incubation, enzyme activity was stopped by adding about 50 μl of methanol buffer (methanol:water:concentrated ammonium hydroxide at a 10:9:1 ratio, respectively) to each vial and removing the vials from the heat block. To measure labeled juvenile hormone acid, about 250 μl isooctane was added to each vial. Each vial was vortexed for about 15 seconds or until an emulsion formed. Each vial was then centrifuged in a microfuge for about 1 minute to separate aqueous and organic phases. About 75 μl of the aqueous layer was removed from each vial and added to abou' 2 nl Eco-lume scintillation fluid (available from ICN). The amount of 3 H-juvenile hormone acid contained in each vial was determined using a Beckman LS- 1801 liquid scintillation counter (available from Beckman, Fullerton, CA). The results shown in Fig.5 indicated that all flea tissues tested contain active JHE. Referring to Example 2, the level of CE activity differed from JHE activity in various tissue samples. The combined JHE and CE data indicated the differential expression of these two enzymatic activities during the development of a flea. Example 8 This example describes the purification of JHE protein from cat blood-fed adult midguts. About 23,000 cat blood-fed adult midguts were collected and prepared using the method described in Example 1. The extract was then added in 4 aliquots to columns containing about 3 to about 5 ml of p-aminobenzamidine linked agarose beads (available from Sigma), equilibrated in 50 mM Tris (pH 8.0), 100 mM CaCl 2 , 400 mM NaCl, and incubated overnight at 4°C. The columns were then washed with about 15 to about 125 ml of the equilibration Tris buffer to remove unbound protein. The collected unbound protein was pooled and then concentrated to a volume of about 5 ml using an Ultrafree- 20 10 kD centrifugal concentrator (available from Millipore, Bedford, MA) and filtered sequentially through a 0.2 μm centrifugal ultrafiltration membrane (available from Lida, Kenosha, Wl) to clarify the sample for cliromatography. Aliquots of about 0.5 ml were loaded onto a Superdex 200 HR gel filtration column using the method described in Example 4. Repeated runs were performed until about 10 ml of each fraction was collected. The fractions were analyzed for JHE activity using the assay described in Example 7. In preparation for anion exchange chromatography, fractions having JHE activity (V e =17-18 ml) were combined and dialyzed overnight against about 1 L of 20 mM Tris buffer, pH 8.0, containing 10 mM NaCl. The sample was then loaded onto a Poros 10 HQ anion exchange column using the method described in Example 4. Resulting fractions were tested for JHE activity as described in Example 7. The results indicated that midgut JHE activity was eluted from the anion exchange column in a single peak at about 120 mM NaCl. Example 9 This example describes partial purification of JHE from prepupal flea larvae and 3rd instar larvae. A. JHE Purification from Prepupal Tissue. Using the extract preparation methods described in Example 1 , gel filtration fractions were obtained using a Superdex 200 HR gel filtration column (available from Pharmacia) using the method described in Example 4, from about 15,000 bovine blood- fed prepupal flea larvae. The fractions were analyzed for JHE activity using the assay described above in Example 7. Those fractions containing protein having JHE activity (V e =T6-18 ml) were combined and dialyzed using the method described in Example 8. The fractions were then further purified by passing the fractions over a Bio-Scale S2 cation exchange column (available from BioRad) at a rate of about 0.5 ml/min. The column was washed with MES until all unbound protein was eluted. Bound protein was then eluted with a linear gradient of 20 mM MES buffer, pH 6.0, containing 10 mM NaCl to 1 M NaCl. Resulting fractions were assayed for JHE activity using the method described in Example 7. The results indicated that proteins having JHE activity using prepupal tissue eluted from the column in about 200 to 300 mM NaCl. The fractions containing JHE activity were combined and the pH adjusted to pH 7 using 0.5 M Tris buffer (pH 8.0). The fractions were then dialyzed twice against about 1 liter of 10 mM phosphate buffer (pH 7.2) containing 10 mM NaCl at 4°C. The resulting dialyzed fractions were then loaded onto a Bio-Scale CHT2-I Hydroxyapatite Column (available from BioRad) at a rate of about 0.5 ml/min. Unbound protein was washed from the column using the dialysis buffer. Bound protein was then eluted with a linear gradient of from 10 mM phosphate buffer, pH 7.2, containing 10 mM NaCl to 0.5 M phosphate buffer pH 6.5 containing 10 mM NaCl. One ml fractions were collected and each tested for JHE activity by the method described in Example 7. The results indicated that JHE eluted in 2 overlapping peaks at about 100 mM and 150 mM phosphate. These two JHE activities were designated PJ JHE I and PP JHE II, and were kept separate for the remainder of the purification. Both JHE samples, were dialyzed overnight against 20 mM Tris buffer (pH 8.0) containing 10 mM NaCl. The two samples were then loaded, separately, onto a 4.5 mm x 50 mm Poros 10 HQ anion exchange chromatography column (available from PerSeptive Biosystems) equilibrated with 20 mM Tris buffer, pH 8.0, containing 10 mM NaCl. Unbound proteins were washed from the column using the same buffer. Bound proteins were eluted with a linear gradient of from 10 mM to 1 M NaCl in 20 mM Tris buffer, pH 8.0. Resulting fractions were tested for JHE activity using the method described in Example 7. The results indicated that in both samples, JHE activity was eluted from the column in a single peak at about 100 mM NaCl. B. JHE Purification from 3 rd Instar Tissue Using the procedure described above in Section A, proteins having JHE activity were obtained using about 5,000 bovine blood-fed 3 rd instar flea larvae. Following purification by cation exchange, proteins having JHE activity using 3 rd instar tissue were found to elute in 2 peaks. The first peak having JHE activity was not retained on the column and also exhibited CE activity (referred to herein as CE/JHE fractions). The second peak having JHE activity eluted from the column in about 100-200 mM NaCl and did not contain CE activity. The CE/JHE fractions were pooled and adjusted to about pH 7 using 0.5 M Tris, pH 8.0. The fractions were then loaded onto a 4.5 mm x 50 mm Poros 10 HQ anion exchange chromatography column (available from PerSeptive Biosystems) and the column was equilibrated in 25 mM Tris buffer, pH 6.8. The column was washed with the same buffer and bound proteins were eluted with a linear gradient of 0 to 1 M NaCl in 25 mM Tris buffer, pH 6.8. Fractions were then tested for JHE activity using the method described in Example 7. JHE activity was eluted in two overlapping peaks at about 120 mM and 210 mM NaCl. The fraction containing JHE activity also contained CE activity when tested using the method described in Example 2. Fractions from the cation exchange column containing only JHE activity were combined, diluted in 20 mM Tris bυ f fe , pH 8.0 containing 10 mM NaCl, and concentrated to about 5 ml. The fractions were purified on a Poros 10 HQ anion exchange chromatography column as described immediately above. Fractions were then tested for JHE activity using the method described in Example 7. The JHE activity was eluted in a single peak at about 120 mM. The peak contained no detectable CE activity. Example 10 This example describes the purification of JHE protein from unfed adult midguts. About 16,000 unfed adult midguts were collected in 20 mM Tris buffer (pH 7.7), containing 130 mM NaCl, 1 mM sodium EDTA, 1 mM Pefabloc® (available from Boehringer Mannheim, Indianapolis, IN), 1 microgram/ml (μg/ml) leupeptin and 1 μg/ml pepstatin. The midguts were homogenized by freeze-fracture and sonication, and then centrifuged at about 14,000 x g for 20 min. The soluble material from the centrifugation step was recovered. The soluble material was then concentrated to about 1 ml using an Ultrafree-20 10 kD centrifugal concentrator (available from Millipore) and filtered sequentially through a 0.2 μm centrifugal ultrafiltration membrane to clarify the sample for chromatography. Aliquots of about 0.5 ml were loaded onto a Superdex 200 HR gel filtration column using the method described in Example 4. Repeated column runs were performed until about 2 ml of each fraction was collected. The fractions were analyzed for JHE activity using the assay described in Example 7. In preparation for cation exchange chromatography, fractions having JHE activity (V e =15-17 ml) were combined and dialyzed overnight against about 1 L of 20 mM MES buffer, pH 6.0, containing 10 mM NaCl. The sample was then applied to a Bio-Scale S2 cation exchange column using the method described in Example 4. Fractions of eluate were assayed for JHE activity using the method described in Example 7. The results indicate that JHE is present in unfed midguts in two forms, one that is not retained on the cation exchange column and one that is bound to the column under low salt conditions at about 100 mM NaCl. The form that was not retained under low salt conditions was shown to have general CE activity using the methods described in Example 2. Example 11 This example describes the identification of certain esterase nucleic acid molecules of the present invention. Several flea esterase nucleic acid molecules, representing one or more partial flea esterase genes, were PCR amplified from a flea mixed instar cDNA library or a flea prepupal cDNA library. The flea mixed instar cDNA library was produced using unfed 1st instar, bovine blood-fed 1st instar, bovine blood- fed 2 nd instar and bovine blood-fed 3 rd instar flea larvae (this combination of tissues is referred to herein as mixed instar larval tissues for puφoses of this example). The flea prepupal cDNA library was produced using prepupal flea larvae. For each library, total RNA was extracted from mixed instar or prepupal tissue, respectfully, using an acid-guanidinium-phenol- chloroform method similar to that described by Chomczynski et al., 1987, Anal. Biochem. 162, p. 156-159. Approximately 5,164 mixed instar larvae or 3,653 prepupal larvae were used in each RNA preparation. Poly A+ selected RNA was separated from each total RNA preparation by oligo-dT cellulose chromatography using Poly(A)Quick© mRNA isolation kits (available from Stratagene Cloning Systems, La Jolla, CA), according to the method recommended by the manufacturer. A mixed instar cDNA expression library and a prepupal cDNA expression library were constructed in lambda (λ) Uni-ZAP™XR vector (available from Stratagene Cloning Systems) using Stratagene's ZAP-cDNA Synthesis Kit® protocol. About 6.34 μg of mixed instar poly A+ RNA were used to produce the mixed instar library and about 6.72 μg of prepupal poly A+ RNA were used to produce the prepupal library. The resultant mixed instar library was amplified to a titer of about 2.17 x 10 10 pfu/ml with about 97% recombinants. The resultant prepupal library was amplified to a titer of about 3.5 x 10'° pfu/ml with about 97% recombinants. A pair of primers was used to amplify DNA from the cDNA libraries. A sense vector primer T-3X (corresponding to the vector in which nucleic acid molecules of the present invention had been ligated), having the nucleic acid sequence AATTAACCCT CACTAAAGGG (available from Gibco BRL, Gaithersburg, MD; denoted SEQ ID NO:45), was used in combination with a degenerate primer, the design of which was based on a highly conserved esterase amino acid sequence (disclosed in Hanzlik et al., J. Biol. Chem. 264:12419-12423, 1989; I Y H G G G F/L) located in a region downstream from the mature amino terminus in a number of known esterases. The degenerate primer, referred to herein as FCEF, is an anti-sense primer having the nucleic acid sequence ARDCCDCCDC CRTRDAT ( R indicating an A or G; and D indicating an A, G or T; denoted SEQ ID NO:46). The resultant PCR products from the mixed instar cDNA library, obtained using standard PCR conditions (e.g., Sambrook et al., ibid.), were about 550 nucleotides. The resultant PCR products from the prepupal cDNA library were from about 500 nucleotides to about 860 nucleotides. A. PCR Products. PCR products were gel purified and cloned into the TA Vector™ (available from InVitrogen Coφ., San Diego, CA). Approximately 8 clones were identified from the prepupal library and 6 clones were identified from the mixed instar library. These nucleic acid molecules were subjected to nucleic acid sequencing using the Sanger dideoxy chain termination method, as described in Sambrook et al., ibid. 1. Flea esterase clone 1 isolated from the mixed instar cDNA library was determined to comprise nucleic acid molecule nfEl 401 , the nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:l. Translation of SEQ ID NO:l suggests that nucleic acid molecule nfEl 40 , encodes a non-full-length flea esterase protein of about 103 amino acids, referred to herein as PfEl , 03 , having amino acid sequence SEQ ID NO:2, assuming an initiation codon spanning from nucleotide 92 through nucleotide 94 of SEQ ID NO: 1. The complement of SEQ ID NO: 1 is represented herein by SEQ ID NO:3. Comparison of amino acid sequence SEQ ID NO:2 (i.e., the amino acid sequence of PfEl , 03 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:2, showed the most homology, i.e., about 33% identity, between SEQ ID NO:2 and alpha esterase protein from Drosophila melanogaster. 2. Flea esterase clone 2 isolated from the mixed instar cDNA library was determined to comprise nucleic acid molecule nfE2 364 , the nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:4. Translation of SEQ ID NO:4 suggests that nucleic acid molecule nfE2 364 encodes a non-full-length flea esterase protein of about 121 amino acids, referred to herein as PfE 9 . 12 -, having amino acid sequence SEQ ID NO:5, assuming the first codon spans from nucleotide 2 through nucleotide 4 of SEQ ID NO:4. The complement of SEQ ID NO:4 is represented herein by SEQ ID NO:6. Comparison of nucleic acid sequence SEQ ID NO:4 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:4 showed the most homology, i.e., about 43% identity, between SEQ ID NO:4 and a H. virescens JHE gene. Comparison of amino acid sequence SEQ ID NO:5 (i.e., the amino acid sequence of PfE2, 21 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:5, showed the most homology, i.e., about 38%> identity, between SEQ ID NO:5 and alpha esterase protein from Drosophila melanogaster. 3. Flea esterase clone 3 isolated from the prepupal cDNA library was determined to comprise nucleic acid molecule nfE3 421 , the nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:7. Translation of SEQ ID NO:7 suggests that nucleic acid molecule nfE3 42 , encodes a non-full-length flea esterase protein of about 103 amino acids, referred to herein as PfE3, 03 , having amino acid sequence SEQ ID NO: 8, assuming an initiation codon spanning from nucleotide 113 through nucleotide 115 of SEQ ID NO:7. The complement of SEQ ID NO:7 is represented herein by SEQ ID NO:9. Comparison of nucleic acid sequence SEQ ID NO:7 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:7 showed the most homology, i.e., about 53% identity, between SEQ ID NO:7 and a Torpedo marmorata acetylcholinesterase gene. Comparison of amino acid sequence SEQ ID NO:8 (i.e., the amino acid sequence of PfE3, 03 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:8, showed the most homology, i.e., about 39%o identity, between SEQ ID NO:5 and alpha esterase protein from Drosophila melanogaster. 4. Flea esterase clone 4 isolated from the prepupal cDNA library was determined to comprise nucleic acid molecule nfE4 524 , the nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO: 10. Translation of SEQ ID NO: 10 suggests that nucleic acid molecule nfE4 524 encodes a non-full-length flea esterase protein of about 137 amino acids, referred to herein as PfE4, 37 , having amino acid sequence SEQ ID NO: 11, rssi .ming ar initiation codon spanning from nucleotide 113 through nucleotide 115 of SEQ ID NO: 10. The complement of SEQ ID NO: 10 is represented herein by SEQ ID NO: 12. Comparison of nucleic acid sequence SEQ ID NO: 10 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO: 10 showed the most homology, i.e., about 47%o identity, between SEQ ID NO: 10 and an Anas platyrhyncos thioesterase B gene. Comparison of amino acid sequence SEQ ID NO:l 1 (i.e., the amino acid sequence of PfE4, 37 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:l 1, showed the most homology, i.e., about 30% identity, between SEQ ID NO:l 1 and Leptinotarsa decemlineata acetylcholinesterase. B. cDNA Clones. Certain amplified PCR fragments were used as probes to identify full-length flea esterase genes in the prepupal cDNA library. 1. Nucleic acid molecule nfE2 364 was labeled with 32 P and used as a probe to screen the mixed instar cDNA library described in Section A, using standard hybridization techniques. Two clones were isolated. A first clone included about a 2300-nucleotide insert, referred to herein as nfE5 2300 . Nucleic acid sequence was obtained using standard techniques from nfE5 2300 , to yield a flea esterase nucleic acid molecule named nfE5 1982 having a nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO: 13. Translation of SEQ ID NO: 13 suggests that nucleic acid molecule nfE5, 982 encodes a non-full-length flea esterase protein of about 505 amino acids, referred to herein as PfE5 5 o 5 , having amino acid sequence SEQ ID NO: 14, assuming the first codon spans from nucleotide 1 through nucleotide 3 of SEQ ID NO: 13 and the stop codon spans from nucleotide 1518 through nucleotide 1520 of SEQ ID NO:13. The complement of SEQ ID NO:13 is represented herein by SEQ ID NO:15. The amino acid sequence of PfE5 505 (i.e., SEQ ID NO: 14) predicts that PfE5 505 has an estimated molecular weight of about 56.8 kD and an estimated pi of about 5.5. The nucleic acid molecule representing the coding region for PfE5 505 is referred to herein as nfE5, 5 , 5 ; the nucleic acid sequences of the coding strand and the complementary strand are represented by SEQ ID NO: 16 and SEQ ID NO: 17, respectively. The nucleic acid sequence of nfE5, 982 was used to design primers to use in combi ation with a vector primer to PCR amplify the 5' terminal fragment of the remainder of the flea esterase coding region from the flea mixed instar cDNA library. A pair of primers was used to amplify DNA from the cDNA library. A sense vector primer T3-X (corresponding to the vector in which nucleic acid molecules of the present invention had been ligated), having the nucleic acid sequence 5' AATTAACCCT CACTAAAGGG 3' (denoted SEQ ID NO:45), was used in combination with an anti- sense primer M6/M265', having the nucleic acid sequence 5' GTGCGTACAC GTTTACTACC 3' (denoted SEQ ID NO:56). The resultant PCR product from the mixed instar cDNA library, obtained using standard PCR conditions (e.g., Sambrook et al., ibid.), were about 354 nucleotides. The PCR product was subjected to DNA sequencing analysis, and a composite sequence representing a full-length flea esterase coding region was deduced. The nucleic acid sequence of the composite nucleic acid molecule, referred to herein as nfE5 2l44 is denoted herein as SEQ ID NO:57. Translation of SEQ ID NO:57 suggests that nucleic acid molecule nfE5 2144 encodes a full-length flea esterase protein of about 550 amino acids, referred to herein as PfE5 550 , having amino acid sequence SEQ ID NO:58, assuming an open reading frame in which the initiation codon spans from nucleotide 30 through nucleotide 32 of SEQ ID NO:57 and the stop codon spans from nucleotide 1680 through nucleotide 1682 of SEQ ID NO:57. The complement of SEQ ID NO:57 is represented herein by SEQ ID NO:59. The coding region encoding PfE5 550 is represented by the nucleic acid molecule nfE5 1650 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:60 and a complementary strand with nucleic acid sequence SEQ ID NO:61. The amino acid sequence of PfE5 550 (i.e., SEQ ID NO:58) predicts that PfE5 55 ohas an estimated molecular weight of about 61.8 kD and an estimated pi of about 5.5. Comparison of nucleic acid sequence SEQ ID NO:57 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:57 showed the most homology, i.e., about 41 % identity, between SEQ ID NO:57 and a M. persicae esterase FE4 mRNA sequence. Comparison of amino acid sequence SEQ ID NO:58 (i.e., the amino acid sequence of PfE5 550 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:58 showed the most homology, i.e., about 36% identity between SEQ ID NO:58 and Drosophila melanogster alpha esterase protein. A second clone included about a 1900 nucleotide insert, referred to herein as nfE6, 9 o 0 . Nucleic acid sequence was obtained using standard teclmiques from nfE6 1900 , to yield a flea esterase nucleic acid molecule named nfE6 1792 having a nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO: 18. Translation of SEQ ID NO: 18 suggests that nucleic acid molecule nfE6 1792 encodes a full-length flea esterase protein of about 550 amino acids, referred to herein as PfE6 550 , having amino acid sequence SEQ ID NO: 19, assuming an open reading frame in which the initiation codon spans from nucleotide 49 through nucleotide 51 of SEQ ID NO: 18 and a stop codon spanning from nucleotide 1699 through nucleotide 1701 of SEQ ID NO:18. The complement of SEQ ID NO: 18 is represented herein by SEQ ID NO:20. The coding region encoding PfE6 550 , is represented by nucleic acid molecule nfE6 1650 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:21 and a complementary strand with nucleic acid sequence SEQ ID NO:22. The proposed mature protein, denoted herein as PfE6 530 , contains about 530 amino acids which is represented herein as SEQ ID NO:53. The nucleic acid molecule encoding PfE6 530 is denoted herein as nfE6 1590 and has a coding strand having the nucleic acid sequence SEQ ID NO:23. The amino acid sequence of PfE6 55 o(i.e., SEQ ID NO: 19) predicts that PfE6 55 ohas an estimated molecular weight of about 61.8 kD and an estimated pi of about 5.5. Comparison of nucleic acid sequence SEQ ID NO:l 8 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO: 18 showed the most homology, i.e., about 41% identity, between SEQ ID NO: 18 and a Myzus pericae esterase gene. Comparison of amino acid sequence SEQ ID NO: 19 (i.e., the amino acid sequence of PfE6 550 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO: 19 showed the most homology, i.e., about 28% identity between SEQ ID NO: 19 and Drosophila melanogaster alpha esterase protein. 2. Nucleic acid molecule nfE4 524 was labeled with 32 P and used as a probe to screen the prepupal cDNA library described in Example 11, using standard hybridization techniques (e.g., Sambrook et al., ibid.). Two clones were isolated. A first clone included about a 3000 nucleotide insert, referred to herein as nfE7 3000 . Nucleic acid sequence was obtained using standard techniques from nfE7 30 oo, to yield a flea esterase nucleic acid molecule named nfE7 2836 having a nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:24. Translation of SEQ ID NO:24 suggests that nucleic acid molecule nfE7 2836 encodes a full-length flea esterase protein of about 596 amino acids, referred to herein as PfE7 596 , having amino acid sequence SEQ ID NO:25, assuming an open reading frame in which the initiation codon spans from nucleotide 99 through nucleotide 101 of SEQ ID NO:24 and a stop codon spanning from nucleotide 1887 through nucleotide 1889 of SEQ ID NO:25. The complement of SEQ ID NO:24 is represented herein by SEQ ID NO:26. The coding region encoding PfE7 596 , is represented by nucleic acid molecule nfE7, 788 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:28 and a complementary strand with nucleic acid sequence SEQ ID NO:29. The proposed mature protein, denoted herein as PfE7 570 , contains about 570 amino acids which is represented herein as SEQ ID NO:54. The nucleic acid molecule encoding PfE7 570 is denoted herein as nfE7 1710 and has a coding strand having the nucleic acid sequence SEQ ID NO:27. The amino acid sequence of PfE7 596 (i.e., SEQ ID NO:25) predicts that PfE7 596 has an estimated molecular weight of about 68.7 kD and an estimated pi of about 6.1. Comparison of nucleic acid sequence SEQ ID NO:24 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:24 showed the most homology, i.e., about 48%> identity, between SEQ ID NO:24 and an Anas platychyncos thioesterase B gene. Comparison of amino acid sequence SEQ ID NO:25 (i.e., the amino acid sequence of PfE7 596 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:25 showed the most homology, i.e., about 27% identity between SEQ ID NO:25 and Drosophila melanogaster alpha esterase protein. A second clone included about a 3000 nucleotide insert, referred to herein as nfE8 30 o 0 . Nucleic acid sequence was obtained using standard techniques from nfE8 3000 , to yield a flea esterase nucleic acid molecule named nfE8 2801 having a nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:30. Translation of SEQ ID NO:30 suggests that nucleic acid molecule nfE8 2801 encodes a full-length flea esterase protein of about 595 amino acids, referred to herein as PfE8 595 , h? 'irg amino acid sequence SEQ ID NO:31, assuming an open reading frame in which the initiation codon spans from nucleotide 99 through nucleotide 101 of SEQ ID NO:30 and a stop codon spanning from nucleotide 1884 through nucleotide 1886 of SEQ ID NO:30. The complement of SEQ ID NO:30 is represented herein by SEQ ID NO:32. The coding region encoding PfE8 595 , is represented by nucleic acid molecule nfE8 1785 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:34 and a complementary strand with nucleic acid sequence SEQ ID NO:35. The proposed mature protein, denoted herein as PfE8 570 , contains about 570 amino acids which is represented herein as SEQ ID NO:55. The nucleic acid molecule encoding PfE8 570 is denoted herein as nfE8, 7 ,o and has a coding strand having the nucleic acid sequence SEQ ID NO:33. The amino acid sequence of PfE8 595 (i.e., SEQ ID NO:31) predicts that PfE8 595 has an estimated molecular weight of about 68.6 kD and an estimated pi of about 6.1. Comparison of nucleic acid sequence SEQ ID NO:30 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:30 showed the most homology, i.e., about 46% identity, between SEQ ID NO:30 and a Mus musculus carboxyl ester lipase gene. Comparison of amino acid sequence SEQ ID NO:31 (i.e., the amino acid sequence of PfE8 595 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:31 showed the most homology, i.e., about 28% identity between SEQ ID NO:31 and estalpha-2 esterase of Culex pipiens quinquefasciatus. 3. Nucleic acid molecule nfE3 421 was labeled with 32 P and used as a probe to screen the prepupal cDNA library using standard hybridization techniques (e.g., Sambrook et al., ibid.). Two clones were isolated. One clone included about a 1900 nucleotide insert, referred to herein as nfE9, 900 . Nucleic acid sequence was obtained using standard techniques from nfE9 1900 , to yield a flea esterase nucleic acid molecule named nfE9 2007 having nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:36. Translation of SEQ ID NO:36 suggests that nucleic acid molecule nfE9 2007 encodes a full-length flea esterase protein of about 528 amino acids, referred to herein as PfE9 528 , having amino acid sequence SEQ ID NO:37, assuming an open reading frame in which the initiation codon spans from nucleotide 11 through nucleotide 13 of SEQ ID NO:36 and a stop co Jon spanning from nucleotide 1595 through nucleotide 1597 of SEQ ID NO:36. The complement of SEQ ID NO:36 is represented herein by SEQ ID NO:38. The coding region encoding PfE9 528 , is represented by nucleic acid molecule nfE9, 584 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:51 and a complementary strand with nucleic acid sequence SEQ ID NO:52. The amino acid sequence of PfE9 528 (i.e., SEQ ID NO:37) predicts that PfE9 52g has an estimated molecular weight of about 60 kD and an estimated pi of about 5.43. Comparison of nucleic acid sequence SEQ ID NO:36 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:36 showed the most homology, i.e., about 47% identity, between SEQ ID NO:36 and a hamster mRNA for carboxylesterase precursor gene. Comparison of amino acid sequence SEQ ID NO:37 (i.e., the amino acid sequence of PfE9 528 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:37 showed the most homology, i.e., about 37% identity between SEQ ID NO:37 and alpha esterase protein from Drosophila melanogaster. As is the case for any of the nucleic acid molecules described in this example, variations between sequences may be due to a number of factors, such as but not limited to, sequencing errors or allelic variation. 4. Nucleic acid molecule nfEl 401 was labeled with 32 P and used as a probe to screen the mixed instar cDNA library using standard hybridization techniques (e.g., Sambrook et al., ibid.). A clone was isolated that included about a 2000 nucleotide insert, referred to herein as nfE10 200 o- Nucleic acid sequence was obtained using standard techniques from nfE10 2000 , to yield a flea esterase nucleic acid molecule named nfE10, 987 having nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:67. Translation of SEQ ID NO:67 suggests that nucleic acid molecule nfE10 1987 encodes a full-length flea esterase protein of about 530 amino acids, referred to herein as PfE10 530 , having amino acid sequence SEQ ID NO:68, assuming an open reading frame in which the initiation codon spans from nucleotide 231 through nucleotide 233 of SEQ ID NO:67 and a stop codon spanning from nucleotide 1821 through nud -o'lde 1823 of SEQ ID NO:67. The complement of SEQ ID NO:67 is represented herein by SEQ ID NO:69. The coding region encoding PfE10 530 , is represented by nucleic acid molecule nfE10ι 590 , having a coding strand with the nucleic acid sequence represented by SEQ ID NO:70 and a complementary strand with nucleic acid sequence SEQ ID NO:71. The amino acid sequence of PfE10 530 (i.e., SEQ ID NO:68) predicts that PfE10 530 has an estimated molecular weight of about 59.5 kD and an estimated pi of about 5.5. Comparison of nucleic acid sequence SEQ ID NO:67 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:67 showed the most homology, i.e., about 48% identity, between SEQ ID NO:67 and a Lucilia cuprina alpha esterase gene (genembl # U56636) gene. Comparison of amino acid sequence SEQ ID NO:68 (i.e., the amino acid sequence of PfE10 530 ) with amino acid sequences reported in GenBank indicates that SEQ ID NO:68 showed the most homology, i.e., about 30% identity between SEQ ID NO:68 and Culex pipens esterase bl precurser protein (swissprot # P16854). As is the case for any of the nucleic acid molecules described in this example, variations between sequences may be due to a number of factors, such as but not limited to, sequencing errors or allelic variation. Example 12 This Example demonstrates the production of esterase proteins of the present invention in E. coli cells. A. Flea esterase protein PHIS-PfE7 570 and flea esterase protein PHIS-PfE8 570 were produced in the following manner. A pair of primers was used to amplify DNA from flea esterase nucleic acid molecule nfE7 2836 or nfE8 2801 produced as described in Example 11. A sense primer containing an Xliol site (shown in bold) having the nucleic acid sequence 5' TGTGCTCGAG ATGGGATAAC CTAGATCAGC ATTTGTGC 3' (denoted SEQ ID NO:47), was used in combination with an anti-sense primer containing a Kpnϊ site (shown in bold) having the nucleic acid sequence 5' TTAAGGTACC TCATCTAATA CTTCCTTCAT TACAG 3' (denoted SEQ ID NO:48). A PCR product was derived from nfE7 2836 , and is referred to herein as nfE7, 710 , having nucleic acid sequence SEQ ID NO:27. The PCR product was digested with Xlwl and Kpnl restriction endonucleases, gel purified and subcloned into expression vector pTrcHisB (available from InVitrogen). The resultant recombinant molecule, referred to herein as pTrc-nfE7, 710 , was transformed into E. coli HB101 competent cells (available from Gibco BRL) to form recombinant cell E. cø/z:pTrc-nfE7, 710 . The PCR product derived from nfE8 2801 using the primers is referred to herein as nfE8, 710 , having nucleic acid sequence SEQ ID NO:33. PCR product nfE8 17 , 0 was digested with Xlwl and Kpnl restriction endonucleases, gel purified and subcloned into expression vector pTrcHisB. The resultant recombinant molecule, referred to herein as pTrc-nfE8, 7 ,o, was transformed into E. coli HB101 competent cells to form recombinant cell E. co/ :pTrc-nfE8 1710 . The recombinant cells were cultured in enriched bacterial growth medium containing 0.1 mg/ml ampicillin and 0.1% glucose at about 32 °C. When the cells reached an OD 600 of about 0.4-0.5, expression of recombinant protein was induced by the addition of 0.5 mM isopropyl-B-D-thiogalactoside (IPTG), and the cells were cultured for about 2 hours at about 32 °C. Immunoblot analysis of recombinant cell E. coli:pTτc- nfE7, 7 ,o and E. co/f :pTrc-nfE8 1710 lysates using a T7 tag monoclonal antibody (available from Novagen, Inc., Madison, Wl) directed against the fusion portion of the recombinant PHIS-PfE7 570 and PHIS-PfE8 570 fusion proteins identified proteins of appropriate size, namely an about 65 kD protein for each fusion protein. B. Flea esterase protein PHIS-PfE6 540 was produced in the following manner. A pair of primers was used to amplify DNA from flea esterase nucleic acid molecule nfE6 1792 produced as described in Example 11. A sense primer containing an Xliol site having the nucleic acid sequence 5' AAACTCGAGT CCCCCGACTG TAACTTTGC 3' (denoted SEQ ID NO:62; Xliol site shown in bold), was used in combination with an anti-sense primer containing a Pstl site having the nucleic acid sequence 5' TCATCTGCAG TTATTGACTG TGCAAAGTTT TTGTGG 3' (denoted SEQ ID NO:63; Pstl site shown in bold). A PCR product was derived from nfE6 1792 , and is referred to herein as nfE6, 488 , having nucleic acid sequence SEQ ID NO:76. The PCR product was digested with Xliol and Pstl restriction endonvcleases, gel purified and subcloned into expression vector lambdaP R /T 2 oπ ' /S10HIS-RSET-A9, that had been digested with Xlwl and Pstl and dephosphorylated.. The resultant recombinant molecule, referred to herein as pCro-nfE6, 488 , was transformed into E. coli HB101 competent cells (available from Gibco BRL) to form recombinant cell E. coli:pCro- nfE6 1488 . The recombinant cells were cultured using the method generally described in Section A of this example, except that the cells were grown under heat shift conditions rather than in the presence of IPTG. The cells were grown at 32 °C for about 2 hours, and then grown at 42°C. Immunoblot analysis of recombinant cell E. cø/z ' :pCro-nfE6 14g8 lysate using a T7 tag monoclonal antibody directed against the fusion portion of the recombinant PHIS-Pf£6 540 fusion protein identified proteins of appropriate size, namely an about 60 kD protein for each fusion protein. Expression of the recombinant PHIS-PfE6 540 fusion protein was improved by transforming supercoiled plasmid pCro-nf£6, 48g DNA harvested from E. colv.pCro- nfE6 148g cells into the BL-21 strain of E. coli (available from Novagen). The amount of expression PHIS-PfE6 540 was confirmed by immunoblot using the method described immediately above. E. coli cells expressing PHIS-PfE6 540 protein were harvested from about 2 liters of media and suspended in about 140 ml of 50 mM Tris, pH 8.0, 50 mM NaCl, 0.1 mM phenylmethylsulfonylfluoride (PMSF) (Solubilization Buffer). The cells were broken by passage through a microfluidizer at 30 psi for 30 cycles. The sample was centrifuged at about 16,000 X g for 30 min at 4°C. The supernatant (SI) was recovered and the pellet was resuspended in about 80 ml of Solubilization Buffer and centrifuged at about 16,000 X g for 30 min at 4°C. The supernatant (S2) was recovered and the pellet was resuspended in about 80 ml of Solubilization Buffer containing 0.1 % Triton-Xl 00 and centrifuged at about 16,000 X g for 30 min at 4°C. The supernatant (S3) was recovered and the pellet was resuspended in about 140 mis 50 mM Tris, pH 8.0, 8 M Urea, 0.1 M PMSF and centrifuged at about 16,000 X g. The supernatant (S4) was recovered and the pellet was resuspended in 40 mis 50 mM Tris, 8 M Urea, 0.1 M PMSF. Aliquots of each pellet and supernatant were analyz "d \>y SDS-PAGE and immunoblot using the T7 tag monoclonal antibody described above. The results indicated that the PHIS-PfE6 540 protein was located in the final supernatant (S4). The PHIS-Pf£6 540 protein was loaded onto a 5.0 ml, Metal chelating HiTrap column charged with NiCl 2 (obtained from Pharmacia Biotech Inc., Piscataway, NJ), previously equilibrated with 50 mM Tris, 1 mM PMSF, 1 mM β-mercaptoethanol (βME), 8 M urea, pH 8.0 (Buffer A). The column was washed with 10 column volumes (cv) of Buffer A and then with 10 cv with 50 mM Tris, 25 mM sodium acetate, 1 mM PMSF, 1 mM βME, 8 M urea, pH 6.0 (Buffer B) to remove loosely bound proteins. Bound PHIS-PfE6 540 protein was eluted with 10 cv of 50 mM Tris, 25 mM sodium acetate, 1 mM PMSF, 1 mM βME, 8 M urea, pH 4.0 (Buffer C). Column fractions were analyzed for the presence of PHIS-PfE6 540 protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the majority of the PHIS-PfE6 540 protein was eluted by Buffer C. The fractions containing the PHIS-PfE6 540 protein were combined and loaded onto a 5 ml SP- Sepharose HiTrap column (obtained from Pharmacia Biotech Inc.) previously equilibrated with 50 mM Tris, 25 mM Sodium Acetate, 1 mM PMSF, 1 mM βME, 8 M Urea, pH 4.5 (SP-Sepharose Buffer). The column was washed with SP-Sepharose Buffer until most of the unbound protein was removed. Bound protein was eluted with an increasing salt gradient to 1 M NaCl over 100 ml (20 cv) in SP-sepharose buffer. Column fractions were analyzed for the presence of PHIS-PfE6 540 protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the PHIS-PfE6 540 protein was eluted at about 0.75 M NaCl. The purified PHIS-PfE6 I48g protein was used to produce an anti-M6 polyclonal antiserum as follows. Rabbits were immunized with PHIS-PfE6 1 88 protein diluted to a concentration of about 0.1 mg/ml in PBS. One milliliter of the dilution was mixed 1 : 1 mix with Complete Freunds Adjuvant. In the primary immunization, about 500 μl of the 1:1 mix was injected subcutaneously into 5 different sites (0.1 ml/site) and 500 μl was injected intradermally into 5 different sites (0.1 ml/site) on the rabbit. Booster shots were administered to the rabbit intramuscularly in 4 sites using 250 μl/site of a 1 :1 mix of PHIS-PfE6 148g protein with Incomplete Freunds Adjuvant. The booster shots were adrr m : stered at days 14 and 35. Serum samples were obtained prior to immunization (pre-bleed), and at day 14 after primary immunization and day 14 after the first and second boost. C. Flea esterase protein PHIS-PfE9 528 was produced in the following manner. A pair of primers was used to amplify DNA from flea esterase nucleic acid molecule nfE9 2007 produced as described in Example 11. A sense primer containing an BamHl site having the nucleic acid sequence 5' -TTC CGG ATC CGG CTG ATC TAC AAG TGA CTT TG - 3' (denoted SEQ ID NO:64; BaniHI site shown in bold), was used in combination with an anti-sense primer containing a Xlwl site having the nucleic acid sequence 5' TGG TAC TCG AGT CAT AAA AAT TTA TTC CAA AAT C 3' (denoted SEQ ID NO:65; Xhόl site shown in bold). A PCR product was derived from nfE9 2007 , and is referred to herein as nf£9 154 o, having nucleic acid sequence SEQ ID NO:51. The PCR product was digested with Bam and Xliol restriction endonucleases, gel purified and subcloned into expression vector pTrcHisB (available from InVitrogen). The resultant recombinant molecule, referred to herein as pTrc-nfE9, 540 , was transformed into E. coli HB101 competent cells (available from Gibco BRL) to form recombinant cell E. coli :pTrc-nfE9 , 540 . The recombinant cells were cultured using the method described in Section A of this example. Immunoblot analysis of recombinant cell E. co//:pTrc-nfE9, 540 lysate using a T7 tag monoclonal antibody directed against the fusion portion of the recombinant PHIS-PfE9 528 fusion protein identified proteins of appropriate size, namely an about 59 kD protein for each fusion protein. Expression of the recombinant PHIS-PfE9 528 fusion protein was improved by transforming supercoiled plasmid pTrc-nfE9ι 584 DNA harvested from E. coli:pTτc- nfE9, 540 cells into the BL-21 strain of E. coli. The amount of expression PHIS-PfE9 52s was confirmed by immunoblot using the method described immediately above. Two liters of media from cultures of E. coli cells expressing PHIS-PfE9 528 protein were harvested and S4 supernatant was prepared using the method described above in section B. The PHIS-PfE9 528 protein contained in the S4 supernatant was loaded onto a 5.0 ml, Metal chelating HiTrap column, charged with NiCl 2 (available from Pharmacia Biotech Inc., Piscataway, NT), previously equilibrated with 50 mM Tris, 1 mM PMSF, 1 mM βME, 8 M urea, pH 8.0 (Buffer A). The column was washed with 5 cv of Buffer A until all unbound protein was removed. Bound protein was eluted with a linear gradient from Buffer A to 50 mM Tris, 1 mM PMSF, 1 mM βME, 8 M urea, 1 M NaCl, pH 4.0. Column fractions were analyzed for the presence of PHIS-PfE9 528 protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the majority of the PHIS-PfE9 528 protein was eluted at about 250 mM NaCl. The fractions containing the PHIS-PfE9 528 protein were combined and loaded onto a C4-reversed phase column (obtained from Vydak, Hesperia, CA), previously equilibrated with 0.05% trifluoroacetic acid (TFA). The column was washed with 0.05%) TFA until all unbound protein was removed. Bound proteins were eluted with a linear gradient from 0.05%o TFA to 0.05%> TFA in acetonitrile. Column fractions were analyzed for the presence of PHIS-PfE9 528 protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the PHIS-PfE9 528 protein was eluted at about 40% acetonitrile. The fractions containing the PHIS-PfE9 528 protein were combined and loaded onto a 5 ml Q-Sepharose HiTrap column previously equilibrated with 50 mM Tris, 25 mM Sodium Acetate, 1 mM PMSF, 1 mM βME, 8 M Urea, pH 8.5 (Q-Sepharose Buffer). The column was washed with Q-Sepharose Buffer until all unbound protein was removed. Bound protein was eluted with an increasing salt gradient to 1 M NaCl over 100 ml (20 cv) in Q-sepharose buffer. Column fractions were analyzed for the presence of PHIS-PfE9 528 protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the PHIS-PfE9 528 protein was eluted at about 0.3 M NaCl. The purified PHIS-PfE9 528 protein was used to produce an anti -PI polyclonal antiserum as follows. Rabbits were immunized with PHIS-PfE9 528 protein diluted to a concentration of about 0.1 mg/ml in PBS. One milliliter of the dilution was mixed 1 :1 mix with Complete Freunds Adjuvant. In the primary immunization, about 500 μl of the 1 :1 mix was injected subcutaneously into 5 different sites (0.1 ml/site) and 500 μl was injected intradermally into 5 different sites (0.1 ml/site) on the rabbit. Booster shots were administered to the rabbit intramuscularly in 4 sites using 250 μl/site of a 1:1 mix of PHIS-PfE9 528 protein with Incomplete Freunds Adjuvant The booster shots were administered at days 14 and 35. Serum samples were obtained prior to immunization (pre-bleed), and at day 14 after primary immunization and day 14 after the first and second boost. D. Flea esterase protein PHIS-PfE7 275 was produced in the following manner. A 650-bp fragment was produced by digesting nfE7 2836 DNA with the restriction enzymes BaniΑl and Bglll. The BamHl and Bglϊl fragment derived from nfE7 2836 is referred to herein as nfE7 650 , having nucleic acid sequence SEQ ID NO:72 and amino acid SEQ ID NO: 73. The fragment was purified using a Qiaquick™ Kit (available from Qiagen, Santa Clarita, CA), according to methods provided by the manufacturer. The purified fragment was subcloned into expression vector pTrcHisC which had been digested with BamHl and Bglll. The resultant recombinant molecule, referred to herein as pTrc-nfE7 650 was transformed into E. coli DH-5a competent cells (available from Gibco BRL) to form recombinant cell E. co//:pTrc-nfE7 650 . The recombinant cells were cultured using the method described above in section A. Immunoblot analysis of recombinant cell E. co//:pTrc-nfE7 650 lysate using a T7 tag monoclonal antibody directed against the fusion portion of the recombinant PHIS- PfE7 275 fusion protein identified proteins of appropriate size, namely an about 35 kD protein for each fusion protein. Expression of the recombinant fusion protein was improved by transforming supercoiled plasmid pTrc-nfE7 650 DNA harvested from E. co/z :pTrc-nfE7 650 cells into the BL-21 strain of E. coli. The amount of expression E. co//:pTrc-nfE7 650 was confirmed by immunoblot using the method described immediately above. Example 13. This Example demonstrates the production of esterase proteins of the present invention in eukaryotic cells. A. Recombinant molecule pBv-nfE7, 788 , containing a flea esterase nucleic acid molecule spanning nucleotides from about 99 through about 1886 of SEQ ID NO:24, and pBv-nfE8 I785 , containing a flea esterase nucleic acid molecule spanning nucleotides from about 99 through about 1883 of SEQ ID NO:30 each, operatively linked to baculovirus pob he Iron transcription control sequences were produced in the following manner. In order to subclone a flea esterase nucleic acid molecule into baculovirus expression vectors, flea esterase nucleic acid molecule-containing fragments were separately PCR amplified from nfE7 2836 or nfE8 280 , DNA. A PCR fragment of 1858 nucleotides, named nfE7 185g , was amplified from nfE7 2836 using a sense primer El 113 FWD having the nucleic acid sequence 5'- AAAACTGCAG TATAAATATG TTACCTCACA GTAGTG - 3' (SEQ ID NO:49; Pstl site shown in bold) and an antisense primer E 1113/2212 REV having the nucleic acid sequence 5'- TGCTCTAGAT TATCTAATAC TTCCTTCATT ACAG (SEQ ID NO:50; Xbal site shown in bold). A PCR fragment of 1858 nucleotides, named nfE8 1858 , was amplified from nfE8 2801 using a sense primer E2212 FWD having the nucleic acid sequence 5'- AAAACTGCAG TATAAATATG TTACCTCACA GTGCATTAG -3' (SEQ ID NO:66; Pstl site shown in bold), and the antisense primer E 1 113/2212 REV. The N- terminal primer was designed from the pol h sequence of baculovirus with modifications to enhance expression in the baculovirus system. In order to produce a baculovirus recombinant molecule capable of directing the production of PfE7 596 , the about 1,802 base pair PCR product (referred to as Bv-nfE7 I802 ) was digested with Pstl and Xbal and subcloned into unique Pstl and Xbal sites of pVL1392 baculovirus shuttle plasmid (available from Pharmingen, San Diego, CA) to produce the recombinant molecule referred to herein as pVL-nfE7 1802 . In order to produce a baculovirus recombinant molecule capable of directing the production of PfE8 595 , the about 1,792 base pair PCR product (referred to as Bv-nfE8, 792 ) was digested with Pstl and Xbal and subcloned into Pstl and Xbal digested to produce the recombinant molecule referred to herein as pVL-nfE8 I792 . The resultant recombinant molecules, pVL-nfE7 1802 and pVL-nfE8, 792 , were verified for proper insert orientation by restriction mapping. Such a recombinant molecule can be co-transfected with a linear Baculogold baculovirus DNA (available from Pharmingen) into S. frugiperda Sf9 cells (available from InVitrogen) to form the recombinant cells denoted S. frugiperda:pVL-nfE7 m2 and S. frugiperda:pVL-fES, m2 . S. frugiperda:pVL-nfEl m2 can be cultured in order to produce a flea esterase protein PfE7 596 . S. frugiperda:pVL-nfE8 π92 can be cultured in order to produce a flea esterase protein PfE8 595 . B. Recombinant molecule pBv-PfE9 52g , containing a flea esterase nucleic acid molecule spanning nucleotides from 14 through 1595 of SEQ ID NO:36, operatively linked to baculovirus polyhedron transcription control sequences were produced in the following manner. In order to subclone a flea esterase nucleic acid molecule into baculovirus expression vectors, a flea esterase nucleic acid molecule- containing fragment was PCR amplified from nfE9 2007 DNA. A PCR fragment of about 1600 nucleotides, named nfE9 1600 , was amplified from nfE9 2007 using a sense primer P121B1 Sense having the nucleic acid sequence 5'- CGC GGA TCC GCT GAT CTA CAA GTG ACT TTG C - 3' (SEQ ID NO:75; BamHl site shown in bold) and an antisense primer PI 2 IB 1 Anti having the nucleic acid sequence 5'- CCG AGC GGC CGC ATA AAA ATT TAT TCC AAA ATC TAA GTC G-3' (SEQ ID NO:76; Notl site shown in bold). The Ν-terminal primer was designed from the pol h sequence of baculovirus with modifications to enhance expression in the baculovirus system. In order to produce a baculovirus recombinant molecule capable of directing the production of PfE9 528 , the about 1,600 base pair PCR product (referred to as Bv-nfE9, 600 ) was digested with BamHl and Notl and subcloned into unique BamHl and Notl sites of pVL1393 baculovirus shuttle plasmid (available from Pharmingen, San Diego, CA) to produce the recombinant molecule referred to herein as pVL-nfE9, 60 o. The resultant recombinant molecule, pVL-nfE9, 600 , was verified for proper insert orientation by restriction mapping. Such a recombinant molecule can be co-transfected with a linear Baculogold baculovirus DΝA into S. frugiperda Sf9 cells to form the recombinant cells denoted S. frugiperda:pWL-nfE9 mo . S.frugiperda:pVL-nfE9 mo can be cultured in order to produce a flea esterase protein PfE9 528 . An immunoblot of supernatant from cultures of S. frugiperda:p ' V -nfE9 mo cells producing the flea esterase protein PfE9 528 was performed using the anti-Pi polyclonal antiserum described in detail in Example 12. Blots were incubated using serum samples from the pre-bleed or from serum collected 14 days after the first boost of the rabbit. Analysis of the supernatent from cultures of S.frugiperda:pWL-nfE9 mo cells identified an about 66 kD protein C. Recombinant molecule pBv-PfE6 530 , containing a flea esterase nucleic acid molecule spanning nucleotides from 50 through 1701 of SEQ ID NO: 18, operatively linked to baculovirus polyhedron transcription control sequences were produced in the following manner. In order to subclone a flea esterase nucleic acid molecule into baculovirus expression vectors, a flea esterase nucleic acid molecule- containing fragment was PCR amplified from nfE6 1792 DNA. A PCR fragment of about 1679 nucleotides, named nfE10, 679 , was amplified from nfE6, 792 using a sense primer M6M32 Sense having the nucleic acid sequence 5'- GCG AGG CCT TAT AAA TAT GTC TCG TGT TAT TTT TTT AAG TTG - 3' (SEQ ID NO:75; Stul site shown in bold) and an antisense primer M6M32 Anti having the nucleic acid sequence 5'- GCA CTG CAG TTA TTG ACT GTG CAA AGT TTT TGT GG-3' (SEQ ID NO:76; Pstl site shown in bold). The N-terminal primer was designed from the pol h sequence of baculovirus with modifications to enhance expression in the baculovirus system. In order to produce a baculovirus recombinant molecule capable of directing the production of PfE6 530 , the about 1,679 base pair PCR product (referred to as Bv-nfE6, 679 ) was digested with Stul and Pstl and subcloned into unique Stul and Pstl sites of FAST BAC™ baculovirus shuttle plasmid (obtained from Gibco-BRL) to produce the recombinant molecule referred to herein as pFB-nfE6, 679 . The resultant recombinant molecule, pFB-nfE6, 679 , was verified for proper insert orientation by restriction mapping. Such a recombinant molecule can be transformed into E. coli strain DH10 (obtained from Gibco-BRL) according to the manufacturer's instructions. The pFB-nfE6 1679 isolated from the transformed DH10 cells can then be co- transfected with a linear Baculogold baculovirus DNA into S. frugiperda Sf9 cells to form the recombinant cells denoted S. frugiperda:pFB-nfE6 l679 . S. frugiperda:pFB- nfE6 1679 can be cultured in order to produce a flea esterase protein PfE6 530. An immunoblot of supernatant from cultures of S. frugiperda:pFB-nfE6 lύl9 cells producing the flea esterase protein PfE6 530 was performed using the anti-M6 polyclonal antiserum described in detail in Example 12. Blots were incubated using serum samples from the pre-bleed or from serum collected 14 days after the first boost of the rabbit. Analysis of the supematent from cultures of S. -u iperda:pFB-nfE6 i679 cells identified an about 66 kD protein. N-terminal amino acid sequence was obtained using standard methods for the about 66 kD protein identified using the anti-M6 polyclonal antiserum. The N-terminal amino acid sequence was determined to be identical to the N-terminal amino acid sequence of SEQ ID NO:44. Example 14 This example describes the purification of carboxylesterase protein from fed flea midguts. About 43,000 cat blood-fed adult flea midguts were collected and prepared as previously described in Example 1. The extract was then added in 2 aliquots to columns containing about 1 to about 2 ml ofp-aminobenzamidine linked agarose beads (available from Sigma), equilibrated in 50 mM Tris (pH 8.0), 400 mM NaCl, and incubated overnight at 4°C. The columns were then drained to remove unbound protein and the two aliquots of unbound protein were combined. The collected unbound protein was then concentrated and diafiltered into a total volume of about 16 ml of 25 mM Tris (pH 8), 10 mM NaCl using an Ultrafree-20 10 kD centrifugal concentrator (available from Millipore, Bedford, MA). Aliquots of about 8 ml were loaded onto an Uno Q6 anion exchange column (available from Bio-Rad, Hercules, CA) equilibrated in 25 mM Tris (pH 8), 10 mM NaCl, operated on a BioLogic liquid chromatography system (available from Bio-Rad). The column was washed with 25 mM Tris (pH 8), 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 25 mM Tris, pH 8. Fractions were assayed for CE activity using the assay described previously. The results indicated that CE activity was eluted at about 220 mM NaCl. Fractions containing CE activity were pooled and diafiltered into a total volume of about 3 ml of 20 mM MES buffer (2-(N-moφholino)ethanesulfonic acid), pH 6.0, containing 10 mM NaCl, in preparation for cation exchange cliromatography. The sample was then applied to an Uno SI cation exchange column (available from Bio-Rad) equilibrated in I IFS buffer. The column was washed with MES buffer until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 20 mM MES buffer, pH 6. Fractions were assayed for CE activity using the assay described previously. The results indicated that CE activity was not retained on the cation exchange column using the above conditions, and all of the activity was found in the flow-through fractions. Fractions containing CE activity were pooled and diafiltered into a total volume of about 3 ml of 25 mM Tris (pH 8), 10 mM NaCl, in preparation for an additional anion exchange chromatography step. The sample was then applied to a Bio-Scale Q2 anion exchange column (available from Bio-Rad). The column was washed with 25 mM Tris (pH 8), 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 25 mM Tris, pH 8. Fractions were assayed for CE activity using the assay described previously. The results indicated that CE activity was eluted at about 130 mM NaCl. A fraction containing CE activity was diluted into a total volume of about 4 ml of 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl, in preparation for hydroxyapafite chromatography. The sample was then applied to a Bio-Scale CHT2-I column (available from Bio-Rad) at a flow rate of about 0.5 ml/min. The column was washed with 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl to 0.5 M 10 mM phosphate buffer, pH 6.5 containing 10 mM NaCl. Fractions were assayed for CE activity using the assay described previously. The results indicated that CE activity was eluted at about 200 mM phosphate. Example 15 This example describes the purification of a carboxylesterase protein from wandering flea larvae. About 120,000 bovine blood-fed adult wandering flea larvae were homogenized in 3 batches of about 40,000 wandering larvae in each batch, in Tris buffered saline (TBS), pH 8.0 as previously described, except that about 1.2 mg of phenylthiourea was added to each ml of TBS during the extraction procedure to inhibit cross linking reactions. The extracts were dialyzed against 2 changes of about 2 L of 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl in preparation for hydroxyapafite batch chromatography. The samples were then filtered through glass Acrodiscs ® (available from Gelman Sciences, Ann Arbor, MI) and added to 14 g of Macro-Prep Ceramic Hydroxyapafite, Type I, 40 μm beads (available from Bio-Rad), previously equilibrated in 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl. The extracts and beads were rocked at room temperature for about 30 minutes. Following incubation, the beads were centrifuged for about 5 minutes at 500 x g and the supematants removed. The beads were washed with about 40 ml 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl, centrifuged as above, and washed and centrifuged again to eliminate all unbound protein. Bound proteins were eluted by washing the beads with about 40 ml of each of 100 mM, 200 mM, 300 mM, and 400 mM phosphate buffer, pH 6.5 containing 10 mM NaCl. Following elution, the supematants from each concentration of phosphate buffer were tested for juvenile hormone esterase activity as described previously in Example 7. The juvenile hormone esterase activity eluted at different phosphate concentrations in each batch, but the activity was generally found in the 200 mM to 300 mM phosphate fractions. The fractions that contained the highest juvenile hormone esterase activity were combined and diafiltered into a total volume of about 50 ml of 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl using a stirred cell concentrator fitted with a YM10 ultrafiltration membrane (available from Amicon, Beverly, MA). Aliquots of about 5 ml to 10 ml were applied to a chromatography column containing about 10 ml of Macro- Prep Ceramic Hydroxyapatite, Type I, 20 μm beads, previously equilibrated with 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl. The column was washed with 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl to 0.5 M 10 mM phosphate buffer, pH 6.5 containing 10 mM NaCl. Fractions were assayed for carboxylesterase activity using the assay described previously. The results indicated that carboxylesterase activity was eluted at about 160 mM phosphate. The fractions that contained the highest carboxylesterase activity were combined and diafiltered into a total volume of about 15 ml of 20 mM sodium acetate buffer, pH 4.0 in preparation for cation exchange chromatography. Aliquots of about 3 ml were applied to a PolyCat A cation exchange column (available from PolyLC, Columbia, MD) equilibrated in 20 mM sodium acetate buffer, pH 6.0, operated on a Waters high performance liquid chromatography system (available from Waters Coφoration, Milford, MA). The column was washed with 20 mM sodium acetate buffer, pH 6.0 until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 20 mM sodium acetate buffer, pH 6.0 to 20 mM sodium acetate buffer, pH 6.0 containing 1 M NaCl. Fractions were assayed for CE activity using the assay described previously. The results indicated that there were two pools of CE activity. The first pool was not retained on the cation exchange column, and the second pool was eluted at about 170 mM NaCl. The fractions from the second pool that contained the highest carboxylesterase activity were combined and diafiltered into a total volume of about 10 ml of 25 mM Tris (pH 8), 10 mM NaCl, in preparation for anion exchange cliromatography. The sample was then applied to a Bio-Scale Q2 anion exchange column (available from Bio-Rad). The column was washed with 25 mM Tris (pH 8), 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 25 mM Tris, pH 8. Fractions were assayed for carboxylesterase activity using the assay described previously. The results indicated that carboxylesterase activity was eluted at about 350 mM NaCl. Fractions containing carboxylesterase activity were combined and concentrated to about 175 μl using a Centricon 10 centrifugal concentrator (available from Amicon, Beverly, MA) in preparation for size exclusion cliromatography. The sample was applied to a Bio-Select SEC 125-5 size exclusion chromatography column (available from Bio-Rad), previously equilibrated in TBS, pH 7.2. About 250 μl fractions were then collected. The fractions were assayed for carboxylesterase activity using the assay described previously. The results indicated that the carboxylesterase activity was eluted in about 5.5 to 6 ml of buffer, corresfin ling to a molecular weight of about 40 to 100 kDa based on the elution volumes of gel filtration molecular weight standard proteins (available from Sigma, St. Louis, MO). Example 16 This example describes the purification of juvenile hormone esterase activity from unfed adult flea midguts by affinity chromatography. About 16,000 unfed adult flea midguts were collected in 20 mM Tris buffer (pH 7.7), containing 130 mM NaCl, 1 mM sodium EDTA, 1 mM Pefabloc ® (available from Boehrmger Mannheim, Indianapolis, IN), 1 microgram/ml (μg/ml) leupeptin and 1 μg/ml pepstatin. The midguts were homogenized by freeze-fracture and sonication, and then centrifuged at about 14,000 x g for 20 min. The soluble material from the centrifugation step was recovered, diafiltered into Tris buffered saline (TBS), and applied to a disposable plastic column containing about 1 ml of 3-[(4'- mercapto)butylthio]-l,l,l-trifluoropropan-2-one linked Sepharose 6B beads, prepared similarly to the method described by Venkatesh et al. ( J. Biol. Chem., Vol. 265, No. 35, 21727-21732, 1990) (the 3-[(4'-mercaρto)butylthio]-l ,l ,l-trifluoropropan-2-one was a gift from Novartis Coφ., Basel, Switzerland; and the Epoxy-activated Sepharose 6B is available from Pharmacia Biotech Inc., Piscataway, NJ). After overnight incubation at 4 °C, the column was drained and the beads were washed with about 10 nil TBS, then about 10 ml TBS containing 0.1% (w/v) n-octylglucoside (OG; available from Boehringer Mannheim). The pre-column, flow-through, and wash fractions were tested for juvenile hormone esterase activity by the method previously described above in Example 7. The results indicate that the flow-through fraction contained approximately 40%) less juvenile hormone esterase activity than the pre-column material, and that the washes contained very little activity. Bound protein was eluted from the beads by adding about 10 ml of TBS containing 0.1 %> (w/v) OG and 1 mM 3-octylthio-l,l,l-trifluoropropan-2-one (OTFP; a gift from Novartis Coφ.). After a 2 hour incubation at 4°C, about 5 ml of the eluate was collected, and the remaining 5 ml was incubated with the beads overnight at 4°C. The following day, the beads were drained, the eluate collected, and an additional 10 ml of TBS cr nt άning 0.1 % (w/v) OG and 1 mM OTFP was added to the beads. After an overnight incubation at 4°C, the beads were drained and the eluate collected. The final 10 ml elution step was repeated 3 additional times so that we had 6 eluted fractions. The first elution fraction was dialyzed overnight twice against 1 liter of fresh TBS to remove excess OTFP. The second elution fraction was also dialyzed overnight against 1 liter of fresh TBS to remove OTFP. The third through sixth elution fractions were not dialyzed. All six eluted fractions were tested for juvenile hormone esterase activity by the method previously described above in Example 7. The results indicate that only the third elution fraction contained detectable juvenile hormone esterase activity. Analysis of the eluted fractions by silver-stained SDS-PAGE indicated that several proteins were specifically bound to the affinity beads and were eluted by OTFP. The apparent molecular weights of these proteins, as determined by SDS-PAGE, were about 66 kDa, 55 kDa, and 33 kDa. About 3.5 ml of each elution fraction were combined and concentrated to about 110 μl using a Centriplus 10 centrifugal concentrator (available from Amicon, Beverly, MA). This pool was separated by SDS-PAGE and blotted onto a polyvinylidene difluoride (PVDF) membrane as described previously in Example 5. The stained protein band at about 66 kDa was excised and subjected to N-terminal sequence analysis as described previously. The results indicated that the N-terminal amino acid sequence of the putative 66 kDa juvenile hormone esterase protein was DL y/g V k/y/g v/q/n LQGTLKGKE (denoted herein as SEQ ID NO:74), in which the lower case letters designate uncertainties. Below is shown a comparison between different esterase amino acid sequences of the present invention. SEQ ID NO:74: DL (y/g) V (k/y/g) (v/q/n) LQGTLKGKE SEQ ID NO:37: DL Q V T L LQGTLKGKE (Residues 3-17) Example 17 This example describes the purification of an active recombinant juvenile hormone esterase protein from baculovirus supematants. About 1 liter of supernatant from cultures of S. frugiperda:pY -nfE9 mo cells producing the flea esterase protein PfE9 528 was brought to about 50% sauration with ammonium sulfate and centrifuged at about 20000 x g for about 30 minutes at 4°C to pellet the precipitated material. After centrifugation, the pellet was retained and the supernatant was brought to about 100%> saturation with ammonium sulfate and centrifuged as above. The material in both pellets were resuspended separately in about 35 ml of Tris buffered saline (TBS), pH 8.0. The resuspended pellets were assayed for the presence of flea esterase protein PfE9 528 using standard Western blot techniques and a polyclonal antiserum that binds specifically to PfE9 528 protein. Briefly, a rabbit was immunized with PHIS-PfE9 528 protein purified from E. co/ :pTrc-nfE9ι 584 cells (described above in Example 12C) and boosted using standard procedures. The results indicated that the flea esterase protein PfE9 528 was present in the S. frugiperda:pV - nfE9, 60 o supematants and the protein was precipitated by adjusting the ammonium sulfate concentration from about 50%> saturation to about 100% saturation. The resuspended flea protein PfE9 528 was diafiltered into about 10 ml of 25 mM Tris (pH 8.0), 10 mM NaCl using an Ultrafree-20 10 kD centrifugal concentrator in preparation for anion exchange chromatography. Aliquots of about 5 ml were loaded onto an Uno Q6 anion exchange column equilibrated in 25 mM Tris (pH 8.0), 10 mM NaCl. The column was washed with 25 mM Tris (pH 8.0), 10 mM NaCl until most of the unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 25 mM Tris buffer (pH 8.0). Fractions were assayed for the presence of flea esterase protein PfE9 528 by the immunoblot method described above. The results indicated that the flea esterase protein PfE9 528 was eluted at about 200 mM NaCl. Fractions containing the flea esterase protein PfE9 528 were pooled and concentrated to about 440 μl using a Centricon 10 kD centrifugal concentrator in preparation for size exclusion cliromatography. The sample was applied in 3 aliquots to a Bio-Select SEC 125-5 size exclusion chromatography column (available from BioRad), previously equilibrated in TBS, pH 7.2. The column was eluted with TBS, pH 7.2 at a flow rate of about 0.5 ml/min, and fractions of about 250 μl were collected. The fractions were assayed for the presence of flea esterase protein PfE9 528 by the immunoblot method described above. The results indicate ' t 1 at the flea esterase protein PfE9 528 was eluted with about 6 ml of buffer, corresponding to a molecular weight of about 40 to 100 kDa based on the elution volumes of gel filtration molecular weight standard proteins (available from Sigma, St. Louis, MO). Fractions containing flea esterase protein PfE9 528 were then assayed for juvenile hormone esterase activity as described in Example 7 and carboxylesterase activity as described in Example 2. The results indicated that the purified flea esterase protein PfE9 528 had both juvenile hormone esterase activity and carboxylesterase activity. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Heska Corporation (B) STREET: 1825 Sharp Point Drive (C) CITY: Fort Collins (D) STATE: CO (E) COUNTRY: US (F) POSTAL CODE (ZIP) : 80525 (G) TELEPHONE: (970) 493-7272 (H) TELEFAX: (970) 484-9505 (ii) TITLE OF INVENTION: Novel Carboxylesterase Nucleic Acid Molecules, Proteins and Uses Thereof (iii) NUMBER OF SEQUENCES: 76 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: LAHIVE & COCKFIELD, LLP (B) STREET: 28 STATE STREET (C) CITY: BOSTON (D) STATE: MA (E) COUNTRY: US (F) ZIP: 02109 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: Windows 95 (D) SOFTWARE: ASCII DOS TEXT (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/747,221 (B) FILING DATE: November 12, 1996 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Rothenberger , Scott D. (B) REGISTRATION NUMBER: 41,277 (C) REFERENCE/DOCKET NUMBER: HKV-OIOPC (FC-1-Cl-PCT) (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (617) 227-7400 (B) TELEFAX: (617) 742-4214 (2) INFORMATION FOR SEQ ID NO : 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 401 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 92..400 (iv) FEATURE: (A) NAME/KEY: Xaa = He, Thr Lys or Arg (B) LOCATION: 218 (v) FEATURE : (A) NAME/KEY: Xaa = Lys, Glu or Gin (B) LOCATION: 275, 329 (vi) FEATURE: (A) NAME/KEY: Xaa = Asn, Tyr or Asp (B) LOCATION: 332 (vii) SEQUENCE DESCRIPTION: SEQ ID NO : 1 : TTTACATCAT TAATAAACAT AAATCTAATA AATCTTGTGG ATCAAGATCA 50 AGTTTATTAG TGAGAGTGTT GGATTTGTGA AATATTTCAA A ATG AAT 97 Met Asn 1 TCT TTA ATT GTA AAA ATT TCT CAA GGA GCT ATT GAG GGG AAG 139 Ser Leu He Val Lys He Ser Gin Gly Ala He Glu Gly Lys 5 10 15 GAA ATG ATT AAT GAT AAT GGA AAG TCG TTT AGA GGA TTT TTG 181 Glu Met He Asn Asp Asn Gly Lys Ser Phe Arg Gly Phe Leu 20 25 30 GGT ATA CCT TAT GCT AAA CCG CCT ATA GGA AAT CTT ANA TTT 223 Gly He Pro Tyr Ala Lys Pro Pro He Gly Asn Leu Xaa Phe 35 40 AAG CCT CCT CAA AAG CCT GAT GAT TGG AAT GAT GTT CGA CCA 265 Lys Pro Pro Gin Lys Pro Asp Asp Trp Asn Asp Val Arg Pro 45 50 55 GCT ACT GAA NAA GCA AAT GGT TGT AGA TCG AAA CAT ATG CTG 307 Ala Thr Glu Xaa Ala Asn Gly Cys Arg Ser Lys His Met Leu 60 65 70 CAG CAT CAT ATT ATT GGA GAC NAA NAT TGT CTA TAC CTA AAC 349 Gin His His He He Gly Asp Xaa Xaa Cys Leu Tyr Leu Asn 75 80 85 GTN TAT GTT CCA TTG ACT TCC AAA TTG GAG AAA CTA CCA GTA 391 Val Tyr Val Pro Leu Thr Ser Lys Leu Glu Lys Leu Pro Val 90 95 100 ATG TTC TGG G 401 Met Phe Trp (2) INFORMATION FOR SEQ ID NO : 2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 103 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) FEATURE (A) NAME/KEY: Xaa = He, Thr, Lys or Arg (B) LOCATION: 43 (iv) FEATURE (A) NAME/KEY: Xaa = Lys, Glu or Gin (B) LOCATION: 62, 80 (v) FEATURE (A) NAME/KEY: Xaa = Asn, Tyr or Asp (B) LOCATION: 81 (vi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : Met Asn Ser Leu He Val Lys He Ser Gin Gly Ala He Glu 1 5 10 Gly Lys Glu Met He Asn Asp Asn Gly Lys Ser Phe Arg Gly 15 20 25 Phe Leu Gly He Pro Tyr Ala Lys Pro Pro He Gly Asn Leu 30 35 40 Xaa Phe Lys Pro Pro Gin Lys Pro Asp Asp Trp Asn Asp Val 45 50 55 Arg Pro Ala Thr Glu Xaa Ala Asn Gly Cys Arg Ser Lys His 60 65 70 Met Leu Gin His His He He Gly Asp Xaa Xaa Cys Leu Tyr 75 80 Leu Asn Val Tyr Val Pro Leu Thr Ser Lys Leu Glu Lys Leu 85 90 95 Pro Val Met Phe Trp 100 (2) INFORMATION FOR SEQ ID NO : 3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 401 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) OPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO : 3 : CCCAGAACAT TACTGGTAGT TTCTCCAATT TGGAAGTCAA TGGAACATAN 50 ACGTTTAGGT ATAGACAATN TTNGTCTCCA ATAATATGAT GCTGCAGCAT 100 ATGTTTCGAT CTACAACCAT TTGCTTNTTC AGTAGCTGGT CGAACATCAT 150 TCCAATCATC AGGCTTTTGA GGAGGCTTAA ATNTAAGATT TCCTATAGGC 200 GGTTTAGCAT AAGGTATACC CAAAAATCCT CTAAACGACT TTCCATTATC 250 ATTAATCATT TCCTTCCCCT CAATAGCTCC TTGAGAAATT TTTACAATTA 300 AAGAATTCAT TTTGAAATAT TTCACAAATC CAACACTCTC ACTAATAAAC 350 TTGATCTTGA TCCACAAGAT TTATTAGATT TATGTTTATT AATGATGTAA 400 A 401 (2) INFORMATION FOR SEQ ID NO : 4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iϋ) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..364 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4 : G TCT CGT GTT ATT TTT TTA AGT TGT ATT TTT TTG TTT AGT 40 Ser Arg Val He Phe Leu Ser Cys He Phe Leu Phe Ser 1 5 10 TTT AAT TTT ATA AAC TGT GAT TCC CCG ACT GTA ACT TTG CCC 82 Phe Asn Phe He Asn Cys Asp Ser Pro Thr Val Thr Leu Pro 15 20 25 CAA GGC GAA TTG GTT GGA AAA GCT TTG ACG AAC GAA AAT GGA 124 Gin Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu Asn Gly 30 35 40 AAA GAG TAT TTT AG TAC ACA GGT GTA CCT TAT GCT AAA CCT 166 Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro 45 50 55 CCT GTT GGA GAA CTT AGA TTT AAG CCT CCA CAG AAA GCT GAG 208 Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu 60 65 CCA TGG CAA GGT GTT TTC AAC GCC ACA TTA TAC GGA AAT GTG 250 Pro Trp Gin Gly Val Phe Asn Ala Thr Leu Tyr Gly Asn Val 70 75 80 TGT AAA TCT TTA AAT TTC TTC TTG AAG AAA ATT GAA GGA GAC 292 Cys Lys Ser Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp 85 90 95 GAA GAC TGC TTG GTA GTA AAC GTG TAC GCA CCA AAA ACA ACT 334 Glu Asp Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 TCT GAT AAA AAA CTT CCA GTA TTT TTC TGG 364 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp 115 120 (2) INFORMATION FOR SEQ ID NO : 5 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 121 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO : 5 : Ser Arg Val He Phe Leu Ser Cys He Phe Leu Phe Ser Phe 1 5 10 Asn Phe He Asn Cys Asp Ser Pro Thr Val Thr Leu Pro Gin 15 20 25 Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu Asn Gly Lys 30 35 40 Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro Pro 45 50 55 Val Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu Pro 60 65 70 Trp Gin Gly Val Phe Asn Ala Thr Leu Tyr Gly Asn Val Cys 75 80 Lys Ser Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp Glu 85 90 95 Asp Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr Ser 100 105 110 Asp Lys Lys Leu Pro Val Phe Phe Trp 115 120 (2) INFORMATION FOR SEQ ID NO : 6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : CCAGAAAAAT ACTGGAAGTT TTTTATCAGA AGTTGTTTTT GGTGCGTACA 50 CGTTTACTAC CAAGCAGTCT TCGTCTCCTT CAATTTTCTT CAAGAAGAAA 100 TTTAAAGATT TACACACATT TCCGTATAAT GTGGCGTTGA AAACACCTTG 150 CCATGGCTCA GCTTTCTGTG GAGGCTTAAA TCTAAGTTCT CCAACAGGAG 200 GTTTAGCATA AGGTACACCT GTGTAGCTAA AATACTCTTT TCCATTTTCG 250 TTCGTCAAAG CTTTTCCAAC CAATTCGCCT TGGGGCAAAG TTACAGTCGG 300 GGAATCACAG TTTATAAAAT TAAAACTAAA CAAAAAAATA CAACTTAAAA 350 AAATAACACG AGAC 364 (2) INFORMATION FOR SEQ ID NO : 7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 421 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 113..421 (iv) SEQUENCE DESCRIPTION: SEQ ID NO : 7 : TTTACATTAC ATCAAATCAT ATTTTTATTA GTATATTTTT TAGAAGAACC 50 TAGCCAAAAA ATATGGACTT TAGACTGTGA TTAATTTATT TTACCTGAGA 100 TTTTCCTTTA CA ATG GGT GAT CTT CAA GTG ACT TTG TTA CAA 142 Met Gly Asp Leu Gin Val Thr Leu Leu Gin 1 5 10 GGT TCT TTG AGA GGA AAA GAG CAA ATT AAT GAA AAG GGA AAT 184 Gly Ser Leu Arg Gly Lys Glu Gin He Asn Glu Lys Gly Asn 15 20 GTG TTT TAT AGT TAT TCT GGA ATT CCA TAT GCC AAA CCT CCA 226 Val Phe Tyr Ser Tyr Ser Gly He Pro Tyr Ala Lys Pro Pro 25 30 35 GTT GGT GAT CTA AGA TTC AAG CCA CCT CAA CCT GCA GAA CCT 268 Val Gly Asp Leu Arg Phe Lys Pro Pro Gin Pro Ala Glu Pro 40 45 50 TGG TCA GGT GTC CTT GAT GCT ACT AAA GAA GGG AAT AGT TGT 310 Trp Ser Gly Val Leu Asp Ala Thr Lys Glu Gly Asn Ser Cys 55 60 65 AGA TCT GTA CAT TTT ATT AAA AAG ATT AAA GTA GGG GCT GAA 352 Arg Ser Val His Phe He Lys Lys He Lys Val Gly Ala Glu 70 75 80 GAT TGT CTA TAC CTC AAT GTC TAT GTA CCA AAA ACA TCA GAG 394 Asp Cys Leu Tyr Leu Asn Val Tyr Val Pro Lys Thr Ser Glu 85 90 AAA TCC CTT CTT CCA GTA ATG GTA TGG 421 Lys Ser Leu Leu Pro Val Met Val Trp 95 100 (2) INFORMATION FOR SEQ ID NO : 8 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 103 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO : 8 : Met Gly Asp Leu Gin Val Thr Leu Leu Gin Gly Ser Leu Arg 1 5 10 Gly Lys Glu Gin He Asn Glu Lys Gly Asn Val Phe Tyr Ser 15 20 25 Tyr Ser Gly He Pro Tyr Ala Lys Pro Pro Val Gly Asp Leu 30 35 40 Arg Phe Lys Pro Pro Gin Pro Ala Glu Pro Trp Ser Gly Val 45 50 55 Leu Asp Ala Thr Lys Glu Gly Asn Ser Cys Arg Ser Val His 60 65 70 Phe He Lys Lys He Lys Val Gly Ala Glu Asp Cys Leu Tyr 75 80 Leu Asn Val Tyr Val Pro Lys Thr Ser Glu Lys Ser Leu Leu 85 90 95 Pro Val Met Val Trp 100 (2) INFORMATION FOR SEQ ID NO : 9 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 421 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO : 9 : CCATACCATT ACTGGAAGAA GGGATTTCTC TGATGTTTTT GGTACATAGA 50 CATTGAGGTA TAGACAATCT TCAGCCCCTA CTTTAATCTT TTTAATAAAA 100 TGTACAGATC TACAACTATT CCCTTCTTTA GTAGCATCAA GGACACCTGA 150 CCAAGGTTCT GCAGGTTGAG GTGGCTTGAA TCTTAGATCA CCAACTGGAG 200 GTTTGGCATA TGGAATTCCA GAATAACTAT AAAACACATT TCCCTTTTCA 250 TTAATTTGCT CTTTTCCTCT CAAAGAACCT TGTAACAAAG TCACTTGAAG 300 ATCACCCATT GTAAAGGAAA ATCTCAGGTA AAATAAATTA ATCACAGTCT 350 AAAGTCCATA TTTTTTGGCT AGGTTCTTCT AAAAAATATA CTAATAAAAA 400 TATGATTTGA TGTAATGTAA A 421 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 524 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 113..523 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 10: GAACGTTGAT ACGATAGACA TGTCGTCTTC AAAACGTCTA TTTTATCATA 50 AACAAAACGA GATAAATAAT AACAATTAAG CAACCAAAAT GCATTAAAAA 100 ACACAATAAA AA ATG TTA CCT CAC AGT AGT GCA TTA GTT TTA 142 Met Leu Pro His Ser Ser Ala Leu Val Leu 1 5 10 TTT TTA TTT TTT TTA TTT TTC TTA TTT ACA CCT ATC TTG TGC 184 Phe Leu Phe Phe Leu Phe Phe Leu Phe Thr Pro He Leu Cys 15 20 ATA CTA TGG GAT AAC CTA GAT CAG CAT TTG TGC AGA GTT CAA 226 He Leu Trp Asp Asn Leu Asp Gin His Leu Cys Arg Val Gin 25 30 35 TTT AAC AGG ATC ACG GAA GGA AAA CCG TTC CGA TAT AAA GAT 268 Phe Asn Arg He Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp 40 45 50 CAT AGG AAT GAT GTA TAT TGT TCT TAT TTG GGA ATT CCT TAT 310 His Arg Asn Asp Val Tyr Cys Ser Tyr Leu Gly He Pro Tyr 55 60 65 GCC GAA CCG CCT ATT GGA CCA TTA CGA TTT CAG TCT CCA AAA 352 Ala Glu Pro Pro He Gly Pro Leu Arg Phe Gin Ser Pro Lys 70 75 80 CCA ATA TCA AAT CCA AAA ACA GGA TTC GTA CAG GCT CGA ACT 394 Pro He Ser Asn Pro Lys Thr Gly Phe Val Gin Ala Arg Thr 85 90 TTG GGA GAC AAA TGT TTC CAG GAA AGT CTA ATA TAT TCT TAT 436 Leu Gly Asp Lys Cys Phe Gin Glu Ser Leu He Tyr Ser Tyr 95 100 105 GCA GGA AGC GAA GAT TGC TTA TAT CTG AAT ATA TTC ACG CCA 478 Ala Gly Ser Glu Asp Cys Leu Tyr Leu Asn He Phe Thr Pro 110 115 120 GAG ACT GTT AAT TCT GCG AAC AAT ACA AAA TAT CCT GTA ATG 520 Glu Thr Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val Met 125 130 135 TTC T 524 Phe (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 137 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 11: Met Leu Pro His Ser Ser Ala Leu Val Leu Phe Leu Phe Phe 1 5 10 Leu Phe Phe Leu Phe Thr Pro He Leu Cys He Leu Trp Asp 15 20 25 Asn Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn Arg He 30 35 40 Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Arg Asn Asp 45 50 55 Val Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu Pro Pro 60 65 70 He Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He Ser Asn 75 80 Pro Lys Thr Gly Phe Val Gin Ala Arg Thr Leu Gly Asp Lys 85 90 95 Cys Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly Ser Glu 100 105 110 Asp Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr Val Asn 115 120 125 Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe 130 135 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 524 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO : 12 : AGAACATTAC AGGATATTTT GTATTGTTCG CAGAATTAAC AGTCTCTGGC 50 GTGAATATAT TCAGATATAA GCAATCTTCG CTTCCTGCAT AAGAATATAT 100 TAGACTTTCC TGGAAACATT TGTCTCCCAA AGTTCGAGCC TGTACGAATC 150 CTGTTTTTGG ATTTGATATT GGTTTTGGAG ACTGAAATCG TAATGGTCCA 200 ATAGGCGGTT CGGCATAAGG AATTCCCAAA TAAGAACAAT ATACATCATT 250 CCTATGATCT TTATATCGGA ACGGTTTTCC TTCCGTGATC CTGTTAAATT 300 GAACTCTGCA CAAATGCTGA TCTAGGTTAT CCCATAGTAT GCACAAGATA 350 GGTGTAAATA AGAAAAATAA AAAAAATAAA AATAAAACTA ATGCACTACT 400 GTGAGGTAAC ATTTTTTATT GTGTTTTTTA ATGCATTTTG GTTGCTTAAT 450 TGTTATTATT TATCTCGTTT TGTTTATGAT AAAATAGACG TTTTGAAGAC 500 GACATGTCTA TCGTATCAAC GTTC 524 (2) INFORMATION FOR SEQ ID NO : 13 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1982 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 31..1517 (iv) FEATURE: (A) NAME/KEY: Asx = Asn or Asp (B) LOCATION: 300 (v) SEQUENCE DESCRIPTION: SEQ ID NO: 13: AT TTT AGC TAC ACA GGT GTA CCT TAT GCT AAA CCT CCT GTT 41 Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro Pro Vr 1 1 5 10 GGA GAA CTT AGA TTT AAG CCT CCA CAG AAA GCT GAG CCA TGG 83 Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu Pro Trp 15 20 25 CAA GGT GTT TTC AAC GCC ACA TTA TAC GGA AAT GTG TGT AAA 125 Gin Gly Val Phe Asn Ala Thr Leu Tyr Gly Asn Val Cys Lys 30 35 40 TCT TTA AAT TTC TTC TTG AAG AAA ATT GAA GGA GAC GAA GAC 167 Ser Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp Glu Asp 45 50 55 TGC TTG GTA GTA AAC GTG TAC GCA CCA AAA ACA ACT TCT GAT 209 Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp 60 65 AAA AAA CTT CCA GTA TTT TTC TGG GTT CAT GGT GGT GGT TTT 251 Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe 70 75 80 GTG ACT GGA TCC GGA AAT TTA GAA TTC CAA AGC CCA GAT TAT 293 Val Thr Gly Ser Gly Asn Leu Glu Phe Gin Ser Pro Asp Tyr 85 90 95 TTA GTA RAT TTT GAT GTT ATT TTC GTA ACT TTC AAT TAC CGA 335 Leu Val Asx Phe Asp Val He Phe Val Thr Phe Asn Tyr Arg 100 105 110 TTG GGA CCT CTC GGA TTT CTG AAT TTG GAG TTG GAG GGT GCT 377 Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala 115 120 125 CCA GGA AAT GTA GGA TTA TTG GAT CAG GTG GCA GCT CTG AAA 419 Pro Gly Asn Val Gly Leu Leu Asp Gin Val Ala Ala Leu Lys 130 135 TGG ACC AAA GAA AAC ATT GAG AAA TTT GGT GGA GAT CCA GAA 461 Trp Thr Lys Glu Asn He Glu Lys Phe Gly Gly Asp Pro Glu 140 145 150 AAT ATT ACA ATT GGT GGT GTT TCT GCT GGT GGA GCA AGT GTT 503 Asn He Thr He Gly Gly Val Ser Ala Gly Gly Ala Ser Val 155 160 165 CAT TAT CTT TTG TTA TCT CAT ACA ACC ACT GGA CTT TAC AAA 545 His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu Tyr Lys 170 175 180 AGG GCA ATT GCT CAA AGT GGA AGT GCT TTT AAT CCA TGG GCC 587 Arg Ala He Ala Gin Ser Gly Ser Ala Phe Asn Pro Trp Ala 185 190 195 TTC CAA AGA CAT CCA GTA APG JGT AGT CTT CAA CTT GCT GAG 629 Phe Gin Arg His Pro Val Lys Arg Ser Leu Gin Leu Ala Glu 200 205 ATA TTG GGT CAT CCC ACA AAC AAT ACT CAA GAT GCT TTA GAA 671 He Leu Gly His Pro Thr Asn Asn Thr Gin Asp Ala Leu Glu 210 215 220 TTC TTA CAA AAA GCC CCC GTA GAC AGT CTC CTG AAG AAA ATG 713 Phe Leu Gin Lys Ala Pro Val Asp Ser Leu Leu Lys Lys Met 225 230 235 CCA GCT GAA ACA GAA GGT GAA ATA ATA GAA GAG TTT GTC TTC 755 Pro Ala Glu Thr Glu Gly Glu He He Glu Glu Phe Val Phe 240 245 250 GTA CCA TCA ATT GAA AAA GTT TTC CCA TCC CAC CAA CCT TTC 797 Val Pro Ser He Glu Lys Val Phe Pro Ser His Gin Pro Phe 255 260 265 TTG GAA GAA TCA CCA TTG GCC AGA ATG AAA TCC GGA TCC TTT 839 Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly Ser Phe 270 275 AAC AAA GTA CCT TTA TTA GTT GGA TTT AAC AGT GCA GAA GGA 881 Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala Glu Gly 280 285 290 CTT TTG TTC AAA TTC TTC ATG AAA GAA AAA CCA GAG ATG CTG 923 Leu Leu Phe Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu 295 300 305 AAC CAA GCT GAA GCA GAT TTT GAA AGA CTC GTA CCA GCC GAA 965 Asn Gin Ala Glu Ala Asp Phe Glu Arg Leu Val Pro Ala Glu 310 315 320 TTT GAA TTA GTC CAT GGA TCA GAG GAA TCG AAA AAA CTT GCA 1007 Phe Glu Leu Val His Gly Ser Glu Glu Ser Lys Lys Leu Ala 325 330 335 GAA AAA ATC AGG AAG TTT TAC TTT GAC GAT AAA CCC GTT CCA 1049 Glu Lys He Arg Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro 340 345 GAA AAT GAA CAG AAA TTT ATT GAC TTG ATA GGA GAT ATT TGG 1091 Glu Asn Glu Gin Lys Phe He Asp Leu He Gly Asp He Trp 350 355 360 TTT ACT AGA GGT GTT GAC AAG CAT GTC AAG TTG TCT GTG GAG 1133 Phe Thr Arg Gly Val Asp Lys His Val Lys Leu Ser Val Glu 365 370 375 AAA CAA GAC GAA CCA GTT TAT TAT TAT GAA TAT TCC TTC TCG 1175 Lys Gin Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser 380 385 390 GAA AGT CAT CCT GCA AAA GGA ACA TTT GGT GAT CAT AAT CTG 1217 Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His Asn Leu 395 400 405 ACT GGT GCA TGC CAT GGA GAA GAA CTT GTG AAT TTA TTC AAA 1259 Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys 410 415 GTC GAG ATG ATG AAG CTG GAA AAA GAT AAA CCT AAT GTT CTA 1301 Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn Val Leu 420 425 430 TTA ACA AAA GAT AGA GTA CTT GCC ATG TGG ACT AAC TTC ATC 1343 Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe He 435 440 445 AAA AAT GGA AAT CCT ACT CCT GAA GTA ACA GAA TTA TTG CCA 1385 Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu Leu Pro 450 455 460 GTT AAA TGG GAA CCT GCC ACA AAA GAC AAG TTG AAT TAT TTG 1427 Val Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu 465 470 475 AAC ATT GAT GCC ACC TTA ACT TTG GGA ACA AAT CCT GAG GCA 1469 Asn He Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro Glu Ala 480 485 AAC CGA GTC AAA TTT TGG GAA GAC GCC ACA AAA TCT TTG CAC 1511 Asn Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Ser Leu His 490 495 500 GGT CAA TAA TAATTTATGA AAATTGTTTT AAATACTTTA GGTAATATAT 1560 Gly Gin TAGGTAAATA AAAATTAAAA AATAACAATT TTTATGTTTT ATGTATTGGC 1610 TTATGTGTAT CAGTTCTAAT TTTATTTATT TATTCTTGTT TTGCTTGTTT 1660 TGAAATATCA TGGTTTTAAT TTTCAAAACA CAACGTCGTT TGTTTTTAGC 1710 AAAATTTCCA ATAGATATGT TATATTAAGT ACTCTGAAGT ATTTTTATAT 1760 ATACACTAAA ATCAGTAAAA ATACATTAAC TAAAAATATA AGATATTTTC 1810 AATAATTTTT TTTAAAGAAA ATACCAAAAA TAAAGTAAAA TTCCAAACGG 1860 AATTTTTGTT TAACTTAAAA ATAAAATTAA CTCTTCAATA ATTTTGATAA 1910 TTAGTATTTC TGATATCATT AGTGAAAATT ATATTTTGAT AATACGTATT 1960 TATATTTAAA ATAAAATTAT GT 1982 (2) INFORMATION FOR SEQ ID NO : 14 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 505 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO : 14 : Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly 1 5 10 Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu Pro Trp Gin 15 20 25 Gly Val Phe Asn Ala Thr Leu Tyr Gly Asn Val Cys Lys Ser 30 35 40 Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp Glu Asp Cys 45 50 55 Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp Lys 60 65 70 Lys Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe Val 75 80 Thr Gly Ser Gly Asn Leu Glu Phe Gin Ser Pro Asp Tyr Leu 85 90 95 Val Asx Phe Asp Val He Phe Val Thr Phe Asn Tyr Arg Leu 100 105 110 Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro 115 120 125 Gly Asn Val Gly Leu Leu Asp Gin Val Ala Ala Leu Lys Trp 130 135 140 Thr Lys Glu Asn He Glu Lys Phe Gly Gly Asp Pro Glu Asn 145 150 He Thr He Gly Gly Val Ser Ala Gly Gly Ala Ser Val His 155 160 165 Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu Tyr Lys Arg 170 175 180 Ala He Ala Gin Ser Gly Ser Ala Phe Asn Pro Trp Ala Phe 185 190 195 Gin Arg His Pro Val Lys Arg Ser Leu Gin Leu Ala Glu He 200 205 210 Leu Gly His Pro Thr Asn Asn Thr Gin Asp Ala Leu Glu Phe 215 220 Leu Gin Lys Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro 225 230 235 Ala Glu Thr Glu Gly Glu He He Glu Glu Phe Val Phe Val 240 245 250 Pro Ser He Glu Lys Val Phe Pro Ser His Gin Pro Leu Leu 255 260 265 Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly Ser Phe Asn 270 275 280 Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala Glu Gly Leu 285 290 Leu Phe Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu Asn 295 300 305 Gin Ala Glu Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe 310 315 320 Glu Leu Val His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu 325 330 335 Lys He Arg Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu 340 345 350 Asn Glu Gin Lys Phe He Asp Leu He Gly Asp He Trp Phe 355 360 Thr Arg Gly Val Asp Lys His Val Lys Leu Ser Val Glu Lys 365 370 375 Gin Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser Glu 380 385 390 Ser His Pro Ala Lys Gly Thr Phe Gly Asp His Asn Leu Thr 395 400 405 Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys Val 410 415 420 Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu 425 430 Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe He Lys 435 440 445 Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val 450 455 460 Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu Asn 465 470 475 He Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro Glu Ala Asn 480 485 490 Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Ser Leu His Gly 495 500 Gin 505 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1982 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 15: ACATAATTTT ATTTTAAATA TAAATACGTA TTATCAAAAT ATAATTTTCA 50 CTAATGATAT CAGAAATACT AATTATCAAA ATTATTGAAG AGTTAATTTT 100 ATTTTTAAGT TAAACAAAAA TTCCGTTTGG AATTTTACTT TATTTTTGGT 150 ATTTTCTTTA AAAAAAATTA TTGAAAATAT CTTATATTTT TAGTTAATGT 200 ATTTTTACTG ATTTTAGTGT ATATATAAAA ATACTTCAGA GTACTTAATA 250 TAACATATCT ATTGGAAATT TTGCTAAAAA CAAACGACGT TGTGTTTTGA 300 AAATTAAAAC CATGATATTT CAAAACAAGC AAAACAAGAA TAAATAAATA 350 AAATTAGAAC TGATACACAT AAGCCAATAC ATAAAACATA AAAATTGTTA 400 TTTTTTAATT TTTATTTACC TAATATATTA CCTAAAGTAT TTAAAACAAT 450 TTTCATAAAT TATTATTGAC CGTGCAAAGA TTTTGTGGCG TCTTCCCAAA 500 ATTTGACTCG GTTTGCCTCA GGATTTGTTC CCAAAGTTAA GGTGGCATCA 550 ATGTTCAAAT AATTCAACTT GTCTTTTGTG GCAGGTTCCC ATTTAACTGG 600 CAATAATTCT GTTACTTCAG GAGTAGGATT TCCATTTTTG ATGAAGTTAG 650 TCCACATGGC AAGTACTCTA TCTTTTGTTA ATAGAACATT AGGTTTATCT 700 TTTTCCAGCT TCATCATCTC GACTTTGAAT AAATTCACAA GTTCTTCTCC 750 ATGGCATGCA CCAGTCAGAT TATGATCACC AAATGTTCCT TTTGCAGGAT 800 GACTTTCCGA GAAGGAATAT TCATAATAAT AAACTGGTTC GTCTTGTTTC 850 TCCACAGACA ACTTGACATG CTTGTCAACA CCTCTAGTAA ACCAAATATC 900 TCCTATCAAG TCAATAAATT TCTGTTCATT TTCTGGAACG GGTTTATCGT 950 CAAAGTAAAA CTTCCTGATT TTTTCTGCAA GTTTTTTCGA TTCCTCTGAT 1000 CCATGGACTA ATTCAAATTC GGCTGGTACG AGTCTTTCAA AATCTGCTTC 1050 AGCTTGGTTC AGCATCTCTG GTTTTTCTTT CATGAAGAAT TTGAACAAAA 1100 GTCCTTCTGC ACTGTTAAAT CCAACTAATA AAGGTACTTT GTTAAAGGAT 1150 CCGGATTTCA TTCTGGCCAA TGGTGATTCT TCCAAGAAAG GTTGGTGGGA 1200 TGGGAAAACT TTTTCAATTG ATGGTACGAA GACAAACTCT TCTATTATTT 1250 CACCTTCTGT TTCAGCTGGC ATTTTCTTCA GGAGACTGTC TACGGGGGCT 1300 TTTTGTAAGA ATTCTAAAGC ATCTTGAGTA TTGTTTGTGG GATGACCCAA 1350 TATCTCAGCA AGTTGAAGAC TACGCTTTAC TGGATGTCTT TGGAAGGCCC 1400 ATGGATTAAA AGCACTTCCA CTTTGAGCAA TTGCCCTTTT GTAAAGTCCA 1450 GTGGTTGTAT GAGATAACAA AAGATAATGA ACACTTGCTC CACCAGCAGA 1500 AACACCACCA ATTGTAATAT TTTCTGGATC TCCACCAAAT TTCTCAATGT 1550 TTTCTTTGGT CCATTTCAGA GCTGCCACCT GATCCAATAA TCCTACATTT 1600 CCTGGAGCAC CCTCCAACTC CAAATTCAGA AATCCGAGAG GTCCCAATCG 1650 GTAATTGAAA GTTACGAAAA TAACATCAAA ATYTACTAAA TAATCTGGGC 1700 TTTGGAATTC TAAATTTCCG GATCCAGTCA CAAAACCACC ACCATGAACC 1750 CAGAAAAATA CTGGAAGTTT TTTATCAGAA GTTGTTTTTG GTGCGTACAC 1800 GTTTACTACC AAGCAGTCTT CGTCTCCTTC AATTTTCTTC AAGAAGAAAT 1850 TTAAAGATTT ACACACATTT CCGTATAATG TGGCGTTGAA AACACCTTGC 1900 CATGGCTCAG CTTTCTGTGG AGGCTTAAAT CTAAGTTCTC CAACAGGAGG 1950 TTTAGCATAA GGTACACCTG TGTAGCTAAA AT 1982 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1515 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1515 (iv) FEATURE: (A) NAME/KEY: Asx = Asn or Asp (B) LOCATION: 298 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: TTT AGC TAC ACA GGT GTA CCT TAT GCT AAA CCT CCT GTT 39 Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro Pro Val 1 5 10 GGA GAA CTT AGA TTT AAG CCT CCA CAG AAA GCT GAG CCA TGG 81 Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu Pro Trp 15 20 25 CAA GGT GTT TTC AAC GCC ACA TTA TAC GGA AAT GTG TGT AAA 123 Gin Gly Val Phe Asn Ala Thr Leu Tyr Gly Asn Val Cys Lys 30 35 40 TCT TTA AAT TTC TTC TTG AAG AAA ATT GAA GGA GAC GAA GAC 165 Ser Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp Glu Asp 45 50 55 TGC TTG GTA GTA AAC GTG TAC GCA CCA AAA ACA ACT TCT GAT 207 Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp 60 65 AAA AAA CTT CCA GTA TTT TTC TGG GTT CAT GGT GGT GGT TTT 249 Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe 70 75 80 GTG ACT GGA TCC GGA AAT TTA GAA TTC CAA AGC CCA GAT TAT 291 Val Thr Gly Ser Gly Asn Leu Glu Phe Gin Ser Pro Asp Tyr 85 90 95 TTA GTA RAT TTT GAT GTT ATT TTC GTA ACT TTC AAT TAC CGA 333 Leu Val Asx Phe Asp Val He Phe Val Thr Phe Asn Tyr Arg 100 105 110 TTG GGA CCT CTC GGA TTT CTG AAT TTG GAG TTG GAG GGT GCT 375 Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala 115 120 125 CCA GGA AAT GTA GGA TTA TTG GAT CAG GTG GCA GCT CTG AAA 417 Pro Gly Asn Val Gly Leu Leu Asp Gin Val Ala Ala Leu Lys 130 135 TGG ACC AAA GAA AAC ATT GAG AAA TTT GGT GGA GAT CCA GAA 459 Trp Thr Lys Glu Asn He Glu Lys Phe Gly Gly Asp Pro Glu 140 145 150 AAT ATT ACA ATT GGT GGT GTT TCT GCT GGT GGA GCA AGT GTT 501 Asn He Thr He Gly Gly Val Ser Ala Gly Gly Ala Ser Val 155 160 165 CAT TAT CTT TTG TTA TCT CAT ACA ACC ACT GGA CTT TAC AAA 543 His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu Tyr Lys 170 175 180 AGG GCA ATT GCT CAA AGT GGA AGT GCT TTT AAT CCA TGG GCC 585 Arg Ala He Ala Gin Ser Gly Ser Ala Phe Asn Pro Trp Ala 185 190 195 TTC CAA AGA CAT CCA GTA AAG CGT AGT CTT CAA CTT GCT GAG 627 Phe Gin Arg His Pro Val Lys Arg Ser Leu Gin Leu Ala Glu 200 205 ATA TTG GGT CAT CCC ACA AAC AAT ACT CAA GAT GCT TTA GAA 669 He Leu Gly His Pro Thr Asn Asn Thr Gin Asp Ala Leu Glu 210 215 220 TTC TTA CAA AAA GCC CCC GTA GAC AGT CTC CTG AAG AAA ATG 711 Phe Leu Gin Lys Ala Pro Val Asp Ser Leu Leu Lys Lys Met 225 230 235 CCA GCT GAA ACA GAA GGT GAA ATA ATA GAA GAG TTT GTC TTC 753 Pro Ala Glu Thr Glu Gly Glu He He Glu Glu Phe Val Phe 240 245 250 GTA CCA TCA ATT GAA AAA GTT TTC CCA TCC CAC CAA CCT TTC 795 Val Pro Ser He Glu Lys Val Phe Pro Ser His Gin Pro Leu 255 260 265 TTG GAA GAA TCA CCA TTG GCC AGA ATG AAA TCC GGA TCC TTT 837 Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly Ser Phe 270 275 AAC AAA GTA CCT TTA TTA GTT GGA TTT AAC AGT GCA GAA GGA 879 Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala Glu Gly 280 285 290 CTT TTG TTC AAA TTC TTC ATG AAA GAA AAA CCA GAG ATG CTG 921 Leu Leu Phe Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu 295 300 305 AAC CAA GCT GAA GCA GAT TTT GAA AGA CTC GTA CCA GCC GAA 963 Asn Gin Ala Glu Ala Asp Phe Glu Arg Leu Val Pro Ala Glu 310 315 320 TTT GAA TTA GTC CAT GGA TCA GAG GAA TCG AAA AAA CTT GCA 1005 Phe Glu Leu Val His Gly Ser Glu Glu Ser Lys Lys Leu Ala 325 330 335 GAA AAA ATC AGG AAG TTT TAC TTT GAC GAT AAA CCC GTT CCA 1047 Glu Lys He Arg Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro 340 345 GAA AAT GAA CAG AAA TTT ATT GAC TTG ATA GGA GAT ATT TGG 1089 Glu Asn Glu Gin Lys Phe He Asp Leu lb Gly Asp He Trp 350 355 360 TTT ACT AGA GGT GTT GAC AAG CAT GTC AAG TTG TCT GTG GAG 1131 Phe Thr Arg Gly Val Asp Lys His Val Lys Leu Ser Val Glu 365 370 375 AAA CAA GAC GAA CCA GTT TAT TAT TAT GAA TAT TCC TTC TCG 1173 Lys Gin Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser 380 385 390 GAA AGT CAT CCT GCA AAA GGA ACA TTT GGT GAT CAT AAT CTG 1215 Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His Asn Leu 395 400 405 ACT GGT GCA TGC CAT GGA GAA GAA CTT GTG AAT TTA TTC AAA 1257 Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys 410 415 GTC GAG ATG ATG AAG CTG GAA AAA GAT AAA CCT AAT GTT CTA 1299 Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn Val Leu 420 425 430 TTA ACA AAA GAT AGA GTA CTT GCC ATG TGG ACT AAC TTC ATC 1341 Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe He 435 440 445 AAA AAT GGA AAT CCT ACT CCT GAA GTA ACA GAA TTA TTG CCA 1383 Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu Leu Pro 450 455 460 GTT AAA TGG GAA CCT GCC ACA AAA GAC AAG TTG AAT TAT TTG 1425 Val Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu 465 470 475 AAC ATT GAT GCC ACC TTA ACT TTG GGA ACA AAT CCT GAG GCA 1467 Asn He Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro Glu Ala 480 485 AAC CGA GTC AAA TTT TGG GAA GAC GCC ACA AAA TCT TTG CAC 1509 Asn Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Ser Leu His 490 495 500 GGT CAA 1515 Gly Gin (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1515 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 17: TTGACCGTGC AAAGATTTTG TGGCGTCTTC CCAAAATTTG ACTCGGTTTG 50 CCTCAGGATT TGTTCCCAAA GTTAAGGTGG CATCAATGTT CAAATAATTC 100 AACTTGTCTT TTGTGGCAGG TTCCCATTTA ACTGGCAATA ATTCTGTTAC 150 TTCAGGAGTA GGATTTCCAT TTTTGATGAA GTTAGTCCAC ATGGCAAGTA 200 CTCTATCTTT TGTTAATAGA ACATTAGGTT TATCTTTTTC CAGCTTCATC 250 ATCTCGACTT TGAATAAATT CACAAGTTCT TCTCCATGGC ATGCACCAGT 300 CAGATTATGA TCACCAAATG TTCCTTTTGC AGGATGACTT TCCGAGAAGG 350 AATATTCATA ATAATAAACT GGTTCGTCTT GTTTCTCCAC AGACAACTTG 400 ACATGCTTGT CAACACCTCT AGTAAACCAA ATATCTCCTA TCAAGTCAAT 450 AAATTTCTGT TCATTTTCTG GAACGGGTTT ATCGTCAAAG TAAAACTTCC 500 TGATTTTTTC TGCAAGTTTT TTCGATTCCT CTGATCCATG GACTAATTCA 550 AATTCGGCTG GTACGAGTCT TTCAAAATCT GCTTCAGCTT GGTTCAGCAT 600 CTCTGGTTTT TCTTTCATGA AGAATTTGAA CAAAAGTCCT TCTGCACTGT 650 TAAATCCAAC TAATAAAGGT ACTTTGTTAA AGGATCCGGA TTTCATTCTG 700 GCCAATGGTG ATTCTTCCAA GAAAGGTTGG TGGGATGGGA AAACTTTTTC 750 AATTGATGGT ACGAAGACAA ACTCTTCTAT TATTTCACCT TCTGTTTCAG 800 CTGGCATTTT CTTCAGGAGA CTGTCTACGG GGGCTTTTTG TAAGAATTCT 850 AAAGCATCTT GAGTATTGTT TGTGGGATGA CCCAATATCT CAGCAAGTTG 900 AAGACTACGC TTTACTGGAT GTCTTTGGAA GGCCCATGGA TTAAAAGCAC 950 TTCCACTTTG AGCAATTGCC CTTTTGTAAA GTCCAGTGGT TGTATGAGAT 1000 AACAAAAGAT AATGAACACT TGCTCCACCA GCAGAAACAC CACCAATTGT 1050 AATATTTTCT GGATCTCCAC CAAATTTCTC AATGTTTTCT TTGGTCCATT 1100 TCAGAGCTGC CACCTGATCC AATAATCCTA CATTTCCTGG AGCACCCTCC 1150 AACTCCAAAT TCAGAAATCC GAGAGGTCCC AATCGGTAAT TGAAAGTTAC 1200 GAAAATAACA TCAAAATYTA CTAAATAATC TGGGCTTTGG AATTCTAAAT 1250 TTCCGGATCC AGTCACAAAA CCACCACCAT GAACCCAGAA AAATACTGGA 1300 AGTTTTTTAT CAGAAGTTGT TTTTGGTGCG TACACGTTTA CTACCAAGCA 1350 GTCTTCGTCT CCTTCAATTT TCTTCAAGAA GAAATTTAAA GATTTACACA 1400 CATTTCCGTA TAATGTGGCG TTGAAAACAC CTTGCCATGG CTCAGCTTTC 1450 TGTGGAGGCT TAAATCTAAG TTCTCCAACA GGAGGTTTAG CATAAGGTAC 1500 ACCTGTGTAG CTAAA 1515 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1792 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 49..1701 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 18: ACTGTGTGCT AATAATTCAG TACACACAGT CAATAGTCTA GATCCAAG 48 ATG TCT CGT GTT ATT TTT TTA AGT TGT ATT TTT TTG TTT AGT 90 Met Ser Arg Val He Phe Leu Ser Cys He Phe Leu Phe Ser 1 5 10 TTT AAT TTT ATA AAA TGT GAT CCC CCG ACT GTA ACT TTG CCC 132 Phe Asn Phe He Lys Cys Asp Pro Pro Thr Val Thr Leu Pro 15 20 25 CAG GGC GAA TTG GTT GGA AAA GCT TTG ACG AAC GAA AAT GGA 174 Gin Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu Asn Gly 30 35 40 AAA GAG TAT TTT AGC TAC ACA GGT GTG CCT TAT GCT AAA CCT 216 Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro 45 50 55 CCA GTT GGA GAA CTT AGA TTT AAG CCT CCA CAG AAA GCT GAG 258 Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu 60 65 70 CCA TGG AAT GGT GTT TTC AAC GCC ACA TCA CAT GGA AAT GTG 300 Pro Trp Asn Gly Val Phe Asn Ala Thr Ser His Gly Asn Val 75 80 TGC AAA GCT TTG AAT TTC TTC TTG AAA AAA ATT GAA GGA GAC 342 Cys Lys Ala Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp 85 90 95 GAA GAC TGC TTG TTG GTG AAT GTG TAC GCA CCA AAA ACA ACT 384 Glu Asp Cys Leu Leu Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 TCT GAC AAA AAA CTT CCA GTA TTT TTC TGG GTT CAT GGT GGC 426 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly 115 120 125 GGT TTT GTG ACT GGA TCC GGA AAT TTA GAA TTT CAA AGC CCA 468 Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gin Ser Pro 130 135 140 GAT TAT TTA GTA AAT TAT GAT GTT ATT TTT GTA ACT TTC AAT 510 Asp Tyr Leu Val Asn Tyr Asp Val He Phe Val Thr Phe Asn 145 150 TAC CGA TTG GGA CCA CTC GGA TTT TTG AAT TTG GAG TTG GAA 552 Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu 155 160 165 GGT GCT CCT GGA AAT GTA GGA TTA TTG GAT CAG GTA GCA GCT 594 Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gin Val Ala Ala 170 175 180 TTG AAA TGG ACC AAA GAA AAT ATT GAG AAA TTT GGT GGA GAT 636 Leu Lys Trp Thr Lys Glu Asn He Glu Lys Phe Gly Gly Asp 185 190 195 CCA GAA AAT ATT ACA ATT GGT GGT GTT TCT GCT GGT GGA GCA 678 Pro Glu Asn He Thr He Gly Gly Val Ser Ala Gly Gly Ala 200 205 210 AGT GTT CAT TAT CTT TTA TTG TCA CAT ACA ACC ACT GGA CTT 720 Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 215 220 TAC AAA AGG GCA ATT GCT CAA AGT GGA AGT GCT TTA AAT CCA 762 Tyr Lys Arg Ala He Ala Gin Ser Gly Ser Ala Leu Asn Pro 225 230 235 TGG GCC TTC CAA AGA CAT CCA GTA AAG CGT AGT CTT CAA CTT 804 Trp Ala Phe Gin Arg His Pro Val Lys Arg Ser Leu Gin Leu 240 245 250 GCT GAG ATA TTA GGT CAT CCC ACA AAC AAC ACT CAA GAT GCT 846 Ala Glu He Leu Gly His Pro Thr Asn Asn Thr Gin Asp Ala 255 260 265 TTA GAA TTC TTA CAA AAA GCC CCA GTA GAC AGT CTC CTG AAA 888 Leu Glu Phe Leu Gin Lys Ala Pro Val Asp Ser Leu Leu Lys 270 275 280 AAA ATG CCA GCT GAA ACA GAA GGT GAA ATA ATA GAA GAG TTC 930 Lys Met Pro Ala Glu Thr Glu Gly Glu He He Glu Glu Phe 285 290 GTC TTC GTA CCA TCA ATT GAA AAA GTT TTC CCA TCC CAC CAA 972 Val Phe Val Pro Ser He Glu Lys Val Phe Pro Ser His Gin 295 300 305 CCT TTC TTG GAA GAA TCA CCA TTG GCC AGA ATG AAA TCT GGA 1014 Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly 310 315 320 TCC TTT AAC AAA GTA CCT TTA TTA GTT GGA TTC AAC AGC GCA 1056 Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 325 330 335 GAA GGA CTT TTG TAC AAA TTC TTT ATG AAA GAA AAA CCA GAG 1098 Glu Gly Leu Leu Tyr Lys Phe Phe Met Lys Glu Lys Pro Glu 340 345 350 ATG CTG AAC CAA GCT GAA GCA GAT TTC GAA AGA CTC GTA CCA 1140 Met Leu Asn Gin Ala Glu Ala Asp Phe Glu Arg Leu Val Pro 355 360 GCC GAA TTT GAA TTA GCC CAT GGA TCA GAA GAA TCG AAA AAA 1182 Ala Glu Phe Glu Leu Ala His Gly Ser Glu Glu Ser Lys Lys 365 370 375 CTT GCA GAA AAA ATC AGG AAG TTT TAC TTT GAC GAT AAA CCC 1224 Leu Ala Glu Lys He Arg Lys Phe Tyr Phe Asp Asp Lys Pro 380 385 390 GTT CCT GAA AAT GAG CAG AAA TTT ATT GAC TTG ATA GGA GAT 1266 Val Pro Glu Asn Glu Gin Lys Phe He Asp Leu He Gly Asp 395 400 405 ATT TGG TTT ACT AGA GGC ATT GAC AAG CAT GTC AAG TTG TCT 1308 He Trp Phe Thr Arg Gly He Asp Lys His Val Lys Leu Ser 410 415 420 GTA GAA AAA CAA GAC GAG CCA GTA TAT TAT TAT GAA TAT TCT 1350 Val Glu Lys Gin Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser 425 430 TTC TCT GAA AGT CAT CCT GCA AAA GGA ACA TTT GGT GAC CAT 1392 Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 435 440 445 AAC TTG ACT GGA GCA TGT CAT GGT GAA GAA CTT GTG AAT TTA 1434 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu 450 455 460 TTC AAA GTC GAG ATG ATG AAG CTG GAA AAA GAT AAA CCG AAT 1476 Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn 465 470 475 GTT TTA TTA ACA AAA GAT AGG GTA CTT GCT ATG TGG ACG AAC 1518 Val Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn 480 485 490 TTC ATC AAA AAT GGA AAT CCT ACT CCT GAA GTA ACT GAA TTA 1560 Phe He Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu 495 500 TTG CCA GTT AAA TGG GAA CCT GCC ACA AAA GAC AAG TTG AAT 1602 Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn 505 510 515 TAT TTG AAC ATT GAT GCC ACC TTA ACT TTG GGA ACA AAT CCA 1644 Tyr Leu Asn He Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro 520 525 530 GAA GAA ACC CGA GTC AAA TTY TGG GAA GAT GCC ACA AAA ACT 1686 Glu Glu Thr Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Thr 535 540 545 TTG CAC AGT CAA TAA AAATGTATGA AAATTGTTTT AATTATTTTA 1731 Leu His Ser Gin 550 GGTAATACAT TAGGTAAATA AAAATTNAAA AATAACNAAA AAAAAAAAAA 1781 AAAAAAAAAA A 1792 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 550 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ("ii) SEQUENCE DESCRIPTION: SEQ ID NO: 19: Met Ser Arg Val He Phe Leu Ser Cys He Phe Leu Phe Ser 1 5 10 Phe Asn Phe He Lys Cys Asp Pro Pro Thr Val Thr Leu Pro 15 20 25 Gin Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu Asn Gly 30 35 40 Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro 45 50 55 Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu 60 65 70 Pro Trp Asn Gly Val Phe Asn Ala Thr Ser His Gly Asn Val 75 80 Cys Lys Ala Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp 85 90 95 Glu Asp Cys Leu Leu Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly 115 120 125 Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gin Ser Pro 130 135 140 Asp Tyr Leu Val Asn Tyr Asp Val He Phe Val Thr Phe Asn 145 150 Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu 155 160 165 Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gin Val Ala Ala 170 175 180 Leu Lys Trp Thr Lys Glu Asn He Glu Lys Phe Gly Gly Asp 185 190 195 Pro Glu Asn He Thr He Gly Gly Val Ser Ala Gly Gly Ala 200 205 210 Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 215 220 Tyr Lys Arg Ala He Ala Gin Ser Gly Ser Ala Leu Asn Pro 225 230 235 Trp Ala Phe Gin Arg His Pro Val Lys Arg Ser Leu Gin Leu 240 245 250 Ala Glu He Leu Gly His Pro Thr Asn Asn Thr Gin Asp Ala 255 260 265 Leu Glu Phe Leu Gin Lys Ala Pro Val Asp Ser Leu Leu Lys 270 275 280 Lys Met Pro Ala Glu Thr Glu Gly Glu He He Glu Glu Phe 285 290 Val Phe Val Pro Ser He Glu Lys Val Phe Pro Ser His Gin 295 300 305 Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly 310 315 320 Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 325 330 335 Glu Gly Leu Leu Tyr Lys Phe Phe Met Lys Glu Lys Pro Glu 340 345 350 Met Leu Asn Gin Ala Glu Ala Asp Phe Glu Arg Leu Val Pro 355 360 Ala Glu Phe Glu Leu Ala His Gly Ser Glu Glu Ser Lys Lys 365 370 375 Leu Ala Glu Lys He Arg Lys Phe Tyr Phe Asp Asp Lys Pro 380 385 390 Val Pro Glu Asn Glu Gin Lys Phe He Asp Leu He Gly Asp 395 400 405 He Trp Phe Thr Arg Gly He Asp Lys His Val Lys Leu Ser 410 415 420 Val Glu Lys Gin Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser 425 430 Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 435 440 445 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu 450 455 460 Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn 465 470 475 Val Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn 480 485 490 Phe He Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu 495 500 Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn 505 510 515 Tyr Leu Asn He Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro 520 525 530 Glu Glu Thr Arg Val Lys Phe Trp Glu Asp Ala Thr ,ys Thr 535 540 545 Leu His Ser Gin 550 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1792 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO:20: TTTTTTTTTT TTTTTTTTTT TTTTNGTTAT TTTTNAATTT TTATTTACCT 50 AATGTATTAC CTAAAATAAT TAAAACAATT TTCATACATT TTTATTGACT 100 GTGCAAAGTT TTTGTGGCAT CTTCCCARAA TTTGACTCGG GTTTCTTCTG 150 GATTTGTTCC CAAAGTTAAG GTGGCATCAA TGTTCAAATA ATTCAACTTG 200 TCTTTTGTGG CAGGTTCCCA TTTAACTGGC AATAATTCAG TTACTTCAGG 250 AGTAGGATTT CCATTTTTGA TGAAGTTCGT CCACATAGCA AGTACCCTAT 300 CTTTTGTTAA TAAAACATTC GGTTTATCTT TTTCCAGCTT CATCATCTCG 350 ACTTTGAATA AATTCACAAG TTCTTCACCA TGACATGCTC CAGTCAAGTT 400 ATGGTCACCA AATGTTCCTT TTGCAGGATG ACTTTCAGAG AAAGAATATT 450 CATAATAATA TACTGGCTCG TCTTGTTTTT CTACAGACAA CTTGACATGC 500 TTGTCAATGC CTCTAGTAAA CCAAATATCT CCTATCAAGT CAATAAATTT 550 CTGCTCATTT TCAGGAACGG GTTTATCGTC AAAGTAAAAC TTCCTGATTT 600 TTTCTGCAAG TTTTTTCGAT TCTTCTGATC CATGGGCTAA TTCAAATTCG 650 GCTGGTACGA GTCTTTCGAA ATCTGCTTCA GCTTGGTTCA GCATCTCTGG 700 TTTTTCTTTC ATAAAGAATT TGTACAAAAG TCCTTCTGCG CTGTTGAATC 750 CAACTAATAA AGGTACTTTG TTAAAGGATC CAGATTTCAT TCTGGCCAAT 800 GGTGATTCTT CCAAGAAAGG TTGGTGGGAT GGGAAAACTT TTTCAATTGA 850 TGGTACGAAG ACGAACTCTT CTATTATTTC ACCTTCTGTT TCAGCTGGCA 900 TTTTTTTCAG GAGACTGTCT ACTGGGGCTT TTTGTAAGAA TTCTAAAGCA 950 TCTTGAGTGT TGTTTGTGGG ATGACCTAAT ATCTCAGCAA GTTGAAGACT 1000 ACGCTTTACT GGATGTCTTT GGAAGGCCCA TGGATTTAAA GCACTTCCAC 1050 TTTGAGCAAT TGCCCTTTTG TAAAGTCCAG TGGTTGTATG TGACAATAAA 1100 AGATAATGAA CACTTGCTCC ACCAGCAGAA ACACCACCAA TTGTAATATT 1150 TTCTGGATCT CCACCAAATT TCTCAATATT TTCTTTGGTC CATTTCAAAG 1200 CTGCTACCTG ATCCAATAAT CCTACATTTC CAGGAGCACC TTCCAACTCC 1250 AAATTCAAAA ATCCGAGTGG TCCCAATCGG TAATTGAAAG TTACAAAAAT 1300 AACATCATAA TTTACTAAAT AATCTGGGCT TTGAAATTCT AAATTTCCGG 1350 ATCCAGTCAC AAAACCGCCA CCATGAACCC AGAAAAATAC TGGAAGTTTT 1400 TTGTCAGAAG TTGTTTTTGG TGCGTACACA TTCACCAACA AGCAGTCTTC 1450 GTCTCCTTCA ATTTTTTTCA AGAAGAAATT CAAAGCTTTG CACACATTTC 1500 CATGTGATGT GGCGTTGAAA ACACCATTCC ATGGCTCAGC TTTCTGTGGA 1550 GGCTTAAATC TAAGTTCTCC AACTGGAGGT TTAGCATAAG GCACACCTGT 1600 GTAGCTAAAA TACTCTTTTC CATTTTCGTT CGTCAAAGCT TTTCCAACCA 1650 ATTCGCCCTG GGGCAAAGTT ACAGTCGGGG GATCACATTT TATAAAATTA 1700 AAACTAAACA AAAAAATACA ACTTAAAAAA ATAACACGAG ACATCTTGGA 1750 TCTAGACTAT TGACTGTGTG TACTGAATTA TTAGCACACA GT 1792 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1650 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 21: ATG TCT CGT GTT ATT TTT TTA AGT TGT ATT TTT TTG TTT AGT 42 Met Ser Arg Val He Phe Leu Ser Cys He Phe Leu Phe Ser 1 5 10 TTT AAT TTT ATA AAA TGT GAT CCC CCG ACT GTA ACT TTG CCC 84 Phe Asn Phe He Lys Cys Asp Pro Pro Thr Val Thr Leu Pro 15 20 25 CAG GGC GAA TTG GTT GGA AAA GCT TTG ACG AAC GAA AAT GGA 126 Gin Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu Asn Gly 30 35 40 AAA GAG TAT TTT AGC TAC ACA GGT GTG CCT TAT GCT AAA CCT 168 Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro 45 50 55 CCA GTT GGA GAA CTT AGA TTT AAG CCT CCA CAG AAA GCT GAG 210 Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu 60 65 70 CCA TGG AAT GGT GTT TTC AAC GCC ACA TCA CAT GGA AAT GTG 252 Pro Trp Asn Gly Val Phe Asn Ala Thr Ser His Gly Asn Val 75 80 TGC AAA GCT TTG AAT TTC TTC TTG AAA AAA ATT GAA GGA GAC 294 Cys Lys Ala Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp 85 90 95 GAA GAC TGC TTG TTG GTG AAT GTG TAC GCA CCA AAA ACA ACT 336 Glu Asp Cys Leu Leu Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 TCT GAC AAA AAA CTT CCA GTA TTT TTC TGG GTT CAT GGT GGC 378 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly 115 120 125 GGT TTT GTG ACT GGA TCC GGA AAT TTA GAA TTT CAA AGC CCA 420 Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gin Ser Pro 130 135 140 GAT TAT TTA GTA AAT TAT GAT GTT ATT TTT GTA ACT TTC AAT 462 Asp Tyr Leu Val Asn Tyr Asp Val He Phe Val Thr Phe Asn 145 150 TAC CGA TTG GGA CCA CTC GGA TTT TTG AAT TTG GAG TTG GAA 504 Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu 155 160 165 GGT GCT CCT GGA AAT GTA GGA TTA TTG GAT CAG GTA GCA GCT 546 Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gin Val Ala Ala 170 175 180 TTG AAA TGG ACC AAA GAA AAT ATT GAG AAA TTT GGT GGA GAT 588 Leu Lys Trp Thr Lys Glu Asn He Glu Lys Phe Gly Gly Asp 185 190 195 CCA GAA AAT ATT ACA ATT GGT GGT GTT TCT GCT GGT GGA GCA 630 Pro Glu Asn He Thr He Gly Gly Val Ser Ala Gly Gly Ala 200 205 210 AGT GTT CAT TAT CTT TTA TTG TCA CAT ACA ACC ACT GGA CTT 672 Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 215 220 TAC AAA AGG GCA ATT GCT CAA AGT GGA AGT GCT TTA AAT CCA 714 Tyr Lys Arg Ala He Ala Gin Ser Gly Ser Ala Leu Asn Pro 225 230 235 TGG GCC TTC CAA AGA CAT CCA GTA AAG CGT AGT CTT CAA CTT 756 Trp Ala Phe Gin Arg His Pro Val Lys Arg Ser Leu Gin Leu 240 245 250 GCT GAG ATA TTA GGT CAT CCC ACA AAC AAC ACT CAA GAT GCT 798 Ala Glu He Leu Gly His Pro Thr Asn Asn Thr Gin Asp Ala 255 260 265 TTA GAA TTC TTA CAA AAA GCC CCA GTA GAC AGT CTC CTG AAA 840 Leu Glu Phe Leu Gin Lys Ala Pro Val Asp Ser Leu Leu Lys 270 275 280 AAA ATG CCA GCT GAA ACA GAA GGT GAA ATA ATA GAA GAG TTC 882 Lys Met Pro Ala Glu Thr Glu Gly Glu He He Glu Glu Phe 285 290 GTC TTC GTA CCA TCA ATT GAA AAA GTT TTC CCA TCC CAC CAA 924 Val Phe Val Pro Ser He Glu Lys Val Phe Pro Ser His Gin 295 300 305 CCT TTC TTG GAA GAA TCA CCA TTG GCC AGA ATG AAA TCT GGA 966 Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly 310 315 320 TCC TTT AAC AAA GTA CCT TTA TTA GTT GGA TTC AAC AGC GCA 1008 Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 325 330 335 GAA GGA CTT TTG TAC AAA TTC TTT ATG AAA GAA AAA CCA GAG 1050 Glu Gly Leu Leu Tyr Lys Phe Phe Met Lys Glu Lys Pro Glu 340 345 350 ATG CTG AAC CAA GCT GAA GCA GAT TTC GAA AGA CTC GTA CCA 109° Met Leu Asn Gin Ala Glu Ala Asp Phe Glu Arg Leu Val Pro 355 360 GCC GAA TTT GAA TTA GCC CAT GGA TCA GAA GAA TCG AAA AAA 1134 Ala Glu Phe Glu Leu Ala His Gly Ser Glu Glu Ser Lys Lys 365 370 375 CTT GCA GAA AAA ATC AGG AAG TTT TAC TTT GAC GAT AAA CCC 1176 Leu Ala Glu Lys He Arg Lys Phe Tyr Phe Asp Asp Lys Pro 380 385 390 GTT CCT GAA AAT GAG CAG AAA TTT ATT GAC TTG ATA GGA GAT 1218 Val Pro Glu Asn Glu Gin Lys Phe He Asp Leu He Gly Asp 395 400 405 ATT TGG TTT ACT AGA GGC ATT GAC AAG CAT GTC AAG TTG TCT 1260 He Trp Phe Thr Arg Gly He Asp Lys His Val Lys Leu Ser 410 415 420 GTA GAA AAA CAA GAC GAG CCA GTA TAT TAT TAT GAA TAT TCT 1302 Val Glu Lys Gin Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser 425 430 TTC TCT GAA AGT CAT CCT GCA AAA GGA ACA TTT GGT GAC CAT 1344 Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 435 440 445 AAC TTG ACT GGA GCA TGT CAT GGT GAA GAA CTT GTG AAT TTA 1386 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu 450 455 460 TTC AAA GTC GAG ATG ATG AAG CTG GAA AAA GAT AAA CCG AAT 1428 Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn 465 470 475 GTT TTA TTA ACA AAA GAT AGG GTA CTT GCT ATG TGG ACG AAC 1470 Val Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn 480 485 490 TTC ATC AAA AAT GGA AAT CCT ACT CCT GAA GTA ACT GAA TTA 1512 Phe He Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu 495 500 TTG CCA GTT AAA TGG GAA CCT GCC ACA AAA GAC AAG TTG AAT 1554 Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn 505 510 515 TAT TTG AAC ATT GAT GCC ACC TTA ACT TTG GGA ACA AAT CCA 1596 Tyr Leu Asn He Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro 520 525 530 GAA GAA ACC CGA GTC AAA TTY TGG GAA GAT GCC ACA AAA ACT 1638 Glu Glu Thr Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Thr 535 540 545 TTG CAC AGT CAA 1650 Leu His Ser Gin (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1650 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO:22: TTGACTGTGC AAAGTTTTTG TGGCATCTTC CCARAATTTG ACTCGGGTTT 50 CTTCTGGATT TGTTCCCAAA GTTAAGGTGG CATCAATGTT CAAATAATTC 100 AACTTGTCTT TTGTGGCAGG TTCCCATTTA ACTGGCAATA ATTCAGTTAC 150 TTCAGGAGTA GGATTTCCAT TTTTGATGAA GTTCGTCCAC ATAGCAAGTA 200 CCCTATCTTT TGTTAATAAA ACATTCGGTT TATCTTTTTC CAGCTTCATC 250 ATCTCGACTT TGAATAAATT CACAAGTTCT TCACCATGAC ATGCTCCAGT 300 CAAGTTATGG TCACCAAATG TTCCTTTTGC AGGATGACTT TCAGAGAAAG 350 AATATTCATA ATAATATACT GGCTCGTCTT GTTTTTCTAC AGACAACTTG 400 ACATGCTTGT CAATGCCTCT AGTAAACCAA ATATCTCCTA TCAAGTCAAT 450 AAATTTCTGC TCATTTTCAG GAACGGGTTT ATCGTCAAAG TAAAACTTCC 500 TGATTTTTTC TGCAAGTTTT TTCGATTCTT CTGATCCATG GGCTAATTCA 550 AATTCGGCTG GTACGAGTCT TTCGAAATCT GCTTCAGCTT GGTTCAGCAT 600 CTCTGGTTTT TCTTTCATAA AGAATTTGTA CAAAAGTCCT TCTGCGCTGT 650 TGAATCCAAC TAATAAAGGT ACTTTGTTAA AGGATCCAGA TTTCATTCTG 700 GCCAATGGTG ATTCTTCCAA GAAAGGTTGG TGGGATGGGA AAACTTTTTC 750 AATTGATGGT ACGAAGACGA ACTCTTCTAT TATTTCACCT TCTGTTTCAG 800 CTGGCATTTT TTTCAGGAGA CTGTCTACTG GGGCTTTTTG TAAGAATTCT 850 AAAGCATCTT GAGTGTTGTT TGTGGGATGA CCTAATATCT CAGCAAGTTG 900 AAGACTACGC TTTACTGGAT GTCTTTGGAA GGCCCATGGA TTTAAAGCAC 950 TTCCACTTTG AGCAATTGCC CTTTTGTAAA GTCCAGTGGT TGTATGTGAC 1000 AATAAAAGAT AATGAACACT TGCTCCACCA GCAGAAACAC CACCAATTGT 1050 AATATTTTCT GGATCTCCAC CAAATTTCTC AATATTTTCT TTGGTCCATT 1100 TCAAAGCTGC TACCTGATCC AATAATCCTA CATTTCCAGG AGCACCTTCC 1150 AACTCCAAAT TCAAAAATCC GAGTGGTCCC AATCGGTAAT TGAAAGTTAC 1200 AAAAATAACA TCATAATTTA CTAAATAATC TGGGCTTTGA AATTCTAAAT 1250 TTCCGGATCC AGTCACAAAA CCGCCACCAT GAACCCAGAA AAATACTGGA 1300 AGTTTTTTGT CAGAAGTTGT TTTTGGTGCG TACACATTCA CCAACAAGCA 1350 GTCTTCGTCT CCTTCAATTT TTTTCAAGAA GAAATTCAAA GCTTTGCACA 1400 CATTTCCATG TGATGTGGCG TTGAAAACAC CATTCCATGG CTCAGCTTTC 1450 TGTGGAGGCT TAAATCTAAG TTCTCCAACT GGAGGTTTAG CATAAGGCAC 1500 ACCTGTGTAG CTAAAATACT CTTTTCCATT TTCGTTCGTC AAAGCTTTTC 1550 CAACCAATTC GCCCTGGGGC AAAGTTACAG TCGGGGGATC ACATTTTATA 1600 AAATTAAAAC TAAACAAAAA AATACAACTT AAAAAAATAA CACGAGACAT 1650 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1590 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1590 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 23: GAT CCC CCG ACT GTA ACT TTG CCC CAG GGC GAA TTG GTT GGA 42 Asp Pro Pro Thr Val Thr Leu Pro Gin Gly Glu Leu Val Gly 1 5 10 AAA GCT TTG ACG AAC GAA AAT GGA AAA GAG TAT TTT AGC TAC 84 Lys Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr 15 20 25 ACA GGT GTG CCT TAT GCT AAA CCT CCA GTT GGA GAA CTT AGA 126 Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg 30 35 40 TTT AAG CCT CCA CAG AAA GCT GAG CCA TGG AAT GGT GTT TTC 168 Phe Lys Pro Pro Gin Lys Ala Glu Pro Trp Asn Gly Val Phe 45 50 55 AAC GCC ACA TCA CAT GGA AAT GTG TGC AAA GCT TTG AAT TTC 210 Asn Ala Thr Ser His Gly Asn Val Cys Lys Ala Leu Asn Phe 60 65 70 TTC TTG AAA AAA ATT GAA GGA GAC GAA GAC TGC TTG TTG GTG 252 Phe Leu Lys Lys He Glu Gly Asp Glu Asp Cys Leu Leu Val 75 80 AAT GTG TAC GCA CCA AAA ACA ACT TCT GAC AAA AAA CTT CCA 294 Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp Lys Lys Leu Pro 85 90 95 GTA TTT TTC TGG GTT CAT GGT GGC GGT TTT GTG ACT GGA TCC 336 Val Phe Phe Trp Val His Gly Gly Gly Phe Val Thr Gly Ser 100 105 110 GGA AAT TTA GAA TTT CAA AGC CCA GAT TAT TTA GTA AAT TAT 378 Gly Asn Leu Glu Phe Gin Ser Pro Asp Tyr Leu Val Asn Tyr 115 120 125 GAT GTT ATT TTT GTA ACT TTC AAT TAC CGA TTG GGA CCA CTC 420 Asp Val He Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu 130 135 140 GGA TTT TTG AAT TTG GAG TTG GAA GGT GCT CCT GGA AAT GTA 462 Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn Val 145 150 GGA TTA TTG GAT CAG GTA GCA GCT TTG AAA TGG ACC AAA GAA 504 Gly Leu Leu Asp Gin Val Ala Ala Leu Lys Trp Thr Lys Glu 155 160 165 AAT ATT GAG AAA TTT GGT GGA GAT CCA GAA AAT ATT ACA ATT 546 Asn He Glu Lys Phe Gly Gly Asp Pro Glu Asn He Thr He 170 175 180 GGT GGT GTT TCT GCT GGT GGA GCA AGT GTT CAT TAT CTT TTA 588 Gly Gly Val Ser Ala Gly Gly Ala Ser Val His Tyr Leu Leu 185 190 195 TTG TCA CAT ACA ACC ACT GGA CTT TAC AAA AGG GCA ATT GCT 630 Leu Ser His Thr Thr Thr Gly Leu Tyr Lys Arg Ala He Ala 200 205 210 CAA AGT GGA AGT GCT TTA AAT CCA TGG GCC TTC CAA AGA CAT 672 Gin Ser Gly Ser Ala Leu Asn Pro Trp Ala Phe Gin Arg His 215 220 CCA GTA AAG CGT AGT CTT CAA CTT GCT GAG ATA TTA GGT CAT 714 Pro Val Lys Arg Ser Leu Gin Leu Ala Glu He Leu Gly His 225 230 235 CCC ACA AAC AAC ACT CAA GAT GCT TTA GAA TTC TTA CAA AAA 756 Pro Thr Asn Asn Thr Gin Asp Ala Leu Glu Phe Leu Gin Lys 240 245 250 GCC CCA GTA GAC AGT CTC CTG AAA AAA ATG CCA GCT GAA ACA 798 Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala Glu Thr 255 260 265 GAA GGT GAA ATA ATA GAA GAG TTC GTC TTC GTA CCA TCA ATT 840 Glu Gly Glu He He Glu Glu Phe Val Phe Val Pro Ser He 270 275 280 GAA AAA GTT TTC CCA TCC CAC CAA CCT TTC TTG GAA GAA TCA 882 Glu Lys Val Phe Pro Ser His Gin Pro Phe Leu Glu Glu Ser 285 290 CCA TTG GCC AGA ATG AAA TCT GGA TCC TTT AAC AAA GTA CCT 924 Pro Leu Ala Arg Met Lys Ser Gly Ser Phe Asn Lys Val Pro 295 300 305 TTA TTA GTT GGA TTC AAC AGC GCA GAA GGA CTT TTG TAC AAA 966 Leu Leu Val Gly Phe Asn Ser Ala Glu Gly Leu Leu Tyr Lys 310 315 320 TTC TTT ATG AAA GAA AAA CCA GAG ATG CTG AAC CAA GCT GAA 1008 Phe Phe Met Lys Glu Lys Pro Glu Met Leu Asn Gin Ala Glu 325 330 335 GCA GAT TTC GAA AGA CTC GTA CCA GCC GAA TTT GAA TTA GCC 1050 Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu Leu Ala 340 345 350 CAT GGA TCA GAA GAA TCG AAA AAA CTT GCA GAA AAA ATC AGG 1092 His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys He Arg 355 360 AAG TTT TAC TTT GAC GAT AAA CCC GTT CCT GAA AAT GAG CAG 1134 Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn Glu Gin 365 370 375 AAA TTT ATT GAC TTG ATA GGA GAT ATT TGG TTT ACT AGA GGC 1176 Lys Phe He Asp Leu He Gly Asp He Trp Phe Thr Arg Gly 380 385 390 ATT GAC AAG CAT GTC AAG TTG TCT GTA GAA AAA CAA GAC GAG 1218 He Asp Lys His Val Lys Leu Ser Val Glu Lys Gin Asp Glu 395 400 405 CCA GTA TAT TAT TAT GAA TAT TCT TTC TCT GAA AGT CAT CCT 1260 Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser Glu Ser His Pro 410 415 420 GCA AAA GGA ACA TTT GGT GAC CAT AAC TTG ACT GGA GCA TGT 1302 Ala Lys Gly Thr Phe Gly Asp His Asn Leu Thr Gly Ala Cys 425 430 CAT GGT GAA GAA CTT GTG AAT TTA TTC AAA GTC GAG ATG ATG 1344 His Gly Glu Glu Leu Val Asn Leu Phe Lys Val Glu Met Met 435 440 445 AAG CTG GAA AAA GAT AAA CCG AAT GTT TTA TTA ACA AAA GAT 1386 Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr Lys Asp 450 455 460 AGG GTA CTT GCT ATG TGG ACG AAC TTC ATC AAA AAT GGA AAT 1428 Arg Val Leu Ala Met Trp Thr Asn Phe He Lys Asn Gly Asn 465 470 475 CCT ACT CCT GAA GTA ACT GAA TTA TTG CCA GTT AAA TGG GAA 1470 Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys Trp Glu 480 485 490 CCT GCC ACA AAA GAC AAG TTG AAT TAT TTG AAC ATT GAT GCC 1512 Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu Asn He Asp Ala 495 500 ACC TTA ACT TTG GGA ACA AAT CCA GAA GAA ACC CGA GTC AAA 1554 Thr Leu Thr Leu Gly Thr Asn Pro Glu Glu Thr Arg Val Lys 505 510 515 TTY TGG GAA GAT GCC ACA AAA ACT TTG CAC AGT CAA 1590 Phe Trp Glu Asp Ala Thr Lys Thr Leu His Ser Gin 520 525 530 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2836 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 99..1889 (iv) SEQUENCE DESCRIPTION: SEQ ID NO:24: TAGACATGTC GTCTTCAAAA CGTCTATTTT ATCATAAACA AAACGAGATA 50 AATAATAACA ATTAAGCAAC CAAAATGCAT TAAAAAACAC AATAAAAA 98 ATG TTA CCT CAC AGT AGT GCA TTA GTT TTA TTT TTA TTT TTT 140 Met Leu Pro His Ser Ser Ala Leu Val Leu Phe Leu Phe Phe 1 5 10 TTA TTT TTC TTA TTT ACA CCT ATC TTG TGC ATA CTA TGG GAT 182 Leu Phe Phe Leu Phe Thr Pro He Leu Cys He Leu Trp Asp 15 20 25 AAC CTA GAT CAG CAT TTG TGC AGA GTT CAA TTT AAC GGG ATC 224 Asn Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn Gly He 30 35 40 ACG GAA GGA AAA CCG TTC CGA TAT AAA GAt CAT AGG AAT GAT 266 Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Arg Asn Asp 45 50 55 GTA TAT TGT TCT TAT TTG GGA ATT CCT TAT GCC GAA CCG CCT 308 Val Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu Pro Pro 60 65 70 TTT GGA CCA TTA CGA TTT CAG TCT CCA AAA CCA ATA TCA AAT 350 Phe Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He Ser Asn 75 80 CCA AAA ACA GGA TTC GTA CAG GCT CGA ACT TTG GGA GAC AAA 392 Pro Lys Thr Gly Phe Val Gin Ala Arg Thr Leu Gly Asp Lys 85 90 95 TGT TTC CAG GAA AGT CTA ATA TAT TCT TAT GCA GGA AGC GAA 434 Cys Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly Ser Glu 100 105 110 GAT TGC TTA TAT CTG AAT ATA TTC ACG CCA GAG ACT GTT AAT 476 Asp Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr Val Asn 115 120 125 TCT GCG AAC AAT ACA AAA TAT CCT GTA ATG TTC TGG ATC CAT 518 Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp He His 130 135 140 GGA GGC GCA TTC AAC CAA GGA TCA GGA TCT TAT AAT TTT TTT 560 Gly Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn Phe Phe 145 150 GGA CCT G sT TAT TTG ATC AGG GAA GGA ATT ATT TTG GTC ACT 602 Gly Pro Asp Tyr Leu He Arg Glu Gly He He Leu Val Thr 155 160 165 ATC AAC TAT AGA TTA GGA GTT TTC GGT TTT CTA TCA GCG CCG 644 He Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro 170 175 180 GAA TGG GAT ATC CAT GGA AAT ATG GGT CTA AAA GAC CAG AGA 686 Glu Trp Asp He His Gly Asn Met Gly Leu Lys Asp Gin Arg 185 190 195 TTG GCA CTA AAA TGG GTT TAC GAC AAC ATC GAA AAG TTT GGT 728 Leu Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys Phe Gly 200 205 210 GGA GAC AGA GAA AAA ATT ACA ATT GCT GGA GAA TCT GCT GGA 770 Gly Asp Arg Glu Lys He Thr He Ala Gly Glu Ser Ala Gly 215 220 GCA GCA AGT GTC CAT TTT CTG ATG ATG GAC AAC TCG ACT AGA 812 Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg 225 230 235 AAA TAC TAC CAA AGG GCC ATT TTG CAG AGT GGG ACA TTA CTA 854 Lys Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr Leu Leu 240 245 250 AAT CCG ACT GCT AAT CAA ATT CAA CTT CTG CAT AGA TTT GAA 896 Asn Pro Thr Ala Asn Gin He Gin Leu Leu His Arg Phe Glu 255 260 265 AAA CTC AAA CAA GTG CTA AAC ATC ACG CAA AAA CAA GAA CTC 938 Lys Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin Glu Leu 270 275 280 CTA AAC CTG GAT AAA AAC CTA ATT TTA CGA GCA GCC TTA AAC 980 Leu Asn Leu Asp Lys Asn Leu He Leu Arg Ala Ala Leu Asn 285 290 AGA GTT CCT GAT AGC AAC GAC CAT GAC CGA GAC ACA GTA CCA 1022 Arg Val Pro Asp Ser Asn Asp His Asp Arg Asp Thr Val Pro 295 300 305 GTA TTT AAT CCA GTC TTA GAA TCA CCA GAA TCT CCA GAT CCA 1064 Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro Asp Pro 310 315 320 ATA ACA TTT CCA TCT GCC TTG GAA AGA ATG AGA AAT GGT GAA 1106 He Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu 325 330 335 TTT CCT GAT GTC GAT GTC ATC ATT GGT TTC AAT AGT GCT GAA 1148 Phe Pro Asp Val Asp Val He He Gly Phe Asn Ser Ala Glu 340 345 350 GGT TTA AGA TCT ATG GCA AGA GTA ACC AGA GGA AAC ATG GAA 1190 Gly Leu Arg Ser Met Ala Arg Val Thr Arg Gly Asn Met Glu 355 360 GTT CAC AAG ACT TTG ACA AAT ATA GAA AGG GCT ATA CCT AGA 1232 Val His Lys Thr Leu Thr Asn He Glu Arg Ala He Pro Arg 365 370 375 GAT GCT AAT ATT TGG AAA AAT CCA AAT GGT ATT GAG GAG AAA 1274 Asp Ala Asn He Trp Lys Asn Pro Asn Gly He Glu Glu Lys 380 385 390 AAA CTA ATA AAA ATG CTT ACA GAG TTT TAT GAC CAA GTG AAA 1316 Lys Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin Val Lys 395 400 405 GAA CAA AAC GAT GAC ATT GAA GCC TAC GTC CAA CTA AAA GGC 1358 Glu Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu Lys Gly 410 415 420 GAT GCT GGT TAC CTC CAA GGA ATC TAC CGT ACC TTG AAA GCC 1400 Asp Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu Lys Ala 425 430 ATA TTT TTC AAT GAA TTC AGA AGG AAT TCC AAT TTG TAT TTG 1442 He Phe Phe Asn Glu Phe Arg Arg Asn Ser Asn Leu Tyr Leu 435 440 445 TAC AGG TTA TCA GAC GAT ACG TAT AGT GTA TAT AAA AGT TAT 1484 Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr 450 455 460 ATC TTG CCC TAT CGA TGG GGT TCC TTG CCA GGA GTT AGT CAT 1526 He Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His 465 470 475 GGT GAT GAT TTA GGA TAT CTT TTT GCA AAC TCG TTG GAT GTT 1568 Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val 480 485 490 CCT ATT TTG GGA ACA ACG CAC ATT TCT ATA CCG CAA GAT GCT 1610 Pro He Leu Gly Thr Thr His He Ser He Pro Gin Asp Ala 495 500 ATG CAG ACT CTG GAA AGG ATG GTC AGG ATC TGG ACC AAT TTT 1652 Met Gin Thr Leu Glu Arg Met Val Arg He Trp Thr Asn Phe 505 510 515 GTA AAG AAT GGA AAA CCT ACA TCA AAC ACT GAA GAT GCA TCA 1694 Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser 520 525 530 TGT GAT ACA AAA AGA CAT TTA AAC GAC ATT TTT TGG GAA CCA 1736 Cys Asp Thr Lys Arg His Leu Asn Asp He Phe Trp Ov Pro 535 540 545 TAC AAC GAC GAA GAA CCA AAA TAT TTG GAC ATG GGA AAA GAA 1778 Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu 550 555 560 AAT TTT GAA ATG AAA AAT ATT TTG GAA CTA AAA CGC ATG ATG 1820 Asn Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg Met Met 565 570 CTT TGG GAT GAA GTT TAT AGA AAT GCG AAT TTG CGG TTT AGA 1862 Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg 575 580 585 GTC TGT AAT GAA GAA AGT ATT AGA TGA GTTTTTTTAA 1899 Val Cys Asn Glu Glu Ser He Arg 590 595 TTTTACATAC AGCCGAGAGG AAACATGACT AAAATTGGAA AGAAAAATCA 1949 GAAAAAGAAA AATCACATGG ACCATAGTAA CTTTATTACA TGATTTAGTT 1999 TCAAGTGTAT CAAGAAAACT TATTGCATCA AAGAAAATAT TATTTTGCCA 2049 AAATTCTTGG AAAAACACTT TTTATGACTG ACATGGCCCA TAATTGAAGC 2099 TTTTTCTTCT TTTACCAAAT CGCCAAATTT TGTAGCGTCA GACACATTTA 2149 TTTATGACAT GGCAATTAAT GTGTTAAACA TTCAACTCTA TATTAAAAAT 2199 GGTAGTATTT TCTAATAAGA AGGTTATATA AAAAGACTTG AAAATAATAA 2249 GATTTGCTCG GCTATATATA AAAACTTANC GTCTCGTTAT GCTAAACTTT 2299 TTTGATGGTA AAAATATGTT GATTTTCCTA ATAATCTAAG ATATTATATT 2349 TTAGATTAAA TTAAAATATG ATATTTTCAA TTAATTAATT TTAGTTTTAA 2399 ATGTACTATA TTTACCAGTA CTATGAAACT ATTTTAAATA TATTTTTTAT 2449 TACAATATTT ATTTCTCAAA AATGTTTAGT GTAACAAGAC CATTAAATTA 2499 GAGTTAATGT TGTAAATTAA ACTATTTTTT ATCTATCACA ACCGCTTAAT 2549 TGGTGCAAAG AAAAATTTTA CTGTGATAAT ATTTGACATT TACACAATAT 2599 TACGAATTGT AAACTCACAA TTATGTGAAT ATTGTTTTTT GTTAAAAAAA 2649 CATACATGAC TTTTCTATAT CATTTTATAT TACGGTGATA TGGATTAATG 2699 TCAACATGTA AAATACAAAT GCGGTTGTTA AAAATAATCT GTATTAAAAT 2749 TGTTATATAA AATCTGAATA AATGTACTTT TAAGTAAAAA AAAAAAAAAA 2799 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAA 2836 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 596 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO:25: Met Leu Pro His Ser Ser Ala Leu Val Leu Phe Leu Phe Phe 1 5 10 Leu Phe Phe Leu Phe Thr Pro He Leu Cys He Leu Trp Asp 15 20 25 Asn Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn Gly He 30 35 40 Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Arg Asn Asp 45 50 55 Val Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu Pro Pro 60 65 70 Phe Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He Ser Asn 75 80 Pro Lys Thr Gly Phe Val Gin Ala Arg Thr Leu Gly Asp Lys 85 90 95 Cys Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly Ser Glu 100 105 110 Asp Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr Val Asn 115 120 125 Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp He His 130 135 140 Gly Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn Phe Phe 145 150 Gly Pro Asp Tyr Leu He Arg Glu Gly He He Leu Val Thr 155 160 165 He Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro 170 175 180 Glu Trp Asp He His Gly Asn Met Gly Leu Lys Asp Gin Arg 185 190 195 Leu Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys Phe Gly 200 205 210 Gly Asp Arg Glu Lys He Thr He Ala Gly Glu Ser Ala Gly 215 220 Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg 225 230 235 Lys Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr Leu Leu 240 245 250 Asn Pro Thr Ala Asn Gin He Gin Leu Leu His Arg Phe Glu 255 260 265 Lys Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin Glu Leu 270 275 280 -je a Asn Leu Asp Lys Asn Leu He Leu Arg Ala Ala Leu Asn 285 290 Arg Val Pro Asp Ser Asn Asp His Asp Arg Asp Thr Val Pro 295 300 305 Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro Asp Pro 310 315 320 Ile Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu 325 330 335 Phe Pro Asp Val Asp Val He He Gly Phe Asn Ser Ala Glu 340 345 350 Gly Leu Arg Ser Met Ala Arg Val Thr Arg Gly Asn Met Glu 355 360 Val His Lys Thr Leu Thr Asn He Glu Arg Ala He Pro Arg 365 370 375 Asp Ala Asn He Trp Lys Asn Pro Asn Gly He Glu Glu Lys 380 385 390 Lys Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin Val Lys 395 400 405 Glu Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu Lys Gly 410 415 420 Asp Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu Lys Ala 425 430 He Phe Phe Asn Glu Phe Arg Arg Asn Ser Asn Leu Tyr Leu 435 440 445 Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr 450 455 460 He Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His 465 470 475 Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val 480 485 490 Pro He Leu Gly Thr Thr His He Ser He Pro Gin Asp Ala 495 500 Met Gin Thr Leu Glu Arg Met Val Arg He Trp Thr Asn Phe 505 510 515 Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser 520 525 530 Cys Asp Thr Lys Arg His Leu Asn Asp He Phe Trp Glu Pro 535 540 545 Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu 550 555 560 Asn Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg Met Met 565 570 Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg 575 580 585 Val Cys Asn Glu Glu Ser He Arg 590 595 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2836 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO:26: TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 50 TTACTTAAAA GTACATTTAT TCAGATTTTA TATAACAATT TTAATACAGA 100 TTATTTTTAA CAACCGCATT TGTATTTTAC ATGTTGACAT TAATCCATAT 150 CACCGTAATA TAAAATGATA TAGAAAAGTC ATGTATGTTT TTTTAACAAA 200 AAACAATATT CACATAATTG TGAGTTTACA ATTCGTAATA TTGTGTAAAT 250 GTCAAATATT ATCACAGTAA AATTTTTCTT TGCACCAATT AAGCGGTTGT 300 GATAGATAAA AAATAGTTTA ATTTACAACA TTAACTCTAA TTTAATGGTC 350 TTGTTACACT AAACATTTTT GAGAAATAAA TATTGTAATA AAAAATATAT 400 TTAAAATAGT TTCATAGTAC TGGTAAATAT AGTACATTTA AAACTAAAAT 450 TAATTAATTG AAAATATCAT ATTTTAATTT AATCTAAAAT ATAATATCTT 500 AGATTATTAG GAAAATCAAC ATATTTTTAC CATCAAAAAA GTTTAGCATA 550 ACGAGACGNT AAGTTTTTAT ATATAGCCGA GCAAATCTTA TTATTTTCAA 600 GTCTTTTTAT ATAACCTTCT TATTAGAAAA TACTACCATT TTTAATATAG 650 AGTTGAATGT TTAACACATT AATTGCCATG TCATAAATAA ATGTGTCTGA 700 CGCTACAAAA TTTGGCGATT TGGTAAAAGA AGAAAAAGCT TCAATTATGG 750 GCCATGTCAG TCATAAAAAG TGTTTTTCCA AGAATTTTGG CAAAATAATA 800 TTTTCTTTGA TGCAATAAGT TTTCTTGATA CACTTGAAAC TAAATCATGT 850 AATAAAGTTA CTATGGTCCA TGTGATTTTT CTTTTTCTGA TTTTTCTTTC 900 CAATTTTAGT CATGTTTCCT CTCGGCTGTA TGTAAAATTA AAAAAACTCA 950 TCTAATACTT TCTTCATTAC AGACTCTAAA CCGCAAATTC GCATTTCTAT 1000 AAACTTCATC CCAAAGCATC ATGCGTTTTA GTTCCAAAAT ATTTTTCATT 1050 TCAAAATTTT CTTTTCCCAT GTCCAAATAT TTTGGTTCTT CGTCGTTGTA 1100 TGGTTCCCAA AAAATGTCGT TTAAATGTCT TTTTGTATCA CATGATGCAT 1150 CTTCAGTGTT TGATGTAGGT TTTCCATTCT TTACAAAATT GGTCCAGATC 1200 CTGACCATCC TTTCCAGAGT CTGCATAGCA TCTTGCGGTA TAGAAATGTG 1250 CGTTGTTCCC AAAATAGGAA CATCCAACGA GTTTGCAAAA AGATATCCTA 1300 AATCATCACC ATGACTAACT CCTGGCAAGG AACCCCATCG ΛTAGGGCAAG 1350 ATATAACTTT TATATACACT ATACGTATCG TCTGATAALC TGTACAAATA 1400 CAAATTGGAA TTCCTTCTGA ATTCATTGAA AAATATGGCT TTCAAGGTAC 1450 GGTAGATTCC TTGGAGGTAA CCAGCATCGC CTTTTAGTTG GACGTAGGCT 1500 TCAATGTCAT CGTTTTGTTC TTTCACTTGG TCATAAAACT CTGTAAGCAT 1550 TTTTATTAGT TTTTTCTCCT CAATACCATT TGGATTTTTC CAAATATTAG 1600 CATCTCTAGG TATAGCCCTT TCTATATTTG TCAAAGTCTT GTGAACTTCC 1650 ATGTTTCCTC TGGTTACTCT TGCCATAGAT CTTAAACCTT CAGCACTATT 1700 GAAACCAATG ATGACATCGA CATCAGGAAA TTCACCATTT CTCATTCTTT 1750 CCAAGGCAGA TGGAAATGTT ATTGGATCTG GAGATTCTGG TGATTCTAAG 1800 ACTGGATTAA ATACTGGTAC TGTGTCTCGG TCATGGTCGT TGCTATCAGG 1850 AACTCTGTTT AAGGCTGCTC GTAAAATTAG GTTTTTATCC AGGTTTAGGA 1900 GTTCTTGTTT TTGCGTGATG TTTAGCACTT GTTTGAGTTT TTCAAATCTA 1950 TGCAGAAGTT GAATTTGATT AGCAGTCGGA TTTAGTAATG TCCCACTCTG 2000 CAAAATGGCC CTTTGGTAGT ATTTTCTAGT CGAGTTGTCC ATCATCAGAA 2050 AATGGACACT TGCTGCTCCA GCAGATTCTC CAGCAATTGT AATTTTTTCT 2100 CTGTCTCCAC CAAACTTTTC GATGTTGTCG TAAACCCATT TTAGTGCCAA 2150 TCTCTGGTCT TTTAGACCCA TATTTCCATG GATATCCCAT TCCGGCGCTG ' 2200 ATAGAAAACC GAAAACTCCT AATCTATAGT TGATAGTGAC CAAAATAATT 2250 CCTTCCCTGA TCAAATAATC AGGTCCAAAA AAATTATAAG ATCCTGATCC 2300 TTGGTTGAAT GCGCCTCCAT GGATCCAGAA CATTACAGGA TATTTTGTAT 2350 TGTTCGCAGA ATTAACAGTC TCTGGCGTGA ATATATTCAG ATATAAGCAA 2400 TCTTCGCTTC CTGCATAAGA ATATATTAGA CTTTCCTGGA AACATTTGTC 2450 TCCCAAAGTT CGAGCCTGTA CGAATCCTGT TTTTGGATTT GATATTGGTT 2500 TTGGAGACTG AAATCGTAAT GGTCCAAAAG GCGGTTCGGC ATAAGGAATT 2550 CCCAAATAAG AACAATATAC ATCATTCCTA TGATCTTTAT ATCGGAACGG 2600 TTTTCCTTCC GTGATCCCGT TAAATTGAAC TCTGCACAAA TGCTGATCTA 2650 GGTTATCCCA TAGTATGCAC AAGATAGGTG TAAATAAGAA AAATAAAAAA 2700 AATAAAAATA AAACTAATGC ACTACTGTGA GGTAACATTT TTTATTGTGT 2750 TTTTTAATGC ATTTTGGTTG CTTAATTGTT ATTATTTATC TCGTTTTGTT 2800 TATGATAAAA TAGACGTTTT GAAGACGACA TGTCTA 2836 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1710 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1710 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 27: TGG GAT AAC CTA GAT CAG CAT TTG TGC AGA GTT CAA TTT AAC 42 Trp Asp Asn Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn 1 5 10 GGG ATC ACG GAA GGA AAA CCG TTC CGA TAT AAA GAT CAT AGG 84 Gly He Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Arg 15 20 25 AAT GAT GTA TAT TGT TCT TAT TTG GGA ATT CCT TAT GCC GAA 126 Asn Asp Val Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu 30 35 40 CCG CCT TTT GGA CCA TTA CGA TTT CAG TCT CCA AAA CCA ATA 168 Pro Pro Phe Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He 45 50 55 TCA AAT CCA AAA ACA GGA TTC GTA CAG GCT CGA ACT TTG GGA 210 Ser Asn Pro Lys Thr Gly Phe Val Gin Ala Arg Thr Leu Gly 60 65 70 GAC AAA TGT TTC CAG GAA AGT CTA ATA TAT TCT TAT GCA GGA 252 Asp Lys Cys Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly 75 80 AGC GAA GAT TGC TTA TAT CTG AAT ATA TTC ACG CCA GAG ACT 294 Ser Glu Asp Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr 85 90 95 GTT AAT TCT GCG AAC AAT ACA AAA TAT CCT GTA ATG TTC TGG 336 Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp 100 105 110 ATC CAT GGA GGC GCA TTC AAC CAA GGA TCA GGA TCT TAT AAT 378 He His Gly Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn 115 120 125 TTT TTT GGA CCT GAT TAT TTG ATC AGG GAA GGA ATT ATT TTG 420 Phe Phe Gly Pro Asp Tyr Leu He Arg Glu Gly He He Leu 130 135 140 GTC ACT ATC AAC TAT AGA TTA GGA GTT TTC GGT TTT CTA TCA 462 Val Thr He Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser 145 150 GCG CCG GAA TGG GAT ATC CAT GGA AAT ATG GGT CTA AAA GAC 504 Ala Pro Glu Trp Asp He His Gly Asn Met Gly Leu Lys Asp 155 160 165 CAG AGA TTG GCA CTA AAA TGG GTT TAC GAC AAC ATC GAA AAG 546 Gin Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys 170 175 180 TTT GGT GGA GAC AGA GAA AAA ATT ACA ATT GCT GGA GAA TCT 588 Phe Gly Gly Asp Arg Glu Lys He Thr He Ala Gly Glu Ser 185 190 195 GCT GGA GCA GCA AGT GTC CAT TTT CTG ATG ATG GAC AAC TCG 630 Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser 200 205 210 ACT AGA AAA TAC TAC CAA AGG GCC ATT TTG CAG AGT GGG ACA 672 Thr Arg Lys Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr 215 220 TTA CTA AAT CCG ACT GCT AAT CAA ATT CAA CTT CTG CAT AGA 714 Leu Leu Asn Pro Thr Ala Asn Gin He Gin Leu Leu His Arg 225 230 235 TTT GAA AAA CTC AAA CAA GTG CTA AAC ATC ACG CAA AAA CAA 756 Phe Glu Lys Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin 240 245 250 GAA CTC CTA AAC CTG GAT AAA AAC CTA ATT TTA CGA GCA GCC 798 Glu Leu Leu Asn Leu Asp Lys Asn Leu He Leu Arg Ala Ala 255 260 265 TTA AAC AGA GTT CCT GAT AGC AAC GAC CAT GAC CGA GAC ACA 840 Leu Asn Arg Val Pro Asp Ser Asn Asp His Asp Arg Asp Thr 270 275 280 GTA CCA GTA TTT AAT CCA GTC TTA GAA TCA CCA GAA TCT CCA 882 Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro 285 290 GAT CCA ATA ACA TTT CCA TCT GCC TTG GAA AGA ATG AGA AAT 924 Asp Pro He Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn 295 300 305 GGT GAA TTT CCT GAT GTC GAT GTC ATC ATT GGT TTC AAT AGT 966 Gly Glu Phe Pro Asp Val Asp Val He He Gly Phe Asn Ser 310 315 320 GCT GAA GGT TTA AGA TCT ATG GCA AGA GTA ACC AGA GGA AAC 1008 Ala Glu Gly Leu Arg Ser Met Ala Arg Val Thr Arg Gly Asn 325 330 335 ATG GAA GTT CAC AAG ACT TTG ACA AAT ATA GAA AGG GCT ATA 1050 Met Glu Val His Lys Thr Leu Thr Asn He Glu Arg Ala He 340 345 350 CCT AGA GAT GCT AAT ATT TGG AAA AAT CCA AAT GGT ATT GAG 1092 Pro Arg Asp Ala Asn He Trp Lys Asn Pro Asn Gly He Glu 355 360 GAG AAA AAA CTA ATA AAA ATG CTT ACA GAG TTT TAT GAC CAA 1134 Glu Lys Lys Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin 365 370 375 GTG AAA GAA CAA AAC GAT GAC ATT GAA GCC TAC GTC CAA CTA 1176 Val Lys Glu Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu 380 385 390 AAA GGC GAT GCT GGT TAC CTC CAA GGA ATC TAC CGT ACC TTG 1218 Lys Gly Asp Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu 395 400 405 AAA GCC ATA TTT TTC AAT GAA TTC AGA AGG AAT TCC AAT TTG 1260 Lys Ala He Phe Phe Asn Glu Phe Arg Arg Asn Ser Asn Leu 410 415 420 TAT TTG TAC AGG TTA TCA GAC GAT ACG TAT AGT GTA TAT AAA 1302 Tyr Leu Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys 425 430 AGT TAT ATC TTG CCC TAT CGA TGG GGT TCC TTG CCA GGA GTT 1344 Ser Tyr He Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val 435 440 445 AGT CAT GGT GAT GAT TTA GGA TAT CTT TTT GCA AAC TCG TTG 1386 Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu 450 455 460 GAT GTT CCT ATT TTG GGA ACA ACG CAC ATT TCT ATA CCG CAA 1428 Asp Val Pro He Leu Gly Thr Thr His He Ser He Pro Gin 465 470 475 GAT GCT ATG CAG ACT CTG GAA AGG ATG GTC AGG ATC TGG ACC 1470 Asp Ala Met Gin Thr Leu Glu Arg Met Val Arg He Trp Thr 480 485 490 AAT TTT GTA AAG AAT GGA AAA CCT ACA TCA AAC ACT GAA GAT 1512 Asn Phe Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp 495 500 GCA TCA TGT GAT ACA AAA AGA CAT TTA AAC GAC ATT TTT TGG 1554 Ala Ser Cys Asp Thr Lys Arg His Leu Asn Asp He Phe Trp 505 510 515 GAA CCA TAC AAC GAC GAA GAA CCA AAA TAT TTG GAC ATG GGA 1596 Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly 520 525 530 AAA GAA AAT TTT GAA ATG AAA AAT ATT TTG GAA CTA AAA CGC 1638 Lys Glu Asn Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg 535 540 545 ATG ATG CTT TGG GAT GAA GTT TAT AGA AAT GCG AAT TTG CGG 1680 Met Met Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg 550 555 560 TTT AGA GTC TGT AAT GAA GAA AGT ATT AGA 1710 Phe Arg Val Cys Asn Glu Glu Ser He Arg 565 570 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1788 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (_i ) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1788 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 28: ATG TTA CCT CAC AGT AGT GCA TTA GTT TTA TTT TTA TTT TTT 42 Met Leu Pro His Ser Ser Ala Leu Val Leu Phe Leu Phe Phe 1 5 10 TTA TTT TTC TTA TTT ACA CCT ATC TTG TGC ATA CTA TGG GAT 84 Leu Phe Phe Leu Phe Thr Pro He Leu Cys He Leu Trp Asp 15 20 25 AAC CTA GAT CAG CAT TTG TGC AGA GTT CAA TTT AAC GGG ATC 126 Asn Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn Gly He 30 35 40 ACG GAA GGA AAA CCG TTC CGA TAT AAA GAt CAT AGG AAT GAT 168 Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Arg Asn Asp 45 50 55 GTA TAT TGT TCT TAT TTG GGA ATT CCT TAT GCC GAA CCG CCT 210 Val Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu Pro Pro 60 65 70 TTT GGA CCA TTA CGA TTT CAG TCT CCA AAA CCA ATA TCA AAT 252 Phe Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He Ser Asn 75 80 CCA AAA ACA GGA TTC GTA CAG GCT CGA ACT TTG GGA GAC AAA 294 Pro Lys Thr Gly Phe Val Gin Ala Arg Thr Leu Gly Asp Lys 85 90 95 TGT TTC CAG GAA AGT CTA ATA TAT TCT TAT GCA GGA AGC GAA 336 Cys Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly Ser Glu 100 105 110 GAT TGC TTA TAT CTG AAT ATA TTC ACG CCA GAG ACT GTT AAT 378 Asp Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr Val Asn 115 120 125 TCT GCG AAC AAT ACA AAA TAT CCT GTA ATG TTC TGG ATC CAT 420 Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp He His 130 135 140 GGA GGC GCA TTC AAC CAA GGA TCA GGA TCT TAT AAT TTT TTT 462 Gly Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn Phe Phe 145 150 GGA CCT GAT TAT TTG ATC AGG GAA GGA ATT ATT TTG GTC ACT 504 Gly Pro Asp Tyr Leu He Arg Glu Gly He He Leu Val Thr 155 160 165 ATC AAC TAT AGA TTA GGA GTT TTC GGT TTT CTA TCA GCG CCG 546 He Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro 170 175 180 GAA TGG GAT ATC CAT GGA AAT ATG GGT CTA AAA GAC CAG AGA 588 Glu Trp Asp He His Gly Asn Met Gly Leu Lys Asp Gin Arg 185 190 195 TTG GCA CTA AAA TGG GTT TAC GAC AAC ATC GAA AAG TTT GGT 630 Leu Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys Phe Gly 200 205 210 GGA GAC AGA GAA AAA ATT ACA ATT GCT GGA GAA TCT GCT GGA 672 Gly Asp Arg Glu Lys He Thr He Ala Gly Glu Ser Ala Gly 215 220 GCA GCA AGT GTC CAT TTT CTG ATG ATG GAC AAC TCG ACT AGA 714 Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg 225 230 235 AAA TAC TAC CAA AGG GCC ATT TTG CAG AGT GGG ACA TTA CTA 756 Lys Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr Leu Leu 240 245 250 AAT CCG ACT GCT AAT CAA ATT CAA CTT CTG CAT AGA TTT GAA 798 Asn Pro Thr Ala Asn Gin He Gin Leu Leu His Arg Phe Glu 255 260 265 AAA CTC AAA CAA GTG CTA AAC ATC ACG CAA AAA CAA GAA CTC 840 Lys Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin Glu Leu 270 275 280 CTA AAC CTG GAT AAA AAC CTA ATT TTA CGA GCA GCC TTA AAC 882 Leu Asn Leu Asp Lys Asn Leu He Leu Arg Ala Ala Leu Asn 285 290 AGA GTT CCT GAT AGC AAC GAC CAT GAC CGA GAC ACA GTA CCA 924 Arg Val Pro Asp Ser Asn Asp His Asp Arg Asp Thr Val Pro 295 300 305 GTA TTT AAT CCA GTC TTA GAA TCA CCA GAA TCT CCA GAT CCA 966 Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro Asp Pro 310 315 320 ATA ACA TTT CCA TCT GCC TTG GAA AGA ATG AGA AAT GGT GAA 1008 He Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu 325 330 335 TTT CCT GAT GTC GAT GTC ATC ATT GGT TTC AAT AGT GCT GAA 1050 Phe Pro Asp Val Asp Val He He Gly Phe Asn Ser Ala Glu 340 345 350 GGT TTA AGA TCT ATG GCA AGA GTA ACC AGA GGA AAC ATG GAA 1092 Gly Leu Arg Ser Met Ala Arg Val Thr Arg Gly Asn Met Glu 355 360 GTT CAC AAG ACT TTG ACA AAT ATA GAA AGG GCT ATA CC π AGA 1134 Val His Lys Thr Leu Thr Asn He Glu Arg Ala He ΛJ Arg 365 370 375 GAT GCT AAT ATT TGG AAA AAT CCA AAT GGT ATT GAG GAG AAA 1176 Asp Ala Asn He Trp Lys Asn Pro Asn Gly He Glu Glu Lys 380 385 390 AAA CTA ATA AAA ATG CTT ACA GAG TTT TAT GAC CAA GTG AAA 1218 Lys Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin Val Lys 395 400 405 GAA CAA AAC GAT GAC ATT GAA GCC TAC GTC CAA CTA AAA GGC 1260 Glu Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu Lys Gly 410 415 420 GAT GCT GGT TAC CTC CAA GGA ATC TAC CGT ACC TTG AAA GCC 1302 Asp Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu Lys Ala 425 430 ATA TTT TTC AAT GAA TTC AGA AGG AAT TCC AAT TTG TAT TTG 1344 He Phe Phe Asn Glu Phe Arg Arg Asn Ser Asn Leu Tyr Leu 435 440 445 TAC AGG TTA TCA GAC GAT ACG TAT AGT GTA TAT AAA AGT TAT 1386 Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr 450 455 460 ATC TTG CCC TAT CGA TGG GGT TCC TTG CCA GGA GTT AGT CAT 1428 He Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His 465 470 475 GGT GAT GAT TTA GGA TAT CTT TTT GCA AAC TCG TTG GAT GTT 1470 Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val 480 485 490 CCT ATT TTG GGA ACA ACG CAC ATT TCT ATA CCG CAA GAT GCT 1512 Pro He Leu Gly Thr Thr His He Ser He Pro Gin Asp Ala 495 500 ATG CAG ACT CTG GAA AGG ATG GTC AGG ATC TGG ACC AAT TTT 1554 Met Gin Thr Leu Glu Arg Met Val Arg He Trp Thr Asn Phe 505 510 515 GTA AAG AAT GGA AAA CCT ACA TCA AAC ACT GAA GAT GCA TCA 1596 Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser 520 525 530 TGT GAT ACA AAA AGA CAT TTA AAC GAC ATT TTT TGG GAA CCA 1638 Cys Asp Thr Lys Arg His Leu Asn Asp He Phe Trp Glu Pro 535 540 545 TAC AAC GAC GAA GAA CCA AAA TAT TTG GAC ATG GGA AAA GAA 1680 Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu 550 555 560 AAT TTT GAA ATG AAA AAT AT r .' TTG GAA CTA AAA CGC ATG ATG 1722 Asn Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg Met Met 565 570 CTT TGG GAT GAA GTT TAT AGA AAT GCG AAT TTG CGG TTT AGA 1764 Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg 575 580 585 GTC TGT AAT GAA GAA AGT ATT AGA 1788 Val Cys Asn Glu Glu Ser He Arg 590 595 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1788 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 29: TCTAATACTT TCTTCATTAC AGACTCTAAA CCGCAAATTC GCATTTCTAT 50 AAACTTCATC CCAAAGCATC ATGCGTTTTA GTTCCAAAAT ATTTTTCATT 100 TCAAAATTTT CTTTTCCCAT GTCCAAATAT TTTGGTTCTT CGTCGTTGTA 150 TGGTTCCCAA AAAATGTCGT TTAAATGTCT TTTTGTATCA CATGATGCAT 200 CTTCAGTGTT TGATGTAGGT TTTCCATTCT TTACAAAATT GGTCCAGATC 250 CTGACCATCC TTTCCAGAGT CTGCATAGCA TCTTGCGGTA TAGAAATGTG 300 CGTTGTTCCC AAAATAGGAA CATCCAACGA GTTTGCAAAA AGATATCCTA 350 AATCATCACC ATGACTAACT CCTGGCAAGG AACCCCATCG ATAGGGCAAG 400 ATATAACTTT TATATACACT ATACGTATCG TCTGATAACC TGTACAAATA 450 CAAATTGGAA TTCCTTCTGA ATTCATTGAA AAATATGGCT TTCAAGGTAC 500 GGTAGATTCC TTGGAGGTAA CCAGCATCGC CTTTTAGTTG GACGTAGGCT 550 TCAATGTCAT CGTTTTGTTC TTTCACTTGG TCATAAAACT CTGTAAGCAT 600 TTTTATTAGT TTTTTCTCCT CAATACCATT TGGATTTTTC CAAATATTAG 650 CATCTCTAGG TATAGCCCTT TCTATATTTG TCAAAGTCTT GTGAACTTCC 700 ATGTTTCCTC TGGTTACTCT TGCCATAGAT CTTAAACCTT CAGCACTATT 750 GAAACCAATG ATGACATCGA CATCAGGAAA TTCACCATTT CTCATTCTTT 800 CCAAGGCAGA TGGAAATGTT ATTGGATCTG GAGATTCTGG TGATTCTAAG 850 ACTGGATTAA ATACTGGTAC TGTGTCTCGG TCATGGTCGT TGCTATCAGG 900 AACTCTGTTT AAGGCTGCTC GTAAAATTAG GTTTTTATCC AGGTTTAGGA 950 GTTCTTGTTT TTGCGTGATG TTTAGCACTT GTTTGAGTTT TTCAAATCTA 1000 TGCAGAAGTT GAATTTGATT AGCAGTCGGA TTTAGTAATG TCCCACTCTG 1050 CAAAATGGCC CTTTGGTAGT ATTTTCTAGT CGAGTTGTCC ATCATCAGAA 1100 AATGGACACT TGCTGCTCCA GCAGATTCTC CAGCAATTGT AATTTTTTCT 1150 CTGTCTCCAC CAAACTTTTC GATGTTGTCG TAAACCCATT TTAGTGCCAA 1200 TCTCTGGTCT TTTAGACCCA TATTTCCATG GATATCCCAT TCCGGCGCTG 1250 ATAGAAAACC GAAAACTCCT AATCTATAGT TGATAGTGAC CAAAATAATT 1300 CCTTCCCTGA TCAAATAATC AGGTCCAAAA AAATTATAAG ATCCTGATCC 1350 TTGGTTGAAT GCGCCTCCAT GGATCCAGAA CATTACAGGA TATTTTGTAT 1400 TGTTCGCAGA ATTAACAGTC TCTGGCGTGA ATATATTCAG ATATAAGCAA 1450 TCTTCGCTTC CTGCATAAGA ATATATTAGA CTTTCCTGGA AACATTTGTC 1500 TCCCAAAGTT CGAGCCTGTA CGAATCCTGT TTTTGGATTT GATATTGGTT 1550 TTGGAGACTG AAATCGTAAT GGTCCAAAAG GCGGTTCGGC ATAAGGAATT 1600 CCCAAATAAG AACAATATAC ATCATTCCTA TGATCTTTAT ATCGGAACGG 1650 T-TTCCTTCC GTGATCCCGT TAAATTGAAC TCTGCACAAA TGCTGATCTA 1700 GGTTATCCCA TAGTATGCAC AAGATAGGTG TAAATAAGAA AAATAAAAAA 1750 AATAAAAATA AAACTAATGC ACTACTGTGA GGTAACAT 1788 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2801 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 99..1886 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 30: GACATGTCGT CTTCAAAACG TCTATTTTAT CATAAACAAA ACGAGATAAA 50 TAATAACAAT TAAGCATCCA AAATGCATTA AAAAAAACAT CATAAAAA 98 ATG TTA CCT CAC AGT GCA TTA GTT TTA TTT TTA TTT TTT TTA 140 Met Leu Pro His Ser Ala Leu Val Leu Phe Leu Phe Phe Leu 1 5 10 TTT TTC TTA TTT ACA CCT GTC TTG TGC ATA CTA TGG GAT AAC 182 Phe Phe Leu Phe Thr Pro Val Leu Cys He Leu Trp Asp Asn 15 20 25 CTA GAT CAG CAT TTG TGC AGA GTT CAA TTT AAC GGG ATC ACG 224 Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn Gly He Thr 30 35 40 GAA GGA AAA CCG TTC CGA TAT AAA GAT CAT AAA AAT GAT GTA 266 Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Lys Asn Asp Val 45 50 55 TAT TGT TCC TAT TTG GGA ATT CCT TAT GCA GAA CCG CCT ATT 308 Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu Pro Pro He 60 65 70 GGA CCA TTG CGA TTT CAG TCT CCA AAA CCA ATA TCA AAT CCA 350 Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He Ser Asn Pro 75 80 AAA ACA GGA TTC GTT CAG GCT CGG TCT TTA GGA GAC AAA TGT 392 Lys Thr Gly Phe Val Gin Ala Arg Ser Leu Gly Asp Lys Cys 85 90 95 TTC CAG GAA AGT CTA ATA TAT TCT TAT GCA GGA AGC GAA GAT 434 Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly Ser Glu Asp 100 105 110 TGC TTA TAT CTG AAT ATA TTC ACG CCA GAG ACT GTT AAT TCT 476 Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr Val Asn Ser 115 120 125 GCG AAC AAT ACA AAA TAT CCT GTA ATG TTC TGG ATC CAT GGA 518 Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp He His Gly 130 135 140 GGC GCA TTC AAC CAA GGA TCA GGA TCT TAT AAT TTT TTT GGA 560 Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn Phe Phe Gly CCT GAT TAT TTG ATC AGG GAA GGA ATT ATT TTG GTC ACT ATC 602 Pro Asp Tyr Leu He Arg Glu Gly He He Leu Val Thr He 155 160 165 AAC TAT AGA TTA GGA GTT TTC GGT TTT CTA TCA GCG CCG GAA 644 Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu 170 175 180 TGG GAT ATC CAT GGA AAT ATG GGT CTA AAA GAC CAG AGA TTG 686 Trp Asp He His Gly Asn Met Gly Leu Lys Asp Gin Arg Leu 185 190 195 GCA CTA AAA TGG GTT TAT GAC AAC ATC GAA AAA TTT GGT GGA 728 Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys Phe Gly Gly 200 205 210 GAC AGA GAT AAA ATC ACT ATA GCT GGA GAA TCT GCT GGA GCA 770 Asp Arg Asp Lys He Thr He Ala Gly Glu Ser Ala Gly Ala 215 220 GCA AGT GTT CAT TTT CTG ATG ATG GAC AAT TCT ACT AGA AAA 812 Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg Lys 225 230 235 TAC TAC CAA AGG GCA ATT TTG CAG AGT GGG ACA TTA CTC AAT 854 Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr Leu Leu Asn 240 245 250 CCG ACT GCT AAT CAA ATT CAA CCT CTG CAT AGA TTT GAA AAA 896 Pro Thr Ala Asn Gin He Gin Pro Leu His Arg Phe Glu Lys 255 260 265 CTA AAA CAA GTG CTG AAC ATC ACG CAA AAA CAA GAA CTC CTA 938 Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin Glu Leu Leu 270 275 280 AAT CTG GAC AAA AAT CAA ATT TTG CGA GCA GCC TTA AAC AGA 980 Asn Leu Asp Lys Asn Gin He Leu Arg Ala Ala Leu Asn Arg 285 290 GTC CCA GAT AAC AAC GAC CAC GAA AGG GAC ACA GTA CCA GTA 1022 Val Pro Asp Asn Asn Asp His Glu Arg Asp Thr Val Pro Val 295 300 305 TTT AAT CCA GTC CTA GAA TCA CCA GAA TCT CCA '3AC CCA ATA 1064 Phe Asn Pro Val Leu Glu Ser Pro Glu Ser P ^ o Asp Pro He 310 315 320 ACA TTT CCA TCT GCT TTA GAA AGA ATG AGA AAT GGT GAA TTT 1106 Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu Phe 325 330 335 CCT GAC GTT GAT GTC ATC ATT GGA TTC AAT AGT GCT GAA GGT 1148 Pro Asp Val Asp Val He He Gly Phe Asn Ser Ala Glu Gly 340 345 350 TTA AGA TCT ATG CCA AGA GTA ACC AGA GGA AAC ATG GAA GTT 1190 Leu Arg Ser Met Pro Arg Val Thr Arg Gly Asn Met Glu Val 355 360 TAC AAG ACT TTG ACA AAT ATA GAG AGA GCT ATA CCT AGA GAT 1232 Tyr Lys Thr Leu Thr Asn He Glu Arg Ala He Pro Arg Asp 365 370 375 GCT AAT ATT TGG AAA AAT CCT AAT GGC ATT GAG GAG AAA AAA 1274 Ala Asn He Trp Lys Asn Pro Asn Gly He Glu Glu Lys Lys 380 385 390 CTT ATA AAA ATG CTT ACA GAG TTT TAT GAC CAA GTT AAA GAA 1316 Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin Val Lys Glu 395 400 405 CAA AAC GAT GAC ATC GAA GCC TAT GTC CAA CTA AAA GGC GAT 1358 Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu Lys Gly Asp 410 415 420 GCT GGT TAT CTC CAA GGA ATT TAC CGT ACC TTG AAA GCC ATA 1400 Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu Lys Ala He 425 430 TTT TTC AAT GAA ATC AAA AGA AAT TCC AAC TTG TAT TTG TAT 1442 Phe Phe Asn Glu He Lys Arg Asn Ser Asn Leu Tyr Leu Tyr 435 440 445 AGG TTA TCA GAT GAT ACG TAT AGT GTA TAT AAA AGT TAT ATC 1484 Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr He 450 455 460 TTG CCC TAT CGA TGG GGT TCC TTG CCA GGA GTT AGT CAT GGT 1526 Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His Gly 465 470 475 GAT GAT TTA GGA TAT CTT TTT GCA AAC TCT TTG GAT GTT CCT 1568 Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val Pro 480 485 490 ATT TTG GGA ACA ACG CAC ATT TCT ATA CCG CAA GAT GCT ATG 1610 He Leu Gly Thr Thr His He Ser He Pro Gin Asp Ala Met 495 500 CAG ACT CTG GAA AGG ATG GTC AGG ATC TGG ACC AAT TTT GTA 1652 Gin Thr Leu Glu Arg Met Val Arg He Trp Thr Asn Phe Val 505 510 515 AAG AAT GGA AAA CCT ACA TCA AAC ACT GAA GAT GCA TCA TGT 1694 Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser Cys 520 525 530 GAT ACA AAA AGA CAT TTA AAC GAC ATT TTT TGG GAA CCA TAC 1736 Asp Thr Lys Arg His Leu Asn Asp He Phe Trp Glu Pro Tyr 535 540 545 AAC GAC GAA GAA CCA AAA TAT TTG GAC ATG GGA AAA GAA CAT 1778 Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu His 550 555 560 TTT GAA ATG AAA AAT ATT TTG GAA CTA AAA CGC ATG ATG CTT 1820 Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg Met Met Leu 565 570 TGG GAT GAA GTT TAT AGA AAT GCG AAT TTG CGG TTT AGA GTC 1862 Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg Val 575 580 585 TGT AAT GAA GAA AGT ATT AGA TGA GTTTTTTTAA TTTTACATAC 1906 Cys Asn Glu Glu Ser He Arg 590 595 AGCCGAGAGG AAACATGACT AAAATTGGAA AGAAAAATCA GAAAAAGAAA 1956 AATCACATGG ACCATAGTAA CTTTATTACA TGATTTAGTT TCAAGTGTAT 2006 CAAGAAAACT TATTGCATCA AAGAAAATAT TATTTTGCCA AAATTCTTGG 2056 AAAAACACTT TTTATGACTG ACATGGCCCA TAATTGAAGC TTTTTCTTCT 2106 TTTACCAAAT CGCCAAATTT TGTAGCGTCA GACACATTTA TTTATGACAT 2156 GGCAATTAAT GTGTTAAACA TTCAACTCTA TATTAAAAAT GGTAGTATTT 2206 TCTAATAAGA AGGTTATATA AAAAGACTTG AAAATAATAA GATTTGCTCG 2256 GCTATATATA AAAACTTANC GTCTCGTTAT GCTAAACTTT TTTGATGGTA 2306 AAAATATGTT GATTTTCCTA ATAATCTAAG ATATTATATT TTAGATTAAA 2356 TTAAAATATG ATATTTTCAA TTAATTAATT TTAGTTTTAA ATGTACTATA 2406 TTTACCAGTA CTATGAAACT ATTTTAAATA TATTTTTTAT TACAATATTT 2456 ATTTCTCAAA AATGTTTAGT GTAACAAGAC CATTAAATTA GAGTTAATGT 2506 TGTAAATTAA ACTATTTTTT ATCTATCACA ACCGCTTAAT TGGTGCAAAG 2556 AAAAATTTTA CTGTGATAAT ATTTGACATT TACACAATAT TACGAATTGT 2606 AAACTCACAA TTATGTGAAT ATTGTTTTTT GTTAAAAAAA CATACATGAC 2656 TTTTCTATAT CATTTTATAT TACGGTGATA TGGATTAATG TCAACATGTA 2706 AAATACAAAT GCGGTTGTTA AAAATAATCT GTATTAAAAT TGTTATATAA 2756 AATCTGAATA AATGTACTTT TAAGTAAAAA AAAAAAAAAA AAAAA 2801 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 595 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 31: Met Leu Pro His Ser Ala Leu Val Leu Phe Leu Phe Phe Leu 1 5 10 Phe Phe Leu Phe Thr Pro Val Leu Cys He Leu Trp Asp Asn 15 20 25 Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn Gly He Thr 30 35 40 Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Lys Asn Asp Val 45 50 55 Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu Pro Pro He 60 65 70 Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He Ser Asn Pro 75 80 Lys Thr Gly Phe Val Gin Ala Arg Ser Leu Gly Asp Lys Cys 85 90 95 Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly Ser Glu Asp 100 105 110 Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr Val Asn Ser 115 120 125 Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp He His Gly 130 135 140 Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn Phe Phe Gly 145 150 Pro Asp Tyr Leu He Arg Glu Gly He He Leu Val Thr He 155 160 165 Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu 170 175 180 Trp Asp He His Gly Asn Met Gly Leu Lys Asp Gin Arg Leu 185 190 195 Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys Phe Gly Gly 200 205 210 Asp Arg Asp Lys He Thr He Ala Gly Glu Ser Ala Gly Ala 215 220 Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg Lys 225 230 235 Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr Leu Leu Asn 240 245 250 Pro Thr Ala Asn Gin He Gin Pro Leu His Arg Phe Glu Lys 255 260 265 Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin Glu Leu Leu 270 275 280 Asn Leu Asp Lys Asn Gin He Leu Arg Ala Ala Leu Asn Arg 285 ' 290 Val Pro Asp Asn Asn Asp His Glu Arg Asp Thr Val Pro Val 295 300 305 Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro Asp Pro He 310 315 320 Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu Phe 325 330 335 Pro Asp Val Asp Val He He Gly Phe Asn Ser Ala Glu Gly 340 345 350 Leu Arg Ser Met Pro Arg Val Thr Arg Gly Asn Met Glu Val 355 360 Tyr Lys Thr Leu Thr Asn He Glu Arg Ala He Pro Arg Asp 365 370 375 Ala Asn He Trp Lys Asn Pro Asn Gly He Glu Glu Lys Lys 380 385 390 Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin Val Lys Glu 395 400 405 Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu Lys Gly Asp 410 415 420 Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu Lys Ala He 425 430 Phe Phe Asn Glu He Lys Arg Asn Ser Asn Leu Tyr Leu Tyr 435 440 445 Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr He 450 455 460 Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His Gly 465 470 475 Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val Pro 480 485 490 He Leu Gly Thr Thr His He Ser He Pro Gin Asp Ala Met 495 500 Gin Thr Leu Glu Arg Met Val Arg He Trp Thr Asn Phe Val 505 510 515 Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser Cys 520 525 530 Asp Thr Lys Arg His Leu Asn Asp He ^he Trp Glu Pro Tyr 535 545 545 Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu His 550 555 560 Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg Met Met Leu 565 570 Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg Val 575 580 585 Cys Asn Glu Glu Ser He Arg 590 595 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2801 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 32: TTTTTTTTTT TTTTTTTTTT ACTTAAAAGT ACATTTATTC AGATTTTATA 50 TAACAATTTT AATACAGATT ATTTTTAACA ACCGCATTTG TATTTTACAT 100 GTTGACATTA ATCCATATCA CCGTAATATA AAATGATATA GAAAAGTCAT 150 GTATGTTTTT TTAACAAAAA ACAATATTCA CATAATTGTG AGTTTACAAT 200 TCGTAATATT GTGTAAATGT CAAATATTAT CACAGTAAAA TTTTTCTTTG 250 CACCAATTAA GCGGTTGTGA TAGATAAAAA ATAGTTTAAT TTACAACATT 300 AACTCTAATT TAATGGTCTT GTTACACTAA ACATTTTTGA GAAATAAATA 350 TTGTAATAAA AAATATATTT AAAATAGTTT CATAGTACTG GTAAATATAG 400 TACATTTAAA ACTAAAATTA ATTAATTGAA AATATCATAT TTTAATTTAA 450 TCTAAAATAT AATATCTTAG ATTATTAGGA AAATCAACAT ATTTTTACCA 500 TCAAAAAAGT TTAGCATAAC GAGACGNTAA GTTTTTATAT ATAGCCGAGC 550 AAATCTTATT ATTTTCAAGT CTTTTTATAT AACCTTCTTA TTAGAAAATA 600 CTACCATTTT TAATATAGAG TTGAATGTTT AACACATTAA TTGCCATGTC 650 ATAAATAAAT GTGTCTGACG CTACAAAATT TGGCGATTTG GTAAAAGAAG 700 AAAAAGCTTC AATTATGGGC CATGTCAGTC ATAAAAAGTG TTTTTCCAAG 750 AATTTTGGCA AAATAATATT TTCTTTGATG CAATAAGTTT TCTTGATACA 800 CTTGAAACTA AATCATGTAA TAAAGTTACT ATGGTCCATG TGATTTTTCT 850 TTTTCTGATT TTTCTTTCCA ATTTTAGTCA TGTTTCCTCT CGGCTGTATG 900 TAAAATTAAA AAAACTCATC TAATACTTTC TTCATTACAG ACTCTAAACC 950 GCAAATTCGC ATTTCTATAA ACTTCATCCC AAAGCATCAT GCGTTTTAGT 1000 TCCAAAATAT TTTTCATTTC AAAATGTTCT TTTCCCATGT CCAAATATTT 1050 TGGTTCTTCG TCGTTGTATG GTTCCCAAAA AATGTCGTTT AAATGTCTTT 1100 TTGTATCACA TGATGCATCT TCAGTGTTTG ATGTAGGTTT TCCATTCTTT 1150 ACAAAATTGG TCCAGATCCT GACCATCCTT TCCAGAGTCT GCATAGCATC 1200 TTGCGGTATA GAAATGTGCG TTGTTCCCAA AATAGGAACA TCCAAAGAGT 1250 TTGCAAAAAG ATATCCTAAA TCATCACCAT GACTAACTCC TGGCAAGGAA 1300 CCCCATCGAT AGGGCAAGAT ATAACTTTTA TATACACTAT ACGTATCATC 1350 TGATAACCTA TACAAATACA AGTTGGAATT TCTTTTGATT TCATTGAAAA 1400 ATATGGCTTT CAAGGTACGG TAAATTCCTT GGAGATAACC AGCATCGCCT 1450 TTTAGTTGGA CΛTAGGCTTC GATGTCATCG TTTTGTTCTT TAACTTGGTC 1500 ATAAAACTC'x LTAAGCATTT TTATAAGTTT TTTCTCCTCA ATGCCATTAG 1550 GATTTTTCCA AATATTAGCA TCTCTAGGTA TAGCTCTCTC TATATTTGTC 1600 AAAGTCTTGT AAACTTCCAT GTTTCCTCTG GTTACTCTTG GCATAGATCT 1650 TAAACCTTCA GCACTATTGA ATCCAATGAT GACATCAACG TCAGGAAATT 1700 CACCATTTCT CATTCTTTCT AAAGCAGATG GAAATGTTAT TGGGTCTGGA 1750 GATTCTGGTG ATTCTAGGAC TGGATTAAAT ACTGGTACTG TGTCCCTTTC 1800 GTGGTCGTTG TTATCTGGGA CTCTGTTTAA GGCTGCTCGC AAAATTTGAT 1850 TTTTGTCCAG ATTTAGGAGT TCTTGTTTTT GCGTGATGTT CAGCACTTGT 1900 TTTAGTTTTT CAAATCTATG CAGAGGTTGA ATTTGATTAG CAGTCGGATT 1950 GAGTAATGTC CCACTCTGCA AAATTGCCCT TTGGTAGTAT TTTCTAGTAG 2000 AATTGTCCAT CATCAGAAAA TGAACACTTG CTGCTCCAGC AGATTCTCCA 2050 GCTATAGTGA TTTTATCTCT GTCTCCACCA AATTTTTCGA TGTTGTCATA 2100 AACCCATTTT AGTGCCAATC TCTGGTCTTT TAGACCCATA TTTCCATGGA 2150 TATCCCATTC CGGCGCTGAT AGAAAACCGA AAACTCCTAA TCTATAGTTG 2200 ATAGTGACCA AAATAATTCC TTCCCTGATC AAATAATCAG GTCCAAAAAA 2250 ATTATAAGAT CCTGATCCTT GGTTGAATGC GCCTCCATGG ATCCAGAACA 2300 TTACAGGATA TTTTGTATTG TTCGCAGAAT TAACAGTCTC TGGCGTGAAT 2350 ATATTCAGAT ATAAGCAATC TTCGCTTCCT GCATAAGAAT ATATTAGACT 2400 TTCCTGGAAA CATTTGTCTC CTAAAGACCG AGCCTGAACG AATCCTGTTT 2450 TTGGATTTGA TATTGGTTTT GGAGACTGAA ATCGCAATGG TCCAATAGGC 2500 GGTTCTGCAT AAGGAATTCC CAAATAGGAA CAATATACAT CATTTTTATG 2550 ATCTTTATAT CGGAACGGTT TTCCTTCCGT GATCCCGTTA AATTGAACTC 2600 TGCACAAATG CTGATCTAGG TTATCCCATA GTATGCACAA GACAGGTGTA 2650 AATAAGAAAA ATAAAAAAAA TAAAAATAAA ACTAATGCAC TGTGAGGTAA 2700 CATTTTTTAT GATGTTTTTT TTAATGCATT TTGGATGCTT AATTGTTATT 2750 ATTTATCTCG TTTTGTTTAT GATAAAATAG ACGTTTTGAA GACGACATGT 2800 C 2801 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1710 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1710 (iv) SEQUENCE DESCRIPTION: SEQ ID NO:33: TGG GAT AAC CTA GAT CAG CAT TTG TGC AGA GTT CAA TTT AAC 42 Trp Asp Asn Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn 1 5 10 GGG ATC ACG GAA GGA AAA CCG TTC CGA TAT AAA GAT CAT AAA 84 Gly He Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Lys 15 20 25 AAT GAT GTA TAT TGT TCC TAT TTG GGA ATT CCT TAT GCA GAA 126 Asn Asp Val Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu 30 35 40 CCG CCT ATT GGA CCA TTG CGA TTT CAG TCT CCA AAA CCA ATA 168 Pro Pro He Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He 45 50 55 TCA AAT CCA AAA ACA GGA TTC GTT CAG GCT CGG TCT TTA GGA 210 Ser Asn Pro Lys Thr Gly Phe Val Gin Ala Arg Ser Leu Gly 60 65 70 GAC AAA TGT TTC CAG GAA AGT CTA ATA TAT TCT TAT GCA GGA 252 Asp Lys Cys Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly 75 80 AGC GAA GAT TGC TTA TAT CTG AAT ATA TTC ACG CCA GAG ACT 294 Ser Glu Asp Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr 85 90 95 GTT AAT TCT GCG AAC AAT ACA AAA TAT CCT GTA ATG TTC TGG 336 Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp 100 105 110 ATC CAT GGA GGC GCA TTC AAC CAA GGA TCA GGA TCT TAT AAT 378 He His Gly Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn 115 120 125 TTT TTT GGA CCT GAT TAT TTG ATC AGG GAA GGA ATT ATT TTG 420 Phe Phe Gly Pro Asp Tyr Leu He Arg Glu Gly He He Leu 130 135 140 GTC ACT ATC AAC TAT AGA TTA GGA GTT TTC GGT TTT CTA TCA 462 Val Thr He Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser 145 150 GCG CCG GAA TGG GAT ATC CAT GGA AAT ATG GGT CTA AAA GAC 504 Ala Pro Glu Trp Asp He His Gly Asn Met Gly Leu Lys Asp 155 160 165 CAG AGA TTG GCA CTA AAA TGG GTT TAT GAC AAC ATC GAA AAA 546 Gin Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys 170 175 180 TTT GGT GGA GAC AGA GAT AAA ATC ACT ATA GCT GGA GAA TCT 588 Phe Gly Gly Asp Arg Asp Lys He Thr He Ala Gly Glu Ser 185 190 195 GCT GGA GCA GCA AGT GTT CAT TTT CTG ATG ATG GAC AAT TCT 630 Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser 200 205 210 ACT AGA AAA TAC TAC CAA AGG GCA ATT TTG CAG AGT GGG ACA 672 Thr Arg Lys Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr 215 220 TTA CTC AAT CCG ACT GCT AAT CAA ATT CAA CCT CTG CAT AGA 714 Leu Leu Asn Pro Thr Ala Asn Gin He Gin Pro Leu His Arg 225 230 235 TTT GAA AAA CTA AAA CAA GTG CTG AAC ATC ACG CAA AAA CAA 756 Phe Glu Lys Leu Lys Gin Val Leu Asn He Thr Gin Lys ^ Λ 240 245 250 GAA CTC CTA AAT CTG GAC AAA AAT CAA ATT TTG CGA GCA GCC 798 Glu Leu Leu Asn Leu Asp Lys Asn Gin He Leu Arg Ala Ala 255 260 265 TTA AAC AGA GTC CCA GAT AAC AAC GAC CAC GAA AGG GAC ACA 840 Leu Asn Arg Val Pro Asp Asn Asn Asp His Glu Arg Asp Thr 270 275 280 GTA CCA GTA TTT AAT CCA GTC CTA GAA TCA CCA GAA TCT CCA 882 Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro 285 290 GAC CCA ATA ACA TTT CCA TCT GCT TTA GAA AGA ATG AGA AAT 924 Asp Pro He Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn 295 300 305 GGT GAA TTT CCT GAC GTT GAT GTC ATC ATT GGA TTC AAT AGT 966 Gly Glu Phe Pro Asp Val Asp Val He He Gly Phe Asn Ser 310 315 320 GCT GAA GGT TTA AGA TCT ATG CCA AGA GTA ACC AGA GGA AAC 1008 Ala Glu Gly Leu Arg Ser Met Pro Arg Val Thr Arg Gly Asn 325 330 335 ATG GAA GTT TAC AAG ACT TTG ACA AAT ATA GAG AGA GCT ATA 1050 Met Glu Val Tyr Lys Thr Leu Thr Asn He Glu Arg Ala He 340 345 350 CCT AGA GAT GCT AAT ATT TGG AAA AAT CCT AAT GGC ATT GAG 1092 Pro Arg Asp Ala Asn He Trp Lys Asn Pro Asn Gly He Glu 355 360 GAG AAA AAA CTT ATA AAA ATG CTT ACA GAG TTT TAT GAC CAA 1134 Glu Lys Lys Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin 365 370 375 GTT AAA GAA CAA AAC GAT GAC ATC GAA GCC TAT GTC CAA CTA 1176 Val Lys Glu Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu 380 385 390 AAA GGC GAT GCT GGT TAT CTC CAA GGA ATT TAC CGT ACC TTG 1218 Lys Gly Asp Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu 395 400 405 AAA GCC ATA TTT TTC AAT GAA ATC AAA AGA AAT TCC AAC TTG 1260 Lys Ala He Phe Phe Asn Glu He Lys Arg Asn Ser Asn Leu 410 415 420 TAT TTG TAT AGG TTA TCA GAT GAT ACG TAT AGT GTA TAT AAA 1302 Tyr Leu Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys 425 430 AGT TAT ATC TTG CCC TAT CGA T JG GGT TCC TTG CCA GGA GTT 1344 Ser Tyr He Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val 435 440 445 AGT CAT GGT GAT GAT TTA GGA TAT CTT TTT GCA AAC TCT TTG 1386 Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu 450 455 460 GAT GTT CCT ATT TTG GGA ACA ACG CAC ATT TCT ATA CCG CAA 1428 Asp Val Pro He Leu Gly Thr Thr His He Ser He Pro Gin 465 470 475 GAT GCT ATG CAG ACT CTG GAA AGG ATG GTC AGG ATC TGG ACC 1470 Asp Ala Met Gin Thr Leu Glu Arg Met Val Arg He Trp Thr 480 485 490 AAT TTT GTa AAG AAT GGA AAA CCT ACA TCA AAC ACT GAA GAT 1512 Asn Phe Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp 495 500 GCA TCA TGT GAT ACA AAA AGA CAT TTA AAC GAC aTT TTT TGG 1554 Ala Ser Cys Asp Thr Lys Arg His Leu Asn Asp He Phe Trp 505 510 515 GAA CCA TAC AAC GAC GAA GAA CCA AAA TAT TTG GAC ATG GGA 1596 Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly 520 525 530 AAA GAA CAT TTT GAA ATG AAA AAT ATT TTG GAA CTA AAA CGC 1638 Lys Glu His Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg 535 540 545 ATG ATG CTT TGG GAT GAA GTT TAT AGA AAT GCG AAT TTG CGG 1680 Met Met Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg 550 555 560 TTT AGA GTC TGT AAT GAA GAA AGT ATT AGA 1710 Phe Arg Val Cys Asn Glu Glu Ser He Arg 565 570 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1785 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1785 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 34: ATG T r :A CCT CAC AGT GCA TTA GTT TTA TTT TTA TTT TTT TTA 42 Met Leu Pro His Ser Ala Leu Val Leu Phe Leu Phe Phe Leu 1 5 10 TTT TTC TTA TTT ACA CCT GTC TTG TGC ATA CTA TGG GAT AAC 84 Phe Phe Leu Phe Thr Pro Val Leu Cys He Leu Trp Asp Asn 15 20 25 CTA GAT CAG CAT TTG TGC AGA GTT CAA TTT AAC GGG ATC ACG 126 Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn Gly He Thr 30 35 40 GAA GGA AAA CCG TTC CGA TAT AAA GAT CAT AAA AAT GAT GTA 168 Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Lys Asn Asp Val 45 50 55 TAT TGT TCC TAT TTG GGA ATT CCT TAT GCA GAA CCG CCT ATT 210 Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu Pro Pro He 60 65 70 GGA CCA TTG CGA TTT CAG TCT CCA AAA CCA ATA TCA AAT CCA 252 Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He Ser Asn Pro 75 80 AAA ACA GGA TTC GTT CAG GCT CGG TCT TTA GGA GAC AAA TGT 294 Lys Thr Gly Phe Val Gin Ala Arg Ser Leu Gly Asp Lys Cys 65 90 95 TTC CAG GAA AGT CTA ATA TAT TCT TAT GCA GGA AGC GAA GAT 336 Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly Ser Glu Asp 100 105 110 TGC TTA TAT CTG AAT ATA TTC ACG CCA GAG ACT GTT AAT TCT 378 Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr Val Asn Ser 115 120 125 GCG AAC AAT ACA AAA TAT CCT GTA ATG TTC TGG ATC CAT GGA 420 Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp He His Gly 130 135 140 GGC GCA TTC AAC CAA GGA TCA GGA TCT TAT AAT TTT TTT GGA 462 Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn Phe Phe Gly 145 150 CCT GAT TAT TTG ATC AGG GAA GGA ATT ATT TTG GTC ACT ATC 504 Pro Asp Tyr Leu He Arg Glu Gly He He Leu Val Thr He 155 160 165 AAC TAT AGA TTA GGA GTT TTC GGT TTT CTA TCA GCG CCG GAA 546 Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu 170 175 180 TGG GAT ATC CAT GGA AAT ATG GGT CTA AAA GAC CAG AGA TTG 588 Trp Asp He His Gly Asn Met Gly Leu Lys Asp Gin Arg Leu 185 190 195 GCA CTA AAA TGG GTT TAT GAC AAC ATC GAA AAA TTT GGT GGA 630 Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys Phe Gly Gly 200 205 210 GAC AGA GAT AAA ATC ACT ATA GCT GGA GAA TCT GCT GGA GCA 672 Asp Arg Asp Lys He Thr He Ala Gly Glu Ser Ala Gly Ala 215 220 GCA AGT GTT CAT TTT CTG ATG ATG GAC AAT TCT ACT AGA AAA 714 Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg Lys 225 230 235 TAC TAC CAA AGG GCA ATT TTG CAG AGT GGG ACA TTA CTC AAT 756 Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr Leu Leu Asn 240 245 250 CCG ACT GCT AAT CAA ATT CAA CCT CTG CAT AGA TTT GAA AAA 798 Pro Thr Ala Asn Gin He Gin Pro Leu His Arg Phe Glu Lys 255 260 265 CTA AAA CAA GTG CTG AAC ATC ACG CAA AAA CAA GAA CTC CTA 840 Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin Glu Leu Leu 270 275 280 AAT CTG GAC AAA AAT CAA ATT TTG CGA GCA GCC TTA AAC AGA 882 Asn Leu Asp Lys Asn Gin He Leu Arg Ala Ala Leu Asn Arg 285 290 GTC CCA GAT AAC AAC GAC CAC GAA AGG GAC ACA GTA CCA GTA 924 Val Pro Asp Asn Asn Asp His Glu Arg Asp Thr Val Pro Val 295 300 305 TTT AAT CCA GTC CTA GAA TCA CCA GAA TCT CCA GAC CCA ATA 966 Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro Asp Pro He 310 315 320 ACA TTT CCA TCT GCT TTA GAA AGA ATG AGA AAT GGT GAA TTT 1008 Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu Phe 325 330 335 CCT GAC GTT GAT GTC ATC ATT GGA TTC AAT AGT GCT GAA GGT 1050 Pro Asp Val Asp Val He He Gly Phe Asn Ser Ala Glu Gly 340 345 350 TTA AGA TCT ATG CCA AGA GTA ACC AGA GGA AAC ATG GAA GTT 1092 Leu Arg Ser Met Pro Arg Val Thr Arg Gly Asn Met Glu Val 355 360 TAC AAG ACT TTG ACA AAT ATA GAG AGA GCT ATA CCT AGA GAT 1134 Tyr Lys Thr Leu Thr Asn He Glu Arg Ala He Pro Arg Asp 365 370 375 GCT AAT ATT TGG AAA AAT CCT AAT GGC ATT GAG GAG AAA AAA 1176 Ala Asn He Trp Lys Asn Pro Asn Gly He Glu Glu Lys Lys 380 385 390 CTT ATA AAA ATG CTT ACA GAG TTT TAT GAC CAA GTT AAA GAA 1218 Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin Λ~ Lys Glu 395 400 405 CAA AAC GAT GAC ATC GAA GCC TAT GTC CAA CTA AAA GGC GAT 1260 Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu Lys Gly Asp 410 415 420 GCT GGT TAT CTC CAA GGA ATT TAC CGT ACC TTG AAA GCC ATA 1302 Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu Lys Ala He 425 430 TTT TTC AAT GAA ATC AAA AGA AAT TCC AAC TTG TAT TTG TAT 1344 Phe Phe Asn Glu He Lys Arg Asn Ser Asn Leu Tyr Leu Tyr 435 440 445 AGG TTA TCA GAT GAT ACG TAT AGT GTA TAT AAA AGT TAT ATC 1386 Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr He 450 455 460 TTG CCC TAT CGA TGG GGT TCC TTG CCA GGA GTT AGT CAT GGT 1428 Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His Gly 465 470 475 GAT GAT TTA GGA TAT CTT TTT GCA AAC TCT TTG GAT GTT CCT 1470 Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val Pro 480 485 490 ATT TTG GGA ACA ACG CAC ATT TCT ATA CCG CAA GAT GCT ATG 1512 He Leu Gly Thr Thr His He Ser He Pro Gin Asp Ala Met 495 500 CAG ACT CTG GAA AGG ATG GTC AGG ATC TGG ACC AAT TTT GTA 1554 Gin Thr Leu Glu Arg Met Val Arg He Trp Thr Asn Phe Val 505 510 515 AAG AAT GGA AAA CCT ACA TCA AAC ACT GAA GAT GCA TCA TGT 1596 Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser Cys 520 525 530 GAT ACA AAA AGA CAT TTA AAC GAC ATT TTT TGG GAA CCA TAC 1638 Asp Thr Lys Arg His Leu Asn Asp He Phe Trp Glu Pro Tyr 535 540 545 AAC GAC GAA GAA CCA AAA TAT TTG GAC ATG GGA AAA GAA CAT 1680 Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu His 550 555 560 TTT GAA ATG AAA AAT ATT TTG GAA CTA AAA CGC ATG ATG CTT 1722 Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg Met Met Leu 565 570 TGG GAT GAA GTT TAT AGA AAT GCG AAT TTG CGG TTT AGA GTC 1764 Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg Val 575 580 585 TGT AAT GAA GAA AGT ATT AGA 1785 Cys Asn Glu Glu Ser H, Arg 590 595 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1785 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 35: TCTAATACTT TCTTCATTAC AGACTCTAAA CCGCAAATTC GCATTTCTAT 50 AAACTTCATC CCAAAGCATC ATGCGTTTTA GTTCCAAAAT ATTTTTCATT 100 TCAAAATGTT CTTTTCCCAT GTCCAAATAT TTTGGTTCTT CGTCGTTGTA 150 TGGTTCCCAA AAAATGTCGT TTAAATGTCT TTTTGTATcA CATGATGCAT 200 CTTCAGTGTT TGATGTAGGT TTTCCATTCT TTACAAAATT GGTCCAGATC 250 CTGACCATCC TTTCCAGAGT CTGCATAGCA TCTTGCGGTA TAGAAATGTG 300 CGTTGTTCCC AAAATAGGAA CATCCAAAGA GTTTGCAAAA AGATATCCTA 350 AATCATCACC ATGACTAACT CCTGGCAAGG AACCCCATCG ATAGGGCAAG 400 ATATAACTTT TATATACACT ATACGTATCA TCTGATAACC TATACAAATA 450 CAAGTTGGAA TTTCTTTTGA TTTCATTGAA AAATATGGCT TTCAAGGTAC 500 GGTAAATTCC TTGGAGATAA CCAGCATCGC CTTTTAGTTG GACATAGGCT 550 TCGATGTCAT CGTTTTGTTC TTTAACTTGG TCATAAAACT CTGTAAGCAT 600 TTTTATAAGT TTTTTCTCCT CAATGCCATT AGGATTTTTC CAAATATTAG 650 CATCTCTAGG TATAGCTCTC TCTATATTTG TCAAAGTCTT GTAAACTTCC 700 ATGTTTCCTC TGGTTACTCT TGGCATAGAT CTTAAACCTT CAGCACTATT 750 GAATCCAATG ATGACATCAA CGTCAGGAAA TTCACCATTT CTCATTCTTT 800 CTAAAGCAGA TGGAAATGTT ATTGGGTCTG GAGATTCTGG TGATTCTAGG 850 ACTGGATTAA ATACTGGTAC TGTGTCCCTT TCGTGGTCGT TGTTATCTGG 900 GACTCTGTTT AAGGCTGCTC GCAAAATTTG ATTTTTGTCC AGATTTAGGA 950 GTTCTTGTTT TTGCGTGATG TTCAGCACTT GTTTTAGTTT TTCAAATCTA 1000 TGCAGAGGTT GAATTTGATT AGCAGTCGGA TTGAGTAATG TCCCACTCTG 1050 CAAAATTGCC CTTTGGTAGT ATTTTCTAGT AGAATTGTCC ATCATCAGAA 1100 AATGAACACT TGCTGCTCCA GCAGATTCTC CAGCTATAGT GATTTTATCT 1150 CTGTCTCCAC CAAATTTTTC GATGTTGTCA TAAACCCATT TTAGTGCCAA 1200 TCTCTGGTCT TTTAGACCCA TATTTCCATG GATATCCCAT TCCGGCGCTG 1250 ATAGAAAACC GAAAACTCCT AATCTATAGT TGATAGTGAC CAAAATAATT 1300 CCTTCCCTGA TCAAATAATC AGGTCCAAAA AAATTATAAG ATCCTGATCC 1350 TTGGTTGAAT GCGCCTCCAT GGATCCAGAA CATTACAGGA TATTTTGTAT 1400 TGTTCGCAGA ATTAACAGTC TCTGGCGTGA ATATATTCAG ATATAAGCAA 1450 TCTTCGCTTC CTGCATAAGA ATATATTAGA CTTTCCTGGA AACATTTGTC 1500 TCCTAAAGAC CGAGCCTGAA CGAATCCTGT TTTTGGATTT GATATTGGTT 1550 TTGGAGACTG AAATCGCAAT GGTCCAATAG GCGGTTCTGC ATAAGGAATT 1600 CCCAAATAGG AACAATATAC ATCATTTTTA TGATCTTTAT ATCGGAACGG 1650 TTTTCCTTCC GTGATCCCGT TAAATTGAAC TCTGCACAAA TGCTGATCTA 1700 GGTTATCCCA TAGTATGCAC AAGACAGGTG TAAATAAGAA AAATAAAAAA 1750 AATAAAAATA AAACTAATGC ACTGTGAGGT AACAT 1785 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2007 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 11..1594 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 36: AGTTCCAACG ATG GCT GAT CTA CAA GTG ACT TTG CTT CAA GGT 43 Met Ala Asp Leu Gin Val Thr Leu Leu Gin Gly 1 5 10 ACT TTA AAA GGA AAA GAG CAA ATT AGT GAA AAA GGA AAT GTG 85 Thr Leu Lys Gly Lys Glu Gin He Ser Glu Lys Gly Asn Val 15 20 25 TTC CAT AGT TAT TCT GGA ATT CCA TAT GCC AAA CCT CCT GTA 127 Phe His Ser Tyr Ser Gly He Pro Tyr Ala Lys Pro Pro Val 30 35 GGT GAT CTA AGA TTT AAG CCA CCT CAA CCT GCA GAA CCT TGG 169 Gly Asp Leu Arg Phe Lys Pro Pro Gin Pro Ala Glu Pro Trp 40 45 50 TCA GGT GTT CTT GAT GCT AGT AAA GAA GGG AAT AGT TGT AGA 211 Ser Gly Val Leu Asp Ala Ser Lys Glu Gly Asn Ser Cys Arg 55 60 65 TCA GTA CAT TTT ATT AAA AAA ATT AAA GTA GGG GCT GAA GAT 253 Ser Val His Phe He Lys Lys He Lys Val Gly Ala Glu Asp 70 75 80 TGT TTA TAC CTC AAT GTC TAT GTA CCA AAA ACA TCA GAG AAA 295 Cys Leu Tyr Leu Asn Val Tyr Val Pro Lys Thr Ser Glu Lys 85 90 95 TCA CTT CTT CCA GTA ATG GTA TGG ATA CAT GGA GGA GGC TTC 337 Ser Leu Leu Pro Val Met Val Trp He His Gly Gly Gly Phe 100 105 TTC ATG GGA TCT GGA AAT AGT GAT ATG TAT GGT CCT GAA TAT 379 Phe Met Gly Ser Gly Asn Ser Asp Met Tyr Gly Pro Glu Tyr 110 115 120 TTG ATG GAT TAT GGA ATT GTT CTG GTT ACT TTC AAT TAT CGA 421 Leu Met Asp Tyr Gly He Val Leu Val Thr Phe Asn Tyr Arg 125 130 135 TTA GGT GTT TTG GGA TTT TTG AAC CTG GGA ATA GAA GAA GCG 463 Leu Gly Val Leu Gly Phe Leu Asn Leu Gly He Glu Glu Ala 140 145 150 CCT GGC AAT GTT GGT TTG ATG GAC CAG GTT GAA GCT CTA AAA 505 Pro Gly Asn Val Gly Leu Met Asp Gin Val Glu Ala Leu Lys 155 160 165 TGG GTA AAA AAC AAT ATT GCA TCC TTT GGT GGT GAC CCC AAC 547 Trp Val Lys Asn Asn He Ala Ser Phe Gly Gly Asp Pro Asn 170 175 AAT GTG ACT ATT TTT GGA GAA TCA GCA GGT GGT GCA AGT GTT 589 Asn Val Thr He Phe Gly Glu Ser Ala Gly Gly Ala Ser Val 180 185 190 CAT TAT TTG ATG TTA TCA GAT CTT TCC AAA GGA CTT TTT CAT 631 His Tyr Leu Met Leu Ser Asp Leu Ser Lys Gly Leu Phe His 195 200 205 AAA GCG ATC TCA CAA AGT GGA AGT GCT TTT AAT CCT TGG GCA 673 Lys Ala He Ser Gin Ser Gly Ser Ala Phe Asn Pro Trp Ala 210 215 220 CTT CAA CAT GAT AAT AAT AAA GAA AAT GCA TTC CGC CTC TGC 715 Leu Gin His Asp Asn Asn Lys Glu Asn Ala Phe Arg Leu Cys 225 230 235 AAA CTT CTG GGT CAT CCT GTC GAT AAC GAG ACA GAA GCT CTA 757 Lys Leu Leu Gly His Pro Val Asp Asn Glu Thr Glu Ala Leu 240 245 AAA ATC CTT CGT CAA GCC CCC ATA GAT GAT CTT ATA GAC AAC 799 Lys He Leu Arg Gin Ala Pro He Asp Asp Leu He Asp Asn 250 255 260 AGA ATA AAA CCA AAA GAC AAA GGC CAA CTT ATT ATA GAC TAT 841 Arg He Lys Pro Lys Asp Lys Gly Gin Leu He He Asp Tyr 265 270 275 CCT TTT CTA CCA ACA ATA GAA AAA CGT TAT CAA AAT TTT GAA 883 Pro Phe Leu Pro Thr He Glu Lys Arg Tyr Gin Asn Phe Glu 280 285 290 CCA TTC TTG GAC CAG TCT CCA TTA TCA AAA ATG CAA TCA GGC 925 Pro Phe Leu Asp Gin Ser Pro Leu Ser Lys Met Gin Ser Gly 295 300 305 AAT TTC ACA AAA GTC CCA TTT ATA TGT GGA TAC AAC AGT GCT 967 Asn Phe Thr Lys Val Pro Phe He Cys Gly Tyr Asn Ser Ala 310 315 GAA GGA ATT TTA GGT TTA ATG GAC TTC AAG GAT GAC CCA AAT 1009 Glu Gly He Leu Gly Leu Met Asp Phe Lys Asp Asp Pro Asn 320 325 330 ATA TTT GAG AAG TTT GAA GCT GAT TTT GAA AGA TTT GTA CCA 1051 He Phe Glu Lys Phe Glu Ala Asp Phe Glu Arg Phe Val Pro 335 340 345 GTA GAT TTG AAT CTA ACT TTA AGG TCT AAG GAA TCT AAA AAA 1093 Val Asp Leu Asn Leu Thr Leu Arg Ser L j J 31u Ser Lys Lys 350 355 360 TTG GCT GAA GAA ATG AGA AAG TTT TAT TAC CAA GAC GAA CCT 1135 Leu Ala Glu Glu Met Arg Lys Phe Tyr Tyr Gin Asp Glu Pro 365 370 375 GTT TCT TCA GAC AAC AAA GAA AAA TTT GTC AGT GTT ATT AGT 1177 Val Ser Ser Asp Asn Lys Glu Lys Phe Val Ser Val He Ser 380 385 GAT ACT TGG TTT TTG AGA GGG ATT AAA AAT ACT GCA AGA TAT 1219 Asp Thr Trp Phe Leu Arg Gly He Lys Asn Thr Ala Arg Tyr 390 395 400 ATA ATT GAA CAT TCC TCA GAA CCG TTA TAT TTA TAT GTT TAT 1261 He He Glu His Ser Ser Glu Pro Leu Tyr Leu Tyr Val Tyr 405 410 415 AGT TTT GAT GAT TTT GGT TTT TTG AAG AAA CTT GTA TTA GAT 1303 Ser Phe Asp Asp Phe Gly Phe Leu Lys Lys Leu Val Leu Asp 420 425 430 CCT AAT ATT GAA GGA GCA GCT CAT GGA GAT GAG CTG GGA TAT 1345 Pro Asn He Glu Gly Ala Ala His Gly Asp Glu Leu Gly Tyr 435 440 445 CTT TTC AAG ATG AGT TTT ACA GAA TTT CCA AAA GAT TTA CCA 1387 Leu Phe Lys Met Ser Phe Thr Glu Phe Pro Lys Asp Leu Pro 450 455 AGT GCA GTG GTG AAT AGG GAA CGA TTG TTG CAA CTT TGG ACA 1429 Ser Ala Val Val Asn Arg Glu Arg Leu Leu Gin Leu Trp Thr 460 465 470 AAT TTT GCA AAA ACA GGA AAT CCC ACT CCT GAA ATC AAT GAT 1471 Asn Phe Ala Lys Thr Gly Asn Pro Thr Pro Glu He Asn Asp 475 480 485 GTT ATA ACA ACA AAA TGG GAT AAA GCT ACT GAG GAA AAA TCA 1513 Val He Thr Thr Lys Trp Asp Lys Ala Thr Glu Glu Lys Ser 490 495 500 GAT CAT ATG GAT ATC GAT AAT ACT TTG AGA ATG ATT CCA GAT 1555 Asp His Met Asp He Asp Asn Thr Leu Arg Met He Pro Asp 505 510 515 CCT GAT GCA AAA CGA CTT AGA TTT TGG AAT AAA TTT TTA TGA 1597 Pro Asp Ala Lys Arg Leu Arg Phe Trp Asn Lys Phe Leu 520 525 TAA ATATACCAAT TATCGATTTT ATTATAGAGT TTCTGTATTA 1640 GTATAATTAT CACGTTTAGA TGTACGAGAT TCAATTGGCT CTAATTGAAG 1690 TATATTTCGA TTTCAAATTT ACTCTGATTA TTGGAAAAAA AGCTTTTACA 1740 GTTGTAATAA TCAAGAAGTA GGTGGTAAAT TTAGAACAAA TTCTGTTTTA 1790 GTGATTTGCG CATTC ^ACAG ATGGTGTACT GTGCCTAAAT TTGTCGCTCT 1840 TCTTGAAGAA CT^ -CTAAA AATGTGATTA ATGGACGCCA CATTATTTAT 1890 ATTTGATATT ATTACCATCT TTGTATCATA TTTGCTTTTA TTTTTTCATT 1940 TTTTTTTTAT TTCAAATATA TTGTTTTTTT ATAAAAAAAA AAAAAAAAAA 1990 AAAAAAAAAA AAAAAAA 2007 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 528 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO:37: Met Ala Asp Leu Gin Val Thr Leu Leu Gin Gly Thr Leu Lys 1 5 10 Gly Lys Glu Gin He Ser Glu Lys Gly Asn Val Phe His Ser 15 20 25 Tyr Ser Gly He Pro Tyr Ala Lys Pro Pro Val Gly Asp Leu 30 35 40 Arg Phe Lys Pro Pro Gin Pro Ala Glu Pro Trp Ser Gly Val 45 50 55 Leu Asp Ala Ser Lys Glu Gly Asn Ser Cys Arg Ser Val His 60 65 70 Phe He Lys Lys He Lys Val Gly Ala Glu Asp Cys Leu Tyr 75 80 Leu Asn Val Tyr Val Pro Lys Thr Ser Glu Lys Ser Leu Leu 85 90 95 Pro Val Met Val Trp He His Gly Gly Gly Phe Phe Met Gly 100 105 110 Ser Gly Asn Ser Asp Met Tyr Gly Pro Glu Tyr Leu Met Asp 115 120 125 Tyr Gly He Val Leu Val Thr Phe Asn Tyr Arg Leu Gly Val 130 135 140 Leu Gly Phe Leu Asn Leu Gly He Glu Glu Ala Pro Gly Asn 145 150 Val Gly Leu Met Asp Gin Val Glu Ala Leu Lys Trp Val Lys 155 160 165 Asn Asn He Ala Ser Phe Gly Gly Asp Pro Asn Asn Val Thr 170 175 180 He Phe Gly Glu Ser Ala Gly Gly Ala Ser Val His Tyr Leu 185 190 195 Met Leu Ser Asp Leu Ser Lys Gly Leu Phe His Lys Ala He 200 205 210 Ser Gin Ser Gly Ser Ala Phe Asn Pro Trp Ala Leu Gin His 215 220 Asp Asn Asn Lys Glu Asn Ala Phe Arg Leu Cys Lys Leu Leu 225 230 235 Gly His Pro Val Asp Asn Glu Thr Glu Ala Leu Lys He Leu 240 245 250 Arg Gin Ala Pro He Asp Asp Leu He Asp Asn Arg He Lys 255 260 265 Pro Lys Asp Lys Gly Gin Leu He He Asp Tyr Pro Phe Leu 270 275 280 Pro Thr He Glu Lys Arg Tyr Gin Asn Phe Glu Pro Phe Leu 285 290 Asp Gin Ser Pro Leu Ser Lys Met Gin Ser Gly Asn Phe Thr 295 300 305 Lys Val Pro Phe He Cys Gly Tyr Asn Ser Ala Glu Gly He 310 315 320 Leu Gly Leu Met Asp Phe Lys Asp Asp Pro Asn He Phe Glu 325 330 335 Lys Phe Glu Ala Asp Phe Glu Arg Phe Val Pro Val Asp Leu 340 345 350 Asn Leu Thr Leu Arg Ser Lys Glu Ser Lys Lys Leu Ala Glu 355 360 Glu Met Arg Lys Phe Tyr Tyr Gin Asp Glu Pro Val Ser Ser 365 370 375 Asp Asn Lys Glu Lys Phe Val Ser Val He Ser Asp Thr Trp 380 385 390 Phe Leu Arg Gly He Lys Asn Thr Ala Arg Tyr He He Glu 395 400 405 His Ser Ser Glu Pro Leu Tyr Leu Tyr Val Tyr Ser Phe Asp 410 -415 420 Asp Phe Gly Phe Leu Lys Lys Leu Val Leu Asp Pro Asn He 425 430 Glu Gly Ala Ala His Gly Asp Glu Leu Gly Tyr Leu Phe Lys 435 440 445 Met Ser Phe Thr Glu Phe Pro Lys Asp Leu Pro Ser Ala Val 450 455 460 Val Asn Arg Glu Arg Leu Leu Gin Leu Trp Thr Asn Phe Ala 465 470 475 Lys Thr Gly Asn Pro Thr Pro Glu He Asn Asp Val He Thr 480 485 490 Thr Lys Trp Asp Lys Ala Thr Glu Glu Lys Ser Asp His Met 495 500 Asp He Asp Asn Thr Leu Arg Met He Pro Asp Pro Asp Ala 505 510 515 Lys Arg Leu Arg Phe Trp Asn Lys Phe Leu 520 525 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2007 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO:38: TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTATAAA AAAACAATAT 50 ATTTGAAATA AAAAAAAAAT GAAAAAATAA AAGCAAATAT GATACAAAGA 100 TGGTAATAAT ATCAAATATA AATAATGTGG CGTCCATTAA TCACATTTTT 150 AGTTCAGTTC TTCAAGAAGA GCGACAAATT TAGGCACAGT ACACCATCTG 200 TTGAATGCGC AAATCACTAA AACAGAATTT GTTCTAAATT TACCACCTAC 250 TTCTTGATTA TTACAACTGT AAAAGCTTTT TTTCCAATAA TCAGAGTAAA 300 TTTGAAATCG AAATATACTT CAATTAGAGC CAATTGAATC TCGTACATCT 350 AAACGTGATA ATTATACTAA TACAGAAACT CTATAATAAA ATCGATAATT 400 GGTATATTTA TCATAAAAAT TTATTCCAAA ATCTAAGTCG TTTTGCATCA 450 GGATCTGGAA TCATTCTCAA AGTATTATCG ATATCCATAT GATCTGATTT 500 TTCCTCAGTA GCTTTATCCC ATTTTGTTGT TATAACATCA TTGATTTCAG 550 GAGTGGGATT TCCTGTTTTT GCAAAATTTG TCCAAAGTTG CAACAATCGT 600 TCCCTATTCA CCACTGCACT TGGTAAATCT TTTGGAAATT CTGTAAAACT 650 CATCTTGAAA AGATATCCCA GCTCATCTCC ATGAGCTGCT CCTTCAATAT 700 TAGGATCTAA TACAAGTTTC TTCAAAAAAC CAAAATCATC AAAACTATAA 750 ACATATAAAT ATAACGGTTC TGAGGAATGT TCAATTATAT ATCTTGCAGT 800 ATTTTTAATC CCTCTCAAAA ACCAAGTATC ACTAATAACA CTGACAAATT 850 TTTCTTTGTT GTCTGAAGAA ACAGGTTCGT CTTGGTAATA AAACTTTCTC 900 ATTTCTTCAG CCAATTTTTT AGATTCCTTA GACCTTAAAG TTAGATTCAA 950 ATCTACTGGT ACAAATCTTT CAAAATCAGC TTCAAACTTC TCAAATATAT 1000 TTGGGTCATC CTTGAAGTCC ATTAAACCTA AAATTCCTTC AGCACTGTTG 1050 TATCCACATA TAAATGGGAC TTTTGTGAAA TTGCCTGATT GCATTTTTGA 1100 TAATGGAGAC TGGTCCAAGA ATGGTTCAAA ATTTTGATAA CGTTTTTCTA 1150 TTGTTGGTAG AAAAGGATAG TCTATAATAA GTTGGCCTTT GTCTTTTGGT 1200 TTTATTCTGT TGTCTATAAG ATCATCTATG GGGGCTTGAC GAAGGATTTT 1250 TAGAGCTTCT GTCTCGTTAT CGACAGGATG ACCCAGAAGT TTGCAGAGGC 1300 GGAATGCATT TTCTTTATTA TTATCATGTT GAAGTGCCCA AGGATTAAAA 1350 GCACTTCCAC TTTGTGAGAT CGCTTTATGA AAAAGTCCTT TGGAAAGATC 1400 TGATAACATC AAATAATGAA CACTTGCACC ACCTGCTGAT TCTCCAAAAA 1450 TAGTCACATT GTTGGGGTCA CCACCAAAGG ΛTGCAATATT GTTTTTTACC 1500 CATTTTAGAG CTTCAACCTG GTCCATCA; \ CAACATTGC CAGGCGCTTC 1550 TTCTATTCCC AGGTTCAAAA ATCCCAAAAC ACCTAATCGA TAATTGAAAG 1600 TAACCAGAAC AATTCCATAA TCCATCAAAT ATTCAGGACC ATACATATCA 1650 CTATTTCCAG ATCCCATGAA GAAGCCTCCT CCATGTATCC ATACCATTAC 1700 TGGAAGAAGT GATTTCTCTG ATGTTTTTGG TACATAGACA TTGAGGTATA 1750 AACAATCTTC AGCCCCTACT TTAATTTTTT TAATAAAATG TACTGATCTA 1800 CAACTATTCC CTTCTTTACT AGCATCAAGA ACACCTGACC AAGGTTCTGC 1850 AGGTTGAGGT GGCTTAAATC TTAGATCACC TACAGGAGGT TTGGCATATG 1900 GAATTCCAGA ATAACTATGG AACACATTTC CTTTTTCACT AATTTGCTCT 1950 TTTCCTTTTA AAGTACCTTG AAGCAAAGTC ACTTGTAGAT CAGCCATCGT 2000 TGGAACT 2007 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 39: Asp Pro Pro Thr Val Thr Leu Pro Gin Gly Glu Leu 1 5 10 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) FEATURE: (A) NAME/KEY: Xaa = any amino acid (B) LOCATION: 21 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 40: Asp Pro Pro Thr Val Thr Leu Pro Gin Gly Glu Leu Val Gly 1 5 10 Lys Ala Thr Asn Glu Asn Xaa Lys 15 20 (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii MOLECULE TYPE: peptide (iii) SEQUENCE DESCRIPTION: SEQ ID NO:41: Asp Pro Pro Thr Val Thr Leu Pro Gin Gly Glu Leu 1 5 10 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 42: Asp Pro Pro Thr Val Thr Leu Pro Gin Gly Glu Leu Val Gly 1 5 10 Lys Ala Leu Ser Asn Glu Asn 15 20 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 43: Asp Pro Pro Thr Val Thr Leu Pro 1 5 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 44: Asp Pro Pro Thr Val Thr Leu Pro Gin Gly Glu Leu Val Gly 1 5 10 Lys Ala Leu Thr Asn Glu Asn Gly Lys 15 20 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: AATTAACCCT CACTAAAGGG 20 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) FEATURE: (A) NAME/KEY: R = A or G (B) LOCATION: 2, 12, 14 (iv) FEATURE: (A) NAME/KEY: D = A, G or T (B) LOCATION: 3, 6, 9, 15 (v) SEQUENCE DESCRIPTION: SEQ ID NO: 46: ARDCCDCCDC CRTRDAT 17 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 47: TGTGCTCGAG ATGGGATAAC CTAGATCAGC ATTTGTGC 38 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 48: TTAAGGTACC TCATCTAATA CTTCCTTCAT TACAG 35 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 49: AAAACTGCAG TATAAATATG TTACCTCACA GTAGTG 36 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) SEQUENCE DESCRIPTION: SEQ ID NO:50: TGCTCTAGAT TATCTAATAC TTCCTTCATT ACAG 34 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1540 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1540 (iv) SEQUENCE DESCRIPTION: SEQ ID NO: 51: CTT CAA GGT ACT TTA AAA GGA AAA GAG CAA ATT AGT GAA AAA 42 Leu Gin Gly Thr Leu Lys 3" y Lys Glu Gin He Ser Glu Lys 1 5 10 GGA AAT GTG TTC CAT AGT TAT TCT GGA ATT CCA TAT GCC AAA 84 Gly Asn Val Phe His Ser Tyr Ser Gly He Pro Tyr Ala Lys 15 20 25 CCT CCT GTA GGT GAT CTA AGA TTT AAG CCA CCT CAA CCT GCA 126 Pro Pro Val Gly Asp Leu Arg Phe Lys Pro Pro Gin Pro Ala 30 35 40 GAA CCT TGG TCA GGT GTT CTT GAT GCT AGT AAA GAA GGG AAT 168 Glu Pro Trp Ser Gly Val Leu Asp Ala Ser Lys Glu Gly Asn 45 50 55 AGT TGT AGA TCA GTA CAT TTT ATT AAA AAA ATT AAA GTA GGG 210 Ser Cys Arg Ser Val His Phe He Lys Lys He Lys Val Gly 60 65 70 GCT GAA GAT TGT TTA TAC CTC AAT GTC TAT GTA CCA AAA ACA 252 Ala Glu Asp Cys Leu Tyr Leu Asn Val Tyr Val Pro Lys Thr 75 80 TCA GAG AAA TCA CTT CTT CCA GTA ATG GTA TGG ATA CAT GGA 294 Ser Glu Lys Ser Leu Leu Pro Val Met Val Trp He His Gly 85 90 95 GGA GGC TTC TTC ATG GGA TCT GGA AAT AGT GAT ATG TAT GGT 336 Gly Gly Phe Phe Met Gly Ser Gly Asn Ser Asp Met Tyr Gly 100 105 110 CCT GAA TAT TTG ATG GAT TAT GGA ATT GTT CTG GTT ACT TTC 378 Pro Glu Tyr Leu Met Asp Tyr Gly He Val Leu Val Thr Phe 115 120 125 AAT TAT CGA TTA GGT GTT TTG GGA TTT TTG AAC CTG GGA ATA 420 Asn Tyr Arg Leu Gly Val Leu Gly Phe Leu Asn Leu Gly He 130 135 140 GAA GAA GCG CCT GGC AAT GTT GGT TTG ATG GAC CAG GTT GAA 462 Glu Glu Ala Pro Gly Asn Val Gly Leu Met Asp Gin Val Glu 145 150 GCT CTA AAA TGG GTA AAA AAC AAT ATT GCA TCC TTT GGT GGT 504 Ala Leu Lys Trp Val Lys Asn Asn He Ala Ser Phe Gly Gly 155 160 165 GAC CCC AAC AAT GTG ACT ATT TTT GGA GAA TCA GCA GGT GGT 546 Asp Pro Asn Asn Val Thr He Phe Gly Glu Ser Ala Gly Gly 170 175 180 GCA AGT GTT CAT TAT TTG ATG TTA TCA GAT CTT TCC AAA GGA 588 Ala Ser Val His Tyr Leu Met Leu Ser Asp Leu Ser Lys Gly 185 190 195 CT TTT CAT AAA GCG ATC TCA CAA AGT GGA AGT GCT TTT AAT 630 I U Phe His Lys Ala He Ser Gin Ser Gly Ser Ala Phe Asn 200 205 210 CCT TGG GCA CTT CAA CAT GAT AAT AAT AAA GAA AAT GCA TTC 672 Pro Trp Ala Leu Gin His Asp Asn Asn Lys Glu Asn Ala Phe 215 220 CGC CTC TGC AAA CTT CTG GGT CAT CCT GTC GAT AAC GAG ACA 714 Arg Leu Cys Lys Leu Leu Gly His Pro Val Asp Asn Glu Thr 225 230 235 GAA GCT CTA AAA ATC CTT CGT CAA GCC CCC ATA GAT GAT CTT 756 Glu Ala Leu Lys He Leu Arg Gin Ala Pro He Asp Asp Leu 240 245 250 ATA GAC AAC AGA ATA AAA CCA AAA GAC AAA GGC CAA CTT ATT 798 He Asp Asn Arg He Lys Pro Lys Asp Lys Gly Gin Leu He 255 260 265 ATA GAC TAT CCT TTT CTA CCA ACA ATA GAA AAA CGT TAT CAA 840 He Asp Tyr Pro Phe Leu Pro Thr He Glu Lys Arg Tyr Gin 270 275 280 AAT TTT GAA CCA TTC TTG GAC CAG TCT CCA TTA TCA AAA ATG 882 Asn Phe Glu Pro Phe Leu Asp Gin Ser Pro Leu Ser Lys Met 285 290 CAA TCA GGC AAT TTC ACA AAA GTC CCA TTT ATA TGT GGA TAC 924 Gin Ser Gly Asn Phe Thr Lys Val Pro Phe He Cys Gly Tyr 295 300 305 AAC AGT GCT GAA GGA ATT TTA GGT TTA ATG GAC TTC AAG GAT 966 Asn Ser Ala Glu Gly He Leu Gly Leu Met Asp Phe Lys Asp 310 315 320 GAC CCA AAT ATA TTT GAG AAG TTT GAA GCT GAT TTT GAA AGA 1008 Asp Pro Asn He Phe Glu Lys Phe Glu Ala Asp Phe Glu Arg 325 330 335 TTT GTA CCA GTA GAT TTG AAT CTA ACT TTA AGG TCT AAG GAA 1050 Phe Val Pro Val Asp Leu Asn Leu Thr Leu Arg Ser Lys Glu 340 345 350 TCT AAA AAA TTG GCT GAA GAA ATG AGA AAG TTT TAT TAC CAA 1092 Ser Lys Lys Leu Ala Glu Glu Met Arg Lys Phe Tyr Tyr Gin 355 360 GAC GAA CCT GTT TCT TCA GAC AAC AAA GAA AAA TTT GTC AGT 1134 Asp Glu Pro Val Ser Ser Asp Asn Lys Glu Lys Phe Val Ser 365 370 375 GTT ATT AGT GAT ACT TGG TTT TTG AGA GGG ATT AAA AAT ACT 1176 Val He Ser Asp Thr Trp Phe Leu Arg Gly He Lys Asn Thr 380 385 390 GCA AGA TAT ATA ATT GAA CAT TCC TCA GAA CCG TTA TAT TTA 1218 Ala Arg Tyr He He Glu His Ser Ser Glu Pro Leu Tyr Leu 395 400 405 TAT GTT TAT AGT TTT GAT GAT TTT GGT TTT TTG AAG AAA CTT 1260 Tyr Val Tyr Ser Phe Asp Asp Phe Gly Phe Leu Lys Lys Leu 410 415 420 GTA TTA GAT CCT AAT ATT GAA GGA GCA GCT CAT GGA GAT GAG 1302 Val Leu Asp Pro Asn He Glu Gly Ala Ala His Gly Asp Glu 425 430 CTG GGA TAT CTT TTC AAG ATG AGT TTT ACA GAA TTT CCA AAA 1344 Leu Gly Tyr Leu Phe Lys Met Ser Phe Thr Glu Phe Pro Lys 435 440 445 GAT TTA CCA AGT GCA GTG GTG AAT AGG GAA CGA TTG TTG CAA 1386 Asp Leu Pro Ser Ala Val Val Asn Arg Glu Arg Leu Leu Gin 450 455 460 CTT TGG ACA AAT TTT GCA AAA ACA GGA AAT CCC ACT CCT GAA 1428 Leu Trp Thr Asn Phe Ala Lys Thr Gly Asn Pro Thr Pro Glu 465 470 475 ATC AAT GAT GTT ATA ACA ACA AAA TGG GAT AAA GCT ACT GAG 1470 He Asn Asp Val He Thr Thr Lys Trp Asp Lys Ala Thr Glu 480 485 490 GAA AAA TCA GAT CAT ATG GAT ATC GAT AAT ACT TTG AGA ATG 1512 Glu Lys Ser Asp His Met Asp He Asp Asn Thr Leu Arg Met 495 500 ATT CCA GAT CCT GAT GCA AAA CGA CTT A 1540 He Pro Asp Pro Asp Ala Lys Arg Leu 505 510 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1584 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO:52: TAAAAATTTA TTCCAAAATC TAAGTCGTTT TGCATCAGGA TCTGGAATCA 50 TTCTCAAAGT ATTATCGATA TCCATATGAT CTGATTTTTC CTCAGTAGCT 100 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 52: TAAAAATTTA TTCCAAAATC TAAGTCGTTT TGCATCAGGA TCTGGAATCA 50 TTCTCAAAGT ATTATCGATA TCCATATGAT CTGATTTTTC CTCAGTAGCT 100 TTATCCCATT TTGTTGTTAT AACATCATTG ATTTCAGGAG TGGGATTTCC 150 TGTTTTTGCA AAATTTGTCC AAAGTTGCAA CAATCGTTCC CTATTCACCA 200 CTGCACTTGG TAAATCTTTT GGAAATTCTG TAAAACTCAT CTTGAAAAGA 250 TATCCCAGCT CATCTCCATG AGCTGCTCCT TCAATATTAG GATCTAATAC 300 AAGTTTCTTC AAAAAACCAA AATCATCAAA ACTATAAACA TATAAATATA 350 ACGGTTCTGA GGAATGTTCA ATTATATATC TTGCAGTATT TTTAATCCCT 400 CTCAAAAACC AAGTATCACT AATAACACTG ACAAATTTTT CTTTGTTGTC 450 TGAAGAAACA GGTTCGTCTT GGTAATAAAA CTTTCTCATT TCTTCAGCCA 500 ATTTTTTAGA TTCCTTAGAC CTTAAAGTTA GATTCAAATC TACTGGTACA 550 AATCTTTCAA AATCAGCTTC AAACTTCTCA AATATATTTG GGTCATCCTT 600 GAAGTCCATT AAACCTAAAA TTCCTTCAGC ACTGTTGTAT CCACATATAA 650 ATGGGACTTT TGTGAAATTG CCTGATTGCA TTTTTGATAA TGGAGACTGG 700 TCCAAGAATG GTTCAAAATT TTGATAACGT TTTTCTATTG TTGGTAGAAA 750 AGGATAGTCT ATAATAAGTT GGCCTTTGTC TTTTGGTTTT ATTCTGTTGT 800 CTATAAGATC ATCTATGGGG GCTTGACGAA GGATTTTTAG AGCTTCTGTC 850 TCGTTATCGA CAGGATGACC CAGAAGTTTG CAGAGGCGGA ATGCATTTTC 900 TTTATTATTA TCATGTTGAA GTGCCCAAGG ATTAAAAGCA CTTCCACTTT 950 GTGAGATCGC TTTATGAAAA AGTCCTTTGG AAAGATCTGA TAACATCAAA 1000 TAATGAACAC TTGCACCACC TGCTGATTCT CCAAAAATAG TCACATTGTT 1050 GGGGTCACCA CCAAAGGATG CAATATTGTT TTTTACCCAT TTTAGAGCTT 1100 CAACCTGGTC CATCAAACCA ACATTGCCAG GCGCTTCTTC TATTCCCAGG 1150 TTCAAAAATC CCAAAACACC TAATCGATAA TTGAAAGTAA CCAGAACAAT 1200 TCCATAATCC ATCAAATATT CAGGACCATA CATATCACTA TTTCCAGATC 1250 CCATGAAGAA GCCTCCTCCA TGTATCCATA CCATTACTGG AAGAAGTGAT 1300 TTCTCTGATG TTTTTGGTAC ATAGACATTG AGGTATAAAC AATCTTCAGC 1350 CCCTACTTTA ATTTTTTTAA TAAAATGTAC TGATCTACAA CTATTCCCTT 1400 CTTTACTAGC ATCAAGAACA CCTGACCAAG GTTCTGCAGG TTGAGGTGGC 1450 TTAAATCTTA GATCACCTAC AGGAGGTTTG GCATATGGAA TTCCAGAATA 1500 ACTATGGAAC ACATTTCCTT TTTCACTAAT TTGCTCTTTT CCTTTTAAAG 1550 TACCTTGAAG CAAAGTCACT TGTAGATCAG CCAT 1584 (2) INFORMATION FOR SEQ ID NO:53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 530 amino acids (B) I"PE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 53: Asp Pro Pro Thr Val Thr Leu Pro Gin Gly Glu Leu Val Gly 1 5 10 Lys Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr 15 20 25 Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg 30 35 40 Phe Lys Pro Pro Gin Lys Ala Glu Pro Trp Asn Gly Val Phe 45 50 55 Asn Ala Thr Ser His Gly Asn Val Cys Lys Ala Leu Asn Phe 60 65 70 Phe Leu Lys Lys He Glu Gly Asp Glu Asp Cys Leu Leu Val 75 80 Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp Lys Lys Leu Pro 85 90 95 Val Phe Phe Trp Val His Gly Gly Gly Phe Val Thr Gly Ser 100 105 110 Gly Asn Leu Glu Phe Gin Ser Pro Asp Tyr Leu Val Asn Tyr 115 120 125 Asp Val He Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu 130 135 140 Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn Val 145 150 Gly Leu Leu Asp Gin Val Ala Ala Leu Lys Trp Thr Lys Glu 155 160 165 Asn He Glu Lys Phe Gly Gly Asp Pro Glu Asn He Thr He 170 175 180 Gly Gly Val Ser Ala Gly Gly Ala Ser Val His Tyr Leu Leu 185 190 195 Leu Ser His Thr Thr Thr Gly Leu Tyr Lys Arg Ala He Ala 200 205 210 Gin Ser Gly Ser Ala Leu Asn Pro Trp Ala Phe Gin Arg His 215 220 Pro Val Lys Arg Ser Leu Gin Leu Ala Glu He Leu Gly His 225 230 235 Pro Thr Asn Asn Thr Gin Asp Ala Leu Glu Phe Leu Gin Lys 240 245 250 Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala Glu Thr 255 260 265 Glu Gly Glu He He Glu Glu Phe Val Phe Val Pro Ser He 270 275 280 Glu Lys Val Phe Pro Ser His Gin Pro Phe Leu Glu Glu Ser 285 290 Pro Leu Ala Arg Met Lys Ser Gly Ser Phe Asn Lys Val Pro 295 300 305 Leu Leu Val Gly Phe Asn Ser Ala Glu Gly Leu Leu Tyr Lys 310 315 320 Phe Phe Met Lys Glu Lys Pro Glu Met Leu Asn Gin Ala Glu 325 330 335 Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu Leu Ala 340 345 350 His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys He Arg 355 360 Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn Glu Gin 365 370 375 Lys Phe He Asp Leu He Gly Asp He Trp Phe Thr Arg Gly 380 385 390 He Asp Lys His Val Lys Leu Ser Val Glu Lys Gin Asp Glu 395 400 405 Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser Glu Ser His Pro 410 415 420 Ala Lys Gly Thr Phe Gly Asp His Asn Leu Thr Gly Ala Cys 425 430 His Gly Glu Glu Leu Val Asn Leu Phe Lys Val Glu Met Met 435 440 445 Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr Lys Asp 450 455 460 Arg Val Leu Ala Met Trp Thr Asn Phe He Lys Asn Gly Asn 465 470 475 Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys Trp Glu 480 485 490 Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu Asn He Asp Ala 495 500 Thr Leu Thr Leu Gly Thr Asn Pro Glu Glu Thr Arg Val Lys 505 510 515 Phe Trp Glu Asp Ala Thr Lys Thr Leu His Ser Gin 520 525 530 (2) INFORMATION FOR SEQ ID NO:54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 570 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO : 54 : Trp Asp Asn Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn 1 5 10 Gly He Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Arg 15 20 25 Asn Asp Val Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu 30 35 40 Pro Pro Phe Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He 45 50 55 Ser Asn Pro Lys Thr Gly Phe Val Gin Ala Arg Thr Leu Gly 60 65 70 Asp Lys Cys Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly 75 80 Ser Glu Asp Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr 85 90 95 Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp 100 105 110 He His Gly Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn 115 120 125 Phe Phe Gly Pro Asp Tyr Leu He Arg Glu Gly He He Leu 130 135 140 Val Thr He Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser 145 150 Ala Pro Glu Trp Asp He His Gly Asn M st Gly Leu Lys Asp 155 160 165 Gin Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys 170 175 180 Phe Gly Gly Asp Arg Glu Lys He Thr He Ala Gly Glu Ser 185 190 195 Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser 200 205 210 Thr Arg Lys Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr 215 220 Leu Leu Asn Pro Thr Ala Asn Gin He Gin Leu Leu His Arg 225 230 235 Phe Glu Lys Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin 240 245 250 Glu Leu Leu Asn Leu Asp Lys Asn Leu He Leu Arg Ala Ala 255 260 265 Leu Asn Arg Val Pro Asp Ser Asn Asp His Asp Arg Asp Thr 270 275 280 Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro 285 290 Asp Pro He Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn 295 300 305 Gly Glu Phe Pro Asp Val Asp Val He He Gly Phe Asn Ser 310 315 320 Ala Glu Gly Leu Arg Ser Met Ala Arg Val Thr Arg Gly Asn 325 330 335 Met Glu Val His Lys Thr Leu Thr Asn He Glu Arg Ala He 340 345 350 Pro Arg Asp Ala Asn He Trp Lys Asn Pro Asn Gly He Glu 355 360 Glu Lys Lys Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin 365 370 375 Val Lys Glu Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu 380 385 390 Lys Gly Asp Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu 395 400 405 Lys Ala He Phe Phe Asn Glu Phe Arg Arg Asn Ser Asn Leu 410 415 420 Tyr Leu Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys 425 430 Ser Tyr He Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val 435 440 450 Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu 450 455 460 Asp Val Pro He Leu Gly Thr Thr His He Ser He Pro Gin 465 470 475 Asp Ala Met Gin Thr Leu Glu Arg Met Val Arg He Trp Thr 480 485 490 Asn Phe Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp 495 500 Ala Ser Cys Asp Thr Lys Arg His Leu Asn Asp He Phe Trp 505 510 515 Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly 520 525 530 Lys Glu Asn Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg 535 540 545 Met Met Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg 550 555 560 Phe Arg Val Cys Asn Glu Gly Ser He Arg 565 570 (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 570 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO:55: Trp Asp Asn Leu Asp Gin His Leu Cys Arg Val Gin Phe Asn 1 5 10 Gly He Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Lys 15 20 25 Asn Asp Val Tyr Cys Ser Tyr Leu Gly He Pro Tyr Ala Glu 30 35 40 Pro Pro He Gly Pro Leu Arg Phe Gin Ser Pro Lys Pro He 45 50 55 Ser Asn Pro Lys Thr Gly Phe Val Gin Ala Arg Ser Leu Gly 60 65 70 Asp Lys Cys Phe Gin Glu Ser Leu He Tyr Ser Tyr Ala Gly 75 80 Ser Glu Asp Cys Leu Tyr Leu Asn He Phe Thr Pro Glu Thr 85 90 95 Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp 100 105 110 He His Gly Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn 115 120 125 Phe Phe Gly Pro Asp Tyr Leu He Arg Glu Gly He He Leu 130 135 140 Val Thr He Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser 145 150 Ala Pro Glu Trp Asp He His Gly Asn Met Gly Leu Lys Asp 155 160 165 Gin Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys 170 175 180 Phe Gly Gly Asp Arg Asp Lys He Thr He Ala Gly Glu Ser 185 190 195 Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser 200 205 210 Thr Arg Lys Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr 215 220 Leu Leu Asn Pro Thr Ala Asn Gin He Gin Pro Leu His Arg 225 230 235 Phe Glu Lys Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin 240 245 250 Glu Leu Leu Asn Leu Asp Lys Asn Gin He Leu Arg Ala Ala 255 260 265 Leu Asn Arg Val Pro Asp Asn Asn Asp His Glu Arg Asp Thr 270 275 280 Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro 285 290 Asp Pro He Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn 295 300 305 Gly Glu Phe Pro Asp Val Asp Val He He Gly Phe Asn Ser 310 315 320 Ala Glu Gly Leu Arg Ser Met Pro Arg Val Thr Arg Gly Asn 325 330 335 Met Glu Val Tyr Lys Thr Leu Thr Asn He Glu Arg Ala He 340 345 350 Pro Arg Asp Ala Asn He Trp Lys Asn Pro Asn Gly He Glu 355 360 Glu Lys Lys Leu He Lys Met Leu Thr Glu Phe Tyr Asp Gin 365 370 375 Val Lys Glu Gin Asn Asp Asp He Glu Ala Tyr Val Gin Leu 380 385 390 Lys Gly Asp Ala Gly Tyr Leu Gin Gly He Tyr Arg Thr Leu 395 400 405 Lys Ala He Phe Phe Asn Glu He Lys Arg Asn Ser Asn Leu 410 415 420 Tyr Leu Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys 425 430 Ser Tyr He Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val 435 440 445 Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu 450 455 460 Asp Val Pro He Leu Gly Thr Thr His He Ser He Pro Gin 465 470 475 Asp Ala Met Gin Thr Leu Glu Arg Met Val Arg He Trp Thr 480 485 490 Asn Phe Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp 495 500 Ala Ser Cys Asp Thr Lys Arg His Leu Asn Asp He Phe Trp 505 510 515 Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly 520 525 530 Lys Glu His Phe Glu Met Lys Asn He Leu Glu Leu Lys Arg 535 540 545 Met Met Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg 550 555 560 Phe Arg Val Cys Asn Glu Gly «.r He Arg 565 570 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 56: GTGCGTACAC GTTTACTACC 20 (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2144 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 30..1682 (iv) FEATURE: (A) NAME/KEY: Asx = Asn or Asp (B) LOCATION: 462 (v) SEQUENCE DESCRIPTION: SEQ ID NO: 57: GTACACATAG TCAATAGTCT AGATCCAAG ATG TCT CGT GTT ATT TTT 47 Met Ser Arg Val He Phe 1 5 TTA AGT TGT ATT TTT TTG TTT AGT TTT AAT TTT ATA AAA TGT 89 Leu Ser Cys He Phe Leu Phe Ser Phe Asn Phe He Lys Cys 10 15 20 GAT TCC CCG ACT GTA ACT TTG CCC CAA GGC GAA TTG GTT GGA 131 Asp Ser Pro Thr Val Thr Leu Pro Gin Gly Glu Leu Val Gly 25 30 AAA GCT TTG ACG AAC GAA AAT GGA AAA GAG TAT TTT AGC TAC 173 Lys Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr 35 40 45 ACA GGT GTA CCT TAT GCT AAA CCT CCT GTT GGA GAA CTT AGA 215 Th f ly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg 50 55 60 TTT AAG CCT CCA CAG AAA GCT GAG CCA TGG CAA GGT GTT TTC 257 Phe Lys Pro Pro Gin Lys Ala Glu Pro Trp Gin Gly Val Phe 65 70 75 AAC GCC ACA TTA TAC GGA AAT GTG TGT AAA TCT TTA AAT TTC 299 Asn Ala Thr Leu Tyr Gly Asn Val Cys Lys Ser Leu Asn Phe 80 85 90 TTC TTG AAG AAA ATT GAA GGA GAC GAA GAC TGC TTG GTA GTA 341 Phe Leu Lys Lys He Glu Gly Asp Glu Asp Cys Leu Val Val 95 100 AAC GTG TAC GCA CCA AAA ACA ACT TCT GAT AAA AAA CTT CCA 383 Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp Lys Lys Leu Pro 105 110 115 GTA TTT TTC TGG GTT CAT GGT GGT GGT TTT GTG ACT GGA TCC 425 Val Phe Phe Trp Val His Gly Gly Gly Phe Val Thr Gly Ser 120 125 130 GGA AAT TTA GAA TTC CAA AGC CCA GAT TAT TTA GTA RAT TTT 467 Gly Asn Leu Glu Phe Gin Ser Pro Asp Tyr Leu Val Asx Phe 135 140 145 GAT GTT ATT TTC GTA ACT TTC AAT TAC CGA TTG GGA CCT CTC 509 Asp Val He Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu 150 155 160 GGA TTT CTG AAT TTG GAG TTG GAG GGT GCT CCA GGA AAT GTA 551 Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn Val 165 170 GGA TTA TTG GAT CAG GTG GCA GCT CTG AAA TGG ACC AAA GAA 593 Gly Leu Leu Asp Gin Val Ala Ala Leu Lys Trp Thr Lys Glu 175 180 185 AAC ATT GAG AAA TTT GGT GGA GAT CCA GAA AAT ATT ACA ATT 635 Asn He Glu Lys Phe Gly Gly Asp Pro Glu Asn He Thr He 190 195 200 GGT GGT GTT TCT GCT GGT GGA GCA AGT GTT CAT TAT CTT TTG 677 Gly Gly Val Ser Ala Gly Gly Ala Ser Val His Tyr Leu Leu 205 210 215 TTA TCT CAT ACA ACC ACT GGA CTT TAC AAA AGG GCA ATT GCT 719 Leu Ser His Thr Thr Thr Gly Leu Tyr Lys Arg Ala He Ala 220 225 230 CAA AGT GGA AGT GCT TTT AAT CCA TGG GCC TTC CAA AGA CAT 761 Gin Ser Gly Ser Ala Phe Asn Pro Trp Ala Phe Gin Arg His 235 240 CCA GTA AAG CGT AGT CTT CAA CTT GCT GAG ATA TTG GGT CAT 803 Pro Val Lys Arg Ser Leu Gin Leu Ala Glu He Leu Gly His 245 250 255 CCC ACA AAC AAT ACT CAA GAT GCT TTA GAA TTC TTA CAA AAA 845 Pro Thr Asn Asn Thr Gin Asp Ala Leu Glu Phe Leu Gin Lys 260 265 270 GCC CCC GTA GAC AGT CTC CTG AAG AAA ATG CCA GCT GAA ACA 887 Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala Glu Thr 275 280 285 GAA GGT GAA ATA ATA GAA GAG TTT GTC TTC GTA CCA TCA ATT 929 Glu Gly Glu He He Glu Glu Phe Val Phe Val Pro Ser He 290 295 300 GAA AAA GTT TTC CCA TCC CAC CAA CCT TTC TTG GAA GAA TCA 971 Glu Lys Val Phe Pro Ser His Gin Pro Phe Leu Glu Glu Ser 305 310 CCA TTG GCC AGA ATG AAA TCC GGA TCC TTT AAC AAA GTA CCT 1013 Pro Leu Ala Arg Met Lys Ser Gly Ser Phe Asn Lys Val Pro 315 320 325 TTA TTA GTT GGA TTT AAC AGT GCA GAA GGA CTT TTG TTC AAA 1055 Leu Leu Val Gly Phe Asn Ser Ala Glu Gly Leu Leu Phe Lys 330 335 340 TTC TTC ATG AAA GAA AAA CCA GAG ATG CTG AAC CAA GCT GAA 1097 Phe Phe Met Lys Glu Lys Pro Glu Met Leu Asn Gin Ala Glu 345 350 355 GCA GAT TTT GAA AGA CTC GTA CCA GCC GAA TTT GAA TTA GTC 1139 Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu Leu Val 360 365 370 CAT GGA TCA GAG GAA TCG AAA AAA CTT GCA GAA AAA ATC AGG 1181 His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys He Arg 375 380 AAG TTT TAC TTT GAC GAT AAA CCC GTT CCA GAA AAT GAA CAG 1223 Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn Glu Gin 385 390 395 AAA TTT ATT GAC TTG ATA GGA GAT ATT TGG TTT ACT AGA GGT 1265 Lys Phe He Asp Leu He Gly Asp He Trp Phe Thr Arg Gly 400 405 410 GTT GAC AAG CAT GTC AAG TTG TCT GTG GAG AAA CAA GAC GAA 1307 Val Asp Lys His Val Lys Leu Ser Val Glu Lys Gxr. Asp Glu 415 420 425 CCA GTT TAT TAT TAT GAA TAT TCC TTC TCG GAA AGT CAT CCT 1349 Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser Glu Ser His Pro 430 435 440 GCA AAA GGA ACA TTT GGT GAT CAT AAT CTG ACT GGT GCA TGC 1391 Ala Lys Gly Thr Phe Gly Asp His Asn Leu Thr Gly Ala Cys 445 450 CAT GGA GAA GAA CTT GTG AAT TTA TTC AAA GTC GAG ATG ATG 1433 His Gly Glu Glu Leu Val Asn Leu Phe Lys Val Glu Met Met 455 460 465 AAG CTG GAA AAA GAT AAA CCT AAT GTT CTA TTA ACA AAA GAT 1475 Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr Lys Asp 470 475 480 AGA GTA CTT GCC ATG TGG ACT AAC TTC ATC AAA AAT GGA AAT 1517 Arg Val Leu Ala Met Trp Thr Asn Phe He Lys Asn Gly Asn 485 490 495 CCT ACT CCT GAA GTA ACA GAA TTA TTG CCA GTT AAA TGG GAA 1559 Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys Trp Glu 500 505 510 CCT GCC ACA AAA GAC AAG TTG AAT TAT TTG AAC ATT GAT GCC 1601 Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu Asn He Asp Ala 515 520 ACC TTA ACT TTG GGA ACA AAT CCT GAG GCA AAC CGA GTC AAA 1643 Thr Leu Thr Leu Gly Thr Asn Pro Glu Ala Asn Arg Val Lys 525 530 535 TTT TGG GAA GAC GCC ACA AAA TCT TTG CAC GGT CAA TAA 1682 Phe Trp Glu Asp Ala Thr Lys Ser Leu His Gly Gin 540 545 550 TAATTTATGA AAATTGTTTT AAATACTTTA GGTAATATAT TAGGTAAATA 1732 AAAATTAAAA AATAACAATT TTTATGTTTT ATGTATTGGC TTATGTGTAT 1782 CAGTTCTAAT TTTATTTATT TATTCTTGTT TTGCTTGTTT TGAAATATCA 1832 TGGTTTTAAT TTTCAAAACA CAACGTCGTT TGTTTTTAGC AAAATTTCCA 1882 ATAGATATGT TATATTAAGT ACTCTGAAGT ATTTTTATAT ATACACTAAA 1932 ATCAGTAAAA ATACATTAAC TAAAAATATA AGATATTTTC AATAATTTTT 1982 TTTAAAGAAA ATACCAAAAA TAAAGTAAAA TTCCAAACGG AATTTTTGTT 2032 TAACTTAAAA ATAAAATTAA CTCTTCAATA ATTTTGATAA TTAGTATTTC 2082 TGATATCATT AGTGAAAATT ATATTTTGAT AATACGTATT TATATTTAAA 2132 ATAAAATTAT GT 2144 (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) ENυr,: 550 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 58: Met Ser Arg Val He Phe Leu Ser Cys He Phe Leu Phe Ser 1 5 10 Phe Asn Phe He Lys Cys Asp Ser Pro Thr Val Thr Leu Pro 15 20 25 Gin Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu Asn Gly 30 35 40 Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro 45 50 55 Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu 60 65 70 Pro Trp Gin Gly Val Phe Asn Ala Thr Leu Tyr Gly Asn Val 75 80 Cys Lys Ser Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp 85 90 95 Glu Asp Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly 115 120 125 Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gin Ser Pro 130 135 140 Asp Tyr Leu Val Asx Phe Asp Val He Phe Val Thr Phe Asn 145 150 Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu 155 160 165 Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gin Val Ala Ala 170 175 180 Leu Lys Trp Thr Lys Glu Asn He Glu Lys Phe Gly Gly Asp 185 190 195 Pro Glu Asn He Thr He Gly Gly Val Ser Ala Gly Gly Ala 200 205 210 Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 215 220 Tyr Lys Arg Ala He Ala Gin Ser Gly Ser Ala Phe Asn Pro 225 230 ' 235 Trp Ala Phe Gin Arg His Pro Val Lys Arg Ser Leu Gin Leu 240 245 250 Ala Glu He Leu Gly His Pro Thr Asn Asn Thr Gin Asp Ala 255 260 265 Leu Glu Phe Leu Gin Lys Ala Pro Val Asp Ser Leu Leu Lys 270 275 280 Lys Met Pro Ala Glu Thr Glu Gly Glu He He Glu Glu Phe 285 290 Val Phe Val Pro Ser He Glu Lys Val Phe Pro Ser His Gin 295 300 305 Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly 310 315 320 Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 325 330 335 Glu Gly Leu Leu Phe Lys Phe Phe Met Lys Glu Lys Pro Glu 340 345 350 Met Leu Asn Gin Ala Glu Ala Asp Phe Glu Arg Leu Val Pro 355 360 Ala Glu Phe Glu Leu Val His Gly Ser Glu Glu Ser Lys Lys 365 370 375 Leu Ala Glu Lys He Arg Lys Phe Tyr Phe Asp Asp Lys Pro 380 385 390 Val Pro Glu Asn Glu Gin Lys Phe He Asp Leu He Gly Asp 395 400 405 He Trp Phe Thr Arg Gly Val Asp Lys His Val Lys Leu Ser 410 415 420 Val Glu Lys Gin Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser 425 430 Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 435 440 445 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu 450 455 460 Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn 465 470 475 Val Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn 480 485 490 Phe He Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu 495 500 Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn 505 510 515 Tyr Leu Asn He Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro 520 525 530 Glu Ala Asn Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Ser 535 540 545 Leu His Gly Gin 550 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2144 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 59: ACATAATTTT ATTTTAAATA TAAATACGTA TTATCAAAAT ATAATTTTCA 50 CTAATGATAT CAGAAATACT AATTATCAAA ATTATTGAAG AGTTAATTTT 100 ATTTTTAAGT TAAACAAAAA TTCCGTTTGG AATTTTACTT TATTTTTGGT 150 ATTTTCTTTA AAAAAAATTA TTGAAAATAT CTTATATTTT TAGTTAATGT 200 ATTTTTACTG ATTTTAGTGT ATATATAAAA ATACTTCAGA GTACTTAATA 250 TAACATATCT ATTGGAAATT TTGCTAAAAA CAAACGACGT TGTGTTTTGA 300 AAATTAAAAC CATGATATTT CAAAACAAGC AAAACAAGAA TAAATAAATA 350 AAATTAGAAC TGATACACAT AAGCCAATAC ATAAAACATA AAAATTGTTA 400 TTTTTTAATT TTTATTTACC TAATATATTA CCTAAAGTAT TTAAAACAAT 450 TTTCATAAAT TATTATTGAC CGTGCAAAGA TTTTGTGGCG TCTTCCCAAA 500 ATTTGACTCG GTTTGCCTCA GGATTTGTTC CCAAAGTTAA GGTGGCATCA 550 ATGTTCAAAT AATTCAACTT GTCTTTTGTG GCAGGTTCCC ATTTAACTGG 600 CAATAATTCT GTTACTTCAG GAGTAGGATT TCCATTTTTG ATGAAGTTAG 650 TCCACATGGC AAGTACTCTA TCTTTTGTTA ATAGAACATT AGGTTTATCT 700 TTTTCCAGCT TCATCATCTC GACTTTGAAT AAATTCACAA GTTCTTCTCC 750 ATGGCATGCA CCAGTCAGAT TATGATCACC AAATGTTCCT TTTGCAGGAT 800 GACTTTCCGA GAAGGAATAT TCATAATAAT AAACTGGTTC GTCTTGTTTC 850 TCCACAGACA ACTTGACATG CTTGTCAACA CCTCTAGTAA ACCAAATATC 900 TCCTATCAAG TCAATAAATT TCTGTTCATT TTCTGGAACG GGTTTATCGT 950 CAAAGTAAAA CTTCCTGATT TTTTCTGCAA GTTTTTTCGA TTCCTCTGAT 1000 CCATGGACTA ATTCAAATTC GGCTGGTACG AGTCTTTCAA AATCTGCTTC 1050 AGCTTGGTTC AGCATCTCTG GTTTTTCTTT CATGAaCAAT TTGAACAAAA 1100 GTCCTTCTGC ACTGTTAAAT CCAACTAATA AAGGTACTTT GTTAAAGGAT 1150 CCGGATTTCA TTCTGGCCAA TGGTGATTCT TCCAAGAAAG GTTGGTGGGA 1200 TGGGAAAACT TTTTCAATTG ATGGTACGAA GACAAACTCT TCTATTATTT 1250 CACCTTCTGT TTCAGCTGGC ATTTTCTTCA GGAGACTGTC TACGGGGGCT 1300 TTTTGTAAGA ATTCTAAAGC ATCTTGAGTA TTGTTTGTGG GATGACCCAA 1350 TATCTCAGCA AGTTGAAGAC TACGCTTTAC TGGATGTCTT TGGAAGGCCC 1400 ATGGATTAAA AGCACTTCCA CTTTGAGCAA TTGCCCTTTT GTAAAGTCCA 1450 GTGGTTGTAT GAGATAACAA AAGATAATGA ACACTTGCTC CACCAGCAGA 1500 AACACCACCA ATTGTAATAT TTTCTGGATC TCCACCAAAT TTCTCAATGT 1550 TTTCTTTGGT CCATTTCAGA GCTGCCACCT GATCCAATAA TCCTACATTT 1600 CCTGGAGCAC CCTCCAACTC CAAATTCAGA AATCCGAGAG GTCCCAATCG 1650 GTAATTGAAA GTTACGAAAA TAACATCAAA ATYTACTAAA TAATCTGGGC 1700 TTTGGAATTC TAAATTTCCG GATCCAGTCA CAAAACCACC ACCATGAACC 1750 CAGAAAAATA CTGGAAGTTT TTTATCAGAA GTTGTTTTTG GTGCGTACAC 1800 GTTTACTACC AAGCAGTCTT CGTCTCCTTC AATTTTCTTC AAGAAGAAAT 1850 TTAAAGATTT ACACACATTT CCGTATAATG TGGCGTTGAA AACACCTTGC 1900 CATGGCTCAG CTTTCTGTGG AGGCTTAAAT CTAAGTTCTC CAACAGGAGG 1950 TTTAGCATAA GGTACACCTG TGTAGCTAAA ATACTCTTTT CCATTTTCGT 2000 TCGTCAAAGC TTTTCCAACC AATTCGCCTT GGGGCAAAGT TACAGTCGGG 2050 GAATCACATT TTATAAAATT AAAACTAAAC AAAAAAATAC AACTTAAAAA 2100 AATAACACGA GACATCTTGG ATCTAGACTA TTGACTATGT GTAC 2144 (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1650 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1650 (iv) FEATURE: (A) NAME/KEY: Asx = Asn or Asp (B) LOCATION: 433 (v) SEQUENCE DESCRIPTION: SEQ ID NO: 60: ATG TCT CGT GTT ATT TTT TTA AGT TGT ATT TTT TTG TTT AGT 42 Met Ser Arg Val He Phe Leu Ser Cys He Phe Leu Phe Ser 1 5 10 TTT AAT TTT ATA AAA TGT GAT TCC CCG ACT GTA ACT TTG CCC 84 Phe Asn Phe He Lys Cys Asp Ser Pro Thr Val Thr Leu Pro 15 20 25 CAA GGC GAA TTG GTT GGA AAA GCT TTG ACG AAC GAA AAT GGA 126 Gin Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu Asn Gly 30 35 40 AAA GAG TAT TTT AGC TAC ACA GGT GTA CCT TAT GCT AAA CCT 168 Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro 45 50 55 CCT GTT GGA GAA CTT AGA TTT AAG CCT CCA CAG AAA GCT GAG 210 Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu 60 65 70 CCA TGG CAA GGT GTT TTC AAC GCC ACA TTA TAC GGA AAT GTG 252 Pro Trp Gin Gly Val Phe Asn Ala Thr Leu Tyr Gly Asn Val 75 80 TGT AAA TCT TTA AAT TTC TTC TTG AAG AAA ATT GAA GGA GAC 294 Cys Lys Ser Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp 85 90 95 GAA GAC TGC TTG GTA GTA AAC GTG TAC GCA CCA AAA ACA ACT 336 Glu Asp Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 TCT GAT AAA AAA CTT CCA GTA TTT TTC TGG GTT CAT GGT GGT 378 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly 115 120 125 GGT TTT GTG ACT GGA TCC GGA AAT TTA GAA TTC CAA AGC CCA 420 Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gin Ser Pro 130 135 140 GAT TAT TTA GTA RAT TTT GAT GTT ATT TTC GTA ACT TTC AAT 462 Asp Tyr Leu Val Asx Phe Asp Val He Phe Val Thr Phe Asn 145 150 TAC CGA TTG GGA CCT CTC GGA TTT CTG AAT TTG GAG TTG GAG 504 Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu 155 160 165 GGT GCT CCA GGA AAT GTA GGA TTA TTG GAT CAG GTG GCA GCT 546 Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gin Val Ala Ala 170 175 180 CTG AAA TGG ACC AAA GAA AAC ATT GAG AAA TTT GGT GGA GAT 588 Leu Lys Trp Thr Lys Glu Asn He Glu Lys Phe Gly Gly Asp 185 190 195 CCA GAA AAT ATT ACA ATT GGT GGT GTT TCT GCT GGT GGA GCA 630 Pro Glu Asn He Thr He Gly Gly Val Ser Ala Gly Gly Ala 200 205 210 AGT GTT CAT TAT CTT TTG TTA TCT CAT ACA ACC ACT GGA CTT 672 Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 215 220 TAC AAA AGG GCA ATT GCT CAA AGT GGA AGT GCT TTT AAT CCA 714 Tyr Lys Arg Ala He Ala Gin Ser Gly Ser Ala Phe Asn Pro 225 230 235 TGG GCC TTC CAA AGA CAT CCA GTA AAG CGT AGT CTT CAA CTT 756 Trp Ala Phe Gin Arg His Pro Val Lys Arg Ser Leu Gin Leu 240 245 250 GCT GAG ATA TTG GGT CAT CCC ACA AAC AAT ACT CAA GAT GCT 798 Ala Glu He Leu Gly His Pro Thr Asn Asn Thr Gin Asp Ala 255 260 265 TTA GAA TTC TTA CAA AAA GCC CCC GTA GAC AGT CTC CTG AAG 840 Leu Glu Phe Leu Gin Lys Ala Pro Val Asp Ser Leu Leu Lys 270 275 280 AAA ATG CCA GCT GAA ACA GAA GGT GAA ATA ATA GAA GAG TTT 882 Lys Met Pro Ala Glu Thr Glu Gly Glu He He Glu Glu Phe 285 290 GTC TTC GTA CCA TCA ATT GAA AAA GTT TTC CCA TCC CAC CAA 924 Val Phe Val Pro Ser He Glu Lys Val Phe Pro Ser His Gin 295 300 305 CCT TTC TTG GAA GAA TCA CCA TTG GCC AGA ATG AAA TCC GGA 966 Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly 310 315 320 TCC TTT AAC AAA GTA CCT TTA TTA GTT GGA TTT AAC AGT GCA 1008 Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 325 330 335 GAA GGA CTT TTG TTC AAA TTC TTC ATG AAA GAA AAA CCA GAG 1050 Glu Gly Leu Leu Phe Lys Phe Phe Met Lys Glu Lys Pro Glu 340 345 350 ATG CTG AAC CAA GCT GAA GCA GAT TTT GAA AGA CTC GTA CCA 1092 Met Leu Asn Gin Ala Glu Ala Asp Phe Glu Arg Leu Val Pro 355 360 GCC GAA TTT GAA TTA GTC CAT GGA TCA GAG GAA TCG AAA AAA 1134 Ala Glu Phe Glu Leu Val His Gly Ser Glu Glu Ser Lys Lys 365 370 375 CTT GCA GAA AAA ATC AGG AAG TTT TAC TTT GAC GAT AAA CCC 1176 Leu Ala Glu Lys He Arg Lys Phe Tyr Phe Asp Asp Lys Pro 380 385 390 GTT CCA GAA AAT GAA CAG AAA TTT ATT GAC TTG ATA GGA GAT 1218 Val Pro Glu Asn Glu Gin Lys Phe He Asp Leu He Gly Asp 395 400 405 ATT TGG TTT ACT AGA GGT GTT GAC AAG CAT GTC AAG TTG TCT 1260 He Trp Phe Thr Arg Gly Val Asp Lys His Val Lys Leu Ser 410 415 420 GTG GAG AAA CAA GAC GAA CCA GTT TAT TAT TAT GAA TAT TCC 1302 Val Glu Lys Gin Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser 425 430 TTC TCG GAA AGT CAT CCT GCA AAA GGA ACA TTT GGT GAT CAT 1344 Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 435 440 445 AAT CTG ACT GGT GCA TGC CAT GGA GAA GAA CTT GTG AAT TTA 1386 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu 450 455 460 TTC AAA GTC GAG ATG ATG AAG CTG GAA AAA GAT AAA CCT AAT 1428 Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn 465 470 475 GTT CTA TTA ACA AAA GAT AGA GTA CTT GCC ATG TGG ACT AAC 1470 Val Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn 480 485 490 TTC ATC AAA AAT GGA AAT CCT ACT CCT GAA GTA ACA GAA TTA 1512 Phe He Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu 495 500 TTG CCA GTT AAA TGG GAA CCT GCC ACA AAA GAC AAG TTG AAT 1554 Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn 505 510 515 TAT TTG AAC ATT GAT GCC ACC TTA ACT TTG GGA ACA AAT CCT 1596 Tyr Leu Asn He Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro 520 525 530 GAG GCA AAC CGA GTC AAA TTT TGG GAA GAC GCC ACA AAA TCT 1638 Glu Ala Asn Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Ser 535 540 545 TTG CAC GGT CAA 1650 Leu His Gly Gin 550 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1650 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) SEQUENCE DESCRIPTION: SEQ ID NO:61: TTGACCGTGC AAAGATTTTG TGGCGTCTTC CCAAAATTTG ACTCGGTTTG 50 CCTCAGGATT TGTTCCCAAA GTTAAGGTGG CVTCAATGTT CAAATAATTC 100 AACTTGTCTT TTGTGGCAGG TTCCCATTT Λ .CTGGCAATA ATTCTGTTAC 150 TTCAGGAGTA GGATTTCCAT TTTTGATGAA GTTAGTCCAC ATGGCAAGTA 200 CTCTATCTTT TGTTAATAGA ACATTAGGTT TATCTTTTTC CAGCTTCATC 250 ATCTCGACTT TGAATAAATT CACAAGTTCT TCTCCATGGC ATGCACCAGT 300 CAGATTATGA TCACCAAATG TTCCTTTTGC AGGATGACTT TCCGAGAAGG 350 AATATTCATA ATAATAAACT GGTTCGTCTT GTTTCTCCAC AGACAACTTG 400 ACATGCTTGT CAACACCTCT AGTAAACCAA ATATCTCCTA TCAAGTCAAT 450 AAATTTCTGT TCATTTTCTG GAACGGGTTT ATCGTCAAAG TAAAACTTCC 500 TGATTTTTTC TGCAAGTTTT TTCGATTCCT CTGATCCATG GACTAATTCA 550 AATTCGGCTG GTACGAGTCT TTCAAAATCT GCTTCAGCTT GGTTCAGCAT 600 CTCTGGTTTT TCTTTCATGA AGAATTTGAA CAAAAGTCCT TCTGCACTGT 650 TAAATCCAAC TAATAAAGGT ACTTTGTTAA AGGATCCGGA TTTCATTCTG 700 GCCAATGGTG ATTCTTCCAA GAAAGGTTGG TGGGATGGGA AAACTTTTTC 750 AATTGATGGT ACGAAGACAA ACTCTTCTAT TATTTCACCT TCTGTTTCAG 800 CTGGCATTTT CTTCAGGAGA CTGTCTACGG GGGCTTTTTG TAAGAATTCT 850 AAAGCATCTT GAGTATTGTT TGTGGGATGA CCCAATATCT CAGCAAGTTG 900 AAGACTACGC TTTACTGGAT GTCTTTGGAA GGCCCATGGA TTAAAAGCAC 950 TTCCACTTTG AGCAATTGCC CTTTTGTAAA GTCCAGTGGT TGTATGAGAT 1000 AACAAAAGAT AATGAACACT TGCTCCACCA GCAGAAACAC CACCAATTGT 1050 AATATTTTCT GGATCTCCAC CAAATTTCTC AATGTTTTCT TTGGTCCATT 1100 TCAGAGCTGC CACCTGATCC AATAATCCTA CATTTCCTGG AGCACCCTCC 1150 AACTCCAAAT TCAGAAATCC GAGAGGTCCC AATCGGTAAT TGAAAGTTAC 1200 GAAAATAACA TCAAAATYTA CTAAATAATC TGGGCTTTGG AATTCTAAAT 1250 TTCCGGATCC AGTCACAAAA CCACCACCAT GAACCCAGAA AAATACTGGA 1300 AGTTTTTTAT CAGAAGTTGT TTTTGGTGCG TACACGTTTA CTACCAAGCA 1350 GTCTTCGTCT CCTTCAATTT TCTTCAAGAA GAAATTTAAA GATTTACACA 1400 CATTTCCGTA TAATGTGGCG TTGAAAACAC CTTGCCATGG CTCAGCTTTC 1450 TGTGGAGGCT TAAATCTAAG TTCTCCAACA GGAGGTTTAG CATAAGGTAC 1500 ACCTGTGTAG CTAAAATACT CTTTTCCATT TTCGTTCGTC AAAGCTTTTC 1550 CAACCAATTC GCCTTGGGGC AAAGTTACAG TCGGGGAATC ACATTTTATA 1600 AAATTAAAAC TAAACAAAAA AATACAACTT AAAAAAATAA CACGAGACAT 1650 (2) INFORMATION FOR SEQ ID NO:62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 62: AAACTCGAGT CCCCCGACTG TAACTTTGC 29 (2) INFORMATION FOR SEQ ID NO:63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63: TCATCTGCAG TTATTGACTG TGCAAAGTTT TTGTGG 36 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) SEQUENCE DESCRIPTION: SEQ ID NO : 64 : TTCCGGATCC GGCTGATCTA CAAGTGACTT TG 32 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 65: TGGTACTCGA GTCATAAAAA TTTATTCCAA AATC 34 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 66: AAAACTGCAG TATAAATATG TTACCTCACA GTGCATTAG 39 (2) INFORMATION FOR SEQ ID NO: 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1987 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1650 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: AATTCACAGT GTAAATAATT TTATTTGATA TAAATGTATT TAATTTTTAT 50 TTTAATCTAA TTTTAATTTA AATATATATA GTTTTATTTA TAAAAAAATA 100 TTTTTTTTAT GATCGAAAAG AAATTTTTAT TTATGTTTAT GAGTGTGTGT 150 TTTGGCTATG ATTTACATTA TTTTTGAGCT AGTATAAAAT TAAACCATAT 200 TATATTTTGG ATATATAATA ACATTTTATA ATG TGT GAT CCA TTA 245 Met Cys Asp Pro Leu 1 5 CTA AAA ACA ACA ACA TAT GGA ATT CTG AAA GGC AAG AAA GTT 287 Leu Lys Thr Thr Thr Tyr Gly He Leu Lys Gly Lys Lys Val 10 15 GTA AAC GAA AAT GGT AAA ATT TAC TAT AGT TAC ACA GGT ATA 329 Val Asn Glu Asn Gly Lys He Tyr Tyr Ser Tyr Thr Gly He 20 25 30 CCC TAT GCA AAA TCT CCT GTA AAT GAT CTC AGA TTC AAG CCA 371 Pro Tyr Ala Lys Ser Pro Val Asn Asp Leu Arg Phe Lys Pro 35 40 45 CCA CAA AAA CTT GAT CCT TGG AAT GGT GTT TTT GAC GCC ACT 413 Pro Gin Lys Leu Asp Pro Trp Asn Gly Val Phe Asp Ala Thr 50 55 60 CAG TAT GGA AAT AAT TGT GCT GCT GGG AAA TGG TTT TTG AAA 455 Gin Tyr Gly Asn Asn Cys Ala Ala Gly Lys Trp Phe Leu Lys 65 70 75 TCA GCT GGG GGT TGC GAA GAT TGC CTT TAC TTA AAT ATC TAT 497 Ser Ala Gly Gly Cys Glu Asp Cys Leu Tyr Leu Asn He Tyr 80 85 GTC CCA CAA AAC ACT TCA GAA AAT CCT TTG CCA GTA ATG TTT 539 Val Pro Gin Asn Thr Ser Glu Asn Pro Leu Pro Val Met Phe 90 95 100 TGG ATT CAT GGA GGA GCA TTT GTG GTC GGA TCA GGA AAT TCT 581 Trp He His Gly Gly Ala Phe Val Val Gly Ser Gly Asn Ser 105 110 115 GAT ATA CAT GGT CCT GAT TAT TTA ATA GAA TAT GAT ATT ATC 623 Asp He His Gly Pro Asp Tyr Leu He Glu Tyr Asp He He 120 125 130 TTA GTA ACT ATT AAT TAT CGT CTA GGA CCA CTT GGT TTT CTT 665 Leu Val Thr He Asn Tyr Arg Leu Gly Pro Leu Gly Phe Leu 135 140 145 AAT TTG GAA ATC GAA GAT GCG CCT GGG AAT GTT GGA H ATG 707 Asn Leu Glu He Glu Asp Ala Pro Gly Asn Val Gly Leu Met 150 155 GAT CAA GTT GCA GCC CTA AAA TGG GTA AAT GAA AAT ATT GCA 749 Asp Gin Val Ala Ala Leu Lys Trp Val Asn Glu Asn He Ala 160 165 170 ACC TTT AGT GGA GAC CCA AAA AAT ATT ACA ATT TGT GGA GCA 791 Thr Phe Ser Gly Asp Pro Lys Asn He Thr He Cys Gly Ala 175 180 185 ACT GCT GGA GCT GCA AGT GTA CAT TAT CAC ATT TTG TCA CAA 833 Thr Ala Gly Ala Ala Ser Val His Tyr His He Leu Ser Gin 190 195 200 CTT ACC AAA GGT TTA TTC CAC AAG GCT ATA GCA CAA AGT GGA 875 Leu Thr Lys Gly Leu Phe His Lys Ala He Ala Gin Ser Gly 205 210 215 AGT GCT TTT AAT CCC TGG GCT TTC CAA AAA AAT CCT GTT AAG 917 Ser Ala Phe Asn Pro Trp Ala Phe Gin Lys Asn Pro Val Lys 220 225 AAT GCA CTT CGA CTA TGC AAA ACC TTA GGC CTT ACC ACA AAC 959 Asn Ala Leu Arg Leu Cys Lys Thr Leu Gly Leu Thr Thr Asn 230 235 240 AAC CTT CAA GAA GCC TTG GAT TTT TTG AAA AAC CTA CCA GTA 1001 Asn Leu Gin Glu Ala Leu Asp Phe Leu Lys Asn Leu Pro Val 245 250 255 GAA ACA TTG TTA AAT ACC AAA TTA CCC CAA GAA ATT GAT GGT 1043 Glu Thr Leu Leu Asn Thr Lys Leu Pro Gin Glu He Asp Gly 260 265 270 CAA CTG CTG GAT GAC TTC GTG TTT GTA CCT TCG ATT GAA AAA 1085 Gin Leu Leu Asp Asp Phe Val Phe Val Pro Ser He Glu Lys 275 280 285 ACA TTT CCA GAA CAA GAT TCG TAC TTA ACT GAC TTG CCA ATA 1127 Thr Phe Pro Glu Gin Asp Ser Tyr Leu Thr Asp Leu Pro He 290 295 CCA ATA ATA AAT TCA GGA AAA TTC CAC AAA GTT CCA TTG TTG 1169 Pro He He Asn Ser Gly Lys Phe His Lys Val Pro Leu Leu 300 305 310 ACA GGT TAC AAC AGT GCC GAA GGC AAT CTA TTT TTC ATG TAC 1211 Thr Gly Tyr Asn Ser Ala Glu Gly Asn Leu Phe Phe Met Tyr 315 320 325 TTA AAA ACA GAT CCA GAT TTA TTA AAT AAA TTT GAA GCT GAT 1253 Leu Lys Thr Asp Pro Asp j_eι. Leu Asn Lys Phe Glu Ala Asp 330 335 340 TTT GAA AGA TTT ATA CCA ACT GAC TTA GAA TTA CCT TTG CGA 1295 Phe Glu Arg Phe He Pro Thr Asp Leu Glu Leu Pro Leu Arg 345 350 355 TCA CAA AAA TCT ATT GCA CTG GGT GAA GCA ATC AGG GAA TTT 1337 Ser Gin Lys Ser He Ala Leu Gly Glu Ala He Arg Glu Phe 360 365 TAT TTC CAA AAC AAA ACC ATA TCA GAA AAT ATG CAG AAT TTT 1379 Tyr Phe Gin Asn Lys Thr He Ser Glu Asn Met Gin Asn Phe 370 375 380 GTA GAT GTT TTA AGT GAT AAT TGG TTT ACA CGT GGA ATT GAT 1421 Val Asp Val Leu Ser Asp Asn Trp Phe Thr Arg Gly He Asp 385 390 395 GAG CAA GTA AAG TTA ACT GTT AAA AAT CAG GAA GAA CCA GTT 1463 Glu Gin Val Lys Leu Thr Val Lys Asn Gin Glu Glu Pro Val 400 405 410 TTT TAT TAT GTT TAT AAT TTT GAT GAA AAT TCT CCA AGT CGG 1505 Phe Tyr Tyr Val Tyr Asn Phe Asp Glu Asn Ser Pro Ser Arg 415 420 425 AAA GTT TTT GGT GAT TTT GGA ATA AAA GGC GGT GGT CAT GCT 1547 Lys Val Phe Gly Asp Phe Gly He Lys Gly Gly Gly His Ala 430 435 GAT GAA TTG GGT AAT ATA TTT AAA GCC AAA AGT GCA AAT TTT 1589 Asp Glu Leu Gly Asn He Phe Lys Ala Lys Ser Ala Asn Phe 440 445 450 GGG AAG GAA ACA CCA AAT GCT GTG TTG GTT CAG AGA AGG ATG 1631 Gly Lys Glu Thr Pro Asn Ala Val Leu Val Gin Arg Arg Met 455 460 465 CTG GAG ATG TGG ACT AAT TTT GCT AAA TTT GGA AAT CCT ACT 1673 Leu Glu Met Trp Thr Asn Phe Ala Lys Phe Gly Asn Pro Thr 470 475 480 CCA GCT ATT ACG GAT ACA CTT CCA ATA AAA TGG GAA CCT GCT 1715 Pro Ala He Thr Asp Thr Leu Pro He Lys Trp Glu Pro Ala 485 490 495 TTT AAA GAA AAT ATG ACT TTT GTT CAA ATT GAC ATT GAT TTA 1757 Phe Lys Glu Asn Met Thr Phe Val Gin He Asp He Asp Leu 500 505 AAT TTG AGT ACT GAT CCA CTA AAA AGT CGT ATG GAA TTT GGG 1799 A n Leu Ser Thr Asp Pro Leu Lys Ser Arg Met Glu Phe Gly 510 515 520 AAT AAA ATA AAA TTA TTA AAA TAAGTAACTA TACTTAGCTA 1840 Asn Lys He Lys Leu Leu Lys 525 530 AACCATAATA TACCAAATAA TAGTATAGGA ATACTTCACA ATTTTTTGTT 1890 ACTTCGTTAA GTAAATTTAA TTTTTTATAA AACCAACTTT TACGAATAAA 1940 AAATGTAATT ATTTTGGAAA AAAAAAAGAA AAAAAAAAAA AAAAAAC 1987 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 530 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: Met Cys Asp Pro Leu Leu Lys Thr Thr Thr Tyr Gly He Leu 1 5 10 Lys Gly Lys Lys Val Val Asn Glu Asn Gly Lys He Tyr Tyr 15 20 25 Ser Tyr Thr Gly He Pro Tyr Ala Lys Ser Pro Val Asn Asp 30 35 40 Leu Arg Phe Lys Pro Pro Gin Lys Leu Asp Pro Trp Asn Gly 45 50 55 Val Phe Asp Ala Thr Gin Tyr Gly Asn Asn Cys Ala Ala Gly 60 65 70 Lys Trp Phe Leu Lys Ser Ala Gly Gly Cys Glu Asp Cys Leu 75 80 Tyr Leu Asn He Tyr Val Pro Gin Asn Thr Ser Glu Asn Pro 85 90 95 Leu Pro Val Met Phe Trp He His Gly Gly Ala Phe Val Val 100 105 110 Gly Ser Gly Asn Ser Asp He His Gly Pro Asp Tyr Leu He 115 120 125 Glu Tyr Asp He He Leu Val Thr He Asn Tyr Arg Leu Gly 130 135 140 Pro Leu Gly Phe Leu Asn Leu Glu He Glu Asp Ala Pro Gly 145 150 Asn Val Gly Leu Met Asp Gin Val Ala Ala Leu Lys Trp Val 155 160 165 Asn Glu Asn He Ala Thr Phe Ser Gly Asp Pro Lys Asn He 170 175 180 Thr He Cys Gly Ala Thr Ala Gly Ala Ala Ser Val His Tyr 185 190 195 His He Leu Ser Gin Leu Thr Lys Gly Leu Phe His Lys Ala 200 205 210 He Ala Gin Ser Gly Ser Ala Phe Asn Pro Trp Ala Phe Gin 215 220 Lys Asn Pro Val Lys Asn Ala Leu Arg Leu Cys Lys Thr Leu 225 230 235 Gly Leu Thr Thr Asn Asn Leu Gin Glu Ala Leu Asp Phe Leu 240 245 250 Lys Asn Leu Pro Val Glu Thr Leu Leu Asn Thr Lys Leu Pro 255 260 265 Gin Glu He Asp Gly Gin Leu Leu Asp Asp Phe Val Phe Val 270 275 280 Pro Ser He Glu Lys Thr Phe Pro Glu Gin Asp Ser Tyr Leu 285 290 Thr Asp Leu Pro He Pro He He Asn Ser Gly Lys Phe His 295 300 305 Lys Val Pro Leu Leu Thr Gly Tyr Asn Ser Ala Glu Gly Asn 310 315 320 Leu Phe Phe Met Tyr Leu Lys Thr Asp Pro Asp Leu Leu Asn 325 330 335 Lys Phe Glu Ala Asp Phe Glu Arg Phe He Pro Thr Asp Leu 340 345 350 Glu Leu Pro Leu Arg Ser Gin Lys Ser He Ala Leu Gly Glu 355 360 Ala He Arg Glu Phe Tyr Phe Gin Asn Lys Thr He Ser Glu 365 370 375 Asn Met Gin Asn Phe Val Asp Val Leu Ser Asp Asn Trp Phe 380 385 390 Thr Arg Gly He Asp Glu Gin Val Lys Leu Thr Val Lys Asn 395 400 405 Gin Glu Glu Pro Val Phe Tyr Tyr Val Tyr A ^ Phe Asp Glu 410 415 420 Asn Ser Pro Ser Arg Lys Val Phe Gly Asp Phe Gly He Lys 425 430 Gly Gly Gly His Ala Asp Glu Leu Gly Asn He Phe Lys Ala 435 440 445 Lys Ser Ala Asn Phe Gly Lys Glu Thr Pro Asn Ala Val Leu 450 455 460 Val Gin Arg Arg Met Leu Glu Met Trp Thr Asn Phe Ala Lys 465 470 475 Phe Gly Asn Pro Thr Pro Ala He Thr Asp Thr Leu Pro He 480 485 490 Lys Trp Glu Pro Ala Phe Lys Glu Asn Met Thr Phe Val Gin 495 500 He Asp He Asp Leu Asn Leu Ser Thr Asp Pro Leu Lys Ser 505 510 515 Arg Met Glu Phe Gly Asn Lys He Lys Leu Leu Lys 520 525 530 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1987 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69: GTTTTTTTTT TTTTTTTTTC TTTTTTTTTT CCAAAATAAT TACATTTTTT 50 ATTCGTAAAA GTTGGTTTTA TAAAAAATTA AATTTACTTA ACGAAGTAAC 100 AAAAAATTGT GAAGTATTCC TATACTATTA TTTGGTATAT TATGGTTTAG 150 CTAAGTATAG TTACTTATTT TAATAATTTT ATTTTATTCC CAAATTCCAT 200 ACGACTTTTT AGTGGATCAG TACTCAAATT TAAATCAATG TCAATTTGAA 250 CAAAAGTCAT ATTTTCTTTA AAAGCAGGTT CCCATTTTAT TGGAAGTGTA 300 TCCGTAATAG CTGGAGTAGG ATTTCCAAAT TTAGCAAAAT TAGTCCACAT 350 CTCCAGCATC CTTCTCTGAA CCAACACAGC ATTTGGTGTT TCCTTCCCAA 400 AATTTGCACT TTTGGCTTTA AATATATTAC CCAATTCATC AGCATGACCA 450 CCGCCTTTTA TTCCAAAATC ACCAAAAACT TTCCGACTTG GAGAATTTTC 500 ATCAAAATTA TAAACATAAT AAAAAACTGG TTCTTCCTGA TTTTTAACAG 550 TTAACTTTAC TTGCTCATCA ATTCCACGTG TAAACCAATT ATCACTTAAA 600 ACATCTACAA AATTCTGCAT ATTTTCTGAT ATGGTTTTGT TTTGGAAATA 650 AAATTCCCTG ATTGCTTCAC CCAGTGCAAT AGATTTTTGT GATCGCAAAG 700 GTAATTCTAA GTCAGTTGGT ATAAATCTTT CAAAATCAGC TTCAAATTTA 750 TTTAATAAAT CTGGA'x r GT TTTTAAGTAC ATGAAAAATA GATTGCCTTC 800 GGCACTGTTG TAACCTGTCA ACAATGGAAC TTTGTGGAAT TTTCCTGAAT 850 TTATTATTGG TATTGGCAAG TCAGTTAAGT ACGAATCTTG TTCTGGAAAT 900 GTTTTTTCAA TCGAAGGTAC AAACACGAAG TCATCCAGCA GTTGACCATC 950 AATTTCTTGG GGTAATTTGG TATTTAACAA TGTTTCTACT GGTAGGTTTT 1000 TCAAAAAATC CAAGGCTTCT TGAAGGTTGT TTGTGGTAAG GCCTAAGGTT 1050 TTGCATAGTC GAAGTGCATT CTTAACAGGA TTTTTTTGGA AAGCCCAGGG 1100 ATTAAAAGCA CTTCCACTTT GTGCTATAGC CTTGTGGAAT AAACCTTTGG 1150 TAAGTTGTGA CAAAATGTGA TAATGTACAC TTGCAGCTCC AGCAGTTGCT 1200 CCACAAATTG TAATATTTTT TGGGTCTCCA CTAAAGGTTG CAATATTTTC 1250 ATTTACCCAT TTTAGGGCTG CAACTTGATC CATCAATCCA ACATTCCCAG 1300 GCGCATCTTC GATTTCCAAA TTAAGAAAAC CAAGTGGTCC TAGACGATAA 1350 TTAATAGTTA CTAAGATAAT ATCATATTCT ATTAAATAAT CAGGACCATG 1400 TATATCAGAA TTTCCTGATC CGACCACAAA TGCTCCTCCA TGAATCCAAA 1450 ACATTACTGG CAAAGGATTT TCTGAAGTGT TTTGTGGGAC ATAGATATTT 1500 AAGTAAAGGC AATCTTCGCA ACCCCCAGCT GATTTCAAAA ACCATTTCCC 1550 AGCAGCACAA TTATTTCCAT ACTGAGTGGC GTCAAAAACA CCATTCCAAG 1600 GATCAAGTTT TTGTGGTGGC TTGAATCTGA GATCATTTAC AGGAGATTTT 1650 GCATAGGGTA TACCTGTGTA ACTATAGTAA ATTTTACCAT TTTCGTTTAC 1700 AACTTTCTTG CCTTTCAGAA TTCCATATGT TGTTGTTTTT AGTAATGGAT 1750 CACACATTAT AAAATGTTAT TATATATCCA AAATATAATA TGGTTTAATT 1800 TTATACTAGC TCAAAAATAA TGTAAATCAT AGCCAAAACA CACACTCATA 1850 AACATAAATA AAAATTTCTT TTCGATCATA AAAAAAATAT TTTTTTATAA 1900 ATAAAACTAT ATATATTTAA ATTAAAATTA GATTAAAATA AAAATTAAAT 1950 ACATTTATAT CAAATAAAAT TATTTACACT GTGAATT 1987 (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1590 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1590 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70: ATG TGT GAT CCA TTA CTA AAA ACA ACA ACA TAT GGA ATT CTG 42 Met Cys Asp Pro Leu Leu Lys Thr Thr Thr Tyr Gly He Leu 1 5 10 AAA GGC AAG AAA GTT GTA AAC GAA AAT GGT AAA ATT TAC TAT 84 Lys Gly Lys Lys Val Val Asn Glu Asn Gly Lys He Tyr Tyr 15 20 25 AGT TAC ACA GGT ATA CCC TAT GCA AAA TCT CCT GTA AAT GAT 126 Ser Tyr Thr Gly He Pro Tyr Ala Lys Ser Pro Val Asn Asp 30 35 40 CTC AGA TTC AAG CCA CCA CAA AAA CTT GAT CCT TGG AAT GGT 168 Leu Arg Phe Lys Pro Pro Gin Lys Leu Asp Pro Trp Asn Gly 45 50 55 GTT TTT GAC GCC ACT CAG TAT GGA AAT AAT TGT GCT GCT GGG 210 Val Phe Asp Ala Thr Gin Tyr Gly Asn Asn Cys Ala Ala Gly 60 65 70 AAA TGG TTT TTG AAA TCA GCT GGG GGT TGC GAA GAT TGC CTT 252 Lys Trp Phe Leu Lys Ser Ala Gly Gly Cys Glu Asp Cys Leu 75 80 TAC TTA AAT ATC TAT GTC CCA CAA AAC ACT TCA GAA AAT CCT 294 Tyr Leu Asn He Tyr Val Pro Gin Asn Thr Ser Glu Asn Pro 85 90 95 TTG CCA GTA ATG TTT TGG ATT CAT GGA GGA GCA TTT GTG GTC 336 Leu Pro Val Met Phe Trp He His Gly Gly Ala Phe Val Val 100 105 110 GGA TCA GGA AAT TCT GAT ATA CAT GGT CCT GAT TAT TTA ATA 378 Gly Ser Gly Asn Ser Asp He His Gly Pro Asp Tyr Leu He 115 120 125 GAA TAT GAT ATT ATC TTA GTA ACT ATT AAT TAT CGT CTA GGA 420 Glu Tyr Asp He He Leu Val Thr He Asn Tyr Arg Leu Gly 130 135 140 CCA CTT GGT TTT CTT AAT TTG GAA ATC GAA GAT GCG CCT GGG 462 Pro Leu Gly Phe Leu Asn Leu Glu He Glu Asp Ala Pro Gly 145 150 AAT GTT GGA TTG ATG GAT CAA GTT GCA GCC CTA AAA TGG GTA 504 Asn Val Gly Leu Met Asp Gin Val Ala Ala Leu Lys Trp Val 155 160 165 AAT GAA AAT ATT GCA ACC TTT AGT GGA GAC CCA AAA AAT ATT 546 Asn Glu Asn He Ala Thr Phe Ser Gly Asp Pro Lys Asn He 170 175 180 ACA ATT TGT GGA GCA ACT GCT GGA GCT GCA AGT GTA CAT TAT 588 Thr He Cys Gly Ala Thr Ala Gly Ala Ala Ser Val His Tyr 185 190 195 CAC ATT TTG TCA CAA CTT ACC AAA GGT TTA TTC CAC AAG GCT 630 His He Leu Ser Gin Leu Thr Lys Gly Leu Phe His Lys Ala 200 205 210 ATA GCA CAA AGT GGA AGT GCT TTT AAT CCC TGG GCT TTC CAA 672 He Ala Gin Ser Gly Ser Ala Phe Asn Pro Trp Ala Phe Gin 215 220 AAA AAT CCT GTT AAG AAT GCA CTT CGA CTA TGC AAA ACC TTA 714 Lys Asn Pro Val Lys Asn Ala Leu Arg Leu Cys Lys Thr Leu 225 230 235 GGC CTT ACC ACA AAC AAC CTT CAA GAA GCC TTG GAT TTT TTG 756 Gly Leu Thr Thr Asn Asn Leu Gin Glu Ala Leu Asp Phe Leu 240 245 250 AAA AAC CTA CCA GTA GAA ACA TTG TTA AAT ACC AAA TTA CCC 798 Lys Asn Leu Pro Val Glu Thr Leu Leu Asn Thr Lys Leu Pro 255 260 265 CAA GAA ATT GAT GGT CAA CTG CTG GAT GAC TTC GTG TTT GTA 840 Gin Glu He Asp Gly Gin Leu Leu Asp Asp Phe Val Phe Val 270 275 280 CCT TCG ATT GAA AAA ACA TTT CCA GAA CAA GAT TCG TAC TTA 882 Pro Ser He Glu Lys Thr Phe Pro Glu Gin Asp Ser Tyr Leu 285 290 ACT GAC TTG CCA ATA CCA ATA ATA AAT TCA GGA AAA TTC CAC 924 Thr Asp Leu Pro He Pro He He Asn Ser Gly Lys Phe His 295 300 305 AAA GTT CCA TTG TTG ACA GGT TAC AAC AGT GCC GAA GGC AAT 966 Lys Val Pro Leu Leu Thr Gly Tyr Asn Ser Ala Glu Gly Asn 310 315 320 CTA TTT TTC ATG TAC TTA AAA ACA GAT CCA GAT TTA TTA AAT 1008 Leu Phe Phe Met Tyr Leu Lys Thr Asp Pro Asp Leu Leu Asn 325 330 335 AAA TTT GAA GCT GAT TTT GAA AGA TTT ATA CCA ACT GAC TTA 1050 Lys Phe Glu Ala Asp Phe Glu Arg Phe He Pro Thr Asp Leu 340 345 350 GAA TTA CCT TTG CGA TCA CAA AAA TCT ATT GCA CTG GGT GAA 1092 Glu Leu Pro Leu Arg Ser Gin Lys Ser He Ala Leu Gly Glu 355 360 GCA ATC AGG GAA TTT TAT TTC CAA AAC AAA ACC ATA TCA GAA 1134 Ala He Arg Glu Phe Tyr Phe Gin Asn Lys Thr He Ser Glu 365 370 375 AAT ATG CAG AAT TTT GTA GAT GTT TTA AGT GAT AAT TGG TTT 1176 Asn Met Gin Asn Phe Val Asp Val Leu Ser Asp Asn Trp Phe 380 385 390 ACA CGT GGA ATT GAT GAG CAA GTA AAG TTA ACT GTT AAA AAT 1218 Thr Arg Gly He Asp Glu Gin Val Lys Leu Thr Val Lys Asn 395 400 405 CAG GAA GAA CCA GTT TTT TAT TAT GTT TIT AAT TTT GAT GAA 1260 Gin Glu Glu Pro Val Phe Tyr Tyr Va.. ' yr Asn Phe Asp Glu 410 415 420 AAT TCT CCA AGT CGG AAA GTT TTT GGT GAT TTT GGA ATA AAA 1302 Asn Ser Pro Ser Arg Lys Val Phe Gly Asp Phe Gly He Lys 425 430 GGC GGT GGT CAT GCT GAT GAA TTG GGT AAT ATA TTT AAA GCC 1344 Gly Gly Gly His Ala Asp Glu Leu Gly Asn He Phe Lys Ala 435 440 445 AAA AGT GCA AAT TTT GGG AAG GAA ACA CCA AAT GCT GTG TTG 1386 Lys Ser Ala Asn Phe Gly Lys Glu Thr Pro Asn Ala Val Leu 450 455 460 GTT CAG AGA AGG ATG CTG GAG ATG TGG ACT AAT TTT GCT AAA 1428 Val Gin Arg Arg Met Leu Glu Met Trp Thr Asn Phe Ala Lys 465 470 475 TTT GGA AAT CCT ACT CCA GCT ATT ACG GAT ACA CTT CCA ATA 1470 Phe Gly Asn Pro Thr Pro Ala He Thr Asp Thr Leu Pro He 480 485 490 AAA TGG GAA CCT GCT TTT AAA GAA AAT ATG ACT TTT GTT CAA 1512 Lys Trp Glu Pro Ala Phe Lys Glu Asn Met Thr Phe Val Gin 495 500 ATT GAC ATT GAT TTA AAT TTG AGT ACT GAT CCA CTA AAA AGT 1554 He Asp He Asp Leu Asn Leu Ser Thr Asp Pro Leu Lys Ser 505 510 515 CGT ATG GAA TTT GGG AAT AAA ATA AAA TTA TTA AAA 1590 Arg Met Glu Phe Gly Asn Lys He Lys Leu Leu Lys 520 525 530 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1590 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: TTTTAATAAT TTTATTTTAT TCCCAAATTC CATACGACTT TTTAGTGGAT 50 CAGTACTCAA ATTTAAATCA ATGTCAATTT GAACAAAAGT CATATTTTCT 100 TTAAAAGCAG GTTCCCATTT TATTGGAAGT GTATCCGTAA TAGCTGGAGT 150 AGGATTTCCA A? TTTAGCAA AATTAGTCCA CATCTCCAGC ATCCTTCTCT 200 GAACCAACAC A CATTTGGT GTTTCCTTCC CAAAATTTGC ACTTTTGGCT 250 TTAAATATAT TACCCAATTC ATCAGCATGA CCACCGCCTT TTATTCCAAA 300 ATCACCAAAA ACTTTCCGAC TTGGAGAATT TTCATCAAAA TTATAAACAT 350 AATAAAAAAC TGGTTCTTCC TGATTTTTAA CAGTTAACTT TACTTGCTCA 400 TCAATTCCAC GTGTAAACCA ATTATCACTT AAAACATCTA CAAAATTCTG 450 CATATTTTCT GATATGGTTT TGTTTTGGAA ATAAAATTCC CTGATTGCTT 500 CACCCAGTGC AATAGATTTT TGTGATCGCA AAGGTAATTC TAAGTCAGTT 550 GGTATAAATC TTTCAAAATC AGCTTCAAAT TTATTTAATA AATCTGGATC 600 TGTTTTTAAG TACATGAAAA ATAGATTGCC TTCGGCACTG TTGTAACCTG 650 TCAACAATGG AACTTTGTGG AATTTTCCTG AATTTATTAT TGGTATTGGC 700 AAGTCAGTTA AGTACGAATC TTGTTCTGGA AATGTTTTTT CAATCGAAGG 750 TACAAACACG AAGTCATCCA GCAGTTGACC ATCAATTTCT TGGGGTAATT 800 TGGTATTTAA CAATGTTTCT ACTGGTAGGT TTTTCAAAAA ATCCAAGGCT 850 TCTTGAAGGT TGTTTGTGGT AAGGCCTAAG GTTTTGCATA GTCGAAGTGC 900 ATTCTTAACA GGATTTTTTT GGAAAGCCCA GGGATTAAAA GCACTTCCAC 950 TTTGTGCTAT AGCCTTGTGG AATAAACCTT TGGTAAGTTG TGACAAAATG 1000 TGATAATGTA CACTTGCAGC TCCAGCAGTT GCTCCACAAA TTGTAATATT 1050 TTTTGGGTCT CCACTAAAGG TTGCAATATT TTCATTTACC CATTTTAGGG 1100 CTGCAACTTG ATCCATCAAT CCAACATTCC CAGGCGCATC TTCGATTTCC 1150 AAATTAAGAA AACCAAGTGG TCCTAGACGA TAATTAATAG TTACTAAGAT 1200 AATATCATAT TCTATTAAAT AATCAGGACC ATGTATATCA GAATTTCCTG 1250 ATCCGACCAC AAATGCTCCT CCATGAATCC AAAACATTAC TGGCAAAGGA 1300 TTTTCTGAAG TGTTTTGTGG GACATAGATA TTTAAGTAAA GGCAATCTTC 1350 GCAACCCCCA GCTGATTTCA AAAACCATTT CCCAGCAGCA CAATTATTTC 1400 CATACTGAGT GGCGTCAAAA ACACCATTCC AAGGATCAAG TTTTTGTGGT 1450 GGCTTGAATC TGAGATCATT TACAGGAGAT TTTGCATAGG GTATACCTGT 1500 GTAACTATAG TAAATTTTAC CATTTTCGTT TACAACTTTC TTGCCTTTCA 1550 GAATTCCATA TGTTGTTGTT TTTAGTAATG GATCACACAT 1590 (2) INFORMATION FOR SEQ ID NO:72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 650 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 3..650 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: GG ATC CAT GGA GGC GCA TTC AAC CAA GGA TCA GGA TCT TAT 41 He His Gly Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr 1 5 10 AAT TTT TTT GGA CCT GAT TAT TTG ATC AGG GAA GGA ATT ATT 83 Asn Phe Phe Gly Pro Asp Tyr Leu He Arg Glu Gly He He 15 20 25 TTG GTC ACT ATC AAC TAT AGA TTA GGA GTT TTC GGT TTT CTA 125 Leu Val Thr He Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu 30 35 40 TCA GCG CCG GAA TGG GAT ATC CAT GGA AAT ATG GGT CTA AAA 167 Ser Ala Pro Glu Trp Asp He His Gly Asn Met Gly Leu Lys 45 50 55 GAC CAG AGA TTG GCA CTA AAA TGG GTT TAC GAC AAC ATC GAA 209 Asp Gin Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn He Glu 60 65 AAG TTT GGT GGA GAC AGA GAA AAA ATT ACA ATT GCT GGA GAA 251 Lys Phe Gly Gly Asp Arg Glu Lys He Thr He Ala Gly Glu 70 75 80 TCT GCT GGA GCA GCA AGT GTC CAT TTT CTG ATG ATG GAC AAC 293 Ser Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp Asn 85 90 95 TCG ACT AGA AAA TAC TAC CAA AGG GCC ATT TTG CAG AGT GGG 335 Ser Thr Arg Lys Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly 100 105 110 ACA TTA CTA AAT CCG ACT GCT AAT CAA ATT CAA CTT CTG CAT 377 Thr Leu Leu Asn Pro Thr Ala Asn Gin He Gin Leu Leu His 115 120 125 AGA TTT GAA AAA CTC AAA CAA GTG CTA AAC ATC ACG CAA AAA 419 Arg Phe Glu Lys Leu Lys Gin Val Leu Asn He Thr Gin Lys 130 135 CAA GAA CTC CTA AAC CTG GAT AAA AAC CTA ATT TTA CGA GCA 461 Gin Glu Leu Leu Asn Leu Asp Lys Asn Leu He Leu Arg Ala 140 145 150 GCC TTA AAC AGA GTT CCT GAT AGC AAC GAC CAT GAC CGA GAC 503 Ala Leu Asn Arg Val Pro Asp Ser Asn Asp His Asp Arg Asp 155 160 165 ACA GTA CCA GTA TTT AAT CCA GTC TTA GAA TCA CCA GAA TCT 545 Thr Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser 170 175 180 CCA GAT CCA ATA ACA TTT CCA TCT GCC TTG GAA AGA ATG AGA 587 Pro Asp Pro He Thr Phe Pro Ser Ala Leu Glu Arg Met Arg 185 190 195 AAT GGT GAA TTT CCT GAT GTC GAT GTC ATC ATT GGT TTC AAT 629 Asn Gly Glu Phe Pro Asp Val Asp Val He He Gly Phe Asn 200 205 AGT GCT GAA GGT TTA AGA TCT 650 Ser Ala Glu Gly Leu Arg Ser 210 215 (2) INFORMATION FOR SEQ ID NO: 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 216 nucleotides (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: He His Gly Gly Ala Phe Asn Gin Gly Ser Gly Ser Tyr Asn 1 5 10 Phe Phe Gly Pro Asp Tyr Leu He Arg Glu Gly He He Leu 15 20 25 Val Thr He Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser 30 35 40 Ala Pro Glu Trp Asp He His Gly Asn Met Gly Leu Lys Asp 45 50 55 Gin Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn He Glu Lys 60 65 70 Phe Gly Gly Asp Arg Glu Lys He Thr He Ala Gly Glu Ser 75 80 Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser 85 90 95 Thr Arg Lys Tyr Tyr Gin Arg Ala He Leu Gin Ser Gly Thr 100 105 110 Leu Leu Asn Pro Thr Ala Asn Gin He Gin Leu Leu His Arg 115 120 125 Phe Glu Lys Leu Lys Gin Val Leu Asn He Thr Gin Lys Gin 130 135 140 Glu Leu Leu Asn Leu Asp Lys Asn Leu He Leu Arg Ala Ala 145 150 Leu Asn Arg Val Pro Asp Ser Asn Asp His Asp Arg Asp Thr 155 160 165 Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro 170 175 180 Asp Pro He Thr Phe Pro Ser A_a Leu Glu Arg Met Arg Asn 185 190 195 Gly Glu Phe Pro Asp Val Asp Val He He Gly Phe Asn Ser 200 205 210 Ala Glu Gly Leu Arg Ser 215 (2) INFORMATION FOR SEQ ID NO : 74 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEAT 'URE: (A) NAME/KEY Xxn Tyr or Gly (B) LOCATION 3 (C) NAME/KEY Xxn Lys or Tyr or Gly (D) LOCATION 5 (E) NAME/KRY Xxn Val or Gin or Asn (F) LOCATION 6 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: Asp Leu Xxn Val Xxn Xxn Leu Gin Gly Thr Leu Lys Gly Lys 1 5 10 Glu 15 (2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75: CGCGGATCCG CTGATCTACA AGTGACTTTG C 21 (2) INFORMATION FOR SEQ ID NO: 76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1488 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 3..1487 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76: CC CAG GGC GAA TTG GTT GGA AAA GCT TTG ACG AAC GAA AAT GGA 44 Gin Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu Asn Gly 1 5 10 AAA GAG TAT TTT AGC TAC ACA GGT GTG CCT TAT GCT AAA CCT 86 Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro 15 20 25 CCA GTT GGA GAA CTT AGA TTT AAG CCT CCA CAG AAA GCT GAG 128 Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gin Lys Ala Glu 30 35 40 CCA TGG AAT GGT GTT TTC AAC GCC ACA TCA CAT GGA AAT GTG 170 Pro Trp Asn Gly Val Phe Asn Ala Thr Ser His Gly Asn Val 45 50 55 TGC AAA GCT TTG AAT TTC TTC TTG AAA AAA ATT GAA GGA GAC 212 Cys Lys Ala Leu Asn Phe Phe Leu Lys Lys He Glu Gly Asp 60 65 70 GAA GAC TGC TTG TTG GTG AAT GTG TAC GCA CCA AAA ACA ACT 254 Glu Asp Cys Leu Leu Val Asn Val Tyr Ala Pro Lys Thr Thr 75 80 TCT GAC AAA AAA CTT CCA GTA TTT TTC TGG GTT CAT GGT GGC 296 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly 85 90 95 GGT TTT GTG ACT GGA TCC GGA AAT TTA GAA TTT CAA AGC CCA 338 Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gin Ser Pro 100 105 110 GAT TAT TTA GTA AAT TAT GAT GTT ATT TTT GTA ACT TTC AAT 380 Asp Tyr Leu Val Asn Tyr Asp Val He Phe Val Thr Phe Asn 115 120 125 TAC CGA TTG GGA CCA CTC GGA TTT TTG AAT TTG GAG TTG GAA 422 Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu 130 135 140 GGT GCT CCT GGA AAT GTA GGA TTA TTG GAT CAG GTA GCA GCT 464 Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gin Val Ala Ala 145 150 TTG AAA TGG ACC AAA GAA AAT ATT GAG AAA TTT GGT GGA GAT 506 Leu Lys Trp Thr Lys Glu Asn He Glu Lys Phe Gly Gly Asp 155 160 165 CCA GAA AAT ATT ACA ATT GGT GGT GTT TCT GCT GGT GGA GCA 548 Pro Glu Asn He Thr He Gly Gly Val Ser Ala Gly Gly Ala 170 175 180 AGT GTT CAT TAT CTT TTA TTG TCA CAT ACA ACC ACT GGA CTT 590 Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 185 190 195 TAC AAA AGG GCA ATT GCT CAA AGT GGA AGT GCT TTA AAT CCA 632 Tyr Lys Arg Ala He Ala Gin Ser Gly Ser Ala Leu Asn Pro 200 205 210 TGG GCC TTC CAA AGA CAT CCA GTA AAG CGT AGT CTT CAA CTT 674 Trp Ala Phe Gin Arg His Pro Val Lys Arg Ser Leu Gin Leu 215 220 GCT GAG ATA TTA GGT CAT CCC ACA AAC AAC ACT CAA GAT GCT 716 Ala Glu He Leu Gly His Pro Thr Asn Asn Thr Gin Asp Ala 225 230 235 TTA GAA TTC TTA CAA AAA GCC CCA GTA GAC AGT CTC CTG AAA 758 Leu Glu Phe Leu Gin Lys Ala Pro Val Asp Ser Leu Leu Lys 240 245 250 AAA ATG CCA GCT GAA ACA GAA GGT GAA ATA ATA GAA GAG TTC 800 Lys Met Pro Ala Glu Thr Glu Gly Glu He He Glu Glu Phe 255 260 265 GTC TTC GTA CCA TCA ATT GAA AAA GTT TTC CCA TCC CAC CAA 842 Val Phe Val Pro Ser He Glu Lys Val Phe Pro Ser His Gin 270 275 280 CCT TTC TTG GAA GAA TCA CCA TTG GCC AGA ATG AAA TCT GGA 884 Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly 285 290 TCC TTT AAC AAA GTA CCT TTA TTA GTT GGA TTC AAC AGC GCA 926 Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 295 300 305 GAA GGA CTT TTG TAC AAA TTC TTT ATG AAA GAA AAA CCA GAG 968 Glu Gly Leu Leu Tyr Lys Phe Phe Met Lys Glu Lys Pro Glu 310 315 320 ATG CTG AAC CAA GCT GAA GCA GAT TTC GAA AGA CTC GTA CCA 1010 Met Leu Asn Gin Ala Glu Ala Asp Phe Glu Arg Leu Val Pro 325 330 335 GCC GAA TTT GAA TTA GCC CAT GGA TCA GAA GAA TCG AAA AAA 1052 Ala Glu Phe Glu Leu Ala His Gly Ser Glu Glu Ser Lys Lys 340 345 350 CTT GCA GAA AAA ATC AGG AAG TTT TAC TTT GAC GAT AAA CCC 1094 Leu Ala Glu Lys He Arg Lys Phe Tyr Phe Asp Asp Lys Pro 355 360 GTT CCT GAA AAT GAG CAG AAA TTT ATT GAC TTG ATA GGA GAT 1136 Val Pro Glu Asn Glu Gin Lys Phe He Asp Leu He Gly Asp 365 370 375 ATT TGG TTT ACT AGA GGC ATT GAC AAG CAT GTC AAG TTG TCT 1178 He Trp Phe Thr Arg Gly He Asp Lys His Val Lys Leu Ser 380 385 390 GTA GAA AAA CAA GAC GAG CCA GTA TAT TAT TAT GAA TAT TCT 1220 Val Glu Lys Gin Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser 395 400 405 TTC TCT GAA AGT CAT CCT GCA AAA GGA ACA TTT GGT GAC CAT 1262 Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 410 415 420 AAC TTG ACT GGA GCA TGT CAT GGT GAA GAA CTT GTG AAT TTA 1304 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu 425 430 TTC AAA GTC GAG ATG ATG AAG CTG GAA AAA GAT AAA CCG AAT 1346 Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn 435 440 445 GTT TTA TTA ACA AAA GAT AGG GTA CTT GCT ATG TGG ACG AAC 1388 Val Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn 450 455 460 TTC ATC AAA AAT GGA AAT CCT ACT CCT GAA GTA ACT GAA TTA 1430 Phe He Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu 465 470 475 TTG CCA GTT AAA TGG GAA CCT GCC ACA AAA GAC AAG TTG AAT 1472 Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn 480 485 490 TAT TTG AAC ATT GAT G 1488 Tyr Leu Asn He Asp 495 While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.

Claims: What is claimed is: 1. An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74. 2. An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having a nucleic acid sequence encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO: 11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74. 3. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEg D NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule comprising any of said nucleic acid sequences. 4. An isolated protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to a nucleic acid molecule selected from the group consisting of: a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO: 12, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO: 22, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO: 38, SEQ ID NO:52, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:69, SEQ ID NO: 71; and a nucleic acid molecule encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55 and SEQ ID NO:74. 5. An isolated flea protein selected from the group consisting of: a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:l l, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; and a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein comprising any of said amino acid sequences. 6. A formulation of flea carboxylesterase proteins, wherein said proteins, when submitted to 14% Tris-glycine SDS-PAGE, comprise a fractionation profile as depicted in Fig. 3, wherein said proteins have carooxylesterase activity. 7. A formulation of flea carboxylesterase proteins, wherein said proteins, when submitted to IEF-PAGE, comprise a fractionation profile as depicted in Fig. 4 in a lane selected from the group consisting of lane 3, lane 4, lane 5, lane 6 and lane 7, wherein said proteins have carboxylesterase activity. 8. An isolated flea protein that hydrolyzes α-napthyl acetate to produce α- napthol, when said protein is incubated in the presence of α-napthyl acetate contained in about 20 mM Tris at about pH 8.0 for about 15 minutes at about 37°C. 9. A formulation comprising flea proteins that hydrolyze α-napthyl acetate to produce α-napthol, when said proteins are incubated in the presence of α-napthyl acetate contained in about 20 mM Tris at about pH 8.0 for about 15 minutes at about 37°C. 10. An isolated flea protein that hydrolyzes the methyl ester group of juvenile hormone to produce a juvenile hormone acid. 11. A formulation comprising flea proteins that hydrolyze the methyl ester group of juvenile hormone to produce a juvenile hormone acid. 12. A therapeutic composition that, when administered to an animal, reduces hematophagous ectoparasite infestation, said therapeutic composition comprising an excipient and a protective compound selected from the group consisting of: an isolated hematophagous ectoparasite carboxylesterase protein; a mimetope of an isolated hematophagous ectoparasite carboxylesterase protein; an isolated hematophagous ectoparasite carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene; an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein; and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase. 13. A method to reduce hematophagous ectoparasite infestation comprising treating an animal with a therapeutic composition comprising a protective compound selected from the group consisting of: an isolated hematophagous ectoparasite carboxylesterase protein; a mimetope of a hematophagous ectoparasite carboxylesterase protein; an isolated hematophagous ectoparasite carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene; an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein; and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase. 14. A method to produce a carboxylesterase protein, said method comprising culturing a cell capable of expressing said protein, said protein being encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene. 15. A method to identify a compound capable of inhibiting flea carboxylesterase activity, said method comprising: (a) contacting an isolated flea carboxylesterase with a putative inhibitory compound under conditions in which, in the absence of said compound, said protein has carboxylesterase activity; and (b) determining if said putative inhibitory compound inhibits said activity. 16. A test kit to identify a compound capable of inhibiting flea carboxylesterase activity, said test kit comprising an isolated flea carboxylesterase protein having esterase activity and a means for determining the extent of inhibition of said activity in the presence of a putative inhibitory compound. 17. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule is a flea nucleic acid molecule. 18. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule is selected from the group consisting of Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla nucleic acid molecules. 19. The nucleic acid molecule of Claims 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla (Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans nucleic acid molecules. 20. The nucleic acid molecule of Claims 1 or 2, wherein said nucleic acid molecule comprises a Ctenocephalides felis nucleic acid molecule. 21. The nucleic acid molecule of Claim 1 , wherein said nucleic acid molecule hybridizes under stringent hybridization conditions with a nucleic acid molecule selected from the group consisting of nfEl 401 , nfE2 364 , nfE3 421 , nfE4 524 , nfE5 1982 , nfE5 1515 , nfE5 2144 , nfE5 1650 , nfE6 1488 , nfE6 1792 , nfE6 1650 , nfE7 2836 , nfE7 I788 , nfE7 I710 , nfE7 650 , nfE8 280 i, nfE8 1785 , nfE8 1710 , nfE9 2007 , nfE9 15g4 , nfE9 1540 , nfE10 1987 and nfE10 1590 . 22. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule comprises a nucleic acid molecule selected from the group consisting of nfEl 401 , nfE2 364 , nfE3 421 , nfE4 524 , nfE5ι 982 , nfE5 1515 , nfE5 2144 , nfE5 1650 , nfE6 1488 , nfE6 1792 , nfE6 1650 , nfE7 2836 , nfE7 1788 , nfE7 17I0 , nfE7 650 , nfE8 2801 , nfE8 1785 , nfE8 1710 , nfE9 2007 , nfE9 1584 , nfE9 1540 , nfE10 I987 and nfE10 1590 . 23. The nucleic acid molecule of Claims 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule comprising a nucleic acid sequence that encodes a protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:l l, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule encoding a protein having any of said amino acid sequences. 24. The nucleic acid molecule of Claims 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO: 17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO: 28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO: 34, SEQ ID NO:l , SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO: 52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO: 69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76, a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74 SEQ ID NO:74; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule comprising any of said nucleic acid sequences. 25. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule comprises an oligonucleotide. 26. A recombinant molecule comprising a nucleic acid molecule as set forth in Claims 1 or 2 operatively linked to a transcription control sequence. 27. A recombinant virus comprising a nucleic acid molecule as set forth in Claims 1 or 2. 28. A recombinant cell comprising a nucleic acid molecule as set forth in Claims l or 2. 29. The nucleic acid molecule of Claim 2, wherein said nucleic acid molecule comprises a nucleic acid sequence that encodes a carboxylesterase protein. 30. The nucleic acid molecule of Claim 2, wherein said nucleic acid molecule hybridizes under stringent hybridization conditions with the complement of a nucleic acid sequence encoding said protein. 31. The protein of Claim 4, wherein said protein, when administered to an animal, elicits an immune response against a carboxylesterase protein. 32. The protein of Claim 4, wherein said protein is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE6 1792 . 33. The protein of Claim 4, wherein said protein is selected from the group consisting of: a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO: 11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:5 , ύ EQ ID NO:55, SEQ ID NO:58 SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; and a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74. 34. An isolated antibody that selectively binds to a protein as set forth in Claim 4. 35. The formulation of Claim 6, wherein said proteins are selected from the group consisting of proteins having molecular weights ranging from about 60 kD to about 75 kD as determined by 14% Tris-glycine SDS-PAGE. 36. The formulation of Claim 6, wherein said proteins are isolated by the method comprising: (a) applying soluble proteins of a flea extract to a p-aminobenzamidine agarose bead column; (b) collecting unbound protein from said p-aminobenzamidine agarose bead column and applying said unbound protein to a gel filtration column; (c) eluting proteins bound to said gel filtration column and applying said eluted proteins to a cation exchange chromatography column; (d) eluting proteins bound to said cation exchange column and applying said eluted proteins to an anion exchange chromatography column; and (e) eluting proteins bound to said anion exchange column with about 170 mM NaCl to obtain said flea carboxylesterase proteins. 37. The formulation of Claim 7, wherein said proteins are selected from the group consisting of proteins having pi values ranging from about pi 4.7 to about pi 5.2 as determined by IEF-PAGE. 38. The invention of Claims 8 or 9, wherein said incubation results in the production of from about 0.3 to at least about 2.5 absorbance units in the presence of Fast Blue ,/hen measured at 590 nm. 39. The protein of Claim 8, wherein said protein does not hydrolyze the methyl ester group of juvenile hormone. 40. The invention of Claims 8 or 9 or 10 or 11, wherein the mature form of said protein has a molecular weight ranging from about 60 kD to about 75 kD. 41. The invention of Claims 8 or 9, wherein said protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 19, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44 and SEQ ID NO:53. 42. The invention of Claims 10 or 11 , wherein hydrolyzation of said methyl ester group results in the release of at least about 120 counts per minute of 3 H-juvenile hormone acid when determined by the method comprising: (a) incubating said flea protein in the presence of 3 H-juvenile hormone to create a reaction mixture; (b) combining said reaction mixture with isooctane to produce an aqueous phase and an organic phase; (c) recovering said aqueous phase; and (d) determining the amount of 3 H-juvenile hormone acid present in said aqueous phase. 43. The protein of Claim 10, wherein said protein does not hydrolyze α- napthyl acetate. 44. The invention of Claims 12 or 13, wherein said hematophagous ectoparasite carboxylesterase comprises a flea carboxylesterase. 45. The invention of Claims 12 or 13, wherein said hematophagous ectoparasite is a flea of a genus selected from the group consisting of Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla. 46. The invention of Claims 12 or 13, wherein said hematophagous ectoparasite is a flea of a species selected from the group consisting of Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla (Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans. 47. The invention of Claims 12 or 13, wherein said hematophagous ectoparasite carboxylesterase comprises a juvenile hormone esterase. 48. The invention of Claims 12 or 13, wherein said composition further comprises a component selected from the group consisting of an adjuvant and a carrier. 49. The invention of Claims 12 or 13, wherein said composition further comprises a compound that reduces hematophagous ectoparasite burden by a method other than by reducing hematophagous ectoparasite carboxylesterase activity. 50. The invention of Claims 12 or 13, wherein said protective compound is selected from the group consisting of a naked nucleic acid vaccine, a recombinant virus vaccine and a recombinant cell vaccine. 51. The invention of Claims 12 or 13, wherein said inhibitor comprises a substrate analog of a hematophagous ectoparasite carboxylesterase. 52. The method of Claim 13, wherein said animal is selected from the group consisting of adult hematophagous ectoparasites, hematophagous ectoparasite larvae and animals susceptible to hematophagous ectoparasite infestation. 53. The method of Claim 13, wherein said animal is selected from the group consisting of adult fleas, flea larvae and animals susceptible to flea infestation. 54. The method of Claim 13, wherein hematophagous ectoparasite infestation is reduced by hematophagous ectoparasite larvae ingesting adult hematophagous ectoparasite feces comprising said therapeutic composition. 55. The method of Claim 13, wherein said adult hematophagous ectoparasite feces comprises anti-hematophagous ectoparasite carboxylesterase antibodies. 56. The method of Claim 13, wherein anti-hematophagous ectoparasite carboxylesterase antibodies are elicited in a host animal in response to administration of a reagent selected from the group consisting of one or more of said isolated hematophagous ectoparasite carboxylesterase proteins and one or more of said hematophagous ectoparasite carboxylesterase nucleic acid molecules, said adult hematophagous ectoparasite having fed from said host animal a.ier said administration. 57. The method of Claim 13, wherein said animal is selected from the group consisting of mammals and birds. 58. The method of Claim 13, wherein said animal is selected from the group consisting of cats and dogs. 59. The method of Claim 14, wherein said cell expresses a nucleic acid molecule selected from the group consisting of pCro-nfE6 1488 , pTrc-nfE7 650 , pTrc- nfE7 1710 , pTrc-nfE8 1710ι pTrc-nfE5 1650 , pTrc-nfE9 I540 , pFB-nfE6 1679 , pVL-nf£7 1802 , pVL- fE8 1792 and pVL-nfE9 1600 .

Inventors: BRANDT KEVIN S, SILVER GARY M, WISNEWSKI NANCY, BRANDT, KEVIN, S., SILVER, GARY, M., WISNEWSKI, NANCY
Applicants: BRANDT KEVIN S, HESKA CORP, SILVER GARY M, WISNEWSKI NANCY, BRANDT, KEVIN, S., HESKA CORPORATION, SILVER, GARY, M., WISNEWSKI, NANCY
Application year: 1997
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K45, A61K48, A61P33, C07K16, C12N1, C12N5, C12N7, C12N9, C12N15, C12Q1, G01N33